An offering statement pursuant to regulation a relating to these securities has been filed with the United States Securities and Exchange Commission. Information contained in this preliminary offering circular is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted before the offering statement filed with the Commission is qualified. This preliminary offering circular shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sales of these securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of such state. The company may elect to satisfy its obligation to deliver a final offering circular by sending you a notice within two business days after the completion of the company’s sale to you that contains the URL where the final offering circular or the offering statement in which such final offering circular was filed may be obtained.
PRELIMINARY OFFERING CIRCULAR DATED NOVEMBER 2, 2018
Coherix, Inc.
3980 Ranchero Dr.
Ann Arbor, MI 48108
(734) 922-4073
Up to 2,500,000 shares of Common Stock, par value $0.001
SEE “DESCRIPTION OF CAPITAL STOCK” AT PAGE 46
| Price to Public | Underwriting discount and commissions (2) | Proceeds to issuer | |
| Per share/unit | $ 6.00 | $ 0.00 | $ 6.00 |
| Total Maximum | $ 15,000,000 | $ 0.00 | $ 15,000,000(1) |
(1) Before deducting expenses, estimated to be approximately $500,000 including legal fees, accounting fees, and printer costs. For more details, please see the section of this offering circular captioned “Plan of Distribution.” This is a “best efforts” offering. There is no minimum number of shares that must be distributed in this offering.
(2) The company does not currently intend to use commissioned sales agents or underwriters. In the event it uses commissioned sales agents or underwriters, it will file an amendment to the Offering Statement of which this Offering Circular forms a part.
The offering will commence within two calendar days after the offering statement in which this offering circular is included has been qualified by the US Securities and Exchange Commission (the “Commission” or the “SEC”) and includes an amount of shares that we reasonably expect to be offered and sold within two years from the date of initial qualification, unless subsequently amended. The offering will terminate at the earlier of: (1) the date at which the maximum offering amount has been sold, (2) the date which is one year from this offering being qualified by the Commission, or (3) the date at which the offering is earlier terminated by us in our sole discretion.
There is no minimum number of shares that we must sell in order to conduct a closing in this offering. We have made no arrangements to place subscription funds in an escrow, trust or similar account. Shares issued under this offering will be issued on a continuous basis under Rule 251(d)(3) under the Securities Act, and the company will have access to such funds from the first dollar invested, even if those proceeds do not cover the costs of this offering. For further details please see the section of this offering circular captioned “Plan of Distribution.”
THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SELLING LITERATURE. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.
THE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND THESE SECURITIES ARE OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION. HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE SECURITIES OFFERED HEREUNDER ARE EXEMPT FROM REGISTRATION.
THIS OFFERING CIRCULAR CONTAINS ALL OF THE REPRESENTATIONS BY THE COMPANY CONCERNING THIS OFFERING, AND NO PERSON SHALL MAKE DIFFERENT OR BROADER STATEMENTS THAN THOSE CONTAINED HEREIN. INVESTORS ARE CAUTIONED NOT TO RELY UPON ANY INFORMATION NOT EXPRESSLY SET FORTH IN THIS OFFERING CIRCULAR.
GENERALLY NO SALE MAY BE MADE TO YOU IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(d)(2)(i)(C) OF REGULATION A. FOR GENERAL INFORMATION ON INVESTING, WE ENCOURAGE YOU TO REFER TO www.investor.gov.
This offering is inherently risky. See “Risk Factors” on page 8.
Sales of these securities will commence on approximately [date].
The company is following the Form S-1 format of disclosure under Regulation A.
In this Offering Circular, the terms “Coherix” or “the company,” “us” or “we” refer to Coherix, Inc. and its consolidated subsidiaries.
Statement Regarding Forward-Looking Statements
THIS OFFERING CIRCULAR MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
Industry and Market Data
Although we are responsible for all disclosure contained in this Offering Circular, in some cases we have relied on certain market and industry data obtained from third-party sources that we believe to be reliable. Market estimates are calculated by using independent industry publications in conjunction with our assumptions regarding the machine vision for manufacturing industry and market. While we are not aware of any misstatements regarding any market, industry or similar data presented herein, such data involves risks and uncertainties and is subject to change based on various factors, including those discussed under the headings “Statement Regarding Forward-Looking Statements” and “Risk Factors” in this Offering Circular.
This summary highlights selected information contained elsewhere in this Offering Circular. This summary is not complete and does not contain all the information that you should consider before deciding whether to invest in our Common Stock. You should carefully read the entire Offering Circular, including the risks associated with an investment in the company discussed in the "Risk Factors" section of this Offering Circular, before making an investment decision. Some of the statements in this Offering Circular are forward-looking statements. See the section entitled "Statement Regarding Forward-Looking Statements."
Company Information
The company was organized on October 30, 2003, under the laws of the State of Delaware. Our principal executive office is located at 3980 Ranchero Drive, Ann Arbor, MI 48108, and our telephone number is 734-922-4073. We have a wholly owned subsidiary in Singapore, Coherix Asia PTE Ltd., to market Coherix semiconductor products in the Asia Pacific region and a wholly owned subsidiary in Germany, Coherix GMBH, to market Coherix products in Europe. We have a distribution agreement with Marubeni to market Coherix products in Japan. In March 2018, we began to operate a Chinese Wholly Foreign Owned Enterprise (“WFOE”) in Shanghai, China to market and distribute Coherix, Inc. products in China.
Our website address is www.coherix.com. We do not incorporate the information on or accessible through our website into this Offering Circular, and you should not consider any information on, or that can be accessed through, our website as part of this Offering Circular.
Our Business
Coherix is a leading three-dimensional (“3D”) machine vision provider engaged in the development and application of high-speed error-proofing solutions for the automotive, semiconductor, electronics and general manufacturing sectors. Such solutions support the increasing demand to further automate various manufacturing processes. Coherix’s 3D machine vision products include software and hardware that serve as the “Eyes of Automation” and function like eyes for automation equipment such as robots and other complex machines. Coherix 3D machine vision products can perform many functions human eyes cannot, such as high precision, high speed, in-line error-proofing. To capture 3D information, Coherix uses its proprietary “SHARK™” electronic modules providing advanced sensor technology (the eyes). In addition, our proprietary “i-Cite™” software serves as the brains behind the eyes, and performs high speed processing of the 3D information coming from the sensors. Over 200 field tested powerful i-Cite software modules are adaptable, efficient, and easy-to use, acting as the “brains” of our entire suite of the company’s 3D machine vision products.
Machine vision is used in manufacturing when the requirements of the manufacturing process have surpassed the limits of human eyesight. Our products deliver substantial cost savings which are obtained through improved product quality and higher throughput. Manufactured parts often are produced with tolerances too small to be analyzed by the human eye. Machine vision technology provided by Coherix provides manufacturing solutions with sight, which meet the increasing demands for speed and accuracy in manufacturing processes, as well as smaller tolerances on parts being manufactured. Machine vision technologies have traditionally been two-dimensional (“2D”). It is well known that 2D vision cameras operate based on contrast of light in the scene, therefore, if the ambient light or the color of the part changes, the functions of the 2D vision camera are negatively impacted. Coherix 3D vision systems are not susceptible to ambient light or if the color of the part changes, which we believe is a significant change in inspection (error-proofing) in manufacturing. Industry analysts estimate that the 3D machine vision business could grow at a rate of 30% annually in terms of revenues.
Software and Hardware Platforms for our Products
Our core strategy is to displace temperamental 2D technology by offering manufacturers what we believe to be a more capable, cost-effective, and more reliable 3D solution. Coherix’s high-speed 3D solutions are based on our two proprietary software and hardware platforms: i-Cite modular software platform, and our proprietary modular SHARK hardware platform. The combination of the i-Cite software and SHARK hardware platforms significantly reduce time and effort to develop 3D vision solutions, thereby delivering greater performance at lower cost.
| 1 |
Our Error-Proofing Products
Error-proofing solutions are critical to the manufacturing of high volume and high value parts. Error-proofing is necessary given manufacturers’ stringent focus on quality and safety while delivering higher efficiencies and throughput. Coherix’s 3D error-proofing products are used in the electronics, semiconductor, automotive, and general manufacturing market segments. Our customers implement our high speed Robust3D® error-proofing solutions directly into their manufacturing processes in order to avoid defects in their manufacturing process.
Coherix solves difficult problems in manufacturing with its 3D vision solutions that cannot be performed by humans. Most of the manufacturing problems our products are solving have existed over several decades. Previously they could not be solved with human inspectors, mechanical probes, or 2D machine vision technologies. Solving these difficult manufacturing problems requires robust 3D (capable of performing without failure under a wide range of conditions) machine vision technology.
Coherix’s Robust3D machine vision technology has only been available since 2015 when Coherix introduced three new product lines.
Predator3D™

Our Predator3D™ product line performs error-proofing of the dispensing of sealants and structural adhesives. It is primarily used for structural adhesive bead volume and location in body assembly and room temperature vulcanization, used for sealing in engine and transmission assemblies.
Robust3D®
The second product line Coherix introduced in 2015 is called Robust3D, which is the new standard for assembly error-proofing in manufacturing processes. With its self-contained processor, the Tru3D™ sensor, it can be used for several applications.
Currently Tru3D (one sensor in the Robust3D error-proofing product line) is primarily used in the assembly of auto engines. However, any industry that assembles high value products will benefit from using our Robust3D error-proofing products.
| 2 |
Saber3D™
The third product line is called Saber3D, which is a high-speed, in-line inspection product line that eliminates the need for production machines to stop the assembly to perform inspection. Saber3D is the second generation of the 3DX product line, now featuring enhanced “Field of View” resolution and speed characteristics. It is used for very high speed error-proofing of small parts (maximum size 35 millimeters by 35 millimeters) primarily in the semiconductor and electronics manufacturing processes. However, in the future the company intends to introduce Saber3D products with larger Fields of View into other industries which have a need to perform high speed inspection of small objects.
Diverse End-User Markets
Our products can be used in a number of different markets.
Structural Adhesives
The global structural adhesives market grew to approximately $18.3 billion in 2016 with the compound annual growth rate (“CAGR”) anticipated to be approximately 7.9% from 2016 to 2022. High demand for lightweight metals and composites in applications such as automotive, transportation, building and construction and furniture are expected to fuel the overall demand of structural adhesives in future.
Automotive
The International Organization of Motor Vehicle Manufacturers reported global production of 97.3 million motor vehicles in 2017, up 2.4% over 2016. Automobiles and commercial vehicles require precision and consistency in manufacturing. Our error-proofing solutions enable our customers to reduce variation, resulting in consistent high quality. The automotive industry’s need to reduce vehicle weight promotes the joining of light weight dissimilar materials such as magnesium, aluminum, special light weight steel, and composites. The joining of these dissimilar materials cannot be done by traditional joining methods such as welding. Therefore, sophisticated adhesives and sealers have been developed and their use is accelerating in the aircraft, automotive, truck, and other industries. The requirement to know how much adhesive is applied and where it is applied to join dissimilar materials drives the demand for our Predator3D Bead Verification products. Our Predator3D™ products are used in automotive vehicle assembly plants where the auto bodies are constructed. Some classes of body joints are also subject to federal government safety standards requiring 100% error-proofing inspection. Also, in what is called the general vehicle assembly area, Predator3Ds are used to control the glass bonding of windshield and other glass components into the auto body. We call this Predator3D the GlassMaster™. Coherix continually focuses on adding value to improve the end user’s process control. As an example, the distance between the dispensing nozzle tip and the surface of the part is critical to the quality of the bead. Fortunately, Predator3D is designed with lasers all around the dispensing nozzle. Therefore, there are lasers behind the nozzle to inspect the dispensed bead, and there are also lasers ahead of the bead to control a predetermined distance between the nozzle tip and the surface (the distance in the “Z” dimension). To maintain this distance, Predator3D measures the distance continuously and sends Z height dimension offsets to adjust the robot path.
| 3 |
Predator3Ds are also used for error-proofing to control inspection in the manufacturing of doors, hoods, and trunks. To gain additional competitive advantage, the company has developed a special solution product for verifying the correct shape and volume of mastic dots, which are used to prevent the outer skin of a vehicle from fluttering when being driven. We call this special sensor DotMaster™.
Structural adhesives used in automotive are known for providing better adhesion between distinct substrates such as steel and plastics. Thus, these composites are used in doors, window glass attachments, brakes and clutch plates and others. On account of high demand for passenger cars in countries like China and India, the automotive industry requires adhesives with structural integrity and strong bonding properties that is expected to impact the global structural adhesive market growth.
Other auto manufacturing plants build engines and transmissions. These plants are called powertrain plants. Coherix Robust3D solutions are used for error-proofing the engine assembly process. There are several different applications in a powertrain plant. One application uses Predator3Ds to error proof “form in place gaskets.” This dispensed material eliminates the need to design, build, and stock hard gaskets. The company also has Robust3D error-proofing solutions for piston-pin circlips, rolling finger followers, and valve assembly. Additional applications are in development.
Coherix provides accurate and reliable error-proofing powertrain solutions globally to top automotive industry names. A sample list of these customers is Fiat Chrysler Automotive, Ford Motor Company, General Motors, Toyota, Honda, Nissan, Mazda, and SAIC-GM-Wuling Automobile.
The International Organization of Motor Vehicle Manufacturers reports 5 regions of the world accounted for nearly 70% of global motor vehicle production last year.

Management presentation of data derived from International Organization of Motor Vehicle Manufacturers Global Production Statistics.
| 4 |
Semiconductors
According to industry analysts, the global semiconductor market in 2017 was estimated to grow to approximately $377 billion in annual sales. According to World Semiconductor Trade Statistics, the worldwide semiconductor market is expected to increase by 15.7 percent in 2018 after 21.6 percent growth in 2017.
The semiconductor industry produces billions of components/packages per year. Most high value packages need to be inspected in 3D for several types of defects. Since its founding, Coherix has developed in-depth knowledge of the semiconductor industry through close relationships with several customers serving the “back end assembly and test” part of the semiconductor manufacturing process. We believe as the semiconductor industry moves to wafer level packaging (back end), 3D machine vision error-proofing solutions will need to adapt, and Coherix technology will be used to rapidly develop new applications via SHARK and i-Cite because of its high performance and low cost.
The company serves a significant number of industry leaders through its error-proofing solutions. Coherix views the Chinese market as a focused area of expansion in semiconductors due to the Chinese government’s intended investment of up to $161 billion over the next decade to promote domestic chip manufacturers.
In early 2018, Coherix incorporated Coherix China, Inc., a Chinese Wholly Foreign Owned Enterprise, to capitalize on the opportunities that the company believes exist in the automotive and semiconductor business in China. Coherix’s ability to take advantage of the large market in semiconductor has been limited due to lack of growth capital.
Electronics
The company’s understanding of the electronics industry was increased through a joint development project with Panasonic Factory Solutions Co, Ltd. (“Panasonic”), a large electronics manufacturer. Coherix owns the intellectual property (“IP”) developed during this project, and has licensed its IP portfolio to be used solely on one application. The company’s modular SHARK technology platform was developed during this project.
Other Opportunities
Coherix solutions can be applied across a variety of end markets where precision, speed, and automation are paramount. Examples include aircraft manufacturing, solar panels, biotechnology/medical, robot guidance for packaging, etc. Coherix’s strategy has been to first gain critical mass and exposure in the automotive, semiconductor, electronics, and general manufacturing markets with future plans to capitalize on additional end markets. Many of our large system integrators and dispensing customers not only use our products in their primary industries, but they are also beginning to utilize our products in their other industry segments.
Due to continued miniaturization of electronic systems, the error-proofing challenges are becoming more demanding, and therefore, we believe, increasing the need for Coherix’s products. With the increase in growth capital from this offering, the company plans to expand marketing into the electronics industry.
| 5 |
The Offering
| Securities offered: | 2,500,000 shares of Common Stock |
| Number of outstanding shares of Common Stock before the offering: | 13,091,200 |
| Number of shares of Common Stock to be outstanding after the offering: | 15,591,200 |
| Price per share: | $6.00 |
| Maximum offering amount: | $15,000,000 |
| Use of proceeds: | Growth capital and certain debt repayment |
Risk Factors
Our business is subject to a number of risks and uncertainties, including those highlighted in the section titled “Risk Factors” immediately following this summary. These risks include, but are not limited to, the following:
Risks Related to the Company
| · | We have an evolving business model. |
| · | Our auditors have included a “going concern” explanatory paragraph in their audit opinion indicating substantial doubt about the company’s ability to continue as a going concern. |
| · | We are in default with respect to certain of our liabilities. |
| · | Our failure to introduce new products in a successful and timely manner could result in the loss of our market share and a decrease in our revenues and profits. |
| · | Future disruptive new technologies could have a negative effect on our business. |
| · | The loss of a large customer could have an adverse effect on our business. |
| · | A downturn in the semiconductor, electronics, or automotive industries may adversely affect our business. |
| · | Our inability to penetrate new markets may impede our revenue growth. |
| · | Information security breaches or business system disruptions may adversely affect our business. |
| · | The failure of a key supplier to deliver quality product in a timely manner or our inability to obtain components for our products could adversely affect our operating results. |
| · | We do not have agreements with our suppliers and rely on purchase order requests to obtain components for our products; the inability to obtain components for our products could adversely affect our operating results. |
| · | Our products may contain design or manufacturing defects, which could result in reduced demand, significant delays, or substantial costs. |
| · | Our failure to properly manage the distribution of our products and services could result in the loss of revenues and profits. |
| · | If we fail to successfully protect our intellectual property, our competitive position and operating results could suffer. |
| · | Our company may be subject to time-consuming and costly litigation. |
| · | Increased competition may result in decreased demand or prices for our products and services. |
| · | Our business could suffer if we lose the services of, or fail to attract, key personnel and additional personnel. |
| · | Implementation of our joint venture strategy may not be successful, which could affect our ability to increase our revenue or profitability and result in the impairment of acquired intangible assets. |
| 6 |
| · | Global economic conditions may negatively impact our operating results. |
| · | Financial, political, and other risks associated with international sales and operations could adversely affect our business and operating results. |
| · | The status of our joint venture in China is uncertain. |
| · | The trade war between the United States and China may have a negative impact on our business. |
| · | Fluctuations in foreign currency exchange rates could adversely affect our reported results, liquidity, and competitive position. |
| · | Investment in technologies, products, and regions that are unprofitable could have a negative impact on our company. |
| · | Our bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. |
Risks Related to the Offering and Investment
| · | Our stock price may be volatile. |
| · | We have not paid cash dividends on Common Stock in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our Common Stock. |
| · | There is currently no trading market for our Common Stock and we cannot ensure that one will ever develop or be sustained. |
| · | Sales by our significant stockholders could have an adverse effect on the market price of our stock. |
| · | We may need to implement additional finance and accounting systems, procedures and controls as we grow our business and organization and to satisfy new reporting requirements. |
| · | We have not conducted an evaluation of the effectiveness of our internal control over financial reporting and will not be required to do so until we are a public company. If we are unable to implement and maintain effective internal control over financial reporting investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our Common Stock may be negatively affected. |
| · | There may be implications of being an Emerging Growth Company. |
| · | We may not satisfy NASDAQ’s initial quotation standards and, even if we do, we may be removed from quotation in the future. |
| · | Investors in this offering are bound by the governing law and jurisdiction provision contained in the subscription agreement, which limits an investor’s ability to bring lawsuits in connection with this offering. |
| · | Investors in this offering may not be entitled to a jury trial with respect to claims arising under the subscription agreement, which could result in less favorable outcomes to the plaintiff(s) in any action under the agreement. |
| · | You will experience future dilution as a result of future equity offerings. |
| 7 |
The SEC requires the company to identify risks that are specific to its business and its financial condition. The company is still subject to all the same risks that all companies in its business, and all companies in the economy, are exposed to. These include risks relating to economic downturns, political and economic events and technological developments (such as hacking and the ability to prevent hacking). Additionally, early-stage companies are inherently more risky than more developed companies. You should consider general risks as well as specific risks when deciding whether to invest.
We have an evolving business model.
As machine vision technologies evolve, so will our business model. We may continue to try to offer additional types of products and services, and we cannot offer any assurance that any of them will be successful. From time to time we may also modify aspects of our business model relating to our product mix and service offerings. We cannot offer any assurance that these or any other modifications will be successful or will not result in harm to the business. Among the risks associated with the introduction of new products are research and development costs involved in new products, costs associated with launching new products, difficulty predicting customer demand and effectively managing inventory levels to ensure adequate supply of the new product and avoid excess supply of the legacy product. We may not be able to manage growth effectively, which could damage our reputation, limit our growth, and negatively affect our operating results.
We may strategically enter into non-cancelable commitments with vendors to purchase materials for our products in advance of demand to take advantage of favorable pricing or address concerns about the availability of future supplies or long lead times. This practice may expose us to an increased risk of excess or obsolete inventory and resulting charges if actual demand is lower than anticipated. Our failure to effectively manage product transitions or accurately forecast customer demand, in terms of both volume and configuration, has led to, and may again in the future lead to, an increased risk of excess or obsolete inventory and resulting charges.
Our auditors have included a “going concern” explanatory paragraph in their audit opinion indicating substantial doubt about the company’s ability to continue as a going concern.
As indicated in our December 31, 2017 financial statements and our independent auditor’s report, the financial statements have been prepared assuming that the company will continue as a going concern. The company’s ability to continue as a going concern is dependent on our ability to continue with our increased operating cash flow, debt management, and capital raising. The December 31, 2017 financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets, or the amounts and classification of liabilities that may result if we do not continue as a going concern. Therefore, you should not rely on our balance sheet as an indication of the amount of proceeds that would be available to satisfy claims of creditors, and potentially be available for distribution to stockholders, in the event of liquidation.
We are in default with respect to certain of our liabilities.
We are currently in default with respect to certain of our liabilities. These liabilities consist of:
| · | $1,497,087 in principal amount of convertible debentures owed to investors and service providers who accepted notes in lieu of cash payments. Accrued and unpaid interest on these debentures is a current liability. |
| · | $1,973,627 in principal owed to Volvo Group Venture Capital AB (“Volvo”) under a promissory note. Accrued and unpaid interest on the promissory note is a current liability. |
| · | $2,027,139 owed to employees and consultants who agreed to defer all or a portion of their compensation in 2005-2011 under a plan that we refer to as the “Top Hat Deferred Compensation Plan.” |
| · | $849,963, which represents accrued and unpaid cumulative dividends declared by the Board on previously outstanding shares of the company’s preferred stock that were converted into shares of Common Stock in November 2017. |
If we raise all the funds we are seeking under this offering, we intend to use $5 million of the net proceeds to repay all of the above amounts owed under the convertible debentures, 50% of the principal amount owed to Volvo, $1,471,000 of the amount owed under the Top Hat Deferred Compensation Plan and all of the accrued and unpaid dividends. The amount to be repaid under the Top Hat Deferred Compensation Plan does not include accrued interest. These proceeds will not therefore be available to grow our business. See “Use of Proceeds.”
| 8 |
Our failure to introduce new products in a successful and timely manner could result in the loss of our market share and a decrease in our revenues and profits.
The market for our products is characterized by rapidly changing technology. Accordingly, we believe that our future success will depend upon our ability to accelerate time-to-market for new products with improved functionality, ease-of-use, performance, or price. There can be no assurance that we will be able to introduce new products in accordance with scheduled release dates or that new products will achieve market acceptance. Our ability to keep pace with the rapid rate of technological change in the high-technology marketplace could have a material adverse effect on our operating results.
Product development is often a complex, time-consuming, and costly process involving significant investment in research and development with no assurance of return on investment. Research is by its nature speculative and the ultimate commercial success of a product depends upon various factors, many of which are not under our control. We may not achieve significant revenue from new product investments for a number of years, if at all. Moreover, new products may not generate the operating margins that we have experienced historically.
Future disruptive new technologies could have a negative effect on our business.
We are subject to the risk of future disruptive technologies. If new vision technologies develop that are superior to ours, or are perceived to be superior by consumers, it could have a material adverse effect on the company.
The loss of a large customer could have an adverse effect on our business.
Revenue from a single customer, Panasonic, accounted for 38% and 42% of total revenue in 2017 and 2016, respectively, representing the fourth and third years of a ten-year licensing fee arrangement. Customers of this size may divert management’s attention from other operational matters and pull resources from other areas of the business, resulting in potential loss of revenue from other customers. In addition, the loss of a large customer could be difficult to replace with another large customer or numerous smaller customers, and the company may initially experience a sharp drop in revenue. The market leaders in these industries are able to exert purchasing power over their vendors' supply chains, and our large customers in these industries may decide to purchase fewer products from Coherix or stop purchasing from Coherix altogether.
As a large portion of our sales are through resellers, there may be end customers of our resellers that are large consumers of our products. Furthermore, there may be industry leaders that are able to exert purchasing power over their vendors' supply chains, particularly in the automotive and consumer electronics industries. Our expansion within the factory automation marketplace has reduced our reliance on the revenue from any one customer. Nevertheless, the loss of, or significant curtailment of purchases by, any one or more of our larger customers could have a material adverse effect on our operating results.
A downturn in the semiconductor, electronics, or automotive industries may adversely affect our business.
The industries we currently serve in the factory automation market are the semiconductor, electronics, and automotive industries. We are reliant on sales from these industries and therefore our business is impacted by their economic and cyclical trends, including, the level of capital spending and product design cycles. Factors that negatively impact these industries (including those that reduce levels of capital spending or prolong design cycles), could materially and adversely affect our business.
Our inability to penetrate new markets may impede our revenue growth.
We are pursuing applications in machine vision beyond the automotive, semiconductor, and electronics sectors, including expanding to the aircraft manufacturing, packaging, and other general manufacturing sectors. Our growth plan includes successful penetration of these other manufacturing markets. Therefore, our failure to generate revenue in these new markets in the amounts or within the time periods anticipated may have a material adverse impact on our revenue growth and operating results.
| 9 |
Information security breaches or business system disruptions may adversely affect our business.
We rely on our information technology infrastructure and management information systems to effectively run our business. We may be subject to information security breaches caused by hacking, malicious software, or acts of vandalism or terrorism. Our security measures or those of our third-party service providers may not detect or prevent such breaches. Any such compromise to our information security could result in theft of our intellectual property, a misappropriation of our cash or other assets, an interruption in our operations, the unauthorized publication of our confidential business or proprietary information, the unauthorized release of customer, vendor, or employee data, the violation of privacy or other laws, and the exposure to litigation, any of which could harm our business and operating results.
The failure of a key supplier to deliver quality product in a timely manner or our inability to obtain components for our products could adversely affect our operating results.
A significant portion of our product is manufactured by a third-party contractor located in Livonia, Michigan. We do not have a contract with this contractor. We rely on this contractor to provide quality parts and meet delivery schedules. We engage in extensive product quality programs and processes, including actively monitoring the performance of our third-party manufacturers; however, we may not detect all product quality issues through these programs and processes.
Certain components are presently sourced from a single vendor that is selected based on price and performance considerations. We do not have a contract with this vendor. In the event of a supply disruption from a single-source vendor, these components may be purchased from an alternative vendor, which may result in manufacturing delays. Certain key electronic and mechanical components that are purchased from strategic suppliers, such as processors or imagers, are fundamental to the design of Coherix products. A disruption in the supply of these key components, such as a last-time-buy announcement, natural disaster, financial bankruptcy, or other event, may require us to purchase a significant amount of inventory at unfavorable prices resulting in lower gross margins and higher risk of carrying excess inventory. An interruption in, termination of, or material change in the purchase terms of any key components could have a material adverse effect on our operating results.
We do not have agreements with our suppliers and rely on purchase order requests to obtain components for our products; the inability to obtain components for our products could adversely affect our operating results.
We rely on all of our suppliers to provide us with components through the use of purchase order requests and do not have any agreements with the suppliers of our components. If our suppliers do not continue to satisfy our purchase order requests, we may experience a disruption in the supply of components, which could have a material adverse effect on our operating results.
Our products may contain design or manufacturing defects, which could result in reduced demand, significant delays, or substantial costs.
If flaws in either the design or manufacture of our products were to occur, we could experience a rate of failure in our products that could result in significant delays in shipment and material repair or replacement costs. Our release-to-market process may not be robust enough to detect significant design flaws or software bugs. Our product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers and contract manufacturers, may not be sufficient to avoid a product failure rate that results in:
· |
Substantial delays in shipment, | |
· |
Significant repair or replacement costs, | |
· |
Product liability claims or lawsuits, or | |
· |
Potential damage to our reputation. |
Any of these results could have a material adverse effect on our operating results.
| 10 |
Our failure to properly manage the distribution of our products and services could result in the loss of revenues and profits.
We utilize a direct sales force and several integration and distribution channel partners to sell our products and services. For example, we use a network of machine vision system integrators to serve a wide customer base in automotive, aerospace, electronics and other industries. System integrators provide turnkey inspection solutions, consulting, onsite support, and customer training services to deliver innovative machine vision solutions integrating Coherix Robust3D error-proofing solutions, including Predator3D adhesive and sealant bead inspection.
Successfully managing the interaction of our direct and indirect sales channels to reach various potential customers for our products and services is a complex process. In addition, our reliance upon indirect selling methods may reduce visibility to demand and pricing issues. Each sales channel has distinct risks and costs, and therefore, our failure to implement the most advantageous balance in the sales model for our products and services could adversely affect our revenue and profitability.
If we fail to successfully protect our intellectual property, our competitive position and operating results could suffer.
We rely on our proprietary software technology and hardware designs, as well as the technical expertise, creativity, and knowledge of our personnel to maintain our position as a leading provider of machine vision products. Software piracy and reverse engineering, specifically from companies in Russia and Asia, may result in counterfeit products that are misrepresented in the market as Coherix products. To protect our intellectual property, we never embed the core source code in our products and we do not give out the source code, except for customer specific portions associated with joint developments, which makes copying our software difficult. We also rely on patent, trademark, copyright, and trade secret protection, as well as non-disclosure agreements with customers, suppliers, employees, and consultants as well as restricting access to our proprietary information by a combination of technical and internal security measures. These measures, however, may not be adequate to:
· |
Protect our proprietary technology, | |
· |
Protect our patents from challenge, invalidation, or circumvention, or | |
· |
Ensure that our intellectual property will provide us with competitive advantages. |
Any of these adverse circumstances could have a material adverse effect on our operating results.
Our company may be subject to time-consuming and costly litigation.
From time to time, we may be subject to various claims and lawsuits by competitors, customers, or other parties arising in the ordinary course of business, including lawsuits charging patent infringement, or claims and lawsuits instituted by us to protect our intellectual property or for other reasons. These matters can be time-consuming, divert management’s attention and resources, and cause us to incur significant expenses, regardless of the merit of a particular lawsuit or the eventual outcome. Furthermore, the results of any of these actions may have a material adverse effect on our operating results.
Increased competition may result in decreased demand or prices for our products and services.
The machine vision market is fragmented and Coherix’s competitors are typically other vendors of machine vision systems, controllers, and components; manufacturers of image processing systems, sensors, and components; and system integrators. Any of these competitors may have greater financial and other resources than we do. Ease-of-use and product price are significant competitive factors in the factory automation marketplace. We may not be able to compete successfully in the future and our investments in research and development, sales and marketing, and support activities may be insufficient to enable us to maintain our competitive advantage. In addition, competitive pressures could lead to price erosion that could have a material adverse effect on our gross margins and operating results.
| 11 |
Our business could suffer if we lose the services of, or fail to attract, key personnel and additional personnel.
We are highly dependent on the management and leadership of Dwight Carson, our Chief Executive Officer and Chairman of our Board of Directors, and Doug Davison, Chief Technology Officer, as well as other members of our senior management team. Although we have many experienced and qualified senior managers, the loss of key personnel could have a material adverse effect on our company. Our continued growth and success also depends upon our ability to attract and retain skilled employees and on the ability of our officers and key employees to effectively manage the growth of our business through the implementation of appropriate management information systems and internal controls. If we have difficulty attracting and retaining good employees, any such difficulties could materially adversely affect our business.
Implementation of our joint venture strategy may not be successful, which could affect our ability to increase our revenue or profitability and result in the impairment of acquired intangible assets.
We have in the past partnered, and will in the future consider joint ventures with or acquisition of, businesses and technologies in the machine vision industry. Our business may be negatively impacted by risks related to those acquisitions. These risks include, among others:
· |
The inability to find or close attractive acquisition opportunities, | |
· |
The diversion of management’s attention from other operational matters, | |
· |
The inability to realize expected benefits resulting from the acquisition, | |
· |
Difficulties or delays in integrating the personnel, operations, technologies, products and systems of acquired businesses, | |
· |
Disagreements with joint venture partners, | |
· |
The failure to retain key customers or employees, and | |
· |
The impairment of acquired intangible assets resulting from lower-than-expected cash flows from the acquired assets. |
Joint ventures and acquisitions are inherently risky and the inability to effectively manage these risks could have a material adverse effect on our operating results.
Global economic conditions may negatively impact our operating results.
As we have a significant business presence in other countries throughout the world, our revenue levels are impacted by global economic conditions. If global economic conditions were to deteriorate, our revenue and our ability to generate operating profits could be materially adversely affected.
Unfavorable economic condition could negatively impact our business, including the following risks:
| · | Our customers may not have sufficient cash flow or access to financing to purchase our products, |
| · | Our customers may not pay us within agreed upon terms or may default on their payments altogether, |
| · | Our vendors may be unable to fulfill their delivery obligations to us in a timely manner, |
| · | Lower demand for our products may result in charges for excess and obsolete inventory, |
| · | Lower cash flows may result in impairment charges for acquired intangible assets or goodwill, and |
| · | A decline in our stock price may make stock options a less attractive form of compensation and therefore more difficult or expensive for us to retain our employees. |
Our operating results have been materially adversely affected in the past, and could be materially adversely affected in the future, as a result of unfavorable economic conditions and reduced capital spending by manufacturers worldwide.
| 12 |
Financial, political, and other risks associated with international sales and operations could adversely affect our business and operating results.
In 2016, approximately 62% of our revenue was derived from customers located outside of the United States. During 2017, approximately 65% of our revenue was derived from customers located outside of the United States. We intend to continue to expand our sales and operations outside the United States and expand our presence in international markets. As a result, our business is subject to the risks inherent in international sales and operations, including, among other things:
| · | Global political developments, | |
| · | Various regulatory and statutory requirements, | |
| · | Difficulties in injecting and repatriating cash, | |
| · | Export and import restrictions, | |
| · | Transportation delays, | |
| · | Employment regulations and local labor conditions, | |
| · | Difficulties in staffing and managing foreign sales operations, | |
| · | Instability in economic or political conditions, | |
| · | Difficulties protecting intellectual property, | |
| · | Business systems connectivity issues, and | |
| · | Potentially adverse tax consequences. |
Any of these factors could have a material adverse effect on our operating results.
The status of our joint venture in China is uncertain.
In 2015, we formed a joint venture (“JV”) with Dandong Xintai Electric Company Ltd. (“Dandong Xintai”). In connection with the formation of the JV, Dandong Xintai became an investor in Coherix, Inc. and was granted a board seat pursuant to an investors’ rights agreement. When we formed the JV with Dandong Xintai, Dandong Xintai was a listed public company in China; in June 2017, Dandong Xintai was delisted by the relevant Chinese securities authority. In September 2017, the company was told by a Dandong Xintai representative that Dandong Xintai was in bankruptcy proceedings in China. Recently, the company was informed that Dandong Xintai is now in reorganization proceedings in China. The company has not been able to verify whether Dandong Xintai was in bankruptcy or is now in reorganization proceedings under applicable Chinese law.
On September 27, 2017, we delivered a certified letter to Dandong Xintai, terminating the joint venture contract, based on Dandong Xintai’s defaults under the joint venture contract. Dandong Xintai responded to the letter via e-mail on October 10, 2017 and in a formal letter that was delivered to the company on October 17, 2017, objecting to our unilateral termination of the joint venture contract. Shortly after we sent the letter terminating the JV contract, our Board approved the formation of a WFOE in Shanghai. Dandong Xintai, which has a representative on our Board, objected to this decision. Early in 2018, the Board, including the director appointed by Dandong Xintai, provided written authorization to purchase a Shanghai company and we formed a WFOE to sell our products in China. We have a limited number of employees still on the payroll of the JV while we complete the JV’s existing purchase orders. As of June 30, 2018, we also had approximately $455,619 in past due receivables to collect from the JV. Dandong Xintai believes that the establishment of the WFOE may violate the joint venture contract the company has with Dandong Xintai in China. It has indicated it believes it may have rights under the terminated contract. However, as of the date of this Offering Circular, Dandong Xintai has not taken any legal action against the company with respect to this dispute. We cannot predict whether Dandong Xintai’s reorganization, or its objections to our formation of the WFOE and our sales of the company’s products through the WFOE, will affect the company and/or our operations in China.
| 13 |
The trade war between the United States and China may have a negative impact on our business.
Changes in international trade duties and other aspects of international trade policy, both in the United States and abroad, could materially impact our business. For example, China announced 20% tariffs on optical instruments covering our products. A “trade war” of this nature or other governmental action related to tariffs or international trade agreements or policies has the potential to adversely impact demand for our products, our costs, customers, suppliers and/or the US economy or certain sectors thereof and, thus, to adversely impact our businesses.
Fluctuations in foreign currency exchange rates could adversely affect our reported results, liquidity, and competitive position.
Although, the majority of our business is done in US currency, we may face exposure to foreign currency exchange rate fluctuations in the future. We estimate that approximately 3% of our sales in 2016 and 11% in 2017 were invoiced in currencies other than the US Dollar. Changes in the relative strength of the US Dollar (for example, strengthening of the value of the dollar, making our products more expensive) may have a material impact on our operating results.
Investment in technologies, products, and regions that are unprofitable could have a negative impact on our company.
For several years the company has invested heavily in the development of certain technologies and products, as well as in establishing its presence in several global regions to support the global footprints of its large customers (such as General Motors, Ford, and Fiat Chrysler Automotive). This has resulted in several consecutive years of unprofitable operations, although in 2017 the company achieved a net profit. Although the company’s overall financial performance has reached a state of profitable operations, there are no assurances that this trend will continue. Furthermore, to rapidly accelerate global sales of the company’s product lines, the company intends that some of the proceeds from this offering will be used to increase sales and marketing personnel globally, which would increase the operating expenses, and may cause the company to experience net losses.
Risks Related to
the Offering and Investment
We have not paid cash dividends on Common Stock in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our Common Stock.
We have never paid cash dividends on our Common Stock and do not anticipate doing so in the foreseeable future. The payment of dividends on our Common Stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, our Common Stock may be less valuable because a return on your investment will only occur if our stock price appreciates.
There is currently no trading market for our Common Stock and we cannot ensure that one will ever develop or be sustained.
There is no current market for any of our shares of stock and a market may not develop. We hope to eventually apply to list our Common Stock on the Nasdaq Capital Market (“NASDAQ”) if we raise enough money in this offering, but there is no guarantee that we will be able to do so (see “--We may not satisfy NASDAQ’s initial quotation standards and, even if we do, we may be removed from quotation in the future.”). If not quoted on NASDAQ, shares of Common Stock, when issued, may be traded on the over-the-counter market to the extent any demand exists. Even if quoted on NASDAQ, a liquid trading market may not develop. Investors should assume that they may not be able to liquidate their investment for some time, or be able to pledge their shares as collateral.
| 14 |
We may need to implement additional finance and accounting systems, procedures and controls as we grow our business and organization and to satisfy new reporting requirements.
We are required to comply with a variety of reporting, accounting, and other rules and regulations and those rules and requirements will become more extensive if we become a public company. Compliance with existing requirements is expensive. Further requirements may increase our costs and require additional management time and resources. We may need to implement additional finance and accounting systems, procedures and controls to satisfy our reporting requirements. If our internal controls over financial reporting are determined to be ineffective, such failure could cause investors to lose confidence in our reported financial information, negatively affect the market price of our Common Stock, subject us to regulatory investigations and penalties, and adversely impact our business and financial condition.
We have not conducted an evaluation of the effectiveness of our internal control over financial reporting and will not be required to do so until we are a public company. If we are unable to implement and maintain effective internal control over financial reporting investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our Common Stock may be negatively affected.
We hope to list as a public company eventually, and at that time various accounting rules applicable to public companies will apply to us. We can make no assurances that we have the procedures in place to make sure we meet those requirements, and compliance will be a burden. If and when required, our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, at that time, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our Common Stock could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources.
There may be implications of being an Emerging Growth Company.
As an issuer with less than $1 billion in total annual gross revenues during our last fiscal year, we will qualify as an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). An emerging growth company may take advantage of certain reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. In particular, as an emerging growth company, even if and when we become registered with the SEC, we:
| · | Would not be required to obtain an auditor attestation on our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; |
| · | Would not be required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives (commonly referred to as “compensation discussion and analysis”); |
| · | Would not be required to obtain a non-binding advisory vote from our stockholders on executive compensation or golden parachute arrangements (commonly referred to as the “say-on-pay,” “say-on-frequency” and “say-on-golden-parachute” votes); |
| · | Would be exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure; |
| · | Could present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations; and |
| · | Would be eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act. |
We intend to take advantage of all of these reduced reporting requirements and exemptions, including the longer phase-in periods for the adoption of new or revised financial accounting standards under §107 of the JOBS Act. Our election to use the phase-in periods may make it difficult to compare our financial statements to those of non-emerging growth companies and other emerging growth companies that have opted out of the phase-in periods under §107 of the JOBS Act.
| 15 |
Under the JOBS Act, we may take advantage of the above-described reduced reporting requirements and exemptions for up to five years after our initial sale of common equity pursuant to a registration statement declared effective under the Securities Act, or such earlier time that we no longer meet the definition of an emerging growth company. Note that this offering, while a public offering, is not a sale of common equity pursuant to a registration statement, since the offering is conducted pursuant to an exemption from the registration requirements. In this regard, the JOBS Act provides that we would cease to be an “emerging growth company” if we have more than $1 billion in annual revenues, have more than $700 million in market value of our Common Stock held by non-affiliates, or issue more than $1 billion in principal amount of non-convertible debt over a three-year period.
We may not satisfy NASDAQ’s initial quotation standards and, even if we do, we may be removed from quotation in the future.
We hope to eventually apply to quote our Common Stock on NASDAQ. Our Common Stock will not commence trading on NASDAQ until a number of conditions are met, including that we have raised the minimum amount of offering proceeds necessary for us to meet the initial quotation requirements of NASDAQ. There is no guarantee that we will be able to sell a sufficient number of shares to raise the proceeds required. In addition, in order to be quoted on NASDAQ, we will be required to, among other things, file with the SEC a post qualification amendment to the Offering Statement that this Offering Circular is a part of, and then file an SEC Form 8-A in order to register our shares under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The post qualification amendment of the Offering Statement is subject to review by the SEC, and there is no guarantee that such amendment will be qualified quickly after filing. Any delay in the qualification of the post qualification amendment may cause a delay in the initial trading of our Common Stock on NASDAQ. For all of the foregoing reasons, you may experience a delay between the closing of your purchase of our Common Stock and the commencement of exchange trading of our Common Stock, if such trading were ever to be initiated.
In the event we are able to quote our Common Stock on NASDAQ, we will be required to meet certain financial, public float, bid price and liquidity standards on an ongoing basis in order to continue the quotation of our Common Stock. If we fail to meet these continued listing requirements, our Common Stock may be subject to removal from quotation. If our Common Stock were to no longer be quoted on NASDAQ and we could not list or quote our Common Stock on another national securities exchange, we expect our securities would be quoted on an over-the-counter market. If this were to occur, our stockholders could face significant material adverse consequences, including limited availability of market quotations for our Common Stock and reduced liquidity for the trading of our securities. In addition, we could experience a decreased ability to issue additional securities and obtain additional financing in the future.
Investors in this offering are bound by the governing law and jurisdiction provision contained in the subscription agreement, which limits an investor’s ability to bring lawsuits in connection with this offering.
Investors agree to be bound by the governing law and jurisdiction provisions contained in the subscription agreement. These provisions apply to claims that may be made regarding this offering and, among other things, limit the ability of investors to seek remedies outside of the State of Michigan. As such, these provisions may limit an investor’s ability to bring a claim in a judicial forum that the investor believes is favorable for such disputes and may discourage lawsuits with respect to such claims, or investors located outside the State of Michigan may have difficulty bringing a legal claim against the company due to geographic limitations. This limitation is likely to result in increased costs, both in terms of time and money, to individual investors who wish to pursue claims against us.
| 16 |
Investors in this offering may not be entitled to a jury trial with respect to claims arising under the subscription agreement, which could result in less favorable outcomes to the plaintiff(s) in any action under the agreement.
Investors in this offering will be bound by the subscription agreement, which includes a provision under which investors waive the right to a jury trial of any claim they may have against the company arising out of or relating to the subscription agreement, including any claim under the federal securities laws. If we opposed a jury trial demand based on the waiver, a court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by a federal court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of Michigan, which governs the subscription agreement, by a federal or state court in the State of Michigan. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently prominent such that a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the subscription agreement. You should consult legal counsel regarding the jury waiver provision before entering into the subscription agreement.
If you bring a claim against the company in connection with matters arising under the subscription agreement, including claims under federal securities laws, you may not be entitled to a jury trial with respect to those claims, which may have the effect of limiting and discouraging lawsuits against the company. If a lawsuit is brought against the company under the subscription agreement, it may be heard only by a judge of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in such an action.
Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the subscription agreement with a jury trial. No condition, stipulation or provision of the subscription agreement serves as a waiver by any holder of Common Stock or by us of compliance with any substantive provision of the federal securities laws and the rules and regulations promulgated under those laws.
You will experience future dilution as a result of future equity offerings.
We may in the future offer additional shares of our Common Stock or other securities convertible into or exchangeable for our Common Stock. Although no assurances can be given that we will consummate a financing, in the event we do, or in the event we sell shares of Common Stock or other securities convertible into shares of our Common Stock in the future, additional and substantial dilution will occur. In addition, investors purchasing shares or other securities in the future could have rights superior to investors in this offering. Subsequent offerings at a lower price (a “down round”) could result in additional dilution.
| 17 |
The company estimates that, at a per share price of $6.00, the net proceeds from the sale of 2,500,000 shares in this offering will be approximately $14,500,000, after deducting the estimated offering expenses of approximately $500,000 (including marketing, other legal and accounting professional fees, technology fees associated with hosting our offering online and other expenses).
The following table sets forth a breakdown of our estimated use of our net proceeds as we currently expect to use them, assuming the sale of, respectively, 25%, 50%, 75% and 100% of the maximum number of shares offered for sale in this offering.
| 100% Shares | % | 75% Shares | % | 50% Shares | % | 25% Shares | % | |||||||||||||||||||||||||
| Assumed percentage of shares sold | Sold | Total | Sold | Total | Sold | Total | Sold | Total | ||||||||||||||||||||||||
| Gross Proceeds | $ | 15,000,000 | $ | 11,250,000 | $ | 7,500,000 | $ | 3,750,000 | ||||||||||||||||||||||||
| Offering Expenses | $ | 500,000 | 3% | $ | 375,000 | 3% | $ | 315,000 | 4% | $ | 315,000 | 8% | ||||||||||||||||||||
| Global Sales and Marketing | $ | 5,000,000 | 33% | $ | 5,000,000 | 44% | $ | 2,500,000 | 33% | $ | 1,000,000 | 27% | ||||||||||||||||||||
| Debt Reduction | $ | 5,000,000 | 33% | $ | 3,750,000 | 33% | $ | 2,500,000 | 33% | $ | 2,400,000 | 64% | ||||||||||||||||||||
| Product Development | $ | 2,000,000 | 13% | $ | 1,000,000 | 9% | $ | 500,000 | 7% | $ | 0 | 0% | ||||||||||||||||||||
| General Administration | $ | 1,000,000 | 7% | $ | 750,000 | 7% | $ | 375,000 | 5% | $ | 0 | 0% | ||||||||||||||||||||
| Working Capital & All Other General Corporate Purposes | $ | 1,500,000 | 10% | $ | 375,000 | 3% | $ | 1,310,000 | 17% | $ | 35,000 | 1% | ||||||||||||||||||||
| Total Use of Proceeds | $ | 15,000,000 | 100% | $ | 11,250,000 | 100% | $ | 7,500,000 | 100% | $ | 3,750,000 | 100% | ||||||||||||||||||||
The expected use of net proceeds from this offering represents our intentions based on our current plans and business conditions, which could change in the future as our plans and business conditions evolve and change. The amounts and timing of our actual expenditures, specifically with respect to working capital, may vary significantly depending on numerous factors. As a result, the company reserves the right to change the above use of proceeds if management believes it is in the best interests of the company.
In the event we do not sell all of the shares being offered, we may seek additional financing from other sources to support the intended use of proceeds indicated above. If we secure additional equity funding, investors in this offering would be diluted.
Restructuring and repayment of debt
The company is currently seeking a $15 million credit facility for working capital, general corporate purposes, and debt restructuring. We are in the due diligence stage of this negotiation and there is no guarantee the company will be successful in securing the credit facility, and in all events, there can be no assurance that additional financing would be available to use when wanted or needed and, if available, on terms acceptable to us. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – Line of Credit.”
We plan to use certain of the net proceeds of this offering to repay the following debt:
| · | $1,497,087 in principal amount of convertible debentures owed to investors and service providers who accepted notes in lieu of cash payments. |
| · | $1,036,657, representing 50% of the principal and interest owed to Volvo Group under a promissory note. |
| · | $1,471,000 owed to employees and consultants under the Top Hat Deferred Compensation Plan. |
| · | $849,963 in accrued and unpaid dividends to the former holders of shares of our preferred stock. |
| 18 |
Dilution means a reduction in value, control or earnings of the shares the investor owns.
Immediate Dilution
An early-stage company typically sells its shares (or grants options over its shares) to its founders and early employees at a very low cash cost, because they are, in effect, putting their “sweat equity” into the company. Coherix has a long standing and broadly based option grant program with all full time team members participating.
When the company seeks cash investments from outside investors, like you, the new investors typically pay a much larger sum for their shares than the founders or earlier investors, which means that the cash value of your stake is diluted because all the shares are worth the same amount, and you paid more than earlier investors for your shares.
The following table demonstrates the dilution new investors will experience upon investment in the company. The table uses the company’s net tangible book value deficit as of June 30, 2018 of ($18,988,215), which is derived from the net equity of the company per the unaudited interim financial statements reduced by value of intangible assets as presented in this Offering Circular. This tangible net book value is then adjusted to assume the exercise of all options (1,314,140) and warrants (1,171,046) outstanding as of June 30, 2018, as well as the conversion of all convertible debt as of June 30, 2018. Such assumed exercise and conversion would provide $4,718,106 of proceeds and result in the issuance of 2,853,388 shares of Common Stock, which are considered in the figures used in the calculations presented in the table.
The table presents four scenarios: the sale in this offering of 625,000 shares (representing proceeds of $3,750,000); 1,250,000 shares (representing proceeds of $7,500,000), 1,875,000 shares (representing proceeds of $11,250,000) and 2,500,000 shares (representing proceeds of $15,000,000).
| Assuming the sale of offered shares | ||||||||||||||||
| 25% sold | 50% sold | 75% sold | maximum | |||||||||||||
| SHARES OFFERED | 625,000 | 1,250,000 | 1,875,000 | 2,500,000 | ||||||||||||
| Offering price per share | $ | 6.00 | $ | 6.00 | $ | 6.00 | $ | 6.00 | ||||||||
| Offering proceeds before transaction expenses | $ | 3,750,000 | $ | 7,500,000 | $ | 11,250,000 | $ | 15,000,000 | ||||||||
| Offering expenses | $ | 315,000 | $ | 315,000 | $ | 375,000 | $ | 500,000 | ||||||||
| Net proceeds from offering | $ | 3,435,000 | $ | 7,185,000 | $ | 10,875,000 | $ | 14,500,000 | ||||||||
| Adjusted net tangible book value per share before offering | $ | (0.89 | ) | $ | (0.89 | ) | $ | (0.89 | ) | $ | (0.89 | ) | ||||
| Shares issued before the offering assuming full exercise | 15,944,588 | 15,944,588 | 15,944,588 | 15,944,588 | ||||||||||||
| Shares outstanding after the offering assuming full exercise | 16,569,588 | 17,194,588 | 17,819,588 | 18,444,588 | ||||||||||||
| Adjusted net tangible book value per share after offering | $ | (0.65 | ) | $ | (0.41) | $ | (0.19 | ) | $ | 0.01 | ||||||
| Net increase in adjusted net tangible book value per share to original stockholders | $ | 0.24 | $ | 0.48 | $ | 0.70 | $ | 0.90 | ||||||||
| Decrease in investment to new stockholders | $ | 6.65 | $ | 6.41 | $ | 6.19 | $ | 5.99 | ||||||||
| Dilution to new stockholders (%) | 111 | 107% | 103 | 100% | ||||||||||||
The table above excludes 1,767,088 shares available for future issuance under our existing stock option plan. As of June 30, 2018, there were 1,314,140 options granted under the stock option plan but unexercised.
| 19 |
Future Dilution
Another important way of looking at dilution is the dilution that happens due to future actions by the company. The investor’s stake in a company could be diluted due to the company issuing additional shares. In other words, when the company issues more shares, the percentage of the company that you own will go down, even though the value of the company may go up. You will own a smaller piece of a larger company. This increase in number of shares outstanding could result from a stock offering (such as an initial public offering, a venture capital round, angel investment), employees exercising stock options, or by conversion of certain instruments (e.g. convertible bonds, preferred shares or warrants) into stock.
If the company decides to issue more shares, an investor could experience value dilution, with each share being worth less than before, and control dilution, with the total percentage an investor owns being less than before. There may also be earnings dilution, with a reduction in the amount earned per share (though this typically occurs only if the company offers dividends, and most early stage companies are unlikely to offer dividends, preferring to invest any earnings into the company).
The type of dilution that hurts early-stage investors most occurs when the company sells more shares in a “down round,” meaning at a lower valuation than in earlier offerings.
An example of how this might occur is as follows (numbers are for illustrative purposes only):
| · | In June 2017 Jane invests $20,000 for shares that represent 2% of a company valued at $1 million. | |
| · | In December the company is doing very well and sells $5 million in shares to venture capitalists on a valuation (before the new investment) of $10 million. Jane now owns only 1.3% of the company but her stake is worth $200,000. | |
| · | June 2018 the company has run into serious problems and in order to stay afloat it raises $1 million at a valuation of only $2 million (the “down round”). Jane now owns only 0.89% of the company and her stake is worth only $26,660. |
This type of dilution might also happen upon conversion of convertible notes into shares. Typically, the terms of convertible notes issued by early-stage companies provide that in the event of another round of financing, the holders of the convertible notes get to convert their notes into equity at a “discount” to the price paid by the new investors, i.e., they get more shares than the new investors would for the same price. Additionally, convertible notes may have a “price cap” on the conversion price, which effectively acts as a share price ceiling. Either way, the holders of the convertible notes get more shares for their money than new investors. In the event that the financing is a “down round”, the holders of the convertible notes will dilute existing equity holders, and even more than the new investors do, because they get more shares for their money. Investors should pay careful attention to the amount of convertible notes that the company has issued (and may issue in the future, and the terms of those notes.
If you are making an investment expecting to own a certain percentage of the company or expecting each share to hold a certain amount of value, it’s important to realize how the value of those shares can decrease by actions taken by the company. Dilution can make drastic changes to the value of each share, ownership percentage, voting control, and earnings per share.
| 20 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Financial Results
You should read the following discussion and analysis of our financial condition and results of our operations together with our consolidated financial statements and the notes thereto appearing elsewhere in this Offering Circular. This discussion contains forward-looking statements reflecting our current expectations, whose actual outcomes involve risks and uncertainties. Actual results and the timing of events may differ materially from those stated in or implied by these forward-looking statements due to a number of factors, including those discussed in the sections entitled “Risk Factors,” “Statement Regarding Forward-Looking Statements,” and elsewhere in this Offering Circular.
Overview
Since our incorporation in 2003, we have been engaged primarily in the design and manufacturing of 3D vision products for the automotive and semiconductor industries. Among the products offered, the company produces digital holographic imaging and 3D imaging technologies and related equipment that provide “on-the-fly” measurements within very tight tolerances. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. We expect to incur additional net expenses over the next several years as we continue to maintain and expand our existing operations. The amount of future losses and when, if ever, we will achieve sustained profitability are uncertain.
Results of Operations
The company’s operations include Coherix, Inc., and its wholly-owned subsidiaries which include Coherix Asia Pte. Ltd., located in Singapore, Coherix Europe GmbH, located in Germany, Coherix Europe AB, located in Sweden, and, since March 2018, Coherix China, Inc., located in Shanghai China. Coherix Europe AB was liquidated and dissolved on January 22, 2017.
We derive revenues primarily from the purchases of our products and software to be used in manufacturing plants. The company also has a revenue licensing agreement for usage of certain intellectual property. As of June 30, 2018, we have 175 customers.
The company recognizes revenues when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is probable. In instances when a product has to be completed based on customer specifications, revenue is deferred until tested and approved by the customer. Service and machine rental revenue is generally recognized once services are performed or based on the rental term. In the case of contracts with milestones, the company recognizes revenue for contingent consideration earned from the achievement of a substantive milestone in the entirety in the period in which the substantive milestone is achieved. The company also has a revenue licensing agreement for usage of certain intellectual property. Licensing from the usage of the intellectual property is recorded based on a third party’s use of the property, on a licensing fee per item sold basis.
Results of Operations for the Years Ended December 31, 2017 and December 31, 2016
Net Revenue
Net revenues were $9,383,866 for the year ended December 31, 2017, an increase of 89% or $4,421,563, compared to $4,962,303 in 2016. Predator3D sensor revenues grew by $2,617,562, growing to a level more than five times that of the prior year sales, primarily as a result of new business in adhesive dispenser controls and continued growth in automotive auto body and powertrain error-proofing applications. License fees increased $1,416,780 and sales in semiconductor error-proofing applications accounted for another $600,000 in increased 2017 revenues.
| 21 |
Cost of Revenues
Cost of revenues consists of material, labor and overhead. Cost of revenues increased from $1,179,442 in 2016 to $2,202,011 in 2017. The increase is due to the costs associated with the higher Predator3D sensor revenue and the semiconductor error proofing application revenue over the prior year. The company’s gross profit percentage increased slightly from 76.2% in 2016 to 76.5% in 2017.
Operating Expenses
Company operating expenses grew from $5,320,961 in 2016, to $5,749,249 in 2017. The primary components of our operating expenses are product development, sales and marketing, and general administrative costs.
The growth in operating expenses was driven by a US-based sales and customer support expense increase of $853,056, partially offset by a reduction in R&D project expenses of $260,907 related to the timing of new product investments. The company expects a significant use of the net proceeds of the offering will be to expand sales and customer support investments in key overseas industrial markets to increase revenue growth.
Operating Income (Loss)
Operating income increased to $1,433,606 for 2017, or 15.3% of net revenues, an improvement from an operating loss of ($1,538,100) or (31%) of net revenues for 2016.
Interest Expense
Interest expense increased 11% from $1,125,850 in 2016 to $1,251,772 in 2017, as financing activities continued to include an increase in interest based long-term debt, line of credit borrowings and capital lease financing. The company expects to use some of the net offering proceeds to retire current debts and certain note holders to convert to Common Stock, which will begin to reduce interest expense.
Net Income (Loss)
As a result of the foregoing factors, the company achieved profitability, recording net income of $293,250 in 2017, compared with a net loss of ($2,658,370) in 2016.
Results of Operations for the Six Months Ended June 30, 2018 and June 30, 2017
Net Revenue
Net revenues were $5,740,643 for the six months ended June 30, 2018, an increase of 47% or $1,830,294, compared to $3,910,349 in net revenues for the six month period ended June 30, 2017. Predator 3D sensor revenues grew by $1,834,052, driven primarily by increased revenue from two key North American automotive companies and our first sales in China by team members in our WFOE. License fees increased approximately $500,000 in the first six months of 2018 from the amounts earned in the equivalent period in 2017. Offsetting the increase in Predator 3D sensor and license fees, the company saw a reduction of $503,758 in sales in semiconductor error-proofing applications.
Cost of Revenues
Cost of revenues increased to $1,327,618 for the six months ended June 30, 2018 from $912,248 during the six months ended June 30, 2017. The $415,370 increase is due to the costs associated with the higher Predator 3D sensor revenue offset by the reduction in the semiconductor error-proofing applications revenue over the prior year. The company’s gross profit percentage increased slightly to 76.9% for the six month period ended June 30, 2018 compared to 76.7% in the six month period ended June 30, 2017.
| 22 |
Operating Expenses
Company operating expenses grew just over $1 million to $3,680,325 in the first six months of 2018 compared to $2,659,115 during the first six months of 2017. Current year expense includes an increase in accounting and legal professional fees related to two current year initiatives: the opening in the first quarter of 2018 of the China-based WFOE which also accounted for about $170,000 in new sales, general and administrative and engineering operating expenses as we added our first employees in China and the restructuring of the outstanding debt which required the audits of the 2016 and 2017 financial results. The remainder of the increase was primarily higher compensation and commission expenses related to the higher revenues during the first half of 2018.
Operating expenses as a percentage of net revenues declined to 64.1% of 2018 period revenues from 68% of six-month 2017 revenues.
Operating Income
Operating income increased to $732,700 for the first six months of 2018, or 12.8% of revenues, up from $338,986 or 8.7%, for the first six months of 2017.
Interest Expense
Interest expense declined slightly to $647,872 in the first six months of 2018, due to higher line of credit interest costs, offset by a decrease in long term borrowings.
Net Income (Loss)
The company achieved profitability, recording net income of $95,043 during the first six months of 2018, compared to a net loss of ($330,046) during the first six months of 2017.
Cash Flows
Years Ended December 31, 2017 and December 31, 2016
Net Cash Used in Operating Activities
Improved profitability enabled the company to reduce net cash used in operating activities to $143,497 in 2017 from $1,346,008 in 2016.
Net Cash Used in Investing Activities
Net cash used in investing activities was $508,849 and $6,740 in 2017 and 2016, respectively. In 2017 the company financed an advance of $505,275 for the establishment of a WFOE in China, a large potential market for Coherix solutions.
Net Cash Provided by Financing Activities
Net cash provided by financing activities were $1,080,518 and $1,136,992 in 2017 and 2016, respectively. Proceeds from long-term debt issuance and net borrowings on lines of credit combined contributed $1,461,396 and $902,242 in 2017 and 2016, respectively. Noncash financing activities in 2017 included $5,201,798 of conversions of long- term debt and accrued interest into shares of Common Stock, most of which occurred near the end of 2017.
| 23 |
Six Months Ended June 30, 2018 and June 30, 2017
Net Cash Used in Operating Activities
For the six months ended June 30, 2018, net cash used in operating activities was $445,528, an increase over the net cash used in operating activities of $275,874 in the comparable 2017 period. Operating cash generation, as a result of this year’s net income, was more than offset by a growth in inventories of $722,343 added to support the expected revenue growth.
Net Cash Provided by (Used in) Investing Activities
Net cash provided by investing activities for the six months ended June 30, 2018 was $413,509, an increase over the net cash used in investing activities of ($3,216) for the comparable 2017 period. In March 2018, the $505,275 advance made to establish a Chinese subsidiary in 2017 was transferred to a WFOE and is now reflected in the consolidated company cash as a result of the purchase of the WFOE. Offsetting this cash item is the purchase of property and equipment.
Net Cash Provided by (Used in) Financing Activities
Net cash used in financing activities for the six months ended June 30, 2018 was $172,712 as compared with net cash provided by financing activities in the corresponding 2017 period of $64,277. A reduction in net borrowings under line of credit agreements of $366,633, partially offset by lower payments on long-term debt of $77,865 and capital lease obligations of $41,998 negatively impacted net cash flows from financing activities. Noncash financing activities in the first six months of 2018 included $193,336 of conversions of long-term debt and accrued interest into shares of Common Stock.
We expect to pay down certain debt with the net proceeds from this offering.
Liquidity and Capital Resources
As of June 30, 2018, the company had cash on hand of $694,790. Funding for the company to date has come primarily from debt.
Line of Credit
As of June 30, 2018, the company had a $3 million revolving line of credit with Crestmark Bank. At June 30, 2018, the company had drawn down $1,688,293 under this line of credit. The line of credit is personally guaranteed by the company’s CEO. In October 2018, Crestmark Bank amended the company’s line of credit, increasing the line to $4 million and increasing monthly payments to $250,000 per month. As of October 15, 2018, the company has $1 million credit available under this line. See Note 9 to the company’s unaudited interim financial statements for further information. The company may replace this line of credit under the terms of the new credit facility that the company is currently in due diligence with United Capital Partners LLC. The term sheet for the new credit facility provides for a $15 million credit facility that consists of a $5 million revolving credit line and a $10 million 5-year term loan debt facility, on which the company would only make payments of interest during the first year, with principal amortized over the last four years. There can be no guarantee that the company will enter into this new line of credit.
Promissory Notes; Long-term Debt Instruments
In 2015, the company entered into promissory notes due in 2018 that bore interest at the rate of 8% per year, together with warrants with an exercise price of $3.75 for every $100,000 in principal amount of notes issued. During the first six months of 2018, the company was successful in refinancing approximately $3.1 million of the 2015 notes with 25 different noteholders with new promissory notes due in 2021. In August 2018, the company entered into an additional promissory note due in 2021 for $250,000 and issued an additional 40,000 warrants with an exercise price of $5 to one new investor.
| 24 |
Since June 30, 2018, the company has received $190,000 in loan proceeds from existing investors. The loans pay 10% annual interest on a monthly basis and principal payments are due in July 2020. The proceeds of these loans were used to fund the purchase of materials to build products to meet shipment demands.
Since inception, the company has also funded its operations through the issuance of long-term debt instruments, with existing investors. At June 30, 2018, long-term debt amounted to $11,706,251, of which the current portion was $5,975,345. Convertible notes in the amount of $1,497,087 are past due. A promissory note with Volvo in the principal amount of $1,973,627 is past due and in default. See Note 5 to the company’s unaudited interim financial statements. The company intends to use a portion of the net proceeds of this offering to repay the past due principal on the convertible notes and to pay 50% of the outstanding principal and interest due on the Volvo promissory note. See “Use of Proceeds.” Volvo has informed the company that, upon repayment of 50% of the outstanding principal and interest, it intends to convert the remaining principal and interest into Common Stock of the company.
Sale Leaseback Program
The company has a sale leaseback program with North Coast Capital Corporation to fund demonstration equipment used to promote the company’s products. The company has three lease programs active with North Coast Capital Corporation with total balances due of $487,933 as of June 30, 2018 and monthly payments of $12,670. This program has generated $880,250 in new capital to the company since beginning the program in December 2013.
Other Debt
In September 2013 when investor convertible debt matured, $1,832,861 in convertible debt and accrued interest were converted into promissory notes due in 2020, which pay 4% annual interest on a quarterly basis, with principal payments amortized over the last five years of the notes. As of June 30, 2018, the balance due on these promissory notes was $615,995.
The company was successful in qualifying and closing five EB-5 investments with Green Detroit Regional Center (“GDRC”). Under this program, the company has notes payable to GDRC totaling $2,500,000, representing five (5) EB-5 investors. The company pays GDRC 4% annual interest, which is paid quarterly. The company will not commence principal payments under each note until each respective EB-5 investor has satisfied all conditions to receive a permanent green card. As of the date of this Offering Circular, the company is not yet obligated to repay any of these notes.
As of June 30, 2018, the company has $1,901,458 in balances due under term loans with maturity dates that were six, twelve, eighteen and 24 months from the date of issuance. These loans pay between 10% and 16% annual interest on a monthly basis and mature between February 2019 and August 2020. The company intends to retire this debt using a portion of the term loan debt facility with United Capital Partners LLC (if the company enters into such facility) and/or cash flow from operations. A portion of this balance, $780,069, is being amortized over 18 months, with principal and 10% annual interest currently being paid monthly. The company plans to pay off higher interest term loan debt first and upon maturity of the loans.
Debt Repayment
We anticipate that the level of funding in this offering and planned new long-term debt will be used for:
| (USD thousands) | ||||||
Balances at June 30, 2018 |
Principal | Accrued | Potential Equity | Debt | Unpaid | |
| Description | Priority | Outstanding | Interest | Conversion | Repayment | |
| Volvo Debt | 1 | $1,974 | $100 | ($1,037) | ($1,037) | $ – |
| Convertible Debentures | 2 | 1,497 | – | – | (1,497) | – |
| Deferred Compensation | 3 | 1,471 | 2,376 | – | (1,471) | 2,376 |
| Accrued Preferred Stock Dividends | 4 | 850 | – | – | (850) | – |
| Investor Accrued Interest | 5 | – | 3,728 | – | – | 3,728 |
| Total Debt | $5,792 | $6,204 | ($1,037) | ($4,855) | $6,104 |
| 25 |
Quantitative and Qualitative Disclosures about Market Risk
In the ordinary course of our business, we have operations outside the United States. Operations outside the United States are subject to risks inherent in operating under different legal systems and various political and economic environments. Among the risks are changes in existing tax laws, possible limitations on foreign investments and income repatriation, government price or foreign exchange controls, and restrictions on currency exchange. The company does not engage in hedging activities to mitigate its exposure to fluctuations in foreign currency exchange rates.
Coherix Asia Pte. Ltd., which is located and operates in Singapore, keeps its books and records in US Dollars (“USD”). The functional currency of Coherix Asia Pte. Ltd. is USD. Coherix Europe AB (now dissolved), which was located and operated in Sweden, kept its books and records in Swedish Krona (“SEK”), and Coherix Europe GmbH, which is located and operates in Germany, keeps its books and records in the Euro (“EUR”) and Coherix China, Inc., which is located and operates in China, keeps its books and records in the Chinese Renminbi (“RMB”). The functional currency of Coherix Europe is the EUR, the currency of the primary economic environment in which each respective subsidiary operates. Accordingly, Coherix Europe AB’s, Coherix Europe GmbH’s and Coherix China, Inc.’s financial information is translated from SEK, EUR and RMB, into USD. Assets and liabilities of each of these three entities are translated into USD based on each prevailing exchange rate at each respective balance sheet date. Revenue and expenses are translated into USD based on the average exchange rate for the respective periods. Cumulative translation adjustments are included as a separate component of stockholders’ equity in accumulated other comprehensive income (loss). Currency transaction gains or losses are generally derived from cash, receivables and payables that are stated in a currency other than the local currency, and are recognized as income or expense.
Contingencies
Certain conditions may exist as of the date the financial statements were issued, which may result in a loss to the company, but which will only be resolved when one or more future events occur or fail to occur. The company’s management, in consultation with its legal counsel as appropriate, assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the company or unasserted claims that may result in such proceedings, the company, in consultation with legal counsel, evaluates the perceived merits of any legal proceedings or unasserted claims, as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the company’s financial statements. If the assessment indicates a potentially material loss contingency is not probable, but is reasonably possible, or is probable, but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.
| 26 |
Relaxed Ongoing Reporting Requirements
At some point after the completion of this offering, we expect to seek to qualify our Common Stock for quotation on NASDAQ and elect to become a public reporting company under the Exchange Act. If we elect to do so, we will be required to publicly report on an ongoing basis as an “emerging growth company” (as defined in the JOBS Act) under the reporting rules set forth under the Exchange Act. For so long as we remain an “emerging growth company”, we may take advantage of certain exemptions from various reporting requirements that are applicable to other Exchange Act reporting companies that are not “emerging growth companies”, including but not limited to:
| · | not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act; | |
| · | taking advantage of extensions of time to comply with certain new or revised financial accounting standards; | |
| · | being permitted to comply with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and | |
| · | being exempt from the requirement to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. |
We expect to take advantage of these reporting exemptions
until we are no longer an emerging growth company. We would remain an “emerging growth company” for up to five years,
although if the market value of our Common Stock that is held by non-affiliates exceeds $700 million as of any June 30 before
that time, we would cease to be an “emerging growth company” as of the following December 31.
If we do not become a public reporting company under the Exchange Act for any reason, we will be required to publicly report on an ongoing basis under the reporting rules set forth in Regulation A for Tier 2 issuers. The ongoing reporting requirements under Regulation A are more relaxed than for “emerging growth companies” under the Exchange Act. The differences include, but are not limited to, being required to file only annual and semi-annual reports, rather than annual and quarterly reports. Annual reports are due within 120 calendar days after the end of the issuer’s fiscal year, and semi-annual reports are due within 90 calendar days after the end of the first six months of the issuer’s fiscal year.
In either case, we will be subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not “emerging growth companies”, and our stockholders could receive less information than they might expect to receive from more mature public companies.
| 27 |
OVERVIEW OF MACHINE VISION INDUSTRY
Introduction to Machine Vision
Machine vision involves the ability of a computer to observe, inspect, and scrutinize work performance by employing one or more imaging sensors, digital signal processing and analog to digital conversion. The captured data is then transferred to a computer to analyze and provide the desired output. Resolution and sensitivity are two important aspects of any machine vision system. Resolution is responsible for differentiating between objects whereas sensitivity is the machine’s ability to detect objects or weak impulses despite dim lights or invisible wavelengths.
Machine vision particularly assists in supervising work environments. It offers features such as process control, robotic guidance, and automatic inspection in industrial applications. Industrial production and manufacturing activities are becoming increasingly complicated day-by-day, creating difficulties and increasing unreliability for the human eye to keenly detect, observe, and examine production activities. Machine vision systems deploy smart cameras and image processing to perform measurements and inspections.
The intensifying need for superior inspection and increasing automation are the key influencing factors paving the way for the notable adoption of machine vision technology. Furthermore, the company believes that the need for increased quality control by consumers and manufacturers, coupled with government regulations to abide by prescribed specifications, is expected to significantly increase the adoption of machine vision technology.
The following chart describes the various products and technology in the industry.
| Solution | 3D Error-proofing | Human Inspection | 2D | Touch Probes |
| Attributes |
· Leading method of high speed in-line 3D solutions · Low-maintenance, limited set up time and significantly lower cost of ownership · Offers near 100% reliability, accountability, and traceability · Shatterproof resistant and resilient to all elements of manufacturing |
· Only >85% accurate in real-world applications · Costly manual labor · Highly prone to error, depending on employee experience · Visual and sight limitations |
· Depends on presence of color contrast to depict an accurate image · Temperamental and error prone · Affected by dust, grease, and other manufacturing elements · Results in false readings and “no reads,” causing gaps in inspection · Less flexible to the manufacturing environment |
· Cost prohibitive · Constant maintenance/ calibration · High degree of programming is required |
Hardware and Software
The machine vision industry has been segregated into hardware and software segments. Hardware components comprise several components such as cameras, sensors, processors, frame grabbers, LED lightings, optics, and others. The market for software is application-specific and fragmented based on the necessity of application.
| 28 |
Software Applications
With regard to applications, the market has been segmented into quality assurance and inspection, positioning and guidance, measurement, and identification. The systems are extensively used for scanning and identifying labels, barcodes, and texts, especially in the packaging sector. This automates packaging activities, thereby saving time, avoiding human errors, and increasing efficiency. The technology is frequently used in the consumer goods, pharmaceutical, and packaging sectors.
Identification using machine vision is also used in camera surveillance, monitoring traffic, or recognizing license plate numbers for security purposes.
The following chart details the global machine vision market revenue by application in 2016 (%):

Hardware Products
The product segment can be sub-categorized into personal computer (“PC”) based products and independent smart camera systems. The PC based systems accounted for the largest market share in 2016. However, the smart camera based systems are projected to exhibit a robust growth rate over the forecast period. The segment is projected to grow at the fastest rate of 8.9% from 2017 to 2025. This considerable growth of the segment is attributable to the growing adoption of cameras in 3D imaging.
Regional Trends
The Asia Pacific region accounted for the largest share in the machine vision market in 2016. The company believes that the region will experience considerable growth and will continue to grow at a robust rate from 2017 to 2025. We believe this large market share and regional growth can be accredited to the lucrative opportunities in automotive, packaging, pharmaceutical, and other industrial applications in the Asia Pacific region.
As the region is establishing itself to become a global manufacturing hub, the technology is anticipated to gain significant traction over the forecast period. China and Japan are prominent countries which offer extensive opportunities for the emerging as well as matured technologies such as machine vision. The numerous manufacturing industries are contributing to the growth and prosperity of the region’s overall economic development.
In addition to this, the expenditure and operational benefits coupled with the initiatives being undertaken by the governments of emerging countries, such as South Korea, India, Taiwan, and Singapore, are responsible for catapulting investments and encouraging different industry players to establish their production units in the Asia Pacific region.
Furthermore, increasing investments are being carried out in research and development activities to improve machine vision technology and related developments, and prominent players are undertaking strategic initiatives such as distribution alliances, partnerships, mergers, and acquisitions. As such, all these factors are expected to propel the growth of machine vision market in the Asia Pacific region.
| 29 |
Company Information
The company was organized on October 30, 2003, as a corporation under the laws of the State of Delaware. The company was formed as RealCite Inc. and subsequently changed its name to Coherix, Inc. We have not participated in any bankruptcy, receivership, or similar proceeding. We have not had any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets not in the ordinary course of business.
Coherix was founded with the vision of becoming the world’s first true 3D machine vision company. Upon the inception of the company, founder Dwight Carlson assembled a team of former co-founders and managers from prior industry leading high technology companies that he founded, Perceptron (NASDAQ GM:PRCP) and XYCOM. The company employs a core strategy to displace incumbent 2D technology by offering more capable and cost-effective 3D solutions to solve critical manufacturing problems that the resulting solutions will sell in high volume.
Market Overview
Eyes of Automation
Error-proofing of high value assemblies is generally accomplished by human inspection, use of touch probes, 2D machine vision, and 3D machine vision. Machine vision, generally, is the technology and methods used to provide imaging-based automatic inspection and analysis, for process control, and robot guidance.
There are two general components to 3D machine vision—hardware and software. The products are either PC based or smart camera based. The application of machine vision is generally meant to accomplish:
| · | Quality assurance | |
| · | Positioning and guidance | |
| · | Measurement | |
| · | Identification |
Coherix's products act as the “Eyes of Automation” and today are primarily focused on automotive, semiconductor, electronics manufacturing, and general manufacturing, in which we are an important component of error-proofing automation systems. Coherix sells its products either directly to large end-users or through a number of channel partners. For example, large end users, such as global automotive companies, purchase factory automation systems from a variety of large global system integrators. In turn, these system integrators purchase Coherix solutions and incorporate them into their automation systems. Coherix also has significant relationships with smaller regional system integrators.
The company has other channel partners, including large global adhesive and sealant dispensing equipment companies such as Nordson, Durr, Graco, and Atlas Copco, among other smaller and more regional dispensing equipment companies.
In July 2018, Nordson developed a new dispensing controller product and integrated Coherix Predator3D to provide a fully integrated dispensing system with 3D vision capabilities. This new dispensing system is called the Process Sentry™ Integrated Vision System, providing instant quality feedback on 3 dimensional beads and dispense patterns, for higher production confidence. The system includes a vision dispense gun, Coherix sensor and bead confirmation software, integrated directly into the main system controller.
Coherix's products can help manufacturers who produce high volume assemblies achieve better quality and manufacturing efficiencies by using Coherix 3D error-proofing solutions. To date, Coherix has focused on serving end markets in which Coherix products are mission critical due to customer quality standards, industry standards, and government safety standards.
| 30 |
Principal Product/Services
Technology
Shortly after its inception in 2003, the company acquired a distinct software platform which would become the basis for the company’s 3D machine vision technology: i-Cite3D. Coherix purchased the company, Machine Vision Products Inc. to obtain the i-Cite™ Machine Vision software platform in 2004. The i-Cite 3D software platform development began in 1995 and currently contains over 200 proprietary, highly optimized, field-tested vision modules performing various types of inspection. I-Cite enables rapid creation of new applications and facilitates rapid prototyping. This intuitive and easy-to-use software platform supports all the company’s product lines: Predator 3D™ Saber 3D™, and Robust 3D®).
Our In-Line Inspection / Error-Proofing Solutions
Error-proofing inspection is aimed at assuring that there are zero defects in complex assemblies. Error-proofing is increasingly critical as manufacturers need to meet ever increasing customer demands. The company’s products respond to the market demand for shorter time to market, and more stringent government regulations.
Currently our three main product lines providing error-proofing solutions are the Predator3D, the Robust3D and the Saber3D.
The Predator3D
The Predator3D provides a robust 3D solution used to inspect and control the process of dispensing adhesives and sealants. Four 3D sensors in a compact disc shaped module are installed around the dispensing nozzle allowing for fast and precise bead verification.
Selected Features:
| · | Four 3D laser sensors accurately inspect the dispensed adhesive bead to 0.1 mm accuracy. |
| · | High speed integrated image processing and data transmission capabilities enable high speed 3D bead inspection to be performed at speeds up to 1,000 mm per second. |
| · | Predator3D fits seamlessly around the dispensing nozzle providing 360 degree bead verification with no need for remote expensive factory hardened computer systems. |
| 31 |
Differentiating Factors:
| · | Proven and reliable: machined aluminum casing makes it a factory hardened 3D solution providing immediate feedback on bead volume, shape, and location. |
| · | Once and Done: Four high speed 3D lasers sensors inspect the adhesive bead as it is being dispensed eliminating unscheduled downtime, which increases the throughput of the manufacturing process while significantly improving quality. |
| · | Easy to Integrate: Compact including sensors and processor, and is installed directly on robot and surrounds dispensing nozzle. |
| · | Rugged: Crash resistant machined aluminum ensures durability in rough manufacturing environments. |
Not impacted by changes in ambient light or part color, typically a serious problem for 2D vision systems in manufacturing environments.
Applications:

Indicative Manufacturer’s Problem:
A Tier 1 automotive supplier required a robust 3D solution to replace a dysfunctional 2D bead inspection system. The incumbent technology missed detecting gaps in sealing beads, which caused line stoppage and costly re-work. Also, if not discovered the customer risked a defective vehicle going to its end customer.

Coherix’s Solution to the Manufacturer’s Problem:
Coherix demonstrated its 3D capabilities to the original equipment manufacturer, or “OEM”, proving Predator3D provides the required accuracy, critical process information and delivers the required near 100% reliability.
Result of Coherix’s Solution of Utilizing the Predator3D:
Predator3D’s performance resulted in dollar savings and, most importantly ensured that the federal safety requirements were met. Coherix, by virtue of these results, was able to demonstrate this capability to the OEM’s Supplier Quality management, and secured additional business with other Tier 1 suppliers to this OEM.
| 32 |
A partial list of our Predator3D customers includes:
| · | Fiat Chrysler Automobiles |
| · | Ford |
| · | Gestamp |
| · | Toyota |
| · | Nordson |
| · | Atlas Copco |
| · | Continental Structural |

Robust3D high speed in-line error-proofing solutions are flexible and self-contained 3D vision systems meeting stringent inspection and error-proofing requirements. These products eliminate the problems with 2D vision solutions which have attempted to deliver this capability but failed do to so due to unpredictable exposure to noise, changes in ambient light and part color which causes contrast challenges.
Differentiating Factors:
| · | Robust3D solutions deliver real time 3D manufacturing process performance information to eliminate defects. |
| · | Robust3D architecture: Generates 3D models from a single sensor, providing ultimate flexibility. |
| · | Self-contained: Lighting, optics and processing all contained onboard a durable factory hardened product. |
| · | Easy to Use: One second acquisition time simplify setup and eliminates frequent adjustments typically required with 2D vision systems. |
| · | Versatile: Can be configured for a variety of error-proofing needs with software supporting measurements and positioning. |
Applications:

Indicative Manufacturer’s Problem:
A global automotive company was using unreliable 2D vision cameras to inspect their engine piston assemblies, which failed when changes in ambient lighting or part color changes occurred. The incumbent 2D vision cameras were continuously delivering nuisance false failures, unnecessarily stopping the line and reducing manufacturing throughput (volume).
| 33 |

Coherix’s Solution to the Manufacturer’s Problem:
The Coherix Robust3D solution delivered near 100% reliable verification of the piston assembly eliminating nuisance failures.
Result of using the Coherix Robust3D Solution:
After solving the problem, the customer is implementing Coherix Robust3D piston assembly verification systems in their manufacturer’s bill of process, resulting in installations being made in their engine manufacturing lines around the world.
Our Robust3D customers include:
| · | Cummins |
| · | Fiat Chrysler Automotive |
| · | Ford Motor Company |
| · | SAIC-GM-Wuling Automobile |
| · | Federal Mogul |
The Saber3D high-speed, in-line inspection product line eliminates the need for production machines to stop the assembly to perform inspection. Saber3D is the second generation of the 3DX product line, now featuring enhanced “Field of View” resolution and speed characteristics. Reducing defects increases manufacturing throughput, resulting in improved customer profits.
Selected Features:
| · | 3D high-definition, high speed inspection capability. |
| · | Point and shoot capability needing no lasers, or line scanning. |
| · | High speed freeze frame data acquisition. |
| 34 |
Differentiating Factors:
| · | High Definition 3D: Multi-stereo technology increases the fidelity of information. |
| · | Snapshot measurements: used for high speed applications such as semiconductors. |
| · | Built-in Lighting: Multi-spectral LED lighting provides increased accuracy of measurements. |
| · | Self-contained: No external computing or hardware changes required for use. |
Applications:

Indicative Manufacturer’s Problem:
An electronics manufacturer’s assembly division required a 3D vision system to provide accurate 3D error-proofing within its manufacturing system. In addition to accuracy, the new vision system needed to be ultra-high speed to keep up with demands of the electronics industry.
Coherix’s Solution to the Manufacturer’s Problem:
Leveraging its core software and hardware platforms, Coherix developed a self- contained, high definition 3D vision system. Multiple stereo sensors and a state-of-the-art lighting system allowed Coherix to meet the precision and definition needs of the manufacturer and its end users.
Result of Coherix’s Solution of Utilizing the Saber3D:
The high-speed Saber3D system was designed in conjunction with the manufacturer and tailored to meet precision production needs. Notably, the speed and reliability of Coherix’s Saber3D technology enabled the customer to strengthen its position as the market-leading electronic assembly machines manufacturer.
A partial list of our customers includes:
| · | UST Technology Pte. Ltd. |
| · | Epson |
| · | Panasonic |
| · | Exatron |
| · | Pentamaster |
| · | MCT Worldwide LLC |
| · | System General |
| · | HTC |
| · | Tek Inc. |
| 35 |
Legacy Products
A portion of Coherix’s revenue comes from legacy products. The company has an agreement with Diamond International to supply previously developed software for their egg sorting machines. The software has been stable for several years requiring little support.
Another legacy product is ShaPix®. This holographic based product is a metrology product. It is highly specialized and addresses a small market segment. Today, the annual revenue is less than $1 million. The company will continue to support ShaPix products; however, the company does not intend to focus sales efforts to promote ShaPix products. The company is looking for a metrology equipment company to partner with to leverage its ShaPix technology.
University of Michigan
Over the past two decades, members of Coherix’s management have developed a close relationship with the University of Michigan (the “University”). Members of Coherix’s management and Board of Directors currently serve on the University’s advisory boards, teach, or have studied there. Coherix also employs interns upon graduation.
Professor Jun Ni
Professor Jun Ni is a Coherix Board member, and is the Director of the University of Michigan Manufacturing Research Center. He also serves as Dean of the Multi-Campus National Science Foundation Center for Intelligent Maintenance Systems. For nine years Professor Ni served as Dean of the University of Michigan/Shanghai Jiao Tong University Joint Institute. This relationship supports both Coherix and Coherix China.
In addition the company has strategic relationships with large global dispensing companies who have fully integrated Coherix products in their dispensing systems.
Competition
The machine vision market is fragmented and our competitors are typically other vendors of machine vision systems, controllers, and components; manufacturers of image processing systems, sensors, and components; and system integrators. In addition, in the semiconductor and electronics capital equipment market, and with respect to machine builders in the factory automation market, we compete with the internal engineering departments of current or prospective customers. General purpose machine vision competitors with global presence and are primarily 2D vision companies include Cognex, Keyence, and Omron. Smaller European competitors such as ISRA, Quiss and VMT have been in existence longer than Coherix, therefore, they have higher customer visibility.
Coherix’s ability to compete depends upon our ability to identify specific market niches where 3D vision technology can solve a very difficult industry need and the resulting solutions sell in high volume. The company’s competitive advantage is its experience to create, innovate, design, manufacture, and sell high-quality 3D vision products globally, as well as our ability to develop new products and functionality that meet evolving customer requirements. The primary competitive factors affecting the choice of a 3D machine vision solution include vendor reputation, product functionality and performance, ease of use, price, and post-sales support. The importance of each of these factors varies depending upon the specific customer.
Customers
OEMs and Tier 1 Suppliers (End Users)
OEMs are manufacturing companies making products like cars. The Tier 1 companies supply completed sub-assemblies to the OEMs. Our products heavily influence the use of new technologies, and help OEMs set manufacturing standards – known as the global “bill of process.” Each OEM treats procurement differently, for example, some automobile OEMs tend to do most assembling in-house and others will outsource some of this work, leading to additional opportunities for Coherix through Tier 1 suppliers. We anticipate our company’s largest opportunities are with OEMs, and Tier 1 suppliers, given our ability to support them across their global footprint.
| 36 |
Systems Integrators/Equipment OEMs
Systems integrators are hired by OEMs and Tier 1 suppliers to create entire manufacturing lines. Typically important products included in these manufacturing lines are specified by OEMs in their “bill of process;” however, in some cases the System Integrators will propose proven solutions. System Integrators and equipment makers have a vested interest in having reliable technology providers like Coherix, because they typically receive the first call if an issue arises at the end user.
Tier 1 Suppliers
Tier 1 suppliers are influenced by OEMs and systems integrators. Tier 1 suppliers of automotive sub-assemblies purchase Coherix products to enhance their manufacturing processes. Tier 1 sub-assemblies suppliers share the same needs for precision manufacturing systems as their OEM customers.
Customer Base
Our customer base consists of the world’s largest OEMs, system integrators, dispensing companies, and Tier 1 automotive manufacturers. Our global customer base spans across the globe and includes companies located in Taiwan, China, Singapore, Malaysia, Europe (including Germany, Italy, United Kingdom and Sweden), and the United States. Customers acknowledge the high cost of failure associated with manufacturing and heavily rely on Coherix technology throughout the manufacturing process. Current partnerships are created through product-related success. Coherix has already entrenched itself in the day-to-day operations of our customers. Coherix is currently undergoing “evaluations” and late stage discussions with more than ten industry leading Tier 1 manufacturers and OEMs.
Go-To Market Strategy
Coherix capitalizes on multiple touch points within the value chain, thus, increasing our sales opportunities. We have various touch points within organizations, from plant level to mid-level executives, enabling us to build a broad relationship footprint. We market and sell our products through distribution channels (system integrators, equipment makers, dispensing companies, Tier 1 and OEMs) enabling us to add value at different points in the process. Our distribution channels enable our 3D vision products to be spread throughout their customer’s broad geographic footprint.
Dependence on One or A Few Major Customers
Coherix has one large customer, Panasonic, which is in its fourth year of a ten year IP licensing contract. This contract is the result of the successful completion of a $5.3 million four year joint development project completed in June of 2013. This ten year IP licensing contract calls for payment of a licensing fee to Coherix for each 3D vision module manufactured by the licensee. Very little follow on support has been needed. Any additional support provided to the customer is invoiced and paid. The amount of licensing fees received is steadily increasing each year.
Distribution Methods of Products and Services
Coherix engages with distributors to provide the distribution of its products and services. Coherix engages with:
| · | MSI Viking, a supplier of manufacturing measurement systems in the automotive and manufacturing engineering market to distribute Coherix products in the following states in the United States: Virginia, North Carolina, South Carolina, Georgia, Alabama, Tennessee, and Mississippi. |
| · | Marubeni Information Systems Co., Ltd, Coherix’s exclusive distributor in Japan. |
| · | Integro Technologies, VRSI, Vantage, JR Automation, are a partial list of companies that sell, and support Coherix products as part of their systems sold and marketed in the United States, Canada, and Mexico. |
| · | Visionetx, sales distributor in the United States and Europe for semiconductor sales. |
| 37 |
Suppliers
The company deals with a number of different suppliers:
| · | Odyssey Electronics – Provides contract manufacturing, printed circuit boards and Predator3D sub-assembly |
| · | Y-Squared – Provides contract manufacturing of cables. |
The following suppliers are currently the sole source for their products:
| · | Congatec – Provides custom, single board computer. Adding another supplier would require redesign of hardware and software. |
| · | Keynote Photonics – Custom manufacturer of digital light projector. Adding another supplier would require redesign of hardware and software. |
| · | Osela – Custom manufacturer of lasers for Predator3D product line. |
| · | Agiltron – Optical splitters Shapix products. |
| · | CMOSIS – Single source supplier of optical imagers. (Arrow Electronics is a distributor for CMOSIS imagers). |
The following are providers of raw materials:
| · | Zero Hour Parts – Provides machined components for all product lines |
| · | RTD Manufacturing –Provides machined components for all product lines |
| · | Stratasys Manufacturing – Provides supply plastic parts for the 3DX semiconductor product lines |
| · | Oz Optics – Supplies fiber optic cables for ShaPix product lines |
| · | Dell - Leases computers for Coherix, Inc. purposes and purchases for customer requirements. |
| · | Universal Kogaku – Supplies lenses for all product lines |
| · | Precise Metal – Supplies sheet metal components for all product lines |
| · | Inradoptics – Manufactures custom parabolic mirrors used in ShaPix product line |
Research and Development
In 2016 and 2017, we incurred expenses of approximately $1,615,000 and $1,385,000, respectively, for our development efforts. We expect to continue to incur significant expenditures on development. Our development efforts will focus primarily on additional enhancements to Predator3D that will enable our customers to lower costs and improve performance in the adhesive and sealant dispensing process. Another area of focus will be to further develop Predator3D for use in the electronics industry where there are higher speed, more compact and higher resolution requirements. The third development focus is to expand the number of Robust3D error-proofing applications in the automotive and electronics industries.
Intellectual Property
We need our trademark, domain names, and proprietary technology to remain competitive and we rely on trademark, copyright, patent law, trade-secret protection, and confidentiality and/or license agreements with our employees, customers, partners, and others to protect our proprietary rights. The company holds 12 registered patents in the US, 2 registered in China; 1 registered in Europe and 1 registered in Japan. The company also has 3 registered trademarks "Coherix", "ShaPix" and "Robust3D" with trademark registration in Europe, China and Japan.
Legal Matters
The company is not involved in any litigation, and its management is not aware of any pending or threatened legal actions relating to its intellectual property, conduct of its business activities, or otherwise.
Certain legal matters with respect to the shares of Common Stock offered hereby will be passed upon by CrowdCheck Law LLP.
| 38 |
Employees
At the date of this Offering Circular, Coherix has 50 full-time employees, 3 part-time employees and 26 independent contractors. Twenty-nine full time employees and three part-time employees are based in Ann Arbor, Michigan at the company’s headquarters. All others are performing sales, marketing and application functions around in our wholly owned subsidiaries in Singapore, China and Europe.
Company’s Property
Coherix is a “capital light” company requiring very little capital equipment. We lease our headquarters space at 3980 Ranchero Drive, Ann Arbor, Michigan 48108 from Oxford Companies Ann Arbor LLC, 210 S. Fifth Avenue, P.O. Box 8200, Ann Arbor Michigan 48107.
We lease approximately 2,667 square feet of warehouse/and/or office and/or light industrial facilities designated as Suite 1B at 739 Airport Boulevard, Ann Arbor, Michigan, 48108, beginning December 4, 2015 and continues on a month-by-month lease. Airport Boulevard Associates, LLC is the landlord.
| 39 |
DIRECTORS, EXECUTIVE OFFICERS AND SIGNIFICANT EMPLOYEES
The directors, executive officers, and key employees are set forth in the chart below.
| Name | Position | Age | Term of Office (if indefinite, give date appointed) | Approximate hours per week (if part-time)/full-time |
| Directors: | ||||
| Dwight D. Carlson | Chairman | 74 | 2003 - present | Full time |
| Jun Ni | Director | 57 | 2012 - present | Part-time, Quarterly Board Meetings |
| Philip Rice II | Director | 64 | 2017 - present | Part-time, Quarterly Board Meeting; Annual Compensation Committee Meeting |
| Robert A. Smith | Director | 77 | 2006 - present | Part-time, Quarterly Board Meetings; Annual Compensation Committee |
| Jinyang Wen | Investor Director | 22 | 2018 - present | Part-time, Quarterly Board Meetings |
| Executive Officers: | ||||
| Dwight D. Carlson | Chief Executive Officer (Founder) | 74 | 2003 - present | Full-time |
| Doug Davidson | Chief Technical Officer (Founder) | 59 | 2003 - present | Full-time |
| Michael Schneider | Principal Accountant, Controller |
56 |
2014 - present |
Full-time |
| Key Employees: | |||
| Dr. Zhenhua Huang | General Manager The Americas | 2006 - present | Full-time |
| David Kelly | General Manager Coherix Europe | 2011 - present | Full-time |
| Khalid Rashid | General Manager Asia Pacific | 2006 - present | Full-time |
| Alice M. Grisham | VP Administration and Human Resources (Founder) |
2004 - present |
Full-time |
| Joseph Rupert | Director Manufacturing | 2012 - present | Full-time |
Dwight Carlson, CEO, Chairman and Director
Dwight Carlson has been Chairman and CEO, Founder and Director from October 30, 2003 to present. Prior to Coherix, Inc., Mr. Carlson was Founder, CEO and Director of Perceptron, Inc., taking the company public in 1992 and Founder and CEO of XYCOM, an industrial microcomputer company.
Professor Ni Jun, Director
Professor Ni Jun has been a Director from 2012 to present. He serves as an Associate Editor of the Journal of Manufacturing Systems and a Professor at the University of Michigan. He serves as the Dean of the Joint Institute between Michigan and Jiao Tong University. He has been an Independent Non-Executive Director of Eco-tek Holdings Ltd., since February 2003. He serves as Deputy Director of NSF- Engineering Research Center for Reconfigurable Manufacturing Systems. He serves as a Director in various non-profit making research centers such as the S.M. Wu Manufacturing Research Centre and the Multi-Campus National Science Foundation Centre for Intelligent Maintenance Systems of the University of Michigan. His research interests include: manufacturing process modeling, analysis and prediction; precision engineering and metrology; cutting tool development, quality control methods, intelligent maintenance systems, monitoring and fault diagnosis. He obtained his Ph.D. in 1987 from the University of Wisconsin-Madison. Professor Ni graduated from Shanghai Jiaotong University with a BS Mechanical and Production Engineering in 1982 and graduated from the University of Wisconsin-Madison with an M.S. in Mechanical Engineering in 1984.
| 40 |
Mr. Philip M Rice II, Director
Mr. Philip M Rice II has been a Director since July 20, 2017. He also serves on the Compensation Committee of the Board. Mr. Rice is the Chairman and Chief Financial Officer of Zivo Bioscience, Inc. (“Zivo”). Mr. Rice was appointed Chief Financial Officer of Zivo in November 2011. In January 2012, Mr. Rice was appointed to the Board of Directors. Zivo's Board currently consists of five Directors. The Board has determined that Mr. Rice qualifies as an "Audit Committee Financial Expert" as the term is defined in rules promulgated by the SEC. In 2001, Mr. Rice founded Legacy Results, LLC (now Legacy Results, Inc.) a management consulting firm providing a wide range of consulting services, including strategic planning, business plan development, turnaround management, financial management and mergers and acquisitions, and has served as its Managing Partner since that date. From December 2007 through March 2008, Mr. Rice served as chairman of the board of IMX Solutions, Inc. a technology company providing secure internet transactions including private data transactions. Mr. Rice practiced as a CPA and worked for Deloitte & Touche LLP for thirteen years before founding Legacy Results.
Mr. Robert A. Smith, Director
Mr. Robert A. Smith has been a Director since 2006 and a member of the Compensation Committee of the Board. He served as Senior Vice President at Owens-Illinois Inc. since 2003 and as General Manager, Domestic Glass Container since 2002. Mr. Smith served as Vice President of Owens-Illinois, Inc. from 1993 to 2003. Mr. Smith served as Vice President and Technical Director of Owens-Illinois, Inc. from 1998 to 2002, as Vice President, International Operations from 1997 to 1998 and as Vice President, Glass Container Manufacturing from 1993 to 1997.
Jinyang Wen, Investor Director
At the October 19, 2018 Board Meeting, Ms. Jinyang Wen was elected to the Coherix, Inc. Board of Directors as Investor Director representing Xintai US Investments LLC (”Xintai”), pursuant to the company’s investors’ rights agreement with Xintai (See “Description of Capital Stock – Amended and Restated Investors’ Rights Agreement”). She will also be added to the slate of directors for election at the November 3, 2018 Annual Stockholder Meeting. She studied in the Beijing Xindongfang English School and is attending the University of Washington from 2015 to present. Her major is in Communications. Some of her social and volunteer work includes China Giant Panda Protection and Research Center, the University of Washington Orc Outdoor Organization and employment at the University of Washington Library. She speaks fluent Chinese and English.
Douglas Davidson, Chief Technical Officer (“CTO”)Douglas Davidson is a co-founder, and since October 30, 2003, has been CTO and Chief Architect of the Coherix software suites. He previously served as Director of Software Engineering at Machine Vision Products, Inc. and Senior Manager of Software Engineering at Automated Intelligent Systems, Inc. He has 25 years of software design, implementation and management experience including UNIX, MS-DOS, board level and Microsoft Windows platforms.
Michael Schneider, Principal Accountant
Michael Schneider currently holds the position of Principal Accountant and Controller. Mr. Schneider joined the company in February 2014, and holds a BBA with Business Computer Systems Major degree from Eastern Michigan University. Mr. Schneider is an accomplished financial professional with solid and progressive experience in all facets of accounting, cash and business management. His prior experience includes Controller and CFO in Clover Technologies Group and The Wireless Source, respectfully. He has over 35 years of experience with controller responsibilities ranging from Assistant Controller to CFO.
Board of Directors' Compensation
As of July 20, 2017, the company pays a quarterly payment to each director attending and/or participating in the quarterly meetings, equal to $2,500 per meeting. In addition, directors earn annual restricted warrants to purchase 12,000 shares of Common Stock for each Director.
Compensation Committee
Today, Coherix has one Committee of the Board, the Compensation Committee. Robert Smith and Philip Rice II serve on the Compensation Committee. This Committee reviews and recommends compensation and performance bonuses for the CEO and CTO, as well as for officers of the company. In addition, the Compensation Committee of the Board reviews and recommends companywide bonus/incentive plans. The company does not currently have a Bonus or Incentive Plan for 2018; however, the Compensation Committee plans to review the need for a Total Company Incentive Plan for 2018. Beginning September 28, 2017, members of the Compensation Committee receive $500 per Compensation Committee Meeting and restricted warrants to purchase 1,000 shares of Common Stock.
| 41 |
We are an emerging growth company for purposes of the Commission’s executive compensation disclosure rules. In accordance with such rules, we are required to provide a summary compensation table, as well as limited narrative disclosures regarding executive compensation for our last completed fiscal year. Further, our reporting obligations extend only to our “named executive officers,” who are those individuals serving as our CEO, our CTO and our Principal Accountant and Controller who were serving as executive officers at the end of the last completed fiscal year.
For the fiscal year ended December 31, 2017, our “named executive officers” and their compensation were as follows:
| Name | Capacities in which compensation was received | Cash compensation ($) | Other compensation ($) | Total compensation ($) | ||||||||||
| Dwight D. Carlson | CEO/Chairman | $ | 229,166.65 | $ | 29,000.00 | (1) | $ | 258,166.65 | ||||||
| Douglas L. Davidson | CTO | $ | 161,875.02 | $ | 2,500.00 | $ | 164,375.02 | |||||||
| Michael Schneider | Principal Accountant | $ | 103,166.70 | $ | 4,000.00 | $ | 107,166.70 | |||||||
| (1) | Mr. Carlson’s other compensation includes the value of options received under the 2004 Plan and warrants received in connection with his service as a Director. |
The total number of shares of Common Stock that may be issued pursuant to our 2004 Incentive and Non-qualified Stock Option Plan (the “2004 Plan”) may not exceed an aggregate of 5,100,000 shares. As of June 30, 2018, 2,018,772 shares have been issued in connection with the exercise of stock options; 1,314,140 stock options have been granted but are unexercised and 1,767,088 shares are available under the 2004 Plan for future grants.
For the fiscal year ended December 31, 2016, no cash payments were made to directors. There are five directors in this group. In July 2017, the Board approved paying $2,500 per meeting to each Director participating in a quarterly board meeting and an annual award of 12,000 restricted warrants to each Director. For the fiscal year ended December 31, 2017, the company did not make any cash payments to Directors in connection with their service and issued 46,000 restricted warrants to the 4 Directors other than Mr. Carlson.
| 42 |
Information with respect to related party transactions appears in Note 19 to our audited financial statements for the year ended December 31, 2017 and Note 8 to the unaudited interim financial statements for the six months ended June 30, 2018. Those footnotes reflect all transactions with stockholders of any size; the following discussion complies with the requirements for Offering Statements on Form 1-A under Regulation A.
At December 31, 2017 and 2016, the company had loans receivable from Dwight Carlson, the company’s Chairman, Director and CEO, in the amount of $731,797 used to exercise his stock options during the periods 2010 to 2018. The company owes Mr. Carlson $932,749 under the Top Hat Deferred Compensation Plan, plus accrued interest and short term salary reduction from mid-2016 into 2017. The company has the ability, and intends to, offset the loans receivable with certain deferred compensation liabilities. The company has not been able to pay Mr. Carlson the remaining deferred compensation or the short-term salary reduction due to cash constraints. Mr. Carlson also provides a personal guaranty on the Crestmark line of credit. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – Line of Credit.”
Robert A. Smith, who is one of the company’s Directors, has invested $150,000 in promissory notes due in 2021, with 24,000 warrants with an exercise price of $3.75.
The wife of Philip Rice II, who is one of the company's Directors, has invested $730,000 in promissory notes due in July and August 2018, which earn 16% annual interest, and a convertible debenture in the amount of $100,000, which has accrued and unpaid interest of approximately $128,000 as of June 30, 2018. In August 2018, the company repaid $350,000 of the promissory notes and repayment of the balance was extended until February 2019. The company intends to use the net proceeds of this offering to repay its convertible debentures and, as a result, Mr. Rice's wife will receive $100,000 of the net proceeds.
In December 2017, Xintai converted $4,000,000 of convertible debentures into shares of Common Stock at a conversion price of $3.44 per share. In January 2018, Xintai converted a portion of the accrued interest on such debentures totaling $170,734 into shares of Common Stock at a conversion price of $3.44 per share.
Statement of Policy
Our board of directors recognizes the fact that transactions with related parties present a heightened risk of conflicts of interests and/or improper valuation (or the perception thereof). In the event our shares are approved for quotation on NASDAQ, our board of directors will adopt a written policy on transactions with related parties in conformity with the requirements for issuers having publicly held common stock quoted on the NASDAQ Capital Market. Under the policy, any related-party transaction, and any material amendment or modification of a related-party transaction, will be required to be reviewed and approved or ratified by a committee of the board of directors composed solely of independent directors who are disinterested, or by the disinterested members of the board of directors and any employment relationship or transaction involving an executive officer and any related compensation will be required to be recommended by the Compensation Committee to the board of directors for its approval.
| 43 |
In connection with the review and approval or ratification of a related-party transaction:
| · | The management must disclose to the audit committee or another independent body of the board of directors, as applicable, the name of the related party and the basis on which the party is a related party, the material terms of the related-party transaction, including the approximate dollar value of the amount involved in the transaction, and all the material facts as to the related party’s direct or indirect interest in, or relationship to, the related-party transaction; | |
| · | The management must advise the audit committee or another independent body of the board of directors, as applicable, whether the related-party transaction complies with the terms of our agreements governing any material outstanding indebtedness that limit or restrict our ability to enter into a related-party transaction; | |
| · | The management must advise the audit committee or another independent body of the board of directors, as applicable, whether the related-party transaction will be required to be disclosed in our applicable filings under the Securities Act or the Exchange Act and related rules, and, to the extent required to be disclosed, management must ensure that the related-party transaction is disclosed in accordance with such Acts and related rules; and management must advise the audit committee or another independent body of the board of directors, as applicable, whether the related-party transaction constitutes a "personal loan" for purposes of Section 402 of the Sarbanes-Oxley Act. |
In addition, the related-party transaction policy will provide that the audit committee or another independent body of the board of directors, as applicable, must consider whether any approval or ratification of a related-party transaction involving a non-employee director or director nominee would compromise the director or director nominee's status as an "independent", "outside", or "non-employee" director, as applicable, under the rules and regulations of the SEC, the NASDAQ Capital Market and the Internal Revenue Code.
| 44 |
Security Ownership of Management and Certain Securityholders
The following table sets forth certain information known to us regarding beneficial ownership of our capital stock as of June 30, 2018 for (i) all executive officers and directors as a group and (ii) each person, or group of affiliated persons, known by us to be the beneficial owner of more than five percent (5%) of our capital stock. The percentage of beneficial ownership in the table below is based on 13,091,200 shares of Common Stock deemed to be outstanding as of June 30, 2018.
| Name and address of beneficial owner | Title of | Amount and | Amount and | Percent of |
| class | nature of | nature of | class | |
| beneficial | beneficial | |||
| ownership | ownership | |||
| acquirable | ||||
| Dwight D. Carlson | Common Stock | 1,084,012 | 139,062 | 9.34% |
| 3980 Ranchero Drive | ||||
| Ann Arbor, MI 48108 | ||||
| Xintai US Investment LLC | Common Stock | 2,278,248 | 0 | 17.40% |
| 3980 Ranchero Drive | ||||
| Ann Arbor, MI 48108 | ||||
| All current officers and directors | Common Stock | 3,808,196 | 194,187 | 30.57% |
| as a group (7 people) |
| 45 |
Summary of Securities
The following description summarizes certain terms of our capital stock, as in effect upon the completion of this offering. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this section you should refer to our amended and restated certificate of incorporation and bylaws, which are included as exhibits to the Offering Statement of which this Offering Circular is a part, and to the applicable provisions of Delaware law.
Our authorized capital stock consists of 30,000,000 shares of Common Stock, $0.001 par value per share, and 400,000 shares of preferred stock, $0.001 par value per share. There were 13,091,200 shares of Common Stock and no shares of Preferred Stock issued and outstanding as of June 30, 2018.
Common Stock
Dividend Rights
Since our inception, we have not paid dividends on our Common Stock and we currently expect that, for the foreseeable future, all earnings (if any) will be retained for the development of our business. No dividends will be declared or paid. In the future, the Board of Directors may decide, in their discretion, whether dividends may be declared and paid, taking into consideration, among other things, our earnings (if any), operating results, financial conditions and capital requirements, general business conditions and other pertinent facts.
Voting Rights
Holders of our Common Stock are entitled to one vote per share on any matter to be voted upon by stockholders, however, except as otherwise required by law. We have not provided for cumulative voting for the election of directors in our amended and restated certificate of incorporation. Our bylaws establish a board of directors whose term is for one year, to be elected at the annual meeting of stockholders.
No Preemptive or Similar Rights
Prior to the qualification of the Offering Statement by the SEC, one stockholder, Xintai, has pre-emptive rights under an investors’ rights agreement, dated August 5, 2015 (the “2015 Investors’ Rights Agreement”). The company and Xintai have entered into an Amended and Restated Investors’ Rights Agreement dated July 23, 2018 (the “Amended and Restated Investors’ Rights Agreement”), pursuant to which, upon qualification of the Offering Statement in connection with this offering, all pre-emptive rights will terminate. See “—Amended and Restated Investors’ Rights Agreement.”
Other than Xintai’s pre-emptive rights noted above, no other holder of our Common Stock is entitled to preemptive rights, and the Common Stock is not subject to conversion, redemption, or sinking fund provisions.
Warrants
As of June 30, 2018 there are 1,171,046 warrants issued and outstanding. All warrants have a cashless exercise option.
Options
There are 5,100,000 options authorized under the company’s 2004 Incentive and Non-Qualified Stock Option Plan. Of these options, 2,018,772 options have been exercised and 1,767,088 options are available for new grants as of June 30, 2018.
| 46 |
Ten-Year Royalty Programs
Under the Predator3D programs discussed below, the company will be required to pay royalties for a ten year period to eligible stockholders based on Predator3D sales into the sealant and sealant dispensing industry.
Predator Royalty with Stock Investment Programs
Certain investors agreed to enter into the Predator3D Royalty Program with Common Stock. Each investor investing $1,000 would receive .05% of the Royalty Pool for ten years and 67 shares of Coherix Common Stock (one share for every $15 invested). Under the first pool, Coherix raised $2,000,000 to fund the development of Predator3D and a 5% Pool was created. Commencing on the date of the first shipment of a Predator unit, 5% of the revenue recognized from the sealant and sealant dispensing industry was deposited into the pool and paid to eligible stockholders on a quarterly basis. The first pool was created on June 24, 2014, as amended, and was fully subscribed.
A Second Predator3D Pool was established in the amount of $2,000,000 to fund promotion and sales of the Predator3D and mirrored the June 24, 2014 Program. The company raised only 16% ($332,848) of the $2,000,000 available under the Second Program.
Predator3D Royalty Opportunity Pools
Certain investors with accrued interest balances from their equity conversions agreed to forfeit their right to payment of accrued interest for the opportunity to receive potential future royalties on future shipments of Predator3D units into the sealant and sealant dispensing industry. Each participant understood the risks and that they might never receive any royalties as a result of Predator3D sales into the sealant and sealant dispensing industry. Again the potential for future royalties was for a 10 year period, commencing on the date of the first shipment of a production Predator unit. A smaller Predator3D Opportunity Pool was created for employees who agreed to forfeit a portion of their salary in return for a future opportunity to receive royalties on future Predator3D shipments into the sealant and sealant dispensing industry. Team members also understood the risk associated with their forfeiting a portion of their salary, that they would not be eligible to receive repayment in the future and that there was no guarantee that they would receive any royalties.
In September 2016, all Predator3D Programs were closed. After that date, no new funding was received and/or no additional forfeited accrued interest and/or forfeited salaries were allowed under the programs.
Antitakeover Matters
Charter and Bylaw Provisions
The provisions of Delaware law, our amended and restated certificate of incorporation, and our bylaws include a number of provisions that may have the effect of delaying, deferring, or discouraging another person from acquiring control of our company and discouraging takeover bids. These provisions may also have the effect of encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.
Board Composition and Filling Vacancies
Our bylaws provide that any vacancy on our board of directors may only be filled by the affirmative vote of a majority of our stockholders. The number of directors are determined from time to time by the board of directors. The Board has the right to elect interim directors if a director steps down.
No Cumulative Voting
The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless the certificate of incorporation provides otherwise. Neither our amended and restated certificate of incorporation nor our bylaws provide for cumulative voting.
| 47 |
Limitations of Director Liability and Indemnification of Directors and Officers
We intend to maintain general liability insurance that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or persons who control us, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. We believe that these provisions, the indemnification agreements, and the insurance are necessary to attract and retain talented and experienced directors and officers. At present, there is no pending litigation or proceeding involving any of our directors or officers where indemnification will be required or permitted. We are not aware of any threatened litigation or proceeding that might result in a claim for such indemnification.
Our amended and restated certificate of incorporation provides that to the fullest extent permitted by law, no director of the company shall be personally liable for monetary damages for breach of fiduciary duty as a director. In addition, the corporation may indemnify to the fullest extent permitted by law, any person made or threatened to be made a party to an action or proceedings, whether criminal, civil, administrative, or investigative, by reason of the fact that he, his testator or intestate is or was a director, officer, or employee of the company, or any predecessor the company or serves or served at any other enterprise as a director, officer, or employee, at the request of the company.
Amended and Restated Investors’ Rights Agreement
Upon the qualification of the Offering Statement, the 2015 Investors’ Rights Agreement will terminate and the Amended and Restated Investors’ Rights Agreement will become effective. Under the Amended and Restated Investors’ Rights Agreement, Xintai will have the following rights:
| · | Registration rights in the event that the company executes a firm commitment underwritten public offering of its Common Stock pursuant to the Securities Act that raises at least $25 million at a pre-money valuation of at least $100 million (a “qualified IPO”); |
| · | Information and inspection rights; and |
| · | The right to appoint one member of the Board of Directors (the “Investor Director”), provided Xintai's ownership is 5% or greater. Jinyang Wen is the current Investor Director designated by Xintai under the existing agreement and will continue as the Investor Director after the Amended and Restated Investor Rights Agreement takes effect. |
The Amended and Restated Investors’ Rights Agreement also grants registration rights to the company’s CEO.
All rights other than the registration rights and the right to designate a board seat will terminate immediately prior to the initial closing of this offering. The registration rights will terminate upon the earlier to occur of
| · | when all of a party's registrable securities have been sold under an effective registration statement or pursuant to Rule 144 under the Securities Act; |
| · | when all of a party’s registrable securities can be sold under Rule 144 within 90 days without limitation on the amount of securities that can be sold; and |
| · | the fifth anniversary of a qualified IPO. |
Exchange Listing
We intend to apply to have our Common Stock approved for quotation on NASDAQ, but we cannot guarantee that we will satisfy the quotation requirements or otherwise be accepted for such quotation.
Transfer Agent and Registrar
We intend to appoint Colonial Stock Transfer Company, Inc. (“Colonial”) as the transfer agent and registrar for our Common Stock. Colonial’s address is 66 Exchange Place, 1st floor, Salt Lake City, UT 84111, and its telephone number is 801-355-5740.
| 48 |
Since our inception, we have not paid any dividends on our Common Stock and we currently expect that, for the foreseeable future, all earnings (if any) will be retained for the development of our business and no dividends will be declared or paid. In the future, the Board of Directors may decide, in their discretion, whether dividends may be declared and paid, taking into consideration, among other things, our earnings (if any), operating results, financial conditions and capital requirements, general business conditions and other pertinent facts.
SHARES ELIGIBLE FOR FUTURE SALE
Prior to this offering, there has been no market for our Common Stock. Future sales of substantial amounts of our Common Stock, or securities or instruments convertible into our Common Stock, in the public market, or the perception that such sales may occur, could adversely affect the market price of our Common Stock prevailing from time to time. Furthermore, because there will be limits on the number of shares available for resale shortly after this offering concludes, due to contractual and legal restrictions described below, there may be resale of substantial amounts of our Common Stock in the public market after those restrictions lapse. This could adversely affect the market price of our Common Stock prevailing at that time.
Upon completion of this offering, assuming the maximum number of shares of Common Stock offered in this offering are sold, there will be 15,591,200 shares of our Common Stock outstanding. This number includes additional shares of Common Stock allocated to stock options outstanding as of the date of this Offering Circular.
These 15,591,200 shares of our Common Stock will be freely tradable in the public market, except to the extent they are acquired by an “affiliate” of ours; as such term is defined in Rule 405 under the Securities Act. Under Rule 405, an affiliate of a specified person is a person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the specified person. Any affiliate of ours that acquires our shares can only further transact in such shares in compliance with Rule 144 under the Securities Act, which imposes sales volume limitations and other restrictions on such further transactions. See “— Rule 144,” below.
In addition to the foregoing, shares of our Common Stock not sold in this offering will be restricted securities within the meaning of Rule 144, and would be tradable only if they are sold pursuant to a registration statement under the Securities Act or if they qualify for an exemption from registration, including under Rule 144. See “— Rule 144,” below.
Rule 144
In general, a person who has beneficially owned restricted shares of our Common Stock for at least one year, in the event we are a reporting company under Regulation A, or at least six months, in the event we have been a reporting company under the Exchange Act for at least 90 days, would be entitled to sell such securities, provided that such person is not deemed to be an affiliate of ours at the time of sale or to have been an affiliate of ours at any time during the three months preceding the sale. A person who is an affiliate of ours at such time would be subject to additional restrictions, by which such person would be entitled to sell within any three month period only a number of shares that does not exceed the greater of the following:
| · | 1% of the number of shares of our Common Stock then outstanding; or |
| · | The average weekly trading volume of our Common Stock during the four calendar weeks preceding the filing by such person with the SEC of a notice on Form 144 with respect to the sale; provided that, in each case, we have been subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Persons relying on Rule 144 to transact in our Common Stock must also comply with the manner of sale, notice and other provisions of Rule 144, to the extent applicable. In general, Rule 701 allows a stockholder who purchased shares of our capital stock pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate of ours during the immediately preceding 90 days to sell those shares in reliance upon Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. Persons relying on Rule 701 to transact in our Common Stock, however, are required to wait until 90 days after the date of this Offering Circular before selling shares pursuant to Rule 701. |
| 49 |
The company is offering up to 2,500,000 shares of Common Stock, on a “best efforts basis” as described in this Offering Circular. The company has not engaged a broker-dealer to assist in the placement of its securities.
The company intends to use the online platform, Equity Track, at the domain name Coherixinvest.com (the “Online Platform”) to provide technology tools to allow for the sales of securities in this offering. We have also purchased the domain names coherixinvest.net and coherixinvest.co to prevent fraudulent use. The company will pay a monthly fee of $500 which may be terminated at any time without penalty.
Investment Fee on Sales of Securities
There are no investment fees in connection with purchases of securities under this offering.
Termination of Offering
The offering will terminate at the earlier of (1) the date at which the maximum offering amount has been sold, (2) the date that is twelve months from the date of this Offering Statement being qualified by the Commission, or (3) the date at which the Offering is earlier terminated by the company in its sole discretion, which may happen at any time (the “Offering Termination Date”).
Selling Security holders
No securities are being sold for the account of security holders; all net proceeds of this offering will go to the company.
Investors’ Tender of Funds
After the Offering Statement has been qualified by the Commission, the company will accept tenders of funds to purchase the Common Stock. The company may close on investments on a “rolling” basis (so not all investors will receive their shares on the same date). The funds tendered by potential investors will go directly to the company, and the company will issues shares thereafter, in its discretion. However, the offering will remain open and investor subscriptions will be accepted throughout the entire offering and will not be halted when funds are transferred to the company or the company closes on investments during the offering. Upon closing, funds tendered by investors will be made available to the company for its use. The offering will terminate (and subscriptions will no longer be accepted) at the earlier of: (1) the date at which the maximum offering amount has been sold, (2) the date which is one year from this offering being qualified by the Commission, or (3) the date at which the offering is earlier terminated by us in our sole discretion.
Investors will be required to subscribe to the offering via the Online Platform, and agree to the terms of the offering and subscription agreement. The subscription agreement includes a representation by the investor to the effect that, if you are not an “accredited investor” as defined under securities law, you are investing an amount that does not exceed the greater of 10% of your annual income or 10% of your net worth (excluding your principal residence).
Offering Expenses
We are responsible for all offering fees and expenses, including the following: (i) fees and disbursements of our legal counsel, accountants, and other professionals we engage; (ii) fees and expenses incurred in the production of offering documents, including design, printing, photograph, and written material procurement costs; (iii) all filing fees, including blue sky notice filing fees; and (iv) all of the legal fees related to the filing of notice filings under state securities laws.
Investment Limitations
Generally, no sale may be made to you in this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth (please see below on how to calculate your net worth). Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to www.investor.gov.
| 50 |
Because this is a Tier 2 Regulation A offering, most investors must comply with the 10% limitation on investment in the offering. The only investor in this offering exempt from this limitation is an "accredited investor" as defined under Rule 501 of Regulation D under the Securities Act (an "Accredited Investor"). If you meet one of the following tests you should qualify as an Accredited Investor:
| • | You are a natural person who has had individual income in excess of $200,000 in each of the two most recent years, or joint income with your spouse in excess of $300,000 in each of these years, and have a reasonable expectation of reaching the same income level in the current year; |
| • | You are a natural person and your individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time you purchase offered shares (please see below on how to calculate your net worth); |
| • | You are an executive officer or general partner of the issuer or a manager or executive officer of the general partner of the issuer; |
| • | You are an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, or the Code, a corporation, a Massachusetts or similar business trust or a partnership, not formed for the specific purpose of acquiring the offered shares, with total assets in excess of $5,000,000; |
| • | You are a bank or a savings and loan association or other institution as defined in the Securities Act, a broker or dealer registered pursuant to Section 15 of the Exchange Act, an insurance company as defined by the Securities Act, an investment company registered under the Investment Company Act of 1940 (the "Investment Company Act"), or a business development company as defined in that act, any Small Business Investment Company licensed by the Small Business Investment Act of 1958 or a private business development company as defined in the Investment Advisers Act of 1940; |
| • | You are an entity (including an Individual Retirement Account trust) in which each equity owner is an accredited investor; |
| • | You are a trust with total assets in excess of $5,000,000, your purchase of offered shares is directed by a person who either alone or with his purchaser representative(s) (as defined in Regulation D promulgated under the Securities Act) has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment, and you were not formed for the specific purpose of investing in the offered shares; or |
| • | You are a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has assets in excess of $5,000,000. |
In addition, investments will not be accepted from residents of the following states: Arizona, Florida, Nebraska, North Dakota and Texas. Because we are not engaging a broker-dealer and we are not registering in these states as an issuer-dealer, we will not be selling securities in these states unless and until we engage a broker-dealer or register as an issuer-dealer.
Procedures for Subscribing
If you decide to subscribe for shares in this offering, you should:
Go to www.coherixinvest.com, click on the "Invest Now" button and follow the procedures as described.
| 1. | Electronically receive, review, execute and deliver to us a subscription agreement; and |
| 2. | Deliver funds directly by wire or electronic funds transfer via ACH to the specified account maintained by the company at Comerica Bank. |
Any potential investor will have ample time to review the subscription agreement, along with their counsel, prior to making any final investment decision. We shall only deliver such subscription agreement upon request after a potential investor has had ample opportunity to review this Offering Circular.
Right to Reject Subscriptions
After we receive your complete, executed subscription agreement and the funds required under the subscription agreement have been transferred to the company’s account, we have the right to review and accept or reject your subscription in whole or in part, for any reason or for no reason. We will return all monies from rejected subscriptions immediately to you, without interest or deduction.
| 51 |
Acceptance of Subscriptions
Upon our acceptance of a subscription agreement, we will countersign the subscription agreement and issue the shares subscribed at closing. Once you submit the subscription agreement and it is accepted, you may not revoke or change your subscription or request your subscription funds. All accepted subscription agreements are irrevocable.
Under Rule 251 of Regulation A, non-accredited, investors are subject to the investment limitation and may only invest funds which do not exceed 10% of the greater of the purchaser's revenue or net assets (as of the purchaser's most recent fiscal year end). A non-accredited, natural person may only invest funds which do not exceed 10% of the greater of the purchaser's annual income or net worth (please see below on how to calculate your net worth).
For the purposes of calculating your net worth, it is defined as the difference between total assets and total liabilities. This calculation must exclude the value of your primary residence and may exclude any indebtedness secured by your primary residence (up to an amount equal to the value of your primary residence). In the case of fiduciary accounts, net worth and/or income suitability requirements may be satisfied by the beneficiary of the account or by the fiduciary, if the fiduciary directly or indirectly provides funds for the purchase of the shares.
In order to purchase shares and prior to the acceptance of any funds from an investor, an investor will be required to represent, to the company's satisfaction, that he is either an accredited investor or is in compliance with the 10% of net worth or annual income limitation on investment in this offering.
Forum Selection Provision
The subscription agreement includes a forum selection provision that requires that subscribers bring any claims against the company based on the subscription agreement in a state or federal court of competent jurisdiction in the State of Michigan. The forum selection provision may limit investors’ ability to bring claims in a judicial forum that they believe is favorable to such disputes and may discourage lawsuits with respect to such claims. The company has adopted the provision since Michigan has a well-developed framework for contract law and seeks to limit the time and expense incurred by its management to challenge any such claims. As a company with a small management team, this provision allows our officers to not lose a significant amount of time travelling to any particular forum so they may continue to focus on operations of the company.
Jury Trial Waiver
The subscription agreement provides that subscribers waive the right to a jury trial of any claim they may have against us arising out of or relating to the subscription agreement, including any claim under federal securities laws. If we opposed a jury trial demand based on the waiver, a court would determine whether the waiver was enforceable given the facts and circumstances of that case in accordance with applicable case law. By agreeing to the provision, subscribers will not be deemed to have waived the company’s compliance with the federal securities laws and the rules and regulations promulgated thereunder. The provision only applies to investors who purchase shares in the offering and execute a subscription agreement and not to purchasers in secondary transactions.
| 52 |
INDEPENDENT AUDITORS
The consolidated financial statements of Coherix, Inc. and Subsidiaries as of December 31, 2017 and for the year then ended, appearing elsewhere in this Offering Circular, have been audited by UHY LLP, independent auditors, as stated in their report, which includes an explanatory paragraph as to the company’s ability to continue as a going concern, appearing elsewhere herein.
UHY LLP has not performed any procedures on the consolidated financial statements of the company as of June 30, 2018 and for the six months ended June 30, 2018 and 2017, appearing elsewhere in this Offering Circular, and expresses no opinion or conclusion on these interim consolidated financial statements.
The consolidated financial statements of Coherix, Inc. and Subsidiaries as of December 31, 2016 and for the year then ended, appearing elsewhere in this Offering Circular, have been audited by George Johnson & Company, independent auditors, as stated in their report, appearing elsewhere herein.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We have filed with the SEC a Regulation A Offering Statement on Form 1-A under the Securities Act with respect to the shares of Common Stock offered hereby. This Offering Circular, which constitutes a part of the Offering Statement, does not contain all of the information set forth in the Offering Statement or the exhibits and schedules filed therewith. For further information about us and the Common Stock offered hereby, we refer you to the Offering Statement and the exhibits and schedules filed therewith. Statements contained in this Offering Circular regarding the contents of any contract or other document that is filed as an exhibit to the Offering Statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the Offering Statement. Upon the completion of this offering, we will be required to file ongoing reports with the SEC pursuant to Regulation A. You may read and copy this information at the SEC's Public Reference Room, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website that contains reports, proxy statements and other information about issuers, including us, that file electronically with the SEC. The address of this site is www.sec.gov.
| 53 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
COHERIX, INC. AND SUBSIDIARIES
TABLE OF CONTENTS
| F-1 |
COHERIX, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED BALANCE SHEETS
| June 30, | December 31, | ||||||||
| 2018 | 2017 | ||||||||
| ASSETS | |||||||||
| CURRENT ASSETS | |||||||||
| Cash and cash equivalents | $ | 694,790 | $ | 900,660 | |||||
| Accounts receivable | |||||||||
| Trade, net | 1,584,820 | 1,522,343 | |||||||
| Related party, net | 477,503 | 362,450 | |||||||
| Inventories, net | 1,781,449 | 1,059,105 | |||||||
| Prepaid expenses and other | 217,121 | 110,987 | |||||||
| Total current assets | 4,755,683 | 3,955,545 | |||||||
| PROPERTY AND EQUIPMENT, NET | 120,579 | 93,607 | |||||||
| OTHER ASSETS | |||||||||
| Notes receivable – related parties | 1,142,853 | 1,140,353 | |||||||
| Accrued interest receivable – related parties | 297,386 | 295,803 | |||||||
| Advance to establish Chinese subsidiary | – | 505,275 | |||||||
| Other deposits | 181,470 | 181,470 | |||||||
| Intangible assets, net | 406 | 893 | |||||||
| Total other assets | 1,622,114 | 2,123,794 | |||||||
| TOTAL ASSETS | $ | 6,498,376 | $ | 6,172,946 | |||||
See notes to unaudited consolidated financial statements.
| F-2 |
COHERIX, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED BALANCE SHEETS (Continued)
| June 30, | December 31, | ||||||||
| 2018 | 2017 | ||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | |||||||||
| CURRENT LIABILITIES | |||||||||
| Lines of credit | $ | 1,722,293 | $ | 1,653,997 | |||||
| Current portion of long-term debt | 5,975,345 | 5,192,588 | |||||||
| Current portion of deferred compensation | 2,840,179 | 2,920,546 | |||||||
| Current portion of capital lease obligations | 145,545 | 145,545 | |||||||
| Accounts payable – trade | 472,280 | 174,464 | |||||||
| Accounts payable – related party | 192,697 | 185,076 | |||||||
| Current portion of accrued interest | 6,566,795 | 6,709,459 | |||||||
| Deposits | 5,320 | 38,420 | |||||||
| Preferred dividends payable | 849,963 | 864,648 | |||||||
| Other accrued liabilities | 426,211 | 440,905 | |||||||
| Total current liabilities | 19,196,628 | 18,325,648 | |||||||
| LONG-TERM LIABILITIES | |||||||||
| Long-term debt, less current portion | 5,730,906 | 6,713,071 | |||||||
| Accrued interest, less current portion | 216,263 | 216,263 | |||||||
| Capital lease obligations, less current portion | 342,388 | 412,390 | |||||||
| Total long-term liabilities | 6,289,557 | 7,341,724 | |||||||
| Total liabilities | 25,486,185 | 25,667,372 | |||||||
COMMITMENTS AND CONTINGENCIES | |||||||||
| STOCKHOLDERS’ DEFICIT | |||||||||
| Common stock, $0.001 par value, 30,000,000 authorized, and 13,091,200 and 12,973,604 shares issued and outstanding, respectively | 13,091 | 12,974 | |||||||
| Additional paid-in-capital | 35,618,155 | 35,164,347 | |||||||
| Accumulated deficit | (54,595,062 | ) | (54,690,105 | ) | |||||
| Accumulated other comprehensive income (loss) net of income taxes of $0 | (23,993 | ) | 18,358 | ||||||
| Total stockholders’ deficit | (18,987,809 | ) | (19,494,426 | ) | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $ | 6,498,376 | $ | 6,172,946 | |||||
See notes to unaudited consolidated financial statements.
| F-3 |
COHERIX, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
| Six months ended June 30, | ||||||||
| 2018 | 2017 | |||||||
| Net revenue | $ | 5,740,643 | $ | 3,910,349 | ||||
| Cost of product revenue | 1,327,618 | 912,248 | ||||||
| Gross profit | 4,413,025 | 2,998,101 | ||||||
| Operating expense | 3,680,325 | 2,659,115 | ||||||
| Income from operations | 732,700 | 338,986 | ||||||
| Other income (expense): | ||||||||
| Interest income | 1,609 | – | ||||||
| Interest expense | (647,872 | ) | (665,508 | ) | ||||
| Other income, net | 10,545 | 405 | ||||||
| Net loss on foreign currency transactions | (1,939 | ) | (3,929 | ) | ||||
| Total other expense, net | (637,657 | ) | (669,032 | ) | ||||
| Income (loss) before income tax | 95,043 | (330,046 | ) | |||||
| Income tax expense | – | – | ||||||
| Net income (loss) | $ | 95,043 | $ | (330,046 | ) | |||
| EARNINGS (LOSS) PER SHARE | ||||||||
| Net income (loss) | $ | 95,043 | $ | (330,046 | ) | |||
| Less: cumulative dividends on preferred stock | $ | – | $ | (105,499 | ) | |||
| Net income (loss) attributable to common stockholders | $ | 95,043 | $ | (435,545 | ) | |||
| Weighted-average common shares outstanding | ||||||||
| Basic | 13,065,820 | 9,356,713 | ||||||
| Dilutive effect of stock options, warrants and convertible debt | 1,768,619 | – | ||||||
| Diluted | 14,834,439 | 9,356,713 | ||||||
| Dividends declared per common share | $ | – | $ | – | ||||
| Basic earnings (loss) per share attributable to common stockholders of Coherix, Inc. | $ | 0.01 | $ | (0.05 | ) | |||
| Diluted earnings (loss) per share attributable to common stockholders of Coherix, Inc. | $ | 0.01 | $ | (0.05 | ) | |||
| COMPREHENSIVE INCOME (LOSS) | ||||||||
| Net income (loss) | $ | 95,043 | $ | (330,046 | ) | |||
| Foreign currency translation adjustment, net of income taxes of $-0- | (42,351 | ) | 1,114 | |||||
| COMPREHENSIVE INCOME (LOSS) | $ | 52,692 | $ | (328,932 | ) | |||
See notes to unaudited consolidated financial statements.
| F-4 |
COHERIX, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Six months ended June 30, | ||||||||
| 2018 | 2017 | |||||||
| OPERATING ACTIVITIES | ||||||||
| Net income (loss) | $ | 95,043 | $ | (330,046 | ) | |||
| Adjustments to reconcile net income (loss) to net cash flows from operating activities: | ||||||||
| Depreciation and amortization | 65,133 | 29,167 | ||||||
| Share-based compensation | 252,000 | 254,807 | ||||||
| Net unrealized gain on foreign currency transactions | (41,064 | ) | (3,890 | ) | ||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable | (185,149 | ) | (321,821 | ) | ||||
| Inventories | (722,343 | ) | (189,024 | ) | ||||
| Prepaid expenses and other current assets | (98,515 | ) | 19,325 | |||||
| Accrued interest receivable | (1,583 | ) | 4,052 | |||||
| Accounts payable | 305,438 | (44,921 | ) | |||||
| Accrued interest payable | 28,172 | 229,181 | ||||||
| Other accrued liabilities and deposits | (62,479 | ) | 430 | |||||
| Deferred compensation | (80,181 | ) | 76,866 | |||||
| Net cash used in operating activities | (445,528 | ) | (275,874 | ) | ||||
| INVESTING ACTIVITIES | ||||||||
| Purchase of Chinese subsidiary, net of cash acquired | 505,275 | – | ||||||
| Purchase of property and equipment | (91,766 | ) | (3,216 | ) | ||||
Net cash provided by (used in) investing activities | 413,509 | (3,216 | ) | |||||
| FINANCING ACTIVITIES | ||||||||
| Net borrowings under line of credit agreements | 168,296 | 534,929 | ||||||
| Payments on long-term debt | (306,908 | ) | (384,773 | ) | ||||
| Proceeds from issuance of long-term debt | 30,000 | 25,000 | ||||||
| Proceeds from exercise of stock options for common stock | 5,902 | 1,121 | ||||||
| Payments on capital lease obligations | (70,002 | ) | (112,000 | ) | ||||
| Net cash provided by (used in) financing activities | (172,712 | ) | 64,277 | |||||
| Effect of exchange rate changes on cash | (1,139 | ) | 4,594 | |||||
| NET CHANGE IN CASH | (205,870 | ) | (210,219 | ) | ||||
| CASH, Beginning of Year | 900,660 | 470,206 | ||||||
| CASH, End of June | $ | 649,790 | $ | 259,987 | ||||
See notes to unaudited consolidated financial statements.
| F-5 |
COHERIX, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
| Six months ended June 30, | ||||||||
| 2018 | 2017 | |||||||
| SUPPLEMENTAL CASH FLOW INFORMATION | ||||||||
| Cash paid during the six months for: | ||||||||
| Interest | $ | 448,864 | $ | 249,142 | ||||
| Income taxes | $ | – | $ | – | ||||
| SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES | ||||||||
| Conversion of long-term debt and accrued interest into common stock | $ | 193,336 | $ | – | ||||
| Notes receivable issued to exercise stock options for common stock | $ | 2,500 | $ | – | ||||
| Deferred compensation used to exercise stock options for common stock | $ | 186 | $ | – | ||||
| Issuance of term notes in lieu of accrued interest | $ | – | $ | 14,602 | ||||
See notes to unaudited consolidated financial statements.
| F-6 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 1 – BUSINESS AND OPERATIONS
Coherix, Inc. and Subsidiaries (the “Company”) is primarily engaged in the design and manufacturing of 3-D vision products for the automotive and semiconductor industries in North America, Europe, and Asia. Among the products offered, the Company produces digital holographic imaging and 3-D imaging technologies and related equipment that provide “on-the-fly” measurements within very tight tolerances.
The Company has incurred historical losses, and current liabilities exceed current assets at June 30, 2018, with the majority of the current liabilities tied to maturing long-term notes which have been a primary funding mechanism. The Company had net income for the six months ended June 30, 2018. The Company’s revenue increased significantly and operating cash flow improved during the six months ended June 30, 2018.
Currently, the Company is working with a bank that has supplied a line of credit and agreed to increase the line as discussed in Note 4. Also, the major part of the Company's debt obligations are with stockholders who have consistently extended maturity dates of such obligations.
While the Company has instituted measures to preserve cash and secure additional financing, there are uncertainties as to the success of such measures. Management realizes that the combination of these uncertainties casts substantial doubt upon the Company’s ability to continue as a going concern within one year from issuance of these financial statements. In response, the Company plans to:
| 1. | Continue the recent initiatives to generate profitable growth leading to positive operating cash flow generation |
| 2. | Negotiate extensions to existing debt maturities and/or conversion to equity |
| 3. | Conclude negotiations on a new $15 million long-term debt facility with at least $3.5 million to retire maturing long-term notes |
| 4. | Raise up to $15 million of equity capital through a Regulation A+ offering |
Having considered the above, management of the Company continues using the going concern basis in preparing the consolidated financial statements.
NOTE 2 – SummarY of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The consolidated financial statements include the accounts of Coherix, Inc., and its wholly-owned subsidiaries which include Coherix Asia Pte. Ltd., located in Singapore, Coherix Europe AB, located in Sweden, Coherix Europe GmbH, located in Germany and Coherix China, Inc., located in China. All significant intercompany balances, transactions and equity holdings have been eliminated in consolidation.
The consolidated financial statements for the six months ended June 30, 2018 and 2017 include the operating results of Coherix, Inc. and its subsidiaries for the six months ended June 30, 2018 and 2017, except for Coherix Europe AB which is only included through January 22, 2017, the date it was liquidated and dissolved, and Coherix China, Inc. which is only included since March 20, 2018, the date it was purchased.
| F-7 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Basis of Presentation and Principles of Consolidation (Continued)
In December 2017, the Company executed a 4 for 1 split of its common stock. All periods presented reflect the effect of the stock split in share and per share amounts as noted throughout these consolidated financial statements.
The accompanying interim unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for annual financial statements.
In our opinion, the accompanying interim unaudited consolidated financial statements include all adjustments of a normal, recurring nature considered necessary for a fair presentation of our financial position as of June 30, 2018 and the results of operations for the six months ended June 30, 2018 and 2017. Results of operations for the six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. The accompanying interim unaudited consolidated financial statements and related notes should be read in conjunction with our audited consolidated financial statements and related notes for the year ended December 31, 2017.
Use of Estimates
Preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments, generally with an original maturity of three months or less, to be cash equivalents.
Accounts Receivable
The Company transacts business with companies on an open credit basis. The Company’s trade accounts receivable are generally uncollateralized. The Company carries its accounts receivable at invoiced amount. The Company's policy is not to accrue interest on past due accounts receivable. The Company periodically reviews accounts receivable for collectability and establishes reserves for accounts when the Company considers amounts uncollectible. Balances that remain outstanding after the Company has used reasonable collection efforts are written off. Trade accounts receivable are stated net of an allowance for doubtful accounts of $11,271 at June 30, 2018 and December 31, 2017. Related party accounts receivable are stated net of an allowance for doubtful accounts of $32,623 and $50,000 at June 30, 2018 and December 31, 2017, respectively.
Inventories
Inventories consist of components used in manufacturing and assembling machines and are stated at the lower of cost or net realizable value with cost being determined using the first-in, first-out method. Maintenance, operating and office supplies are not inventoried, but are charged to expense when purchased. Management has deemed it impracticable to track inventories by classes of raw materials, work-in-process and finished goods. The reserve for potentially obsolete inventory totaled $52,042 and $63,183 as of June 30, 2018 and December 31, 2017, respectively.
| F-8 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Property and Equipment
Property and equipment are recorded at cost, net of accumulated depreciation and amortization. For financial statement reporting purposes, property and equipment are depreciated over estimated useful lives ranging from 3 to 7 years, with the exception of leasehold improvements which are amortized over the shorter of the life of the related lease or the useful life, all using the straight-line method of depreciation. Additions of new equipment and major renewals and replacements of existing equipment are capitalized. Repairs and maintenance expenditures are charged to expense in the year incurred. Upon sale, disposal, and retirement of property and equipment, the cost and accumulated depreciation and amortization are written off and any gain or loss is included in earnings.
Intangible Assets
The Company amortizes its intangible assets with finite lives on a straight-line basis over their estimated useful lives. The Company’s intangible assets consist of software and patents and are amortized over 10 and 15 years, respectively.
Long-Lived Assets
Long-lived assets, such as property and equipment, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no impairments recognized during the six months ended June 30, 2018 and 2017.
Income Taxes
Deferred income tax assets and liabilities are classified as noncurrent and are recorded for the estimated future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates in effect for the years in which those temporary differences are expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is recorded against deferred tax assets when the Company is unable to conclude that realization of the deferred tax assets is more likely than not.
The benefit of an uncertain tax position is recognized in the financial statements if it meets a minimum recognition threshold. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more-likely-than-not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. In a case where interest or penalties are incurred, the Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. At June 30, 2018 and December 31, 2017, there were no uncertain tax positions for which a reserve or liability is necessary.
| F-9 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Income Taxes (Continued)
At June 30, 2018 and December 31, 2017, there were no undistributed earnings of foreign subsidiaries as Coherix Asia Pte. Ltd., Coherix Europe GmbH and Coherix China, Inc., had an accumulated deficit. Coherix Europe AB was dissolved in early 2017.
Revenue Recognition
The Company recognizes product revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee if fixed or determinable, and collectability is probable. In instances where a product has to be completed based on customer specifications, revenue is deferred until tested and approved by the customer. Service and machine rental revenue is generally recognized once services are performed or based on the rental term. Cash payments received in advance for product sales are recorded as customer deposits. Cash payments received in advance for services or machine rental are recorded as deposits.
In the case of contracts with milestones, the Company has an accounting policy of recognizing revenue for contingent consideration earned from the achievement of a substantive milestone in its entirety in the period in which the substantive milestone is achieved. Substantive milestone payments are recognized upon achievement of the milestone only if all of the following conditions are met: the milestone payment relates solely to past performance, the milestone payments are non-refundable; achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; substantive effort is involved in achieving the milestone; the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone; and a reasonable amount of time passes between the execution of the contract and the first milestone payment as well as between each subsequent milestone payment. If any of these conditions are not met, the milestone payments are deferred and recognized as revenue over the term of the arrangement as the performance obligations are completed.
The Company also has a revenue licensing agreement for usage of certain intellectual property. Licensing revenue from the usage of the intellectual property is recorded based on a third party’s use of the property, on a licensing fee per item sold basis.
Shipping and Handling
The Company classifies amounts billed to customers in sales transactions related to shipping and handling as revenue, and costs incurred by the Company for shipping and handling as cost of revenue.
| F-10 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Research and Development
Research and development costs are charged to expense as incurred and amounted to approximately $867,000 and $933,000 for the six months ended June 30, 2018 and 2017, respectively.
Share-Based Compensation
Share-based compensation represents the cost related to stock-based awards granted to employees or consultants. The Company measures share-based compensation based on the estimated fair value of the award on the grant date, which is recognized as expense on a straight-line basis over the requisite service period for awards that vest over time. The Company estimates the fair value of stock options using the Black-Scholes valuation model.
Foreign Currency Translation and Transactions
Coherix Asia Pte. Ltd., which is located and operates in Singapore, keeps its books and records in U.S. Dollars (“USD”) as its functional currency is the USD. Currency transaction gains or losses are generally derived from cash, receivables and payables that are stated in a currency other than USD, and are recognized as income or expense.
Coherix Europe AB, which was located and operated in Sweden, kept its books and records in Swedish Krona (“SEK”), Coherix Europe GmbH, which is located and operates in Germany, keeps its books and records in the euro (“EUR”), and Coherix China, Inc., which is located and operates in China, keeps its books and records in the Chinese Renminbi (“RMB”). The functional currency of Coherix Europe AB is the SEK, Coherix Europe GmbH is the EUR, and Coherix China, Inc. is the RMB, the currency of the primary economic environment in which each respective subsidiary operates. Accordingly, Coherix Europe AB’s, Coherix Europe GmbH’s and Coherix China, Inc.’s financial information is translated from SEK, EUR and RMB, into USD. Assets and liabilities of each of these three entities are translated into USD based on each prevailing exchange rate at each respective balance sheet date. Revenue and expenses are translated into USD based on the average exchange rate for the respective periods. Cumulative translation adjustments are included as a separate component of stockholders’ deficit in accumulated other comprehensive income (loss). Currency transaction gains or losses are generally derived from cash, receivables and payables that are stated in a currency other than the local currency, and are recognized as income or expense.
Foreign Operations
Operations outside the United States of America are subject to risks inherent in operating under different legal systems and various political and economic environments. Among the risks are changes in existing tax laws, possible limitations on foreign investment and income repatriation, government price or foreign exchange controls, and restrictions on currency exchange. The Company does not engage in hedging activities to mitigate its exposure to fluctuations in foreign currency exchange rates.
| F-11 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Foreign Operations (Continued)
The consolidated financial statements include the operations of Coherix Asia Pte. Ltd., Coherix Europe AB, Coherix Europe GmbH and Coherix China, Inc., as described above. Included in the consolidated statements of operations and comprehensive income (loss) is net sales of approximately $884,000 and $428,000, and a net loss of approximately $132,000 and $66,000, for the six months ended June 30, 2018 and 2017, respectively, which related to these foreign subsidiaries. The consolidated balance sheet included total assets of approximately $1,225,000 and $256,000 at June 30, 2018 and December 31, 2017, respectively, which related to these foreign subsidiaries.
Comprehensive Income (Loss)
Comprehensive income (loss) is defined as net income (loss) and all non-ownership changes in stockholders’ deficit. For the Company, comprehensive income (loss) for the six months ended June 30, 2018 and 2017 consists of net income (loss) and the foreign currency translation adjustment.
Computation of EPS
Basic and diluted earnings (loss) per share (“EPS”) are computed by dividing net income (loss) attributable to common stockholders by the weighted-average common shares outstanding in the period. Diluted EPS is computed by giving effect to all potentially dilutive securities that are outstanding, and excludes the effects of any potentially antidilutive securities. The number of shares related to options, warrants, and convertible debt included in diluted EPS is based on the treasury stock or if-converted methods, as applicable.
The Company has preferred shares that earn preferred dividends. In the determination of EPS, net income available to common stockholders has been reduced by the amount of preferred dividends.
Recently Adopted Accounting Pronouncements
In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory,” (“ASU 2015-11”). ASU 2015-11 requires inventory be measured at the lower of cost or net realizable value and options that currently exist for market value be eliminated. ASU 2015-11 defines net realizable value as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company adopted this guidance on January 1, 2017 on a prospective basis. The adoption of this guidance did not have a material impact on the consolidated financial statements.
| F-12 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recently Adopted Accounting Pronouncements (Continued)
In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), which requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet instead of separating deferred taxes into current and noncurrent amounts. This amendment was adopted on January 1, 2017 on a retrospective basis. The adoption of this guidance did not have a material impact on the consolidated financial statements.
In March 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), which includes multiple amendments intended to simplify aspects of share-based payment accounting. Amendments to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, and forfeitures will be applied using a modified retrospective transition method through a cumulative-effect adjustment to equity as of the beginning of the period of adoption. Amendments to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement will be applied retrospectively, and amendments requiring the recognition of excess tax benefits and tax deficiencies in the income statement are to be applied prospectively. This ASU was adopted on January 1, 2017 and did not have a material impact on the Company’s consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718), Scope of Modification Accounting” (“ASU 2017-09”) which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. The ASU was adopted on January 1, 2018 and did not have a material impact on the Company’s consolidated financial statements.
Recent Accounting Pronouncements – Not Yet Adopted
The Company has elected to use the extended transition periods for private companies to comply with new or revised accounting standards.
In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which provides guidance for the recognition, measurement and disclosure of revenue resulting from contracts with customers and will supersede virtually all of the current revenue recognition guidance under U.S. GAAP. The FASB has also issued a number of updates to this standard. For the Company, this standard is effective for the fiscal and interim periods beginning after December 15, 2018. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.
In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”)¸which requires that all leases be reflected on the balance sheet as assets and liabilities for the rights and obligations created by these leases. For the Company, ASU 2016-02 is effective for fiscal years and interim periods beginning after December 15, 2019. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments (Topic 230): Statement of Cash Flows” (“ASU 2016-15”), which clarifies how entities should classify certain cash receipts and cash payments on the statement of cash flows. ASU 2016-15 also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. For the Company, ASU 2016-15 is effective for fiscal years and interim periods beginning after December 15, 2018. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.
| F-13 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 3 – NOTES RECEIVABLE – RELATED PARTIES
At June 30, 2018 and December 31, 2017, the Company had 33 notes receivable from stockholders with balances totaling $936,413. As these notes are no longer interest bearing, there was no interest income related to these notes for the six months ended June 30, 2018 and 2017. These notes can be extended at the Company’s option and are classified as long-term assets. The Company has the ability, and intends to, offset these notes receivable with deferred compensation liabilities owed to these related parties. At June 30, 2018 and December 31, 2017, accrued interest receivable related to these notes amounted to $295,072 and $295,072, respectively.
At June 30, 2018 and December 31, 2017, the Company had 13 and 12 notes receivable from stockholders with balances totaling $206,440 and $203,940. These notes were entered into during 2018 and 2017. One of these notes totaling $90,000 bears no interest, and 12 of these notes totaling $116,440 bear interest at 2.75%. These notes can be extended at the Company’s option and are classified as long-term assets. The Company has the ability, and intends to, offset these notes receivable with deferred compensation liabilities owed to these related parties. At June 30, 2018 and December 31, 2017, accrued interest receivable related to these notes amounted to $2,314 and $731, respectively. Related party interest income from these notes amounted to $2,314 and $0 for the six months ended June 30, 2018 and June 30, 2017, respectively.
| F-14 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 4 – LINES OF CREDIT
During the year ended December 31, 2016, the Company entered into a new credit agreement under which the Company may borrow up to $2,000,000. During the year ended December 31, 2017, the limit on this agreement was increased to $3,000,000. The Company may borrow on this line based on eligible accounts receivable, as defined in the credit agreement. The line is due on demand, with interest due monthly at prime plus 2% per annum (effective rate of 7% at June 30, 2018). The balance on the line was $1,688,293 and $1,519,997 at June 30, 2018 and December 31, 2017, respectively. Prior to June 30, 2018, the Company amended certain terms of this line, and as of June 30, 2018 the Company is now required to make monthly principal payments of $166,667 through April 2019. The Company is required to pay an annual fee of 1% of the maximum allowable borrowings, a monthly maintenance fee ranging from 0.45% to 0.65% of the average outstanding monthly balance, an additional monthly maintenance fee of 0.55% of the average outstanding monthly balance of advances made on foreign accounts receivable, and a 2% fee of the maximum allowable borrowings in the event that Company decides to exit the agreement prior to two years from the date of the agreement. The Company is required to pay interest and monthly maintenance fees on a $750,000 minimum outstanding balance. This line of credit is personally guaranteed by the chief executive officer of the Company, who is also a stockholder of the Company. See Note 9 for additional discussion.
The Company also had a line of credit under credit agreements with three stockholders of the Company. The outstanding balance of the line at June 30, 2018 and December 31, 2017 was $34,000 and $134,000, respectively.
Under this line of credit, draws can be made upon receipt of a purchase order from a customer or upon issuance of an invoice to a customer. The Company sends notice to each participant of its intent to borrow against each participant’s commitment to finance a particular purchase order or accounts receivable balance as defined in the credit agreement. Each participant confirms in writing its agreement to loan the amount set forth in the notice. Each participant can decline to loan the amount set forth in the notice. In the event of decline, the Company will immediately send notice to all participants that the participant has declined. The participants will then reach a mutual agreement to either have one or more of the other participants loan the declined amount, or move forward with the financing of the purchase order or accounts receivable balance without funding the declined amount.
Within 10 days of payment in full of the purchase order or accounts receivable balance by the customer, the Company must repay principal and interest related to that purchase order or accounts receivable balance. In the event a customer defaults on payment or a purchase order was cancelled, the Company must repay the participants within sixty days of default or cancellation.
The line bore interest at 10% through September 2016, at which point interest increased to 12.5%. As of June 30, 2018 and December 31, 2017, the Company had unutilized and available credit under this line of credit totaling $150,000 and $16,000, respectively. As of the date of this report, all commitments were beyond their initial twelve-month term and were eligible to be withdrawn by investors.
| F-15 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 5 – LONG-TERM DEBT
At June 30, 2018 and December 31, 2017, long-term debt consists of the following:
| June 30, 2018 | December 31, 2017 | |||||||
| Convertible notes payable with principal and interest ranging from 4% to 10% per annum due at maturity. These convertible notes are all past due. Approximately 28% of these convertible note balances are with related parties. | $ | 1,497,087 | $ | 1,497,087 | ||||
| Note payable with principal payments of $200,000 plus 2.2% interest due quarterly starting December 31, 2015. The note is past due and an in default. | 1,973,627 | 1,973,627 | ||||||
| Notes payable with principal balances due at maturity, and 10% to 16% interest payable at various times, depending on each respective note. As of June 30, 2018, certain of these notes with balances totaling $593,889 were amended such that maturity dates range from 2018 to 2021. These notes are unsecured. 100% of these notes are with related parties. | 251,389 | 601,389 | ||||||
| Notes payable with 4% interest due quarterly for the first two years, and principal and interest due quarterly during years three through seven. Maturity dates range from June 2020 to January 2024. These notes are unsecured. Approximately 24% of these notes are with related parties. | 615,995 | 827,706 | ||||||
| Notes payable with the principal balances due at maturity, and 4% interest due quarterly. Maturity dates range from August 2018 to December 2020. These notes are unsecured. Approximately 20% of these notes are with related parties. | 2,500,000 | 2,500,000 | ||||||
| F-16 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 5 – LONG-TERM DEBT (Continued)
| June 30, 2018 | December 31, 2017 | |||||||
| Notes payable with the principal balances due at maturity, and 8% interest due monthly. As of June 30, 2018, certain of these notes with balances totaling $2,365,000 were amended such that maturity dates range from 2018 to 2021. These notes are unsecured. Approximately 83% of these notes are with related parties. | 3,202,809 | 2,509,000 | ||||||
| Notes payable with either, principal payments due monthly and a balloon payment due at maturity, or the entire principal balance due at maturity. Interest ranging from 13% to 16% is payable due monthly. As of June 30, 2018, these notes were amended such that maturity dates range from 2018 to 2021. These notes are unsecured. Approximately 86% of these note balances are with related parties. | 780,069 | 971,575 | ||||||
| Related party notes payable with the principal balance due at maturity, and 16% interest due monthly. As of June 30, 2018, these notes were amended with a maturity date of 2019. These notes are unsecured. | 380,000 | 520,000 | ||||||
| Note payable with the principal balance due at maturity, and 10% interest due quarterly. The maturity date is September 2019. This note is collateralized by a licensing revenue contract. | 505,275 | 505,275 | ||||||
| 11,706,251 | 11,905,659 | |||||||
| Less: current portion of long-term debt | 5,975,345 | 5,192,588 | ||||||
| $ | 5,730,906 | $ | 6,713,071 | |||||
| F-17 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 5 – LONG-TERM DEBT (Continued)
No beneficial conversion feature discount was applied to the convertible notes payable as the conversion features had no intrinsic value at the date of each respective issuance or amendment to terms. Each creditor can convert the entire principal balance of its convertible note to shares of the Company’s common stock at conversion prices ranging from $2.50 to $6.25 (adjusted for 4 for 1 stock split that occurred in 2017) per common share. As of June 30, 2018, the conversion prices and the related note face amounts are as follows:
| Face Amount | ||||||
| Conversion Price at June 30, 2018 | of Notes | |||||
| 2.50 | $ | 322,289 | ||||
| 4.55 | 825,000 | |||||
| 5.00 | 50,000 | |||||
| 6.25 | 299,798 | |||||
| $ | 1,497,087 | |||||
| F-18 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 6 – CHINESE INVESTMENTS
Chinese Joint Venture
As of June 30, 2018 and December 31, 2017, the Company held 49% ownership in a Chinese joint venture (the “Chinese Affiliate”). The Company accounts for this investment using the cost method as the Company does not have the ability to exercise significant influence over the Chinese Affiliate. On September 27, 2017, the Company sent a notice of termination of the joint venture contract, due to certain events of default by the 51% owner, as defined in the joint venture contract. Pursuant to the joint venture contract, the notice was effective October 1, 2017. The JV partner responded to the letter on October 10, 2017 stating objection to the termination of the joint venture contract. The carrying value of the Company's investment was $0 at June 30, 2018 and December 31, 2017 due to an other-than-temporary impairment prior to 2016.
Advance to Establish Chinese Subsidiary
During 2017, as a result of financial difficulties of the Chinese Affiliate’s other 51% owner, the Company began negotiations to restructure the joint venture and began the process of establishing a new Chinese entity (the “New Chinese Entity”) to increase resources focused on sales and customer support of the Company’s products in China.
At December 31, 2017, under direction of local counsel, the Company had an outstanding advance totaling $505,275 to an agent of our local attorney with whom the Company has a long working relationship. This advance was used for the purpose of providing the paid-in-capital to organize the New Chinese Entity.
On March 20, 2018, ownership of the New Chinese Entity was transferred to the Company at which point the Company began consolidating Coherix China, Inc. into the Company’s financial statements. This was accounted for as an acquisition of assets as the New Chinese Entity was not a business.
NOTE 7 – COMMITMENTS AND CONTINGENCIES
Concentration, Credit, and Market Risks
Revenue from the Company’s largest customer accounted for approximately 36% of net revenue for the six months ended June 30, 2018 and 2017. Approximately 24% and 23% of accounts receivable is related to this customer at June 30, 2018 and December 31, 2017, respectively. This revenue consists of royalties from a licensing agreement for usage of certain intellectual property. The rest of the Company’s revenue relates to sales of machines, parts, or related services.
The Company sells its products and services in domestic and international markets. Ongoing credit evaluations of its customers are performed and, generally, the Company does not require collateral. Losses have historically been insignificant.
The Company from time to time may maintain cash balances with financial institutions in excess of insured limits. Management has deemed this as a normal business risk. Depository institutions are selected by management based on their review of the financial stability of the institutions.
| F-19 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 7 – COMMITMENTS AND CONTINGENCIES (Continued)
Contingencies
From time to time, the Company could be involved in various litigation matters arising in the ordinary course of business. There are no matters, individually or in aggregate, that are currently material to the Company.
Predator Programs
Under the Predator Programs (the “Program”) discussed below, during the six months ended June 30, 2018 and 2017, the Company incurred expense of $391,342 and $152,804 on Predator product sales of $2,897,490 and $1,131,364, respectively. As further described below, the Company will be required to pay royalties under the Program through 2026. The Program has been closed to new participants.
Predator Royalty With Stock Investment Program
Under the Program, investors agreed to pay cash to purchase common stock with a right to receive royalties under the Program. Under the Program, two $2,000,000 pools were established for certain investors who acquire common stock for cash or through conversion of debt. For 10 years, commencing on the date of the first shipment for the sale of a Predator unit, each $2,000,000 pool is entitled to receive 5% of the revenue from Predator product sales. The royalties are deposited into the royalty pool and are paid quarterly to investors based on each investor’s respective interest in each respective pool.
As of both June 30, 2018 and December 31, 2017, pool 1 was filled with $2,000,000 of common stock purchases, and pool 2 was filled with $332,871 of common stock purchases.
Predator Royalty Opportunity Pools
Also under the Program, certain investors with accrued interest balances agreed to forfeit their right to payment for the opportunity to enter the Program. Under the Program, three pools of participating interests were created. Two $2,000,000 pools were established for investors and employees that agreed to forgive the accrued interest owed to them by the Company or forfeit a portion of salaries or consulting fees. Another $200,000 pool was established for employees that agreed to forfeit a portion of their salary. For 10 years, commencing on the date of the first shipment for the sale of a Predator unit, each $2,000,000 pool is entitled to receive 5% of the revenue from Predator product sales and the $200,000 pool is entitled to receive 0.5% of the revenue from Predator product sales. The royalties are deposited into the royalty pool and are paid quarterly to participants based on each participant’s respective interest in the respective pool.
As of both June 30, 2018 and December 31, 2017, pool 1 was filled with $2,000,000 of forgiven accrued interest, pool 2 was filled with $856,713 of forgiven accrued interest, forfeited salaries, and consulting fees, and pool 3 was filled with $199,517 of forfeited salaries.
| F-20 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2018 and 2017
NOTE 7 – COMMITMENTS AND CONTINGENCIES (Continued)
Predator Programs (Continued)
Predator Team Member Pool
Also, under the Program, one pool was established for employees as a bonus. Under this pool, each employee is entitled to 2% of the pool royalties. For 10 years, commencing on the date of the first shipment for the sale of a Predator unit, the pool is entitled to receive 0.125% of the revenue from Predator product sales. The royalties are deposited into the royalty pool and are paid quarterly to employees at a rate of 2% per employee.
As of both June 30, 2018 and December 31, 2017, this pool was filled with 29 employees.
NOTE 8 – RELATED PARTY TRANSACTIONS
During the six months ended June 30, 2018 and 2017, the Company had product revenue from a related party through common ownership of approximately $92,400 and $94,200, respectively. The Company also had product revenue from its Chinese Affiliate of approximately $600,400 and $180,700. Related to these transactions, the Company had net accounts receivable due from related parties totaling $477,503 and $362,450 at June 30, 2018 and December 31, 2017, respectively.
The Company had accounts payable due to employees and related parties through common ownership totaling $192,697 and $185,076 at June 30, 2018 and December 31, 2017, respectively.
NOTE 9 – SUBSEQUENT EVENTS
The Company has performed a review of events subsequent to June 30, 2018. Any effect of subsequent events on these consolidated financial statements has been included as appropriate.
Subsequent to June 30, 2018, the Company amended its line of credit to increase the amount available for borrowing from $3,000,000 to $4,000,000. This amendment also includes an increase in the monthly principal payments to $250,000 through April 2019.
Subsequent to June 30, 2018, the Company amended certain notes as such notes were coming due. The principal balances of these notes totaled approximately $211,000. Subsequent to June 30, 2018, the Company also borrowed an additional $440,000 under new notes payable. In conjunction with certain of these amendments and new financing instruments, the Company issued warrants to purchase 40,000 shares of common stock with an exercise price of $5.00 per share, and reissued or extended warrants to purchase 13,760 shares of common stock with an exercise price of $3.75 per share that were outstanding at December 31, 2017 and scheduled to expire in 2018. All of these warrants now expire in 2021.
Subsequent to June 30, 2018, notes payable with balances totaling $129,000 were used to exercise 34,400 warrants ($3.75 per share).
The Company is in the process of restructuring its outstanding debt and related accrued interest, and is in the process of attempting to raise $30 million in capital through a combination of a Regulation A+ offering and new senior long-term debt.
| F-21 |
To the Board of Directors and Stockholders of
Coherix, Inc.
We have audited the accompanying consolidated financial statements of Coherix, Inc. and Subsidiaries (the “Company”), which comprise the consolidated balance sheet as of December 31, 2017, and the related consolidated statements of operations and comprehensive income (loss), stockholders’ deficit, and cash flows for the year then ended, and the related notes to the consolidated financial statements.
Management’s Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.
Auditor’s Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Coherix, Inc. and Subsidiaries as of December 31, 2017, and the results of their operations and their cash flows for the year then ended, in accordance with accounting principles generally accepted in the United States of America.
Substantial Doubt About the Company's Ability to Continue as a Going Concern
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the consolidated financial statements, the Company had a working capital deficiency of $14,370,103 and stockholders’ deficit of $19,494,426 at December 31, 2017. As discussed in Note 1 to the consolidated financial statements, while the Company has instituted measures to preserve cash and secure additional financing, there are uncertainties as to the future success of such measures. Management has stated that the combination of these uncertainties raises substantial doubt about the Company’s ability to continue as a going concern. Management’s evaluation of the events and conditions and management's plans regarding those matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to that matter.
/s/ UHY LLP
Farmington Hills, Michigan
October 2, 2018
| F-22 |
INDEPENDENT AUDITOR’S REPORT
March 16, 2018, except for Notes 3 and 13, as to which the date is September 19, 2018
To the Board of Directors
Coherix, Inc.
Report on the Consolidated Financial Statements
We have audited the accompanying consolidated financial statements of Coherix, Inc. (the “Company”) and Subsidiaries, which comprise the consolidated balance sheet as of December 31, 2016, and the related consolidated statements of operations and comprehensive income (loss), stockholders’ deficit, and cash flows for the year then ended, as well as the related notes to the consolidated financial statements.
Management’s Responsibility for the Consolidated Financial Statements
The Company’s management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.
Auditor’s Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control. Accordingly, we express no such opinion.
An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the 2016 consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Coherix, Inc. and Subsidiaries as of December 31, 2016, and the consolidated results of their operations and their consolidated cash flows for the year then ended, in accordance with accounting principles generally accepted in the United States of America.
Changes in Presentation
As disclosed in Note 3 to the consolidated financial statements, the Company has updated its 2016 consolidated financial statements to retrospectively disclose earnings (loss) per share information. Also, as disclosed in Note 13 to the consolidated financial statements, the Company has updated its 2016 consolidated financial statements to retrospectively disclose effective income tax rate information. Our opinion is not modified with respect to those matters.
/s/ GEORGE JOHNSON & COMPANY
CERTIFIED PUBLIC ACCOUNTANTS
Detroit, Michigan
| F-23 |
COHERIX, INC. AND SUBSIDIARIES
| December 31, | |||||||||
| 2017 | 2016 | ||||||||
| ASSETS | |||||||||
| CURRENT ASSETS | |||||||||
| Cash and cash equivalents | $ | 900,660 | $ | 470,206 | |||||
| Restricted cash and cash equivalents | – | 209,520 | |||||||
| Accounts receivable | |||||||||
| Trade, net | 1,522,343 | 572,022 | |||||||
| Related party, net | 362,450 | 275,304 | |||||||
| Inventories, net | 1,059,105 | 871,102 | |||||||
| Prepaid expenses and other | 110,987 | 166,281 | |||||||
| Total current assets | 3,955,545 | 2,564,435 | |||||||
| PROPERTY AND EQUIPMENT, NET | 93,607 | 136,209 | |||||||
| OTHER ASSETS | |||||||||
| Notes receivable – related parties | 1,140,353 | 956,413 | |||||||
| Accrued interest receivable – related parties | 295,803 | 299,124 | |||||||
| Advance to establish Chinese subsidiary | 505,275 | – | |||||||
| Other deposits | 181,470 | 232,910 | |||||||
| Intangible assets, net | 893 | 1,868 | |||||||
| Total other assets | 2,123,794 | 1,490,315 | |||||||
| TOTAL ASSETS | $ | 6,172,946 | $ | 4,190,959 | |||||
See notes to consolidated financial statements.
| F-24 |
COHERIX, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (Continued)
| December 31, | |||||||||
| 2017 | 2016 | ||||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | |||||||||
| CURRENT LIABILITIES | |||||||||
| Lines of credit | $ | 1,653,997 | $ | 952,876 | |||||
| Current portion of long-term debt | 5,192,588 | 5,823,695 | |||||||
| Current portion of deferred compensation | 2,920,546 | 2,972,088 | |||||||
| Current portion of capital lease obligations | 145,545 | 197,695 | |||||||
| Accounts payable – trade | 174,464 | 309,778 | |||||||
| Accounts payable – related party | 185,076 | 180,197 | |||||||
| Current portion of accrued interest | 6,709,459 | 7,817,936 | |||||||
| Deposits | 38,420 | 195,820 | |||||||
| Preferred dividends payable | 864,648 | – | |||||||
| Other accrued liabilities | 440,905 | 351,105 | |||||||
| Total current liabilities | 18,325,648 | 18,801,190 | |||||||
| LONG-TERM LIABILITIES | |||||||||
| Long-term debt, less current portion | 6,713,071 | 9,857,602 | |||||||
| Accrued interest, less current portion | 216,263 | 125,502 | |||||||
| Capital lease obligations, less current portion | 412,390 | 369,981 | |||||||
| Total long-term liabilities | 7,341,724 | 10,353,085 | |||||||
| Total liabilities | 25,667,372 | 29,154,275 | |||||||
COMMITMENTS AND CONTINGENCIES | |||||||||
| STOCKHOLDERS’ DEFICIT | |||||||||
| Series A convertible preferred stock, $0.001 par value, 400,000 shares authorized, $10 per share liquidation value, 8% cumulative, -0- and 370,988 shares issued and outstanding, respectively | |
|
– |
|
|
|
371 |
|
|
| Common stock, $0.001 par value, 30,000,000 authorized, and 12,973,604 and 9,355,276 shares issued and outstanding, respectively (a) | 12,974 | 9,355 | |||||||
| Additional paid-in-capital (a) | 35,164,347 | 28,807,834 | |||||||
| Accumulated deficit | (54,690,105 | ) | (53,778,107 | ) | |||||
| Accumulated other comprehensive income (loss) net of income taxes of $0 | 18,358 | (2,769 | ) | ||||||
| Total stockholders’ deficit | (19,494,426 | ) | (24,963,316 | ) | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $ | 6,172,946 | $ | 4,190,959 | |||||
(a) Reflects the effect of the 4 for 1 split of common stock
See notes to consolidated financial statements.
| F-25 |
COHERIX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
| Years ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Net revenue | ||||||||
| Product revenue | $ | 5,552,663 | $ | 2,439,886 | ||||
| Licensing revenue | 3,573,960 | 2,157,180 | ||||||
| Other | 257,243 | 365,237 | ||||||
| Total net revenue | 9,383,866 | 4,962,303 | ||||||
| Cost of product revenue | 2,201,011 | 1,179,442 | ||||||
| Gross profit | 7,182,855 | 3,782,861 | ||||||
| Operating expense | 5,749,249 | 5,320,961 | ||||||
| Income (loss) from operations | 1,433,606 | (1,538,100 | ) | |||||
| Other income (expense): | ||||||||
| Interest income | 1,565 | 7,453 | ||||||
| Interest expense | (1,251,772 | ) | (1,125,850 | ) | ||||
| Other income, net | 113,143 | 11,071 | ||||||
| Net loss on foreign currency transactions | (3,292 | ) | (12,944 | ) | ||||
| Total other expense, net | (1,140,356 | ) | (1,120,270 | ) | ||||
| Income (loss) before income tax | 293,250 | (2,658,370 | ) | |||||
| Income tax expense | – | – | ||||||
| Net income (loss) | $ | 293,250 | $ | (2,658,370 | ) | |||
| EARNINGS (LOSS) PER SHARE (a) | ||||||||
| Basic earnings (loss) per share attributable to common stockholders of Coherix, Inc. | $ | 0.01 | $ | (0.31 | ) | |||
| Diluted earnings (loss) per share attributable to common stockholders of Coherix, Inc. | $ | 0.01 | $ | (0.31 | ) | |||
| Weighted-average common shares outstanding | ||||||||
| Basic | 9,651,443 | 9,200,441 | ||||||
| Diluted | 11,357,258 | 9,200,441 | ||||||
| Dividends declared per common share | $ | – | $ | – | ||||
| COMPREHENSIVE INCOME (LOSS) | ||||||||
| Net income (loss) | $ | 293,250 | $ | (2,658,370 | ) | |||
| Foreign currency translation adjustment, net of income taxes of $-0- | 21,127 | 6 | ||||||
| COMPREHENSIVE INCOME (LOSS) | $ | 314,377 | $ | (2,658,364 | ) | |||
(a) Reflects the effect of the 4 for 1 split of common stock
See notes to consolidated financial statements.
| F-26 |
COHERIX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT
Years Ended December 31, 2017 and 2016
| Series A Convertible Preferred Stock | (a) Common Stock | (a) Additional | Accumulated Other Comprehensive Income (Loss), Net of | Total | ||||||||||||||||||||||||||||
| Number of | Number of | Paid-in | Accumulated | Income | Stockholders’ | |||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Taxes | Deficit | |||||||||||||||||||||||||
| Balance, January 1, 2016 | 370,988 | $ | 371 | 9,108,928 | $ | 9,109 | $ | 27,787,927 | $ | (51,119,737 | ) | $ | (2,775 | ) | $ | (23,325,105 | ) | |||||||||||||||
| Share-based compensation | – | – | – | – | 501,251 | – | – | 501,251 | ||||||||||||||||||||||||
| Issuance of common stock | – | – | 84,924 | 85 | 318,397 | – | – | 318,482 | ||||||||||||||||||||||||
| Exercise of stock options | – | – | 105,100 | 105 | 26,170 | – | – | 26,275 | ||||||||||||||||||||||||
| Conversion of debt and accrued interest into common stock | – | – | 56,324 | 56 | 174,089 | – | – | 174,145 | ||||||||||||||||||||||||
| Net loss | – | – | – | – | – | (2,658,370 | ) | – | (2,658,370 | ) | ||||||||||||||||||||||
| Foreign currency translation adjustment, net of income taxes of $0 | – | – | – | – | – | – | 6 | 6 | ||||||||||||||||||||||||
| Balance, December 31, 2016 | 370,988 | 371 | 9,355,276 | 9,355 | 28,807,834 | (53,778,107 | ) | (2,769 | ) | (24,963,316 | ) | |||||||||||||||||||||
| Share-based compensation | – | – | – | – | 490,477 | – | – | 490,477 | ||||||||||||||||||||||||
| Conversion of preferred stock
to common stock | (370,988 | ) | (371 | ) | 1,483,952 | 1,484 | (1,113 | ) | – | – | – | |||||||||||||||||||||
| Issuance of common stock | – | – | 101,816 | 102 | 508,996 | – | – | 509,098 | ||||||||||||||||||||||||
| Exercise of stock options | – | – | 633,552 | 634 | 157,754 | – | – | 158,388 | ||||||||||||||||||||||||
| Conversion of debt and accrued interest into common stock | – | – | 1,399,008 | 1,399 | 5,200,399 | – | – | 5,201,798 | ||||||||||||||||||||||||
| Preferred stock dividends declared | – | – | – | – | – | (1,205,248 | ) | – | (1,205,248 | ) | ||||||||||||||||||||||
| Net income | – | – | – | – | – | 293,250 | – | 293,250 | ||||||||||||||||||||||||
| Foreign currency translation adjustment, net of income taxes of $0 | – | – | – | – | – | – | 21,127 | 21,127 | ||||||||||||||||||||||||
| Balance, December 31, 2017 | – | $ | – | 12,973,604 | $ | 12,974 | $ | 35,164,347 | $ | (54,690,105 | ) | $ | 18,358 | $ | (19,494,426 | ) | ||||||||||||||||
(a) Reflects the effect of the 4 for 1 split of common stock
See notes to consolidated financial statements.
| F-27 |
COHERIX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Years ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| OPERATING ACTIVITIES | ||||||||
| Net income (loss) | $ | 293,250 | $ | (2,658,370 | ) | |||
| Adjustments to reconcile net income (loss) to net cash flows from operating activities: | ||||||||
| Depreciation and amortization | 47,895 | 54,305 | ||||||
| Share-based compensation | 490,477 | 501,251 | ||||||
| Net unrealized (gain) loss on foreign currency transactions | 20,550 | (868 | ) | |||||
| Forgiveness of accrued interest | (17,502 | ) | (9,068 | ) | ||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable | (1,036,168 | ) | 538,926 | |||||
| Inventories | (188,003 | ) | 15,126 | |||||
| Prepaid expenses and other current assets | 61,533 | 7,862 | ||||||
| Accrued interest receivable | 3,321 | – | ||||||
| Other deposits | 51,440 | 22,000 | ||||||
| Accounts payable | (135,179 | ) | (57,275 | ) | ||||
| Accrued interest payable | 329,601 | 275,473 | ||||||
| Other accrued liabilities and deposits | (72,844 | ) | (939 | ) | ||||
| Deferred compensation | 8,132 | (34,431 | ) | |||||
| Net cash used in operating activities | (143,497 | ) | (1,346,008 | ) | ||||
| INVESTING ACTIVITIES | ||||||||
| Advance to establish Chinese subsidiary | (505,275 | ) | – | |||||
| Purchase of property and equipment | (3,574 | ) | (6,740 | ) | ||||
| Net cash used in financing activities | (508,849 | ) | (6,740 | ) | ||||
| FINANCING ACTIVITIES | ||||||||
| Net borrowings under line of credit agreements | 701,121 | 362,876 | ||||||
| Payments on long-term debt | (600,515 | ) | (1,024,586 | ) | ||||
| Proceeds from issuance of long-term debt | 760,275 | 539,366 | ||||||
| Proceeds from issuance of common stock | – | 318,482 | ||||||
| Proceeds from exercise of stock options for common stock | 19,858 | 23,875 | ||||||
| Change in restricted cash and cash equivalents | 209,520 | 1,218,814 | ||||||
| Proceeds from capital leasing financing | 199,621 | – | ||||||
| Payments on capital lease obligations | (209,362 | ) | (301,835 | ) | ||||
| Net cash provided by financing activities | 1,080,518 | 1,136,992 | ||||||
| Effect of exchange rate changes on cash | 2,282 | (65 | ) | |||||
| NET CHANGE IN CASH | 430,454 | (215,821 | ) | |||||
| CASH, Beginning of Year | 470,206 | 686,027 | ||||||
| CASH, End of Year | $ | 900,660 | $ | 470,206 | ||||
See notes to consolidated financial statements.
| F-28 |
COHERIX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
| Years ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| SUPPLEMENTAL CASH FLOW INFORMATION | ||||||||
| Cash paid during the year for: | ||||||||
| Interest | $ | 922,171 | $ | 850,377 | ||||
| Income taxes | $ | – | $ | – | ||||
| SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES | ||||||||
| Conversion of long-term debt and accrued interest into common stock | $ | 5,201,798 | $ | 74,145 | ||||
| Preferred dividends payable used to purchase common stock | $ | 340,600 | $ | – | ||||
| Notes receivable issued to exercise stock options for common stock | $ | 203,940 | $ | 2,400 | ||||
| Issuance of term notes in lieu of accrued interest | $ | 14,602 | $ | 19,491 | ||||
| Deferred compensation used to purchase common stock or exercise stock options for common stock | $ | 39,674 | $ | – | ||||
| Deferred compensation used to pay off note receivable | $ | 20,000 | $ | – | ||||
| Common stock issued to pay accrued interest | $ | 63,415 | $ | – | ||||
| Issuance of term notes in lieu of lines of credit | $ | – | $ | 10,000 | ||||
| Common stock issued to pay stockholder line of credit | $ | – | $ | 100,000 | ||||
| Transfer of stockholder term notes to stockholder lines of credit | $ | – | $ | 200,000 | ||||
See notes to consolidated financial statements.
| F-29 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 1 – BUSINESS AND OPERATIONS
Coherix, Inc. and Subsidiaries (the “Company”) is primarily engaged in the design and manufacturing of 3-D vision products for the automotive and semiconductor industries in North America, Europe, and Asia. Among the products offered, the Company produces digital holographic imaging and 3-D imaging technologies and related equipment that provide “on-the-fly” measurements within very tight tolerances.
The Company has incurred historical losses, and current liabilities exceed current assets at December 31, 2017, with the majority of the current liabilities tied to maturing long-term notes which have been a primary funding mechanism. The Company had net income for the year ended December 31, 2017. The Company’s revenue increased significantly and operating cash flow dramatically improved during the year ended December 31, 2017. The Company also reduced its debt obligations during the year ended December 31, 2017 as many creditors also converted their debt into common shares as discussed in Note 9.
Currently, the Company is working with a bank that has supplied a line of credit and agreed to increase the line as discussed in Note 8. In 2018, the Company was also able to secure additional financing through new sale leaseback transactions. Also, the major part of the Company's debt obligations are with stockholders who have consistently extended maturity dates of such obligations.
While the Company has instituted measures to preserve cash and secure additional financing, there are uncertainties as to the success of such measures. Management realizes that the combination of these uncertainties casts substantial doubt upon the Company’s ability to continue as a going concern within one year from issuance of these financial statements. In response, the Company plans to:
| 1. | Continue the recent initiatives to generate profitable growth leading to positive operating cash flow generation |
| 2. | Negotiate extensions to existing debt maturities and/or conversion to equity |
| 3. | Conclude negotiations on a new $15 million long-term debt facility with at least $3.5 million to retire maturing long-term notes |
| 4. | Raise up to $15 million of equity capital through a Regulation A+ offering |
Having considered the above, management of the Company continues using the going concern basis in preparing the consolidated financial statements.
| F-30 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 2 – SummarY of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The consolidated financial statements include the accounts of Coherix, Inc., and its wholly-owned subsidiaries which include Coherix Asia Pte. Ltd., located in Singapore, Coherix Europe AB, located in Sweden, and Coherix Europe GmbH, located in Germany. All significant intercompany balances, transactions and equity holdings have been eliminated in consolidation.
The consolidated financial statements for the years ended December 31, 2017 and 2016 include the operating results of Coherix, Inc. and its subsidiaries for the years ended December 31, 2017 and 2016, except for Coherix Europe AB which is only included through January 22, 2017, the date it was liquidated and dissolved.
In December 2017, the Company executed a 4 for 1 split of its common stock. The Company also amended its certificate of incorporation and increased the pool of authorized shares to 30,400,000, consisting of 30,000,000 common shares and 400,000 preferred shares. All periods presented reflect the effect of the stock split in share and per share amounts as noted throughout these consolidated financial statements.
Variable Interest Entity
The Company follows the guidance of accounting for variable interest entities (“VIE”s), which requires certain VIEs to be consolidated by the primary beneficiary of the entities. The Company’s management evaluated the relationship between the Company and the New Chinese Entity discussed in Note 12. The Company concluded that it was not the primary beneficiary of the New Chinese Entity at December 31, 2017 as the Company lacked the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance. At December 31, 2017, the agent owner held the power to direct all activities of the VIE. Therefore consolidation in the Company’s financial statements is not required. As discussed in Note 12, the Company provided implicit financial support to the VIE through the advance made to the agent of our local attorney. This advance represents the maximum exposure to loss at December 31, 2017.
Use of Estimates
Preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
| F-31 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Cash and Cash Equivalents
The Company considers all highly liquid investments, generally with an original maturity of three months or less, to be cash equivalents.
Accounts Receivable
The Company transacts business with companies on an open credit basis. The Company’s trade accounts receivable are generally uncollateralized. The Company carries its accounts receivable at invoiced amount. The Company's policy is not to accrue interest on past due accounts receivable. The Company periodically reviews accounts receivable for collectability and establishes reserves for accounts when the Company considers amounts uncollectible. Balances that remain outstanding after the Company has used reasonable collection efforts are written off. Trade accounts receivable are stated net of an allowance for doubtful accounts of $11,271 at December 31, 2017 and 2016. Related party accounts receivable are stated net of an allowance for doubtful accounts of $50,000 at December 31, 2017 and 2016.
Inventories
Inventories consist of components used in manufacturing and assembling machines and are stated at the lower of cost or net realizable value with cost being determined using the first-in, first-out method. Maintenance, operating and office supplies are not inventoried, but are charged to expense when purchased. Management has deemed it impracticable to track inventories by classes of raw materials, work-in-process and finished goods. The reserve for potentially obsolete inventory totaled $63,183 and $36,259 as of December 31, 2017 and 2016, respectively.
Property and Equipment
Property and equipment are recorded at cost, net of accumulated depreciation and amortization. For financial statement reporting purposes, property and equipment are depreciated over estimated useful lives ranging from 3 to 7 years, with the exception of leasehold improvements which are amortized over the shorter of the life of the related lease or the useful life, all using the straight-line method of depreciation. Additions of new equipment and major renewals and replacements of existing equipment are capitalized. Repairs and maintenance expenditures are charged to expense in the year incurred. Upon sale, disposal, and retirement of property and equipment, the cost and accumulated depreciation and amortization are written off and any gain or loss is included in earnings.
Intangible Assets
The Company amortizes its intangible assets with finite lives on a straight-line basis over their estimated useful lives. The Company’s intangible assets consist of software and patents and are amortized over 10 and 15 years, respectively.
| F-32 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Long-Lived Assets
Long-lived assets, such as property and equipment, and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no impairments recognized during the years ended December 31, 2017 and 2016.
Income Taxes
Deferred income tax assets and liabilities are classified as noncurrent and are recorded for the estimated future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates in effect for the years in which those temporary differences are expected to be realized. The effect on deferred income tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is recorded against deferred tax assets when the Company is unable to conclude that realization of the deferred tax assets is more likely than not.
The benefit of an uncertain tax position is recognized in the financial statements if it meets a minimum recognition threshold. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more-likely-than-not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. In a case where interest or penalties are incurred, the Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. At December 31, 2017 and 2016, there were no uncertain tax positions for which a reserve or liability is necessary.
At December 31, 2017, there were no undistributed earnings of foreign subsidiaries as Coherix Asia Pte. Ltd. and Coherix Europe GmbH had an accumulated deficit. Coherix Europe AB was dissolved in early 2017.
| F-33 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Revenue Recognition
The Company recognizes product revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is probable. In instances where a product has to be completed based on customer specifications, revenue is deferred until tested and approved by the customer. Service and machine rental revenue is generally recognized once services are performed or based on the rental term. Cash payments received in advance for product sales are recorded as customer deposits. Cash payments received in advance for services or machine rental are recorded as deposits.
In the case of contracts with milestones, the Company has an accounting policy of recognizing revenue for contingent consideration earned from the achievement of a substantive milestone in its entirety in the period in which the substantive milestone is achieved. Substantive milestone payments are recognized upon achievement of the milestone only if all of the following conditions are met: the milestone payment relates solely to past performance, the milestone payments are non-refundable; achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; substantive effort is involved in achieving the milestone; the amount of the milestone is reasonable in relation to the effort expended or the risk associated with achievement of the milestone; and a reasonable amount of time passes between the execution of the contract and the first milestone payment as well as between each subsequent milestone payment. If any of these conditions are not met, the milestone payments are deferred and recognized as revenue over the term of the arrangement as the performance obligations are completed.
The Company also has a revenue licensing agreement for usage of certain intellectual property. Licensing revenue from the usage of the intellectual property is recorded based on a third party’s use of the property, on a licensing fee per item sold basis.
Shipping and Handling
The Company classifies amounts billed to customers in sales transactions related to shipping and handling as revenue, and costs incurred by the Company for shipping and handling as cost of revenue.
Research and Development
Research and development costs are charged to expense as incurred and amounted to approximately $1,385,000 and $1,615,000 for the years ended December 31, 2017 and 2016, respectively.
| F-34 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Share-Based Compensation
Share-based compensation represents the cost related to stock-based awards granted to employees or consultants. The Company measures share-based compensation based on the estimated fair value of the award on the grant date, which is recognized as expense on a straight-line basis over the requisite service period for awards that vest over time. The Company estimates the fair value of stock options using the Black-Scholes valuation model.
Foreign Currency Translation and Transactions
Coherix Asia Pte. Ltd., which is located and operates in Singapore, keeps its books and records in U.S. Dollars (“USD”) as its functional currency is the USD. Currency transaction gains or losses are generally derived from cash, receivables and payables that are stated in a currency other than USD, and are recognized as income or expense.
Coherix Europe AB, which was located and operated in Sweden, kept its books and records in Swedish Krona (“SEK”), and Coherix Europe GmbH, which is located and operates in Germany, keeps its books and records in the euro (“EUR”). The functional currency of Coherix Europe AB is the SEK, and Coherix Europe GmbH is the EUR, the currency of the primary economic environment in which the each respective subsidiary operates. Accordingly, Coherix Europe AB’s and Coherix Europe GmbH’s financial information is translated from SEK and EUR, into USD. Assets and liabilities of each of these two entities are translated into USD based on each prevailing exchange rate at each respective balance sheet date. Revenue and expenses are translated into USD based on the average exchange rate for the respective periods. Cumulative translation adjustments are included as a separate component of stockholders’ deficit in accumulated other comprehensive income (loss). Currency transaction gains or losses are generally derived from cash, receivables and payables that are stated in a currency other than the local currency, and are recognized as income or expense.
Foreign Operations
Operations outside the United States of America are subject to risks inherent in operating under different legal systems and various political and economic environments. Among the risks are changes in existing tax laws, possible limitations on foreign investment and income repatriation, government price or foreign exchange controls, and restrictions on currency exchange. The Company does not engage in hedging activities to mitigate its exposure to fluctuations in foreign currency exchange rates.
| F-35 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Foreign Operations (Continued)
The consolidated financial statements include the operations of Coherix Asia Pte. Ltd., Coherix Europe AB, and Coherix Europe GmbH as described above in Note 2. Included in the consolidated statements of operations and comprehensive income (loss) is net sales of approximately $1,075,000 and $63,000, and a net loss of approximately $115,000 and $620,000, for the years ended December 31, 2017 and 2016, respectively, which related to these foreign subsidiaries. The consolidated balance sheet included total assets of approximately $256,000 and $131,000 at December 31, 2017 and 2016, respectively, which related to these foreign subsidiaries.
Comprehensive Income (Loss)
Comprehensive income (loss) is defined as net income (loss) and all non-ownership changes in stockholders’ deficit. For the Company, comprehensive income (loss) for the years ended December 31, 2017 and 2016 consists of net income (loss) and the foreign currency translation adjustment.
Computation of EPS
Basic and diluted earnings (loss) per share (“EPS”) are computed by dividing net income (loss) attributable to common stockholders by the weighted-average common shares outstanding in the period. Diluted EPS is computed by giving effect to all potentially dilutive securities that are outstanding, and excludes the effects of any potentially antidilutive securities. The number of shares related to options, warrants, and convertible debt included in diluted EPS is based on the treasury stock or if-converted methods, as applicable.
The Company has preferred shares that earn preferred dividends. In the determination of EPS, net income available to common stockholders has been reduced by the amount of preferred dividends.
Reclassifications
Certain 2016 amounts have been reclassified to conform to the presentation adopted in 2017. These reclassifications had no effect on net loss or stockholders’ deficit.
| F-36 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recently Adopted Accounting Pronouncements
In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory,” (“ASU 2015-11”). ASU 2015-11 requires inventory be measured at the lower of cost or net realizable value and options that currently exist for market value be eliminated. ASU 2015-11 defines net realizable value as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company adopted this guidance on January 1, 2017 on a prospective basis. The adoption of this guidance did not have a material impact on the consolidated financial statements.
In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”), which requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet instead of separating deferred taxes into current and noncurrent amounts. This amendment was adopted on January 1, 2017 on a retrospective basis. The adoption of this guidance did not have a material impact on the consolidated financial statements.
In March 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), which includes multiple amendments intended to simplify aspects of share-based payment accounting. Amendments to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, and forfeitures will be applied using a modified retrospective transition method through a cumulative-effect adjustment to equity as of the beginning of the period of adoption. Amendments to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement will be applied retrospectively, and amendments requiring the recognition of excess tax benefits and tax deficiencies in the income statement are to be applied prospectively. This ASU was adopted on January 1, 2017 and did not have a material impact on the Company’s consolidated financial statements.
Recent Accounting Pronouncements – Not Yet Adopted
The Company has elected to use the extended transition periods for private companies to comply with new or revised accounting standards.
In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which provides guidance for the recognition, measurement and disclosure of revenue resulting from contracts with customers and will supersede virtually all of the current revenue recognition guidance under U.S. GAAP. The FASB has also issued a number of updates to this standard. For the Company, this standard is effective for the fiscal and interim periods beginning after December 15, 2018. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.
| F-37 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recent Accounting Pronouncements – Not Yet Adopted (Continued)
In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”)¸which requires that all leases be reflected on the balance sheet as assets and liabilities for the rights and obligations created by these leases. For the Company, ASU 2016-02 is effective for fiscal years and interim periods beginning after December 15, 2019. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments (Topic 230): Statement of Cash Flows” (“ASU 2016-15”), which clarifies how entities should classify certain cash receipts and cash payments on the statement of cash flows. ASU 2016-15 also clarifies how the predominance principle should be applied when cash receipts and cash payments have aspects of more than one class of cash flows. For the Company, ASU 2016-15 is effective for fiscal years and interim periods beginning after December 15, 2018. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation (Topic 718), Scope of Modification Accounting” (“ASU 2017-09”) which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The new guidance will reduce diversity in practice and result in fewer changes to the terms of an award being accounted for as modifications. ASU 2017-09 will be applied prospectively to awards modified on or after the adoption date. For the Company, the guidance is effective for annual periods, and interim periods within those annual periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact that this standard will have on its consolidated financial statements.
| F-38 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 3 – EARNINGS PER SHARE
The following table sets forth the computation of basic and diluted earnings per share and reflects the effects of the 4 for 1 split of common stock discussed above in Note 2:
| Years ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Basic earnings (loss) per share | ||||||||
| Net income (loss) | $ | 293,250 | $ | (2,658,370 | ) | |||
| Less: cumulative dividends on preferred stock | (193,414 | ) | (210,734 | ) | ||||
| Net income (loss) attributable to common stockholders | $ | 99,836 | $ | (2,869,104 | ) | |||
| Weighted-average common shares outstanding | 9,651,443 | 9,200,441 | ||||||
| Basic earnings (loss) per share | $ | 0.01 | $ | (0.31 | ) | |||
| Diluted earnings (loss) per share | ||||||||
| Net income (loss) attributable to common stockholders - diluted | $ | 99,836 | $ | (2,869,104 | ) | |||
| Weighted-average common shares outstanding - basic | 9,651,443 | 9,200,441 | ||||||
| Dilutive effect of stock options, warrants, and convertible debt | 1,705,815 | – | ||||||
| Weighted-average common shares outstanding - diluted | 11,357,258 | 9,200,441 | ||||||
| Diluted earnings (loss) per share | $ | 0.01 | $ | (0.31 | ) | |||
There were 2,917,287 and 4,794,426 weighted-average shares of common stock equivalents related to stock options, warrants, convertible debt, and convertible preferred stock which are anti-dilutive and therefore are not included in the computation of the weighted-average number of diluted shares shown above for the years ended December 31, 2017 and 2016, respectively.
NOTE 4 - RESTRICTED CASH AND CASH EQUIVALENTS
Certain cash and cash equivalents are maintained in separate accounts and are restricted from use pursuant to the sale-leaseback agreements discussed in Note 18. The total restricted cash and cash equivalents at December 31, 2017 and 2016 was $-0- and $209,520, respectively.
| F-39 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 5 – PROPERTY AND EQUIPMENT, NET
Property and equipment, net consist of the following:
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Machinery and equipment | $ | 691,442 | $ | 691,442 | ||||
| Computer equipment | 212,535 | 212,535 | ||||||
| Office furniture and equipment | 152,929 | 148,126 | ||||||
| Leasehold improvements | 6,707 | 6,707 | ||||||
| 1,063,613 | 1,058,810 | |||||||
| Less: accumulated depreciation and amortization | 970,006 | 922,601 | ||||||
| Property and equipment, net | $ | 93,607 | $ | 136,209 | ||||
Depreciation and amortization expense charged to operations for the years ended December 31, 2017 and 2016 was $46,920 and $53,330, respectively.
NOTE 6 – NOTES RECEIVABLE – RELATED PARTIES
At December 31, 2017 and 2016, the Company had 33 and 34 notes receivable from stockholders with balances totaling $936,413 and $956,413, respectively. As these notes are no longer interest bearing, there was no interest income related to these notes for the years ended December 31, 2017 and 2016. These notes can be extended at the Company’s option and are classified as long-term assets. The Company has the ability, and intends to, offset these notes receivable with deferred compensation liabilities owed to these related parties. At December 31, 2017 and 2016, accrued interest receivable related to these notes amounted to $295,072 and $299,124, respectively.
At December 31, 2017, the Company had 12 notes receivable from stockholders with balances totaling $203,940. These notes were entered into during 2017. One of these notes totaling $90,000 bears no interest, and 11 of these notes totaling $113,940 bear interest at 2.75%. These notes can be extended at the Company’s option and are classified as long-term assets. The Company has the ability, and intends to, offset these notes receivable with deferred compensation liabilities owed to these related parties. At December 31, 2017, accrued interest receivable related to these notes amounted to $731. Related party interest income from these notes amounted to $731 for the year ended December 31, 2017.
| F-40 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 7 – INTANGIBLE ASSETS, NET
Through a 2004 acquisition, the Company acquired assets which included $183,720 of intangible assets. Below is a summary of intangible assets:
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Software | $ | 169,588 | $ | 169,588 | ||||
| Patents | 14,132 | 14,132 | ||||||
| 183,720 | 183,720 | |||||||
| Less: accumulated amortization | 182,827 | 181,852 | ||||||
| Intangible assets, net | $ | 893 | $ | 1,868 | ||||
No significant residual value is estimated for these intangible assets. Amortization expense for each of the years ended December 31, 2017 and 2016 was $975.
Total estimated amortization of these intangible assets is expected to be $893 during the year ending December 31, 2018.
NOTE 8 – LINES OF CREDIT
During the year ended December 31, 2016, the Company entered into a new credit agreement under which the Company may borrow up to $2,000,000. During the year ended December 31, 2017, the limit on this agreement was increased to $3,000,000. The Company may borrow on this line based on eligible accounts receivable, as defined in the credit agreement. The line is due on demand, with interest due monthly at prime plus 2% per annum (effective rate of 6.5% at December 31, 2017). The balance on the line was $1,519,997 and $673,736 at December 31, 2017 and 2016, respectively. Subsequent to December 31, 2017, the Company amended certain terms of this line, and the Company is now required to make monthly principal payments of $166,667 through April 2019. The Company is required to pay an annual fee of 1% of the maximum allowable borrowings, a monthly maintenance fee ranging from 0.45% to 0.65% of the average outstanding monthly balance, an additional monthly maintenance fee of 0.55% of the average outstanding monthly balance of advances made on foreign accounts receivable, and a 2% fee of the maximum allowable borrowings in the event that Company decides to exit the agreement prior to two years from the date of the agreement. The Company is required to pay interest and monthly maintenance fees on a $750,000 minimum outstanding balance. This line of credit is personally guaranteed by the chief executive officer of the Company, who is also a stockholder of the Company.
| F-41 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 8 – LINES OF CREDIT (Continued)
The Company also had a line of credit under credit agreements with three stockholders of the Company. The outstanding balance of the line at December 31, 2017 and 2016 was $134,000 and $279,140, respectively.
Under this line of credit, draws can be made upon receipt of a purchase order from a customer or upon issuance of an invoice to a customer. The Company sends notice to each participant of its intent to borrow against each participant’s commitment to finance a particular purchase order or accounts receivable balance as defined in the credit agreement. Each participant confirms in writing its agreement to loan the amount set forth in the notice. Each participant can decline to loan the amount set forth in the notice. In the event of decline, the Company will immediately send notice to all participants that the participant has declined. The participants will then reach a mutual agreement to either have one or more of the other participants loan the declined amount, or move forward with the financing of the purchase order or accounts receivable balance without funding the declined amount.
Within 10 days of payment in full of the purchase order or accounts receivable balance by the customer, the Company must repay principal and interest related to that purchase order or accounts receivable balance. In the event a customer defaults on payment or a purchase order was cancelled, the Company must repay the participants within sixty days of default or cancellation.
The line bore interest at 10% through September 2016, at which point interest increased to 12.5%. As of December 31, 2017 and 2016, the Company had unutilized and available credit under this line of credit totaling $16,000 and $180,860, respectively. As of the date of this report, all commitments were beyond their initial twelve-month term and were eligible to be withdrawn by investors.
| F-42 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 9 – LONG-TERM DEBT
At December 31, 2017 and 2016, long-term debt consists of the following:
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Convertible notes payable with principal and interest ranging from 4% to 10% per annum due at maturity. These convertible notes are all past due. Approximately 28% of these convertible note balances are with related parties. | $ | 1,497,087 | $ | 1,512,087 | ||||
| Two convertible notes payable to a stockholder with principal and 2.2% interest due at maturity. These convertible notes were due in July 2020 and August 2020; however, the principal balances were converted to common stock during 2017. | – | 4,000,000 | ||||||
| Note payable with principal payments of $200,000 plus 2.2% interest due quarterly starting December 31, 2015. The note is past due and an in default. | 1,973,627 | 1,973,627 | ||||||
| Notes payable with principal balances due at maturity, and 16% interest due monthly. These notes were paid off during 2017. Approximately 74% of these note balances were with related parties. | – | 190,000 | ||||||
| Notes payable with principal balances due at maturity, and 10% to 16% interest payable at various times, depending on each respective note. Subsequent to December 31, 2017, certain of these notes with balances totaling $593,889 were amended such that maturity dates range from 2018 to 2021. These notes are unsecured. 100% of these notes are with related parties. | 601,389 | 575,000 | ||||||
| F-43 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 9 – LONG-TERM DEBT (Continued)
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Notes payable with 4% interest due quarterly for the first two years, and principal and interest due quarterly during years three through seven. Maturity dates range from June 2020 to January 2024. These notes are unsecured. Approximately 24% and 20% of these note balances, respectively, are with related parties. | 827,706 | 1,246,125 | ||||||
| Notes payable with the principal balances due at maturity, and 4% interest due quarterly. Maturity dates range from August 2018 to December 2020. These notes are unsecured. Approximately 20% of these note balances are with related parties. | 2,500,000 | 2,500,000 | ||||||
| Notes payable with the principal balances due at maturity, and 8% interest due monthly. Subsequent to December 31, 2017, certain of these notes with balances totaling $2,365,000 were amended such that maturity dates range from 2018 to 2021. These notes are unsecured. Approximately 83% of these notes are with related parties. | 2,509,000 | 2,509,000 | ||||||
| Notes payable with either principal payments due monthly and a balloon payment due at maturity or the entire principal balance due at maturity. Interest ranging from 13% to 16% is due monthly. Subsequent to December 31, 2017, these notes were amended such that maturity dates range from 2018 to 2021. These notes are unsecured. Approximately 86% and 87% of these note balances, respectively, are with related parties. | 971,575 | 1,055,967 | ||||||
| Related party notes payable with the principal balance due at maturity, and 16% interest due monthly. Subsequent to December 31, 2017, these notes were amended such that maturity dates range from 2019 to 2021. These notes are unsecured. | 520,000 | 110,000 | ||||||
| F-44 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 9 – LONG-TERM DEBT (Continued)
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Note payable with the principal balance due at maturity, and 10% interest due quarterly. The maturity date is September 2019. This note is collateralized by a licensing revenue contract. | 505,275 | – | ||||||
| Other | – | 9,491 | ||||||
| 11,905,659 | 15,681,297 | |||||||
| Less: current portion of long-term debt | 5,192,588 | 5,823,695 | ||||||
| $ | 6,713,071 | $ | 9,857,602 | |||||
During the year ended December 31, 2017, in light of the Company’s inability to meet its long-term debt obligations, new promissory notes were issued in lieu of term notes and convertible notes with principal balances totaling $206,389 and the related accrued interest of $14,602. During the year ended December 31, 2016, new promissory notes were issued in lieu of term notes and convertible notes with principal balances totaling $225,000 and the related accrued interest of $19,491. During the year ended December 31, 2016, the Company also entered into new agreements with the investors who held the various line of credit agreements discussed in Note 8. Under the new agreements entered into during the year ended December 31, 2016, outstanding line of credit balances to stockholders of $10,000 were converted into term notes, and term note balances of $200,000 were converted into line of credit balances to stockholders.
The Company also offered a program to those investors that converted their notes to equity in the past, but still had accrued interest balances. The Company offered these creditors the opportunity to receive royalty payments based on sales of certain products as defined in the investment offering as further discussed in Note 18, in exchange for forgiveness of accrued interest. During the year ended December 31, 2016, under this arrangement, investors agreed to forgive outstanding accrued interest related to debt totaling $9,068. There were no transactions under this arrangement during the year ended December 31, 2017. See Note 18 for further discussion.
| F-45 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 9 – LONG-TERM DEBT (Continued)
Under the Predator royalty with stock investment program discussed in Note 18, the Company offered certain creditors the opportunity to convert certain debt instruments into shares of common stock. For each $15 investment, the creditor received four shares of common stock (adjusted for 4 for 1 stock split that occurred in 2017) and will be entitled to receive royalty payments based on sales of certain products as defined in the investment offering as further discussed in Note 18. During the year ended December 31, 2016, under this arrangement, a creditor with an outstanding line of credit principal balance totaling $100,000, converted its balance into 26,668 common shares. There were no transactions under this arrangement during the year ended December 31, 2017.
During the year ended December 31, 2017, creditors with convertible notes and accrued interest totaling $5,201,798 converted their notes and accrued interest into 1,399,008 common shares. During the year ended December 31, 2016, creditors with convertible notes and accrued interest totaling $74,145 converted their notes and accrued interest into 29,656 common shares. These conversions were not part of the Predator Programs.
No beneficial conversion feature discount was applied to the convertible notes payable as the conversion features had no intrinsic value at the date of each respective issuance or amendment to terms. Each creditor can convert the entire principal balance of its convertible note to shares of the Company’s common stock at conversion prices ranging from $2.50 to $6.25 (adjusted for 4 for 1 stock split that occurred in 2017) per common share. As of December 31, 2017, the conversion prices and the related note face amounts are as follows:
| Face Amount | ||||||
| Conversion Price at December 31, 2017 | of Notes | |||||
| 2.50 | $ | 322,289 | ||||
| 4.55 | 825,000 | |||||
| 5.00 | 50,000 | |||||
| 6.25 | 299,798 | |||||
| $ | 1,497,087 | |||||
Two convertible notes that had their principal balance converted to common stock during the year ended December 31, 2017 also have a provision that allows the accrued interest to be converted at the same anti-dilutive rate as the principal balance. The anti-dilutive feature requires adjustment to the conversion price for any deemed issuance of common stock in accordance with the agreements. As of December 31, 2017, there was accrued interest related to these convertible notes totaling approximately $216,300 for which the conversion price was estimated to be approximately $3.44 (adjusted for 4 for 1 stock split that occurred in 2017).
| F-46 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 9 – LONG-TERM DEBT (Continued)
See Note 20 for discussion of subsequent events. As of December 31, 2017, the maturities of long-term debt are as follows:
| Year ending December 31, | Amount | |||||
| 2018 | $ | 5,192,588 | ||||
| 2019 | 2,578,926 | |||||
| 2020 | 1,158,597 | |||||
| 2021 | 2,957,757 | |||||
| 2022 | 10,390 | |||||
| Thereafter | 7,401 | |||||
| $ | 11,905,659 | |||||
NOTE 10 – DEFERRED COMPENSATION
Through a five-year deferred compensation plan, the Company offers qualified employees and consultants the opportunity to elect to defer all or a portion of compensation earned. Each participant may elect their respective deferral amount. The deferrals earned interest at 8% compounded annually through August 2015 and ceased accruing interest subsequent to that date. No new deferrals have been made under this five-year deferred compensation plan since 2011.
In 2016, the majority of all employees and consultants took short-term salary reductions which were treated as short-term deferred compensation, accruing interest at 2.75%.
At December 31, 2017 and 2016, deferred compensation totaled $2,920,546 and $2,972,088, respectively, of which $288,654 and $156,223 was accruing interest at 2.75%, respectively. As discussed above, certain deferrals were due five years after the original deferral was made, while others were due upon the Company meeting certain financial criteria as defined in the respective deferred compensation agreements. As of December 31, 2017, all deferred compensation was past due.
During the year ended December 31, 2017, deferred compensation of $39,674 was used to purchase common stock or exercise stock options for common stock.
| F-47 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 11 – ACCRUED INTEREST
Under the terms of the Company’s lines of credit discussed in Note 8, long-term debt arrangements discussed in Note 9, and deferred compensation arrangements discussed in Note 10, the Company has short-term and long-term obligations to pay its accrued interest. The due dates of accrued interest as of December 31, 2017 are as follows:
| Year ending December 31, | Amount | |||||
| Past due or due in 2018 | $ | 6,709,459 | ||||
| 2020 | 216,263 | |||||
| $ | 6,925,722 | |||||
At December 31, 2017, approximately $4,600,000 of accrued interest was frozen and was no longer accruing compounded interest, and approximately $2,200,000 of accrued interest was accruing compounded interest at rates ranging from 2.2%-10% as detailed in Note 9. The remaining accrued interest is being paid in accordance with payment terms as described in Note 9.
As of December 31, 2017 and 2016, accrued interest owed to related parties totaled approximately $5,500,000 and $6,200,000, respectively. Interest expense to related parties totaled approximately $745,000 and $765,000 for the years ended December 31, 2017 and 2016, respectively.
NOTE 12 – CHINESE INVESTMENTS
Chinese Joint Venture
As of December 31, 2017 and 2016, the Company held 49% ownership in a Chinese joint venture (the “Chinese Affiliate”). The Company accounts for this investment using the cost method as the Company does not have the ability to exercise significant influence over the Chinese Affiliate. On September 27, 2017, the Company sent a notice of termination of the joint venture contract, due to certain events of default by the 51% owner, as defined in the joint venture contract. Pursuant to the joint venture contract, the notice was effective October 1, 2017. The carrying value of the Company's investment was $-0- at December 31, 2017 and 2016 due to an other-than-temporary impairment prior to 2016.
Advance to Establish Chinese Subsidiary
During 2017, as a result of financial difficulties of the Chinese Affiliate’s other 51% owner, the Company began negotiations to restructure the joint venture and began the process of establishing a new Chinese entity (the “New Chinese Entity”) to increase resources focused on sales and customer support of the Company’s products in China.
| F-48 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 12 – CHINESE INVESTMENTS (Continued)
At December 31, 2017, under direction of local counsel, the Company had made an advance totaling $505,275 to an agent of our local attorney with whom the Company has a long working relationship. This advance was used for the purpose of providing the paid-in-capital to organize the New Chinese Entity which incurred approximately $27,000 in administrative expenses during 2017.
At December 31, 2017, the New Chinese Entity was a variable interest entity. However, it was determined that the Company was not the primary beneficiary of the New Chinese Entity as the Company could not exercise effective control over the VIE at December 31, 2017. See Note 2 for further discussion regarding the VIE entity.
On March 20, 2018, ownership of the New Chinese Entity was transferred to the Company, at which point the Company began consolidating the New Chinese Entity in the Company’s financial statements.
NOTE 13 – INCOME TAXES
On December 22, 2017, the Tax Cuts and Jobs Act was signed into law. The principal element of the Tax Cuts and Jobs Act relevant to the Company’s consolidated financial statements is a reduction in the U.S. federal corporate tax rate from 34% to 21%, effective for the Company on January 1, 2018. Other provisions of the Tax Cuts and Jobs Act did not have a significant impact on the Company’s consolidated financial statements for the year ended December 31, 2017.
The provision for income taxes for the years ended December 31, 2017 and 2016 is summarized as follows:
| Years ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Current provision (benefit): | ||||||||
| U.S. federal | $ | – | $ | – | ||||
| State | – | – | ||||||
| Foreign | – | – | ||||||
| – | – | |||||||
| Deferred provision (benefit): | ||||||||
| U.S. federal | 136,823 | (494,072 | ) | |||||
| State | 19,537 | (122,299 | ) | |||||
| Foreign | (85,899 | ) | 23,283 | |||||
| Impact of change in enacted tax rates | 5,038,727 | – | ||||||
| Change in valuation allowance | (5,109,188 | ) | 593,088 | |||||
| – | – | |||||||
| Total provision for income taxes | $ | – | $ | – | ||||
| F-49 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 13 – INCOME TAXES (Continued)
The effective tax rate varies from the current U.S. federal statutory income tax rate as follows:
| Year ended December 31, | ||||||||
| 2017 | 2016 | |||||||
| Statutory rate | 34% | 34% | ||||||
| State and local taxes | 7% | 5% | ||||||
| Permanent differences | 2% | -14% | ||||||
| Tax credits | -28% | 3% | ||||||
| Foreign operations | 9% | -6% | ||||||
| Change in enacted tax rates | 1718% | 0% | ||||||
| Valuation allowance | -1742% | -22% | ||||||
| 0% | 0% | |||||||
The components of the Company's deferred income taxes are as follows:
| December 31, | ||||||||
| 2017 | 2016 | |||||||
| Deferred income tax assets: | ||||||||
| Net operating loss carryforwards | $ | 7,383,229 | $ | 11,830,825 | ||||
| R & D credit carryforward | 2,075,076 | 1,951,125 | ||||||
| Capital loss carryforward | 67,030 | – | ||||||
| Accounts receivable | 13,970 | 21,935 | ||||||
| Inventories | 87,594 | 142,553 | ||||||
| Investments | 114,000 | 179,000 | ||||||
| Accounts payable and accrued liabilities | 650,170 | 1,002,288 | ||||||
| Deferred compensation | 665,884 | 1,064,008 | ||||||
| Total deferred tax assets | 11,056,953 | 16,191,734 | ||||||
| Deferred income tax liabilities: | ||||||||
| Property, equipment, and intangible assets | 20,123 | 45,716 | ||||||
| Net deferred tax asset | 11,036,830 | 16,146,018 | ||||||
| Valuation allowance | (11,036,830 | ) | (16,146,018 | ) | ||||
| Net of valuation allowance | $ | – | $ | – | ||||
| F-50 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 13 – INCOME TAXES (Continued)
Due to historical losses and based on management’s estimates of future income, management has recorded a full reserve against the net deferred tax asset as of December 31, 2017 and 2016.
At December 31, 2017, Coherix, Inc. has approximately $32 million of unused operating loss carryforwards in the U.S. that may be applied against future taxable income of Coherix, Inc. and expire beginning in 2026. Coherix, Inc. also has approximately $2.1 million of unused R & D credits that may be applied against future income tax of Coherix, Inc. and expire beginning in 2025. Also at December 31, 2017, Coherix Asia Pte. Ltd. and Coherix Europe AB, respectively, had approximately $1.6 million and $0.6 million of unused operating loss carryforwards that do not expire, and may be applied against future taxable income in each respective country.
Coherix, Inc. and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations by tax authorities for years before fiscal year 2013.
NOTE 14 – SHARE-BASED COMPENSATION
The Company has a stock option plan (the “Plan”) under which officers, key employees, and non-employee directors may be granted options to purchase shares of common stock. As of December 31, 2017, the Company’s Board of Directors and shareholders had approved a pool of 5,100,000 options that could be issued under the plan. Options currently expire no later than 10 years from the grant date and generally vest within 1-4 years.
| F-51 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 14 – SHARE-BASED COMPENSATION (Continued)
Additional information with respect to the Plan’s stock option activity is as follows:
| Weighted | ||||||||||||
| Weighted | Average | |||||||||||
| Average | Remaining | |||||||||||
| Number | Exercise | Contractual | ||||||||||
| of Options | Price | Term in Years | ||||||||||
| Outstanding at January 1, 2016 | 1,764,468 | $ | 0.25 | |||||||||
| Granted | 188,000 | $ | 0.25 | |||||||||
| Exercised | (105,100 | ) | $ | 0.25 | ||||||||
| Cancelled | (188,692 | ) | $ | 0.25 | ||||||||
| Outstanding at December 31, 2016 | 1,658,676 | $ | 0.25 | |||||||||
| Granted | 492,000 | $ | 0.25 | |||||||||
| Exercised | (633,552 | ) | $ | 0.25 | ||||||||
| Cancelled | (161,028 | ) | $ | 0.25 | ||||||||
| Outstanding at December 31, 2017 | 1,356,096 | $ | 0.25 | 7.3 | ||||||||
| Vested and expected to vest in | ||||||||||||
| the future at December 31, 2017 | 1,356,096 | $ | 0.25 | 7.3 | ||||||||
| Options exercisable at | ||||||||||||
| December 31, 2017 | 662,476 | $ | 0.25 | 5.4 | ||||||||
At December 31, 2017, the intrinsic value of options vested and expected to vest totaled approximately $4,746,000, and the intrinsic value of options exercisable totaled approximately $2,319,000.
| F-52 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 14 – SHARE-BASED COMPENSATION (Continued)
The Company recorded share-based compensation expense totaling $490,477 and $458,526 related to outstanding options for the years ended December 31, 2017 and 2016, respectively. At December 31, 2017, unrecognized compensation cost related to stock options totaled approximately $2,651,000, which is expected to be recognized over a weighted-average period of approximately 3.1 years.
During the years ended December 31, 2017 and 2016, options were exercised for $158,388 and $26,275, respectively. As of the exercise dates, there was an intrinsic value of these exercised options of approximately $2,217,000 and $368,000 for the years ended December 31, 2017 and 2016, respectively.
The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2017 and 2016 was $3.55 and $3.54 per option (adjusted for 4 for 1 stock split that occurred in 2017), respectively. These amounts were determined using the Black-Scholes option pricing model, which values options based on the stock price at the grant date, expected term of the option, expected volatility of the stock, expected dividend payments, and risk-free interest rate over the expected term of the option. The Company accounts for any forfeitures of options when they occur. The assumptions used in the Black-Scholes model were as follows for the years ended December 31, 2017 and 2016 (adjusted for 4 for 1 stock split that occurred in 2017):
| Risk-free interest rate | 1.8% - 2.4% | |
| Expected volatility | 30% | |
| Expected dividend yield | 0% | |
| Expected term | 10 years | |
| Stock price | $3.75 |
The Black-Scholes option valuation model was developed for estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Because option valuation models require the use of subjective assumptions, changes in these assumptions can materially affect the fair value of the options. As the Company’s options do not have the characteristics of traded options, the option valuation models do not necessarily provide a reliable measure of the fair value of its options.
| F-53 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 15 – WARRANTS
Warrants were issued to certain board members for their services to the Company and certain investors in conjunction with the Company’s debt. Additional information regarding warrants is as follows:
| Weighted | ||||||||||||||
| Weighted | Average | |||||||||||||
| Average | Remaining | |||||||||||||
| Number | Exercise | Contractual | ||||||||||||
| of Warrants | Price | Term in Years | ||||||||||||
| Outstanding at January 1, 2016 | 705,496 | 3.67 | ||||||||||||
| Granted | 344,148 | 0.51 | ||||||||||||
| Exercised | – | – | ||||||||||||
| Cancelled | (3,000 | ) | 2.50 | |||||||||||
| Outstanding at December 31, 2016 | 1,046,644 | 2.63 | ||||||||||||
| Granted | 74,000 | 0.25 | ||||||||||||
| Exercised | – | – | ||||||||||||
| Cancelled | (62,204 | ) | 2.69 | |||||||||||
| Outstanding at December 31, 2017 | 1,058,440 | 2.47 | 4.0 | |||||||||||
At December 31, 2017 and 2016, 693,440 and 735,644 of the outstanding warrants were exercisable, respectively, and the remaining warrants were restricted. As defined in the warrant agreements, these restricted warrants can only be exercised upon a change in control or liquidity event. The Company recorded share-based compensation expense totaling $-0- and $42,725 related to warrants for the years ended December 31, 2017 and 2016, respectively. At December 31, 2017, unrecognized compensation cost related to warrants totaled approximately $1,360,000, which all related to the restricted warrants and is expected to be recognized upon a change in control or liquidity event, as defined in the warrant agreement.
The weighted-average grant-date fair value of warrants granted during the years ended December 31, 2017 and 2016 was $3.55 and $3.33 per warrant (adjusted for 4 for 1 stock split that occurred in 2017), respectively. The assumptions used in the Black-Scholes model were as follows for the years ended December 31, 2017 and 2016 (adjusted for 4 for 1 stock split that occurred in 2017):
| Risk-free interest rate | 0.5% - 2.2% | |
| Expected volatility | 30% | |
| Expected dividend yield | 0% | |
| Expected term | 1.5 - 10 years | |
| Stock price | $3.75 |
The warrant valuation models do not necessarily provide a reliable measure of the fair value of the Company’s warrants.
| F-54 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 16 – CONVERTIBLE PREFERRED STOCK
The Company’s preferred stock has liquidation preference over the common stock. Each share of preferred stock can be converted into one share of common stock. These preferred shares automatically convert to common shares upon a qualifying initial public offering, as defined in the Company’s amended certificate of incorporation. The shares have a $10 per share liquidation value and accrue cumulative, non-compounding dividends at an annual rate of 8%. The Company has no obligation to pay these preferred dividends until declared by the Board of Directors.
At December 31, 2016, the Company had preferred stock dividends in arrears totaling $1,011,834. These preferred dividends are not recorded as a liability on the Company’s consolidated balance sheet until declared by the Board of Directors.
On November 30, 2017, the Board of Directors declared preferred dividends totaling $1,205,248 which represented the total accrued cumulative dividends on all preferred stock through that date. All preferred stockholders concurrently converted 370,988 preferred shares into 1,483,952 common shares. In conjunction with these transactions, certain preferred stockholders used preferred dividends payable totaling $340,600 to purchase 68,120 common shares.
At December 31, 2017, the Company had a balance of preferred dividends payable totaling $864,648 that is included in the consolidated balance sheet, and there were no preferred stock dividends in arrears that were not declared by the Board of Directors.
| F-55 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 17 – EMPLOYEE RETIREMENT PLAN
The Company provides an employee 401(k) savings and retirement plan in which qualified employees may elect to defer a portion of their gross pay and contribute to the plan. Employer contributions are discretionary. There were no employer contributions made during the years ended December 31, 2017 and 2016.
NOTE 18 – COMMITMENTS AND CONTINGENCIES
Operating Lease Commitments
The Company leases certain office and warehouse space under non-cancelable operating leases. Total rent expense for years ended December 31, 2017 and 2016 was $336,016 and $358,713, respectively, of which approximately $198,000 each year was to stockholders. Future minimum payments required under the aforementioned non-cancelable operating leases as of December 31, 2017 are as follows:
| Year ending December 31, | Amount | |||||
| 2018 | $ | 247,017 | ||||
| 2019 | 103,434 | |||||
| $ | 350,451 | |||||
Sale-Leaseback Transactions
At December 31, 2017 and 2016, the Company was party to various sale-leaseback arrangements. The leases were determined to be capital leases. These transactions were treated as financing transactions, with the related machines retained at their historical cost basis.
| F-56 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 18 – COMMITMENTS AND CONTINGENCIES (Continued)
Sale-Leaseback Transactions (Continued)
The following is a schedule of future lease payments required under the capital leases as of December 31, 2017:
| Year ending December 31, | Amount | |||
| 2018 | $ | 145,399 | ||
| 2019 | 224,382 | |||
| 2020 | 170,082 | |||
| 2021 | 66,314 | |||
| Total minimum lease payments | 606,177 | |||
| Less – amount representing interest | 48,242 | |||
| Present value of minimum capital lease payments | 557,935 | |||
| Less – current portion | 145,545 | |||
| Long-term obligation under capital leases | $ | 412,390 | ||
Under certain sale-leaseback transactions, the Company received restricted cash that was held in an escrow account. During the year ended December 31, 2016, $116,400 was released from escrow, leaving $209,520 still held in escrow at December 31, 2016. During the year ended December 31, 2017, the remaining $209,520 was released from escrow, and the Company received additional proceeds of $199,621 from new sale-leaseback transactions.
At December 31, 2017 and 2016, the cost of equipment held under capital leases totaled $257,311, and accumulated depreciation totaled $133,233 and $168,706, respectively.
Concentration, Credit, and Market Risks
Revenue from the Company’s largest customer accounted for approximately 38% and 42% of net revenue for the years ended December 31, 2017 and 2016, respectively. Approximately 23% and 28% of accounts receivable is related to this customer at December 31, 2017 and 2016, respectively. This revenue consists of royalties from a licensing agreement for usage of certain intellectual property. The rest of the Company’s revenue relates to sales of machines, parts, or related services.
The Company sells its products and services in domestic and international markets. Ongoing credit evaluations of its customers are performed and, generally, the Company does not require collateral. Losses have historically been insignificant.
For the years ended December 31, 2017 and 2016, approximately 65% and 62% of net revenue are from customers located in foreign countries in North America, Europe, and Asia.
| F-57 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 18 – COMMITMENTS AND CONTINGENCIES (Continued)
Concentration, Credit, and Market Risks (Continued)
The Company from time to time may maintain cash balances with financial institutions in excess of insured limits. Management has deemed this as a normal business risk. Depository institutions are selected by management based on their review of the financial stability of the institutions.
Contingencies
From time to time, the Company could be involved in various litigation matters arising in the ordinary course of business. There are no matters, individually or in aggregate, that are currently material to the Company.
Predator Programs
Under the Predator Programs (the “Program”) discussed below, during the years ended December 31, 2017 and 2016, the Company incurred expense of $425,906 and $103,415 on Predator product sales of $3,153,404 and $685,690, respectively. As further described below, the Company will be required to pay royalties under the Program through 2026. The Program has been closed to new participants.
Predator Royalty With Stock Investment Program
Under the Program, investors agreed to pay cash to purchase common stock with a right to receive royalties under the Program. Under the Program, two $2,000,000 pools were established for certain investors who acquire common stock for cash or through conversion of debt. For 10 years, commencing on the date of the first shipment for the sale of a Predator unit, each $2,000,000 pool is entitled to receive 5% of the revenue from Predator product sales. The royalties are deposited into the royalty pool and are paid quarterly to investors based on each investor’s respective interest in each respective pool.
As of both December 31, 2017 and 2016, pool 1 was filled with $2,000,000 of common stock purchases, and pool 2 was filled with $332,871 of common stock purchases.
| F-58 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 18 – COMMITMENTS AND CONTINGENCIES (Continued)
Predator Programs (Continued)
Predator Royalty Opportunity Pools
As discussed in Note 9, certain investors with accrued interest balances agreed to forfeit their right to payment for the opportunity to enter the Program. Under the Program, three pools of participating interests were created. Two $2,000,000 pools were established for investors and employees that agreed to forgive the accrued interest owed to them by the Company or forfeit a portion of salaries or consulting fees. Another $200,000 pool was established for employees that agreed to forfeit a portion of their salary. For 10 years, commencing on the date of the first shipment for the sale of a Predator unit, each $2,000,000 pool is entitled to receive 5% of the revenue from Predator product sales and the $200,000 pool is entitled to receive 0.5% of the revenue from Predator product sales. The royalties are deposited into the royalty pool and are paid quarterly to participants based on each participant’s respective interest in the respective pool.
As of both December 31, 2017 and 2016, pool 1 was filled with $2,000,000 of forgiven accrued interest, pool 2 was filled with $856,713 of forgiven accrued interest, forfeited salaries, and consulting fees, and pool 3 was filled with $199,517 of forfeited salaries.
Predator Team Member Pool
Also, under the Program, one pool was established for employees as a bonus. Under this pool, each employee is entitled to 2% of the pool royalties. For 10 years, commencing on the date of the first shipment for the sale of a Predator unit, the pool is entitled to receive 0.125% of the revenue from Predator product sales. The royalties are deposited into the royalty pool and are paid quarterly to employees at a rate of 2% per employee.
As of both December 31, 2017 and 2016, this pool was filled with 29 employees.
NOTE 19 – RELATED PARTY TRANSACTIONS
During the years ended December 31, 2017 and 2016, the Company had product revenue from a related party through common ownership of approximately $253,000 and $254,000, respectively. The Company also had product revenue from its Chinese Affiliate of approximately $486,000 and $396,000, and support fee revenue of approximately $56,000 and $203,000, respectively. Related to these transactions, the Company had net accounts receivable due from related parties totaling $362,450 and $275,304 at December 31, 2017 and 2016, respectively.
The Company had accounts payable due to employees and related parties through common ownership totaling $185,076 and $180,197 at December 31, 2017 and 2016, respectively.
| F-59 |
COHERIX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2017 and 2016
NOTE 19 – RELATED PARTY TRANSACTIONS (Continued)
In addition, as discussed in Note 6, at December 31, 2017 and 2016, the Company had notes receivable and accrued interest due from stockholders. As discussed in Note 8, the Company has a line of credit with certain stockholders. As discussed in Note 9, the Company has various notes payables and accrued interest due from stockholders.
NOTE 20 – SUBSEQUENT EVENTS
The Company has performed a review of events subsequent to December 31, 2017 through October 2, 2018, the date the consolidated financial statements were available to be issued. Any effect of subsequent events on these consolidated financial statements has been included as appropriate.
As discussed in Note 8, subsequent to December 31, 2017, the Company amended its $3,000,000 line of credit.
As discussed in Note 9, subsequent to December 31, 2017, the Company amended certain notes as such notes were coming due. The principal balances of these notes totaled approximately $4,000,000. Subsequent to December 31, 2017, the Company also borrowed an additional $470,000 under new notes payable and a new leasing arrangement. In conjunction with certain of these amendments and new financing instruments, the Company issued warrants to purchase 40,000 and 122,000 shares of common stock with an exercise price of $5.00 and $3.75 per share, respectively, and reissued or extended warrants to purchase 380,000 shares of common stock with an exercise price of $3.75 per share that were outstanding at December 31, 2017 and scheduled to expire in 2018. All of these warrants now expire in 2021.
Subsequent to December 31, 2017, notes payable with balances totaling $151,500 were used to exercise 40,400 warrants ($3.75 per share).
As of the date of this report, the Company is in the process of restructuring its outstanding debt and related accrued interest, and is in the process of attempting to raise $30 million in capital through a combination of a Regulation A+ offering and new senior long-term debt.
| F-60 |
PART III
INDEX TO EXHIBITS
| 2.1. | Amended and Restated Certificate of Incorporation, as amended |
| 2.2. | Bylaws |
| 3.1. | Amended and Restated Investors’ Rights Agreement, dated July 23, 2018, by and among Coherix, Inc., Xintai US Investment LLC and Dwight D. Carlson |
| 4. | Form of Subscription Agreement* |
| 6.1. | Technical Collaboration and License Agreement, dated March 28, 2012, by and between Coherix, Inc. and Panasonic Factory Solutions Co., Ltd. |
| 6.2. | Loan and Security Agreement dated August 19, 2016, between Crestmark Bank, Coherix ,Inc. and Dwight D. Carlson, as amended |
| 11.1. | Auditors’ Consent |
| 11.2. | Auditors’ Consent |
| 12. | Opinion of CrowdCheck Law LLP* |
| 13. | Testing the Waters materials* |
________________________
*To be filed by amendment
SIGNATURES
Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Ann Arbor, State of Michigan, on November 2, 2018.
| COHERIX, INC. | |
| /s/ Dwight D. Carlson | |
| Dwight D. Carlson, Chief Executive Officer |
The offering statement has been signed by the following persons in the capacities and on the dates indicated.
| Signature | Title | Date |
/s/ Dwight D. Carlson Dwight D. Carlson |
Chief Executive Officer, Chairman of the Board of Directors, Acting CFO | November 2, 2018 |
/s/ Michael Schneider Michael Schneider |
Principal Accountant | November 2, 2018 |
/s/ Jun Ni Jun Ni |
Director | November 2, 2018 |
/s/ Philip Rice II Philip Rice II |
Director | November 2, 2018 |
/s/ Robert A/ Smith Robert A. Smith |
Director | November 2, 2018 |
____________ Jinyang Wen |
Director |
Exhibit 2.1
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
COHERIX, INC.
Coherix, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”) hereby certifies as follows:
1. The original Certificate of Incorporation of Coherix, Inc. (the “Corporation”) was filed with the Secretary of State of the State of Delaware on October 30, 2003, under the name “RealCite Inc.” A Certificate of Amendment to the Certificate of Incorporation was filed on July 20, 2004 changing the name of the Corporation to its present name; a Certificate of Amendment to the Certificate of Incorporation was filed on August 16, 2004 to increase the number of authorized shares of Common Stock of the Corporation; a Certificate of Amendment to the Certificate of Incorporation was filed on December 13, 2005 to increase the number of authorized shares of Common Stock of the Corporation; and a Certificate of Amendment to the Certificate of Incorporation was filed on November 10, 2008 to increase the number of authorized shares of Common Stock of the Corporation.
2. This Amended and Restated Certificate of Incorporation (this “Restated Certificate”) was duly adopted in accordance with Section 141, Section 242 and Section 245 of the Delaware General Corporation Law, and has been duly approved by the written consent of the stockholders of the corporation in accordance with Section 228 of the Delaware General Corporation Law.
3. The Certificate of Incorporation is hereby amended and restated in its entirety to read as follows:
ARTICLE I
The name of the corporation is Coherix, Inc.
ARTICLE II
The registered office of the Corporation in the State of Delaware and New Castle County shall be 1313 Market Street, Suite 5100, Wilmington, Delaware 19801. The registered agent at such address shall be PHS Corporate Services, Inc.
ARTICLE III
The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of the State of Delaware.
ARTICLE IV
The total number of shares of all classes of stock that the Corporation shall have authority to issue is 3,500,000 shares, consisting of (i) 3,300,000 shares of Common Stock, $.001 par value per share (“Common Stock”), and (ii) 200,000 shares of Preferred Stock, $.001 par value per share (“Preferred Stock”).
| 1 |
The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation:
A. Common Stock.
1. General. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of any series as may be designated by the Board of Directors upon any issuance of the Preferred Stock of any series.
2. Voting. The holders of the Common Stock are entitled to vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings); provided, however, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to the Restated Certificate that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Restated Certificate or pursuant to the DGCL. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of the Restated Certificate) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the DGCL.
3. Dividends. Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined by the Board of Directors but subject to any preferential dividend or other rights of any then outstanding Preferred Stock.
4. Liquidation. Upon the dissolution or liquidation of the Corporation, whether voluntary or involuntary, holders of Common Stock will be entitled to receive all assets that may be legally distributed to the Corporation’s stockholders, subject to any preferential rights of any then outstanding Preferred Stock.
B. Series A Preferred Stock. 200,000 shares of the authorized and unissued Preferred Stock of the Corporation are hereby designated “Series A Preferred Stock” with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations.
1. Dividend Rights.
(a) Dividends. The holders of Series A Preferred Stock, in preference to the holders of all other capital stock of the Corporation, shall be entitled to receive cumulative, non-compounding dividends, which shall accrue, whether or not declared by the Board, at an annual rate of 8% of the Original Issue Price (as defined below) on each outstanding share of Series A Preferred Stock. The Corporation shall have no obligation to pay any dividends, except when, as and if declared by the Board of Directors of the Corporation (the “Board”) out of any assets at the time legally available therefor or as otherwise specifically provided in this Restated Certificate. The Corporation shall, upon the written request of any holder of Series A Preferred Stock, furnish or cause to be furnished to such holder a certificate setting forth the accrued dividends with respect to that holder’s shares of Series A Preferred Stock and the basis for calculating the accrued dividends. No dividend shall be paid with respect to the Common Stock during any calendar year unless dividends in the total amount provided for in this Article IV, Section B.1(a) shall have first been paid or declared and set apart for payment to the holders of the Series A Preferred Stock during that calendar year. The “Original Issue Price” of the Series A Preferred Stock shall be $10.00 per share (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after the filing date hereof).
(b) Non-Cash Dividends. Whenever a dividend provided for in this Article IV, Section B.1 shall be payable in property other than cash, the value of such dividend shall be deemed to be the fair market value of such property as determined in good faith by the Board.
| 2 |
2. Liquidation Rights.
(a) Series A Preferred Stock. In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, before any distribution or payment shall be made to the holders of any Common Stock, the holders of Series A Preferred Stock then outstanding shall be entitled to be paid, out of the funds and assets that may be legally distributed to the Corporation’s stockholders, an amount per share equal to the Original Issue Price for the Series A Preferred Stock, plus all accrued but unpaid dividends. If upon any liquidation, dissolution or winding up of the Corporation, the funds and assets of the Corporation to be distributed to the holders of the Series A Preferred Stock pursuant to this Article IV, Section B.2(a) shall be insufficient to permit the payment to such stockholders of their full preferential amount described in this Article IV, Section B.2(a), then such funds and assets shall be distributed among the holders of the then outstanding Series A Preferred Stock pro rata, on an equal priority, pari passu basis.
(b) Remaining Assets. If there are any remaining funds and assets that may be legally distributed to the Corporation’s stockholders after the payment or distribution (or the setting aside for payment or distribution) pursuant to Article IV, Section B.2(a), then all such remaining funds and assets shall be distributed among the holders of the then outstanding shares Common Stock pro rata according to the number of shares of Common Stock held by each holder thereof.
(c) Merger or Sale of Assets. Each of the following transactions shall be deemed to be a liquidation, dissolution or winding up of the Corporation as those terms are used in this Article IV, Section B.2: (a) a reorganization or merger of the Corporation with or into any other corporation or corporations, in which the stockholders of the Corporation immediately prior to the transaction hold fifty percent (50%) or less of the stock entitled to elect the Board immediately after the transaction; (b) a sale, transfer, lease, license or other disposition (but not including a transfer by pledge or mortgage to a bona fide lender) of all or substantially all of the assets, intellectual property or technology of the Corporation; or (c) any transaction or series of related transactions to which the Corporation is a party in which the stockholders of the Corporation immediately prior to the transaction hold fifty percent (50%) or less of the voting stock immediately after the transaction. The treatment of any particular transaction or series of related transactions as a Liquidation Event pursuant to this Article IV, Section B.2(c) may be waived by the vote or written consent of the holders of a majority of the outstanding Preferred Stock (voting together as a single class and not as separate series, and on an as-converted basis).
(d) Non-Cash Consideration. If any assets of the Corporation distributed to stockholders in connection with any liquidation, dissolution, or winding up of the Corporation are other than cash, then the value of such assets shall be their fair market value as determined by the Board in good faith, except that any securities to be distributed to stockholders in a liquidation, dissolution, or winding up of the Corporation shall be valued as follows:
(i) The method of valuation of securities not subject to investment letter or other similar restrictions on free marketability shall be as follows:
(A) unless otherwise specified in a definitive agreement for the acquisition of the Corporation, if the securities are then traded on a national securities exchange or the Nasdaq Global Market (or a similar national quotation system), then the value shall be deemed to be the average of the closing prices of the securities on such exchange or system over the ten (10) day period ending three (3) days prior to the distribution; and
(B) if (i) above does not apply but the securities are actively traded over-the-counter, then, unless otherwise specified in a definitive agreement for the acquisition of the Corporation, the value shall be deemed to be the average of the closing bid prices over the ten (10) calendar day period ending three (3) trading days prior to the distribution; and
(C) if there is no active public market as described in clauses (i) or (ii) above, then the value shall be the fair market value thereof, as determined in good faith by the Board.
(ii) The method of valuation of securities subject to investment letter or other restrictions on free marketability shall be to make an appropriate discount from the market value determined as above in subparagraphs (a)(i), (ii) or (iii) of this Article IV, Section B.2(d) to reflect the appropriate fair market value thereof, as determined in good faith by the Board.
| 3 |
3. Voting Rights.
(a) General. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Series A Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series A Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of this Restated Certificate, holders of Series A Preferred Stock shall vote together with the holders of Common Stock as a single class.
(b) Series A Preferred Stock Protective Provisions. At any time when shares of Series A Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger consolidation or otherwise, amend, alter or repeal any provision of this Restated Certificate or the Bylaws of the Corporation in a manner that adversely affects the powers, preferences or rights of the Series A Preferred Stock without (in addition to any other vote required by law of this Restated Certificate) first obtaining the approval (by vote or written consent as provided by law) of the holders of at least a majority of the outstanding shares of Series A Preferred Stock, voting as a single class on an as-converted basis.
4. Conversion Rights. The outstanding shares of Series A Preferred Stock shall be convertible into Common Stock as follows:
(a) Optional Conversion.
(i) Each share of Series A Preferred Stock shall be convertible into fully paid and nonassessable shares of Common Stock without the payment of any additional consideration by the holder thereof and, at the option of the holder thereof, at any time after the date of issuance of such share, at the office of the Corporation or any transfer agent of the Corporation for the Series A Preferred Stock. Each share of Series A Preferred Stock shall be convertible at the conversion rate determined by dividing the Original Issue Price by the Series A Conversion Price (determined as provided herein) in effect at the time of conversion. The initial “Series A Conversion Price” shall be $10.00. The Series A Conversion Price shall be subject to adjustment as set forth in Article IV, Section B.4(c) below.
(ii) Each holder of Series A Preferred Stock who elects to convert the same into shares of Common Stock shall surrender the certificate or certificates therefor, duly endorsed, at the office of the Corporation or its transfer agent, and shall give written notice to the Corporation at such office that such holder elects to convert the same and shall state therein the number of shares of Series A Preferred Stock being converted. Thereupon the Corporation shall promptly issue and deliver at such office to such holder a certificate or certificates for the number of shares of Common Stock to which such holder is entitled upon such conversion. Such conversion shall be deemed to have been made immediately prior to the close of business on the date of such surrender of the certificate or certificates representing the shares of Series A Preferred Stock to be converted, and the person entitled to receive the shares of Common Stock issuable upon such conversion shall be treated for all purposes as the record holder of such shares of Common Stock on such date.
(b) Automatic Conversion.
(i) Shares of Series A Preferred Stock shall automatically be converted into fully paid and nonassessable shares of Common Stock immediately prior to the closing of a firm commitment underwritten public offering pursuant to an effective registration statement filed under the Securities Act of 1933, as amended, covering the offer and sale of the Corporation’s Common Stock, provided that the aggregate gross proceeds to the Corporation (before underwriting discounts, commissions and fees) are not less than $10,000,000 (a “Qualifying IPO”).
(ii) Upon the occurrence of a Qualifying IPO, the outstanding shares of Series A Preferred Stock shall be converted into Common Stock automatically without the need for any further action by the holders of such shares and whether or not the certificates representing such shares are surrendered to the Corporation or its transfer agent; provided, however, that the Corporation shall not be obligated to issue certificates evidencing the shares of Common Stock issuable upon such conversion unless the certificates evidencing such shares of Series A Preferred Stock are either delivered to the Corporation or its transfer agent as provided below, or the holder notifies the Corporation or its transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in connection with such certificates. Upon the occurrence of such automatic conversion of Series A Preferred Stock, the holders of Series A Preferred Stock shall surrender the certificates representing such shares at the office of the Corporation or its transfer agent. Thereupon, there shall be issued and delivered to such holder promptly at such office and in its name as shown on such surrendered certificate or certificates, a certificate or certificates for the number of shares of Common Stock into which the shares of Preferred Stock surrendered were convertible on the date on which such automatic conversion occurred and a check payable to the holder any accrued but unpaid dividends on such converted Series A Preferred Stock.
| 4 |
(c) Adjustment to Series A Conversion Price.
(i) Adjustment Upon Common Stock Event. Upon the happening of a Common Stock Event (as hereinafter defined), the Series A Conversion Price shall, simultaneously with the happening of such Common Stock Event, be adjusted by multiplying the Series A Conversion Price in effect immediately prior to such Common Stock Event by a fraction, (i) the numerator of which shall be the number of shares of Common Stock issued and outstanding immediately prior to such Common Stock Event, and (ii) the denominator of which shall be the number of shares of Common Stock issued and outstanding immediately after such Common Stock Event, and the product so obtained shall thereafter be the Series A Conversion Price. The Series A Conversion Price shall be readjusted in the same manner upon the happening of each subsequent Common Stock Event. As used herein, the term the “Common Stock Event” shall mean at any time or from time to time after first share of Series A Preferred Stock is issued (the “Original Issue Date”), (i) the issue by the Corporation of additional shares of Common Stock as a dividend or other distribution on outstanding Common Stock, (ii) a subdivision of the outstanding shares of Common Stock into a greater number of shares of Common Stock, or (iii) a combination of the outstanding shares of Common Stock into a smaller number of shares of Common Stock.
(ii) Adjustments for Other Dividends and Distributions. If at any time or from time to time after the Original Issue Date the Corporation makes a dividend or other distribution payable in additional shares of Common Stock, other than an event constituting a Common Stock Event, then in each such event provision shall be made so that the holders of the Series A Preferred Stock shall receive upon conversion thereof, in addition to the number of shares of Common Stock receivable upon conversion thereof, the amount of securities of the Corporation that they would have received had their Series A Preferred Stock been converted into Common Stock on the date of such event (or such record date, as applicable) and had they thereafter, during the period from the date of such event (or such record date, as applicable) to and including the conversion date, retained such securities receivable by them as aforesaid during such period, subject to all other adjustments called for during such period under this Article IV, Section B.4 with respect to the rights of the holders of the Series A Preferred Stock or with respect to such other securities by their terms.
(iii) Adjustment for Reclassification, Exchange and Substitution. If at any time or from time to time after the Original Issue Date the Common Stock issuable upon the conversion of Series A Preferred Stock is changed into the same or a different number of shares of any class or classes of stock, whether by recapitalization, reclassification or otherwise (other than by a Common Stock Event or a Common Stock Dividend, reorganization, merger, or consolidation provided for elsewhere in this Article IV, Section B.4), then in any such event each holder of Series A Preferred Stock shall have the right thereafter to convert such shares of Series A Preferred Stock into the kind and amount of stock and other securities and property receivable upon such recapitalization, reclassification or other change by holders of the number of shares of Common Stock into which such shares of Series A Preferred Stock could have been converted immediately prior to such recapitalization, reclassification or change, all subject to further adjustment as provided herein or with respect to such other securities or property by the terms thereof.
(iv) Reorganizations, Mergers and Consolidations. If at any time or from time to time after the Original Issue Date there is a reorganization of the Corporation (other than a recapitalization, subdivision, combination, reclassification or exchange of shares provided for elsewhere in this Article IV, Section B.4) or a merger or consolidation of the Corporation with or into another corporation (except an event which is governed under Article IV, Section B.2(c)), then, as a part of such reorganization, merger or consolidation, provision shall be made so that the holders of the Series A Preferred Stock thereafter shall be entitled to receive, upon conversion of the Series A Preferred Stock, the number of shares of stock or other securities or property of the Corporation, or of such successor corporation resulting from such reorganization, merger or consolidation, to which a holder of that number of shares of Common Stock deliverable upon conversion of the Series A Preferred Stock would have been entitled on such reorganization, merger or consolidation. In any such case, appropriate adjustment shall be made in the application of the provisions of this Article IV, Section B.4 with respect to the rights of the holders of the Series A Preferred Stock after the reorganization, merger or consolidation to the end that the provisions of this Article IV, Section B.4 (including adjustment of the Series A Conversion Price then in effect and number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock) shall be applicable after that event and be as nearly equivalent to the provisions hereof as may be practicable. This Article IV, Section B.4(c)(iv) shall similarly apply to successive reorganizations, mergers and consolidations.
| 5 |
(d) Certificate of Adjustment. In each case of an adjustment or readjustment of the Conversion Price for a series of Series A Preferred Stock, the Corporation, at its expense, shall cause an officer of the Corporation to compute such adjustment or readjustment in accordance with the provisions hereof and prepare a certificate showing such adjustment or readjustment, and shall mail such certificate, by first class mail, postage prepaid, to each registered holder of Series A Preferred Stock at the holder’s address as shown in the Corporation’s books.
(e) Fractional Shares. No fractional shares of Common Stock shall be issued upon any conversion of Series A Preferred Stock. In lieu of any fractional share to which the holder would otherwise be entitled, the Corporation shall pay the holder cash equal to the product of such fraction multiplied by the Common Stock’s fair market value as determined in good faith by the Board as of the date of conversion.
(f) Reservation of Stock Issuable Upon Conversion. The Corporation shall at all times reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the Series A Preferred Stock, such number of its shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Series A Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of Series A Preferred Stock, the Corporation shall take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose.
(g) Notices. Any notice required by the provisions of this Restated Certificate to be given to the holders of shares of Series A Preferred Stock shall be deemed given upon the earlier of actual receipt or deposit in the United States mail, by certified or registered mail, return receipt requested, postage prepaid, or delivery by a recognized express courier, fees prepaid, addressed to each holder of record at the address of such holder appearing on the books of the Corporation.
(h) No Impairment. The Corporation shall not avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but shall at all times in good faith assist in carrying out all such action as may be reasonably necessary or appropriate in order to protect the rights, preferences and privileges of the holders of the Series A Preferred Stock against impairment.
5. Redemption. The Series A Preferred Stock shall not be redeemable.
ARTICLE V
Subject to any additional vote required by this Restated Certificate, in furtherance and not in limitation of the powers conferred by statute, the Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation.
ARTICLE VI
Whenever a compromise or arrangement is proposed between this Corporation and its creditors or any class of them and/or between this Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this Corporation or of any creditor or stockholder thereof or in the application of any receiver or receivers appointed for this Corporation under the provisions of Section 291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any receiver or receivers appointed for this Corporation under the provisions of Section 279 of Title 8 of the Delaware Code order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this Corporation as a consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the said application has been made, be binding on all the creditors or claims of creditors, and/or on all the stockholders or class of stockholders of this Corporation, as the case may be, and also on this Corporation.
| 6 |
ARTICLE VII
Election of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.
ARTICLE VIII
To the fullest extent permitted by law, no director of the Corporation shall be personally liable for monetary damages for breach of fiduciary duty as a director. Without limiting the effect of the preceding sentence, if the DGCL is hereafter amended to authorize the further elimination or limitation of the liability of a director, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.
The Corporation may indemnify to the fullest extent permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he, his testator or intestate is or was a director, officer or employee of the Corporation or any predecessor of the Corporation or serves or served at any other enterprise as a director, officer or employee at the request of the Corporation or any predecessor to the Corporation.
Neither any amendment nor repeal of this ARTICLE VIII nor the adoption of any provision of this Restated Certificate inconsistent with this ARTICLE VIII, shall eliminate, reduce or otherwise adversely affect any limitation on the personal liability of a director of the Corporation existing at the time of such amendment, repeal or adoption of such an inconsistent provision.
4. This Restated Certificate has been duly approved by the Board.
5. This Restated Certificate was approved by the holders of the requisite number of shares of said corporation in accordance with Section 228 of the DGCL. This Restated Certificate has been duly adopted in accordance with the provisions of Sections 242 and 245 of the DGCL by the stockholders of the corporation.
****************
| 7 |
.
In witness whereof, the Corporation has caused this Restated Certificate to be signed by its authorized officer on this 9 day of December, 2010.
COHERIX, INC.
/s/ Dwight Carlson
Dwight Carlson,
President and Chief Executive Officer
| 8 |
CERTIFICATE OF AMENDMENT
TO THE
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
COHERIX, INC.
Coherix, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify:
FIRST: That the board of directors of the Corporation duly adopted a resolution declaring advisable the Amendment of the Amended and Restated Certificate of Incorporation of the Corporation and submitting the same to the shareholders of the Corporation for approval. The resolution setting forth the proposed amendment is as follows:
RESOLVED, that the Amended and Restated Certificate of Incorporation of the Corporation be amended by deleting the first paragraph in ARTICLE IV thereof and substituting the following:
“The total number of shares of all classes of stock that the Corporation shall have authority to issue is 30,400,000 shares, consisting of (i) 30,000,000 shares of Common Stock, $.001 par value per share (“Common Stock”), and (ii) 400,000 shares of Preferred Stock, $.001 par value per share (“Preferred Stock”).
RESOLVED FURTHER, that the foregoing resolutions be submitted to the shareholders of the Corporation for approval in accordance with 8 Del. C. § 242.
SECOND: That thereafter, pursuant to resolution of the board of directors of the Corporation, a meeting of the shareholders of the Corporation was dully called and held upon notice in accordance with § 222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of shares as required by statute were voted in favor of the Amendment of the Amended and Restated Certificate of Incorporation of the Corporation.
THIRD: That the amendment was duly adopted in accordance with the provisions of §242 of the General Corporation Law of the State of Delaware.
IN WITNESS WHEREOF, the Corporation has caused this certificate to be signed by the undersigned this 18th day of December, 2017.
| By: | /s/ Dwight D. Carlson | |
| Name: | Dwight D. Carlson | |
| Title: | President and Chief Executive Officer |
| 9 |
Exhibit 2.2
BY-LAWS
OF
REALCITE INC.
1. OFFICES:
1.1. The Corporation may have an office or offices at such places as the Board of Directors may from time to time designate.
2. MEETING OF STOCKHOLDERS:
2.1. The annual meeting of stockholders for the election of directors shall be held at such time and date as may be fixed by the Board of Directors.
2.2. Special meetings of the stockholders may be called at any time by the president and shall be called by the president or secretary on the request in writing or by vote of a majority of the directors or at the request in writing of stockholders of record owning a majority in amount of the capital stock outstanding and entitled to vote.
2.3. All meetings of the stockholders may be held at such place or places, within or without the State of Delaware, as may from time to time be fixed by the Board of Directors or as specified and fixed in the respective notices or waiver of notice thereof.
3. DIRECTORS :
3.1. The property and business of the Corporation shall be managed by or under the direction of its Board of Directors, consisting of one or more directors, as determined from time to time by resolution of the Board of Directors.
3.2. The directors shall hold office until the next annual election and until their successor is elected and qualified. Directors shall be elected by the stockholders, except that vacancies in the Board by reason of death, resignation or otherwise and newly created directorships may be filled for the unexpired term by the remaining directors, though less than a quorum, by a majority vote.
4. POWER OF DIRECTORS:
4.1. The Board of Directors shall have such general and specific powers as are conferred upon corporations by the General Corporation Law of the State of Delaware, as amended from time to time, subject only to the provisions of the statutes, Certificate of Incorporation, and these By-Laws, which may restrict or deny such powers.
5. MEETING OF DIRECTORS:
5.1. After each annual election of directors, the newly elected directors may meet for the purpose of organization, the election of officers, and the transaction of other business, at such place and time as shall be fixed by the stockholders at the annual meeting, and if a majority of the directors be present at such place and time, no prior notice of such meeting shall be required to be given to the directors. The place and time of such meeting may also be fixed by written consent of the directors. Regular meetings of the directors may be held without notice at such time and at such place as shall from time to time be determined by the Board of Directors.
5.2. Special meetings of the directors may be called by the president on three (3) days' notice in writing or on one (1) day's notice by telephone to each director and shall be called by the president in like manner on the written request of two directors.
5.3. Special meetings of the directors may be held within or without the State of Delaware at such place as is indicated in the notice or waiver of notice thereof.
5.4. A majority of the directors shall constitute a quorum, but a smaller number may adjourn from time to time, without further notice, until a quorum is secured.
| 1 |
6. EXECUTIVE AND OTHER COMMITTEES:
6.1. The Board of Directors may designate an executive committee and one or more other committees each to consist of one or more of the directors of the Corporation.
6.2. The executive committee shall not have authority to make, alter or amend the By-Laws, but , subject to applicable laws, shall exercise all other powers of the Board of Directors between the meetings of said Board, except the power to fill vacancies in their own membership, which vacancies shall be filled by the Board of Directors.
6.3. The executive committee and such other committees shall meet at stated times or on notice to all by any of their own number. They shall fix their own rules of procedure. A majority shall constitute a quorum, but the affirmative vote of a majority of the whole committee shall be necessary in every case.
6.4. Such other committees shall have and may exercise the powers of the Board of Directors to the extent as provided in such resolution or resolutions.
7. OFFICERS OF THE CORPORATION:
7.1. The officers of the Corporation may be a president, one or more vice presidents, secretary, treasurer, and such other officers as may from time to time be chosen by the Board of Directors.
7.2. The officers of the Corporation shall hold office until their successors are chosen and qualify in their stead. Any officer chosen or appointed by the Board of Directors may be removed either with or without cause at any time by the affirmative vote of a majority of the whole Board of Directors. If the office of any officer or officers becomes vacant for any reason, the vacancy shall be filled by the affirmative vote of a majority of the whole Board of Directors.
8. DUTIES OF THE PRESIDENT:
8.1. The President shall be the chief executive officer of the Corporation. It shall be his duty to preside at all meetings of the stockholders; to have general and active management of the business and the Corporation; to see that all orders and resolutions of the Board of Directors are carried into effect; to execute all contracts, agreements, deeds, bonds, mortgages and other obligations and instruments, in the name of the Corporation, and to affix the corporate seal thereto when authorized by the Board of Directors or the executive committee.
8.2. He shall have the general supervision and direction of the other officers of the Corporation and shall see that their duties are properly performed.
8.3. He shall be ex-officio a member of all standing committees and shall have the general duties and powers of supervision and management usually vested in the office of the President of a corporation.
9. VICE PRESIDENT:
9.1. The Vice Presidents, in the order designated by the Board of Directors, shall be vested with all powers and required to perform all the duties of the President in his absence or disability and shall perform such other duties as may be prescribed by the Board of Directors.
10. PRESIDENT PRO TEM:
10.1. In the absence or disability of the President and the Vice President, the Board may appoint from their own number a president pro tem.
11. SECRETARY:
11.1. The Secretary shall attend all meetings of the Corporation, the Board of Directors, the executive committee and standing committees. He shall act as clerk thereof and shall record all of the proceedings of such meetings in a book kept for that purpose. He shall give proper notice of meetings of stockholders and directors and shall perform such other duties as shall be assigned to him by the President or the Board of Directors.
| 2 |
12. TREASURER:
12.1. The Treasurer shall have custody of the funds and securities of the Corporation and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Board of Directors.
12.2. He shall disburse the funds of the Corporation as may be ordered by the Board, executive committee or President, taking proper vouchers for such disbursements, and shall render to the President and directors, whenever they may require it, an account of all his transactions as treasurer, and of the financial condition of the Corporation, and at the regular meeting of the Board next preceding the annual stockholders' meeting, a like report for the preceding year.
12.3. He shall keep an account of stock registered and transferred in such manner and subject to such regulations as the Board of Directors may prescribe.
12.4. He shall give the Corporation a bond, if required by the Board of Directors, in such sum and in form and with security satisfactory to the Board of Directors for the faithful performance of the duties of his office and the restoration to the Corporation, in case of his death, resignation or removal from office, of all books, papers, vouchers, money and other property of whatever kind in his possession, belonging to the Corporation. He shall perform such other duties as the Board of Directors or executive committee may from time to time prescribe or require.
13. DUTIES OF OFFICERS MAY BE DELEGATED:
13.1. In case of the absence or disability of any officer of the Corporation or for any other reason deemed sufficient by a majority of the Board, the Board of Directors may delegate his powers or duties to any other officer or to any director for the time being.
14. CERTIFICATES OF STOCK:
14.1. Certificates of stock shall be signed by the President or a Vice President and either the Treasurer, Assistant Treasurer, Secretary or Assistant Secretary. If a certificate of stock be lost or destroyed, another may be issued in its stead upon proof of loss or destruction and the giving of a satisfactory bond of indemnity in an amount sufficient to indemnify the Corporation against any claim. A new certificate may be issued without requiring bond when, in the judgment of the directors, it is proper to do so.
15. TRANSFER OF STOCK:
15.1. Upon surrender to the Corporation or the transfer agent of the Corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer, it shall be the duty of the Corporation to issue a new certificate to the person entitled thereto, cancel the old certificate and record the transaction on its books.
16. STOCKHOLDERS OF RECORD:
16.1. The Corporation shall be entitled to treat the holder of record of any share or shares of stock as the holder in fact thereof and accordingly shall not be bound to recognize any equitable or other claim to or interest in such share on the part of any other person whether or not it shall have express or other notice thereof, save as expressly provided by the laws of Delaware.
17. FISCAL YEAR:
17.1. The fiscal year of the Corporation shall be determined by the Board of Directors.
18. DIVIDENDS:
18.1. Dividends upon the capital stock may be declared by the Board of Directors at any regular or special meeting and may be paid in cash or property or in shares of the capital stock. The directors may set apart out of any of the funds of the Corporation available for dividends a reserve or reserves for any proper purposes and may alter or abolish any such reserve or reserves.
| 3 |
19. CHECKS FOR MONEY:
19.1. All checks, drafts or orders for the payment of money shall be signed by the treasurer or by such other officer or officers as the Board of Directors may from time to time designate. No check shall be signed in blank.
20. BOOKS AND RECORDS:
20.1. The books, records and accounts of the Corporation except as otherwise required by the laws of the State of Delaware, may be kept within or without the State of Delaware, at such place or places as may from time to time be designated by the By-Laws or by resolution of the directors.
21. NOTICES:
21.1. Except as otherwise specifically provided herein or required by law, all notices required to be given to any stockholder, director, officer, employee or agent shall be in writing and may in every instance be effectively given by hand delivery to the recipient thereof, by depositing such notice in the mails, postage paid, or by sending such notice by facsimile transmission. Any such notice shall be addressed to such stockholder, director, officer, employee or agent at his or her last known address as the same appears on the books of the Corporation. The time when such notice is received, if hand delivered, or dispatched, if delivered through the mails or by facsimile transmission, shall be the time of the giving of the notice.
21.2. A written waiver of any notice, signed by a stockholder, director, officer, employee or agent, whether before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such stockholder, director, officer, employee or agent. Neither the business nor the purpose of any meeting need be specified in such a waiver.
22. AMENDMENT:
22.1. These By-Laws may be amended, altered, repealed or added to at any regular meeting of the stockholders or Board of Directors or at any special meeting called for that purpose, by affirmative vote of a majority of the stock issued and outstanding and entitled to vote or of a majority of the whole board of directors, as the case may be.
23. INDEMNIFICATION:
23.1. Right to Indemnification:
23.1.1. Each person who was or is a party or is threatened to be made a party to or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative ("Proceeding"), including without limitation Proceedings by or in the right of the Corporation to procure a judgment in its favor, by reason of the fact that he or she or a person for whom he or she is the legal representative is or was a director or officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director or officer, employee or agent of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, whether the basis of such Proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent, shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the General Corporation Law of the State of Delaware, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent such amendment permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment) against all expenses, liability and loss (including attorneys' fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such person in connection therewith. Such right shall be a contract right and shall include the right to be paid by the Corporation for expenses incurred in defending any such Proceeding in advance of its final disposition; provided, however, that the payment of such expenses incurred by a director or officer of the Corporation in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service to an employee benefit plan) in advance of the final disposition of such Proceeding, shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it should be determined ultimately that such director or officer is not entitled to be indemnified under this section or otherwise.
| 4 |
23.2. Right of Claimant to Bring Suit:
23.2.1. If a claim under Section 23.1 is not paid in full by the Corporation within ninety (90) days after a written claim has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any Proceeding in advance of its final disposition where the required undertaking has been tendered to the Corporation) that the claimant has not met the standards of conduct which make it permissible under the General Corporation Law of the State of Delaware for the Corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the General Corporation Law of the State of Delaware, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) that the claimant had not met such applicable standard of conduct, shall create a presumption that claimant had not met the applicable standard of conduct.
23.3. Non-Exclusivity of Rights:
23.3.1. The rights conferred by Sections 23.1 and 23.2 shall not be exclusive of any other right which such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, by-law, agreement, vote of stockholders or disinterested directors or otherwise.
23.4. Insurance:
23.4.1. The Corporation may maintain insurance, at its expense, to protect itself and any such director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law of the State of Delaware.
DATED: October 30, 2003
| 5 |
Exhibit 3.1
AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT
Contents
| Section | Page |
| 1. Definitions. | 1 |
| 2. Registration Rights. | 5 |
| 2.1 Demand Registration. | 5 |
| 2.2 Company Registration. | 7 |
| 2.3 Underwriting Requirements. | 7 |
| 2.4 Obligations of the Company. | 9 |
| 2.5 Furnish Information. | 10 |
| 2.6 Expenses of Registration. | 10 |
| 2.7 Delay of Registration. | 11 |
| 2.8 Indemnification. | 11 |
| 2.9 Reports Under Exchange Act. | 13 |
| 2.10 Limitations on Subsequent Registration Rights. | 14 |
| 2.11 "Market Stand-off" Agreement. | 14 |
| 2.12 Termination of Registration Rights. | 15 |
| 2.13 Non-U.S. IPO. | 15 |
| 3. Information and Nomination Rights. | 16 |
| 3.1 Delivery of Financial Statements. | 16 |
| 3.2 Inspection. | 17 |
| 3.3 Board Composition | 17 |
| 3.4 Quorum | 18 |
| 3.5 Voting | 18 |
| 3.6 Matters Requiring Unanimous Board Consent. | 18 |
| 3.7 Matters Requiring Board Approval. | 20 |
| 3.8 Successor Indemnification. | 20 |
| 3.9 Meeting Minutes | 20 |
| 3.10 Termination of Information and Nomination Rights. | 20 |
| 3.11 Confidentiality. | 20 |
| 4. Rights to Future Stock Issuances. | 21 |
| 4.1 Preemptive Right. | 21 |
| 4.2 Termination. | 22 |
| 5. Transfer to third party | 22 |
| 5.1 Lock-up | 22 |
| 5.2 Right of First Refusal | 23 |
| 5.3 Right of Co-Sale. | 24 |
| 5.4 Effect of Proposed Key Holder Transfer | 25 |
| 5.5 Termination of Covenants | 25 |
| 5.6 Transfer Void; Equitable Relief | 26 |
| 6. [Intentionally Omitted]. | 26 |
| 7. Call Option by Investor | 26 |
| 8. Miscellaneous. | 26 |
| 8.1 Successors and Assigns. | 26 |
| 8.2 Governing Law. | 27 |
| 8.3 Counterparts: Facsimile. | 27 |
| 8.4 Titles and Subtitles. | 27 |
| 8.5 Notices. | 27 |
| 8.6 Amendments and Waivers. | 28 |
| 8.7 Severability. | 28 |
| 8.8 Aggregation of Stock. | 28 |
| 8.9 Entire Agreement. | 28 |
| 8.10 Dispute Resolution. | 28 |
| 8.11 Delays or Omissions. | 29 |
AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT
THIS AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT (the “Agreement”) is made as of July , 2018, by and among Coherix, Inc., a Delaware corporation (the "Company"), and Xintai US Investment LLC (the "Investor") and the stockholder listed on Schedule A hereto, who is referred to herein as the "Key Holder".
RECITALS
WHEREAS, the Company and the Investor previously entered into an Investors’ Rights Agreement dated as of August 5, 2015 (the “Original Investors’ Rights Agreement”) in connection with the issuance by the Company to the Investor of the Company’s Common Stock, a Series 4-1 Convertible Debenture and a Series 4-2 Convertible Debenture (the "Securities") pursuant to that certain Securities Purchase Agreement between the Company and the Investor dated as of August 5, 2015 (the “Purchase Agreement”); and
WHEREAS, the Company’s board of directors has resolved to pursue a Regulation A Offering (as defined below); and
WHEREAS, a condition to moving forward with the Regulation A Offering is that the Original Investors’ Rights Agreement be amended and restated as set forth in this Agreement; and
WHEREAS, according to Section 8.6 of the Original Investors’ Rights Agreement, the Original Investors’ Rights Agreement may be amended and the observance of any term hereof may be waived (either prospectively or retroactively and either generally or in a particular instance) only with the written consent of the Company and Holders of at least seventy-five (75%) of the Registrable Securities then outstanding, which holders are parties hereto.
NOW, THEREFORE, the parties hereby agree to amend and restate the Original Investors’ Rights Agreement, effective as of the date the SEC qualifies the Regulation A Offering (as defined below), in its entirety as follows:
| 1. | Definitions. |
For purposes of this Agreement:
| 1.1. | "Affiliate" means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person, and any Immediate Family Member. |
| 1.2. | "Capital Stock" means (a) shares of Common Stock (whether now outstanding or hereafter issued in any context), (b) shares of Common Stock issued or issuable upon conversion of Derivative Securities, in each case now owned or subsequently acquired by any Key Holder, any investor, or their respective successors or permitted transferees or assigns. For purposes of the number of shares of Capital Stock held by an Investor or Key Holder (or any other calculation based thereon), all Derivative Securities shall be deemed to have been converted into or exercised for Common Stock at the then-applicable conversion ratio or exercise price. |
| 1 |
| 1.3. | "China JV" has the meaning given to it in the Purchase Agreement. |
| 1.4. | "Coherix Products" means all and any of the existing and prospective products of Company, including but not limited to all products referred to in the business plan provided to the Investor. |
| 1.5. | "Common Stock" means shares of the Company's common stock, par value $0.01 per share. |
| 1.6. | "Convertible Debentures" means the Series 4-1 Convertible Debenture and Series 4-2 Convertible Debenture issued to the Investor pursuant to the Purchase Agreement. |
| 1.7. | "Damages" means any loss, damage, or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. |
| 1.8. | "Derivative Securities" means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. |
| 1.9. | "Exchange Act" means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. |
| 1.10. | "Excluded Registration" means (i) a registration relating to the sale of securities to employees of the Company or a Subsidiary pursuant to a stock option, stock purchase, or similar plan; or (ii) a registration relating to an SEC Rule 145 transaction. |
| 1.11. | "Exempted Securities" means: |
| (i) | up to 850,000 shares of Common Stock and options to purchase Common Stock, (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting such shares), issued or issuable pursuant to the 2004 Incentive and Non-Qualified Stock Option Plan of the Company; |
| (ii) | 11,750 shares of Common Stock issued pursuant to Board of Directors Warrants for Board Meeting participation; |
| 2 |
| (iii) | 14,875 shares of Common Stock reserved to fill out Series 3 Predator3D Royalty with Stock Incentive; |
| (iv) | 45,000 warrants, each with exercise price of $15 (including 25,000 warrants at $15 to Dwight Carlson for personal guarantee on Coherix Loans); |
| (v) | 11,000 warrants with exercise price of $10 to Series A Investor and convertible debt reserved for services totaling 24,220 with $20 and $25 exercise price; |
| (vi) | shares of Common Stock or Derivative Securities issued upon the exercise of options or warrants outstanding as of the date of this Agreement or shares of Common Stock issued upon the conversion or exchange of Derivative Securities outstanding as of the date of this Agreement, in each case provided such issuance is pursuant to the terms of such option or Derivative Securities; |
| (vii) | shares of Common Stock or Derivative Securities issued in connection with the Company’s EB-5 Project or shares of Common Stock issued upon the conversion or exchange of such Derivative Securities; |
| (viii) | shares of Common Stock or Derivative Securities issued in connection with the Debt Restructuring (as defined in the Purchase Agreement) or shares of Common Stock issued upon the conversion or exchange of such Derivative Securities; and |
| (ix) | shares of Common Stock issued to stockholders in connection with any stock split, stock dividend or the like. |
| 1.12. | "Form S-1" means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. |
| 1.13. | "Form S-3" means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. |
| 1.14. | "GAAP" means generally accepted accounting principles in the United States. |
| 1.15. | "Holder" means any holder of Registrable Securities. |
| 1.16. | "Immediate Family Member" means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. |
| 1.17. | "Initiating Holders" means, collectively, the Holders who properly initiate a registration request under this Agreement. |
| 1.18. | "Investor Debt" means the aggregate principal amount of Convertible Debentures held by the Investor. |
| 3 |
| 1.19. | "Key Holder" means any holder of Registrable Securities who is a party to this Agreement. |
| 1.20. | "New Securities" means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. |
| 1.21. | "Person" means any individual, corporation, partnership, trust, limited liability company, association or other entity. |
| 1.22. | "Proposed Key Holder Transfer" means any assignment, sale, offer to sell, pledge, mortgage, hypothecation, encumbrance, disposition of or any other like transfer or encumbering of any Transfer Stock (or any interest therein) proposed by the Key Holder. |
| 1.23. | "Proposed Transfer Notice" means written notice from the Key Holder setting forth the terms and conditions of a Proposed Key Holder Transfer. |
| 1.24. | "Prospective Transferee" means any person to whom the Key Holder proposes to make a Proposed Key Holder Transfer. |
| 1.25. | "Qualified IPO" means the sale, in a firm commitment underwritten public offering led by a nationally recognized underwriting firm pursuant to an effective registration statement under the Securities Act, of Common Stock of the Company having an aggregate offering value (net of underwriters' discounts and selling commissions) of at least $25,000,000 at the pre-money valuation of at least USD 100,000,000 (appropriately adjusted for stock splits, stock dividends, combinations, recapitalizations and the like), following which the Common Stock of the Company shall be listed on any national securities exchange registered with the SEC under Section 6(a) of the Exchange Act. |
| 1.26. | “Regulation A Offering” means a public offering of securities exempt from registration under the Securities Act pursuant to Regulation A thereunder. |
| 1.27. | “Regulation A Consummation” means a sale of any securities pursuant to a qualified offering statement on Form 1-A. |
| 1.28. | "Right of Co-Sale" means the right, but not an obligation, of the Investor to participate in a Proposed Key Holder Transfer on the terms and conditions specified in the Proposed Transfer Notice. |
| 1.29. | "Registrable Securities" means (i) the Common Stock issued pursuant to the Purchase Agreement and issuable or issued upon conversion of the Convertible Debentures; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investor after the date hereof; (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 1.7.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.12 of this Agreement. |
| 4 |
| 1.30. | "Registrable Securities then outstanding" means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. |
| 1.31. | "Restricted Securities" means the securities of the Company required to bear the legend set forth in Section 2.12(b) hereof. |
| 1.32. | "SEC" means the Securities and Exchange Commission. |
| 1.33. | "SEC Rule 144" means Rule 144 promulgated by the SEC under the Securities Act. |
| 1.34. | "SEC Rule 144(k)" means Rule 144(k) promulgated by the SEC under the Securities Act. |
| 1.35. | "SEC Rule 145" means Rule 145 promulgated by the SEC under the Securities Act. |
| 1.36. | "Securities Act" means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. |
| 1.37. | "Selling Expenses" means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6. |
| 1.38. | "Shares" means all Capital Stock and Derivative Securities. |
| 1.39. | "Subsidiary" means any Person which the Company now or hereafter shall at the time own, directly or through a Subsidiary, at least 50% of the capital stock (or other beneficial interest) entitled to vote generally or entitled to vote for the election of the board of directors or equivalent management authority. |
| 1.40. | "Transfer Stock" means shares of Capital Stock owned by the Key Holder, or issued to the Key Holder after the date hereof (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like). |
| 1.28. | "Investor Director" means any director of the Company that the Investor is entitled to nominate for election pursuant to this Agreement. |
| 2. | Registration Rights. |
The Company covenants and agrees as follows:
| 2.1 | Demand Registration. |
| 5 |
| (a) | Form S-1 Demand. If at any time after one hundred eighty (180) days after the effective date of the registration statement for the Qualified IPO, the Company receives a request from Holders of at least twenty-five percent (25%) of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to at least twenty-five percent (25%) of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of Selling Expenses, would exceed $5 million), then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the "Demand Notice") to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3. The Company shall be permitted to include shares of Common Stock to be sold in a primary offering in any registration statement initiated under this Section 2.1 only to the extent that the inclusion of such Common Stock will not jeopardize the success of the offering by the Holders. |
| (b) | Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least ten percent (10%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in. each case, subject to the limitations of Section 2.1(c) and Section 2.3. |
| (c) | Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company's chief executive officer stating that in the good faith judgment of the Company's Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than sixty (60) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such sixty (60) day period other than an Excluded Registration. |
| 6 |
| (d) | The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a) (i) after the Company has effected two registrations pursuant to Section 2.1(a); or (ii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i) during the period that is forty-five (45) days before the Company's good faith estimate of the date of filing of, and ending on a date that is forty-five (45) days after the effective date of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Section 2.1 (b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as "effected" for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as "effected" for purposes of this Section 2.1(d). |
| 2.2 | Company Registration. |
If following the Qualified IPO the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder and Key Holder notice of such registration. Upon the request of each Holder and each Key Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration and all of Registrable Securities (which definition shall apply to the Key Holder solely for purposes of this Section 2.2 and the related provisions of Sections 2.3(b) and 2.4). The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder or Key Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6.
| 7 |
| 2.3 | Underwriting Requirements. |
| (a) | If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably acceptable to Initiating Holders holding a majority of the Registrable Securities requested to be registered by the Initiating Holders. In such event, the right of any Holder to include such Holder's Registrable Securities in such registration shall be conditioned upon such Holder's participation in such underwriting and the inclusion of such Holder's Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3. if the managing underwriter(s) advise(s) the Company and the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. |
| (b) | In connection with any offering involving an underwriting of shares of the Company's capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders' or Key Holder’s Registrable Securities in such underwriting unless the Holders and Key Holder accept the terms of the underwriting as agreed upon between the Company and its underwriters. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then none of the Registrable Securities owned by any Key Holder shall be included in such offering and the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable) to the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single "selling Holder," and any pro rata reduction with respect to such "selling Holder" shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such "selling Holder," as defined in this sentence. |
| 8 |
| 2.4 | Obligations of the Company. |
Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:
| (a) | prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration; |
| (b) | prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; |
| (c) | furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; |
| (d) | use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; |
| 9 |
| (e) | in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; |
| (f) | use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; |
| (g) | provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; |
| (h) | promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company's officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; |
| (i) | notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and |
| (j) | after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. |
| 2.5 | Furnish Information. |
It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder's Registrable Securities.
| 2.6 | Expenses of Registration. |
All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers' and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders ("Selling Holder Counsel"), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1(a) if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Section 2.1(a); provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Section 2.1(a). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.
| 10 |
| 2.7 | Delay of Registration. |
No Holder or Key Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.
| 2.8 | Indemnification. |
If any Registrable Securities are included in a registration statement under this Section 2:
| (a) | To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder and Key Holder, and the partners, members, officers, directors, and stockholders of each such Holder or Key Holder; legal counsel and accountants for each such Holder and Key Holder; any underwriter (as defined in the Securities Act) for each such Holder and Key Holder; and each Person, if any, who controls such Holder or Key Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, Key Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder or Key Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. |
| 11 |
| (b) | To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(e) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. |
| (c) | To the extent permitted by law, each selling Key Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Key Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Key Holder, against any Damages and each such selling Key Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(c) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Key Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Key Holder by way of indemnity or contribution under Sections 2.8(c) and 2.8(e) exceed the proceeds foam the offering received by such Key Holder (net of any Selling Expenses paid by such Key Holder), except in the case of fraud or willful misconduct by such Key Holder. |
| 12 |
| (d) | Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices the indemnifying party's ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8. |
| (e) | To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties' relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder or Key Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder or Key Holder pursuant to such registration statement, except in the case of willful misconduct or fraud by such Holder or Key Holder, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder's or Key Holder's liability pursuant to this Section 2.8(e), when combined with the amounts paid or payable by such Holder or Key Holder pursuant to Section 2.8(b) or (c), exceed the proceeds from the offering received by such Holder or Key Holder (net of any Selling Expenses paid by such Holder or Key Holder), except in the case of willful misconduct or fraud by such Holder or Key Holder. |
| 13 |
| (f) | Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders and Key Holder under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement. |
| 2.9 | Reports Under Exchange Act. |
With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall:
| (a) | make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the Qualified IPO; |
| (b) | use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and |
| (c) | furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the Qualified IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). |
| 14 |
| 2.10 | Limitations on Subsequent Registration Rights. |
From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any Holder or prospective Holder that would allow such Holder or prospective Holder to include such securities in any registration unless, under the terms of such agreement, such Holder or prospective Holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included.
| 2.11 | "Market Stand-off" Agreement. |
Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf of shares of its Common Stock or any other equity securities under the Securities Act on a registration statement on Form S-1 in respect of its Qualified IPO and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, which period may be extended upon the request of the managing underwriter, to the extent required by any FINRA rules, for an additional period of up to fifteen (15) days if the Company issues or proposes to issue an earnings or other public release within fifteen (15) days of the expiration of the 180-day lockup period), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company uses reasonable efforts to obtain a similar agreement from all stockholders individually owning more than five percent (5%) of the Company's outstanding Common Stock. The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements, except that, notwithstanding the foregoing, the Company and the underwriters may, in their sole discretion, waive or terminate these restrictions with respect to up to 50,000 shares of the Common Stock.
| 15 |
| 2.12 | Termination of Registration Rights. |
The right of any Holder or, as applicable, Key Holder, to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earlier to occur of
| (a) | when all of such Holder's or Key Holder's Registrable Securities have been sold under an effective registration statement or pursuant to SEC Rule 144; |
| (b) | when all of such Holder's or Key Holder's Registrable Securities can be sold under SEC Rule 144 within 90 days without limitation on the amount of securities that can be sold; and |
| (c) | the fifth anniversary of the Qualified IPO. |
| 2.13 | Non-U.S. IPO. |
If the Company elects to register or sell its shares of Common Stock in an underwritten or similar offering effected under the laws of a country other than the United States, the Company and the Holders shall in good faith amend Section 2 of this Agreement to give each party parallel rights and obligations as those contemplated hereunder in connection with the Qualified IPO.
| 3. | Information and Nomination Rights. |
| 3.1 | Delivery of Financial Statements. |
| 3.1.1 | The Company shall provide to each of the Investor and Key Holder: |
| (a) | as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company, (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year, and (iii) a statement of stockholders' equity as of the end of such year, all such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; |
| (b) | as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders' equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal yearend audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); |
| (c) | as soon as practicable, but in any event within thirty (30) days after the end of each month, unaudited statements of income and of cash flows for such month, and an unaudited balance sheet and a statement of stockholders' equity as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal yearend audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); |
| 16 |
| (d) | a budget and business plan for the fiscal year (collectively, the "Budget"), before the first day of the year to which they relate; |
| (e) | as soon as they are available, full details of any actual or prospective material change in the Business or the financial position or affairs of the Company. |
| (f) | as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, a statement showing the number of shares of each class and series of Capital Stock and securities convertible into or exercisable for shares of Capital Stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Investor to calculate its respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company as being true, complete, and correct; and |
if, for any period, the Company has any Subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.
| 3.1.2 | Each Party shall have the right to appoint accountants to undertake a financial audit and examination of the Company's financial statements at any time, but not more than once per year, and the Company shall provide all reasonable assistance to such accountants. All expenses of such financial audit and examination shall be borne by the appointing party. |
| 3.1.3 | Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this Section 3.1 during the period starting with the date thirty (30) days before the Company's good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company's covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. |
| 3.2 | Inspection. |
The Company shall permit each party, at such party's expense, to visit and inspect the Company's properties; examine its books of account and records; and discuss the Company's affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by such party; provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.
| 17 |
| 3.3 | Board Composition. |
| 3.3.1 | The board of directors of the Company (the "Board") shall consist of five (5) directors (each a "Director"). The Investor shall be entitled to appoint one (1) Director to the Board (and any committee thereof) (“Investor Director”) provided it holds five (5%) percent or more equity ownership in the Company. The Investor may appoint or remove a Director nominated by it by written notice to the Company copied to the other parties. |
| 3.3.2 | Each Director shall be appointed for a term of one (1) year and may serve consecutive terms if re-appointed. |
| 3.4 | Quorum. |
Each meeting of the Board requires a quorum of three (3) Directors. Decisions adopted at any Board meeting at which a quorum is not present are invalid. If a quorum is not present, the chairman or the vice chairman of the Board shall send notice to all Directors within 48 hours, and call a subsequent Board meeting with an identical agenda to be convened within the following five (5) Business Days. If a quorum is still not present at the postponed Board meeting, any Director failing to attend the said meeting shall be deemed to be present for the purposes of constituting a quorum, but shall be deemed to have abstained from voting.
| 3.5 | Voting. |
At a meeting of the Board, each Director shall have one (1) vote. Subject to Section 3.6, resolution of the Directors is passed if a simple majority of Directors present at such meeting vote in favor of it.
| 3.6 | Matters Requiring Unanimous Board Consent. |
Resolutions of the Board of Directors involving any of the following matters or actions in respect of the Company and its subsidiaries shall be adopted only upon a unanimous affirmative vote of all Directors (including the affirmative vote by the Investor Director).
| (a) | effect any merger or consolidation of the Company or any Subsidiary of the Company other than mergers of Subsidiaries into the Company or Subsidiaries into other Subsidiaries; |
| (b) | effect any sale, lease, transfer or other disposition, in a single or series of related transactions, by the Company or any Subsidiary of the Company of all or substantially all of the assets of the Company and its Subsidiaries taken as a whole; |
| (c) | liquidate, dissolve or wind-up the business and affairs of the Company; |
| 18 |
| (d) | amend, alter or repeal any provision of the Certificate of Incorporation and Bylaws of the Company; |
| (e) | the issuance of any Share beyond those issued and outstanding as of the date hereof; except for Exempted Securities; |
| (f) | make, or permit the Company or any Subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the Company or any Subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board; |
| (g) | guarantee, directly or indirectly, or permit any Subsidiary to guarantee, directly or indirectly, any third-party indebtedness, except that Subsidiary can guarantee obligations of the Company and other Subsidiaries and the Company can guarantee obligations of its Subsidiaries; |
| (h) | grant or suffer to exist any lien, security interest, pledge or other encumbrance on any of the properties or assets of the Company in excess of $1,000,000 other than (i) liens and security interests disclosed on the Disclosure Schedule delivered pursuant to the Purchase Agreement; (ii) purchase money security interests; (iii) statutory mechanics and material men's liens arising in the ordinary course of business; and (iv) statutory tax liens arising in the ordinary course of business. |
| (i) | incur any aggregate indebtedness in excess of $1,000,000 other than any indebtedness incurred in connection with the Debt Restructuring (as defined in the Purchase Agreement); |
| (j) | otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any "associate" (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except for transactions made in the ordinary course of business and pursuant to reasonable requirements of the Company's business and upon fair and reasonable terms that are approved by a majority of the Board of Directors; |
| (k) | change the principal business of the Company, enter new lines of business unrelated to vision technology and its applications, or exit the current line of business; |
| (l) | alter policy relating to dividends and other distributions to shareholders; |
| (m) | adopt or amend the Budget or medium term adjustment plan to the Budget; |
| (n) | adopt or amend in any material respects of the annual operating plan and strategic plan of the Company; |
| (o) | appoint and dismiss the CEO, Chief Financial Officer the chief technology officer and, the departmental managers of the Company and determining their remuneration; |
| (p) | establish or amend any share incentive scheme of any nature for directors and employees of the Company; |
| 19 |
| (q) | appoint and dismiss the Company's auditor; |
| (r) | materially change the accounting policies and principles adopted by the Company; |
| (s) | own any stock or other securities of, any Subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; |
| (t) | sell, assign, license (including amendments or terminations of licenses), pledge, or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business; |
| (u) | to effect a Qualified IPO; and |
| (v) | establish any new subsidiary. |
| 3.7 | Matters Requiring Board Approval. |
Unless otherwise determined by the unanimous vote of the Directors then in office, the Board shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee Directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company's travel policy) in connection with attending meetings of the Board. The Company shall as soon as practicable before the end of each fiscal year, provide the Board with the Budget, to be approved by the Board. The Company shall further provide to the Board on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company. The Company shall deliver to the Board as soon as practicable after the end of each fiscal year of the Company, the comparable amounts between the Budget for such fiscal year and (i) the balance sheet as of the end of such year and (ii) statements of income and of cash flows for such year.
| 3.8 | Successor Indemnification. |
If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company's Bylaws, its Certificate of Incorporation, or elsewhere, as the case maybe.
| 3.9 | Meeting Minutes |
Minutes of each Board meeting shall be sent to and signed by all of the Directors and proxies who attended the meeting, and shall be adopted at the following Board meeting. The minutes of the Board meetings and any written resolutions adopted by the Board shall be recorded in English and shall be kept in the minute book of Board meetings of the Company kept at the Company's legal address. A copy of the minutes or resolutions adopted shall be immediately sent by fax or registered post to each Director upon completion of a Board meeting.
| 20 |
| 3.10 | Termination of Information and Nomination Rights. |
The covenants set forth in Section 3 shall terminate and be of no further force or effect (i) immediately before the consummation of a Regulation A IPO and or consummation of a Qualified IPO, or (ii) when the Company first becomes subject to the periodic reporting requirements of the Exchange Act.
| 3.11 | Confidentiality. |
Each Party agrees that it will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company's intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.11 by the such Party), (b) is or has been independently developed or conceived by the Investor without use of the Company's confidential information, or (c) is or has been made known or disclosed to such Party by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that the Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company and the Investor informs such Person that such information is confidential; (ii) to any prospective purchaser of any Registrable Securities from the Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.11; (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of the Investor in the ordinary course of business; or (iv) as may otherwise be required by law.
| 4. | Rights to Future Stock Issuances. |
| 4.1 | Preemptive Right. |
Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to the Investor. The Investor shall be entitled to apportion the preemptive right hereby granted to it among itself and its Affiliates that are "accredited investors" as defined in Rule 501 of Regulation D promulgated under the Securities Act in such proportions as it deems appropriate.
| (a) | The Company shall give notice (the "Offer Notice") to the Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. |
| (b) | By notification to the Company within twenty (20) days after the Offer Notice is given, the Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Convertible Debentures and any other Derivative Securities then held, by the Investor bears to the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of the other Derivative Securities, other than Derivative Securities held by employees, officers or directors of the Company). The closing of any sale pursuant to this Section 4.1(b) shall be conditional upon the Investor having obtained all applicable governmental approvals in China and/or completed all applicable filings with governmental authorities in China and shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Section 4.1(c). |
| 21 |
| (c) | The Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer and sell all New Securities that are not elected to be purchased or acquired as provided in Section 4.1(b), to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investor in accordance with this Section 4.1. |
| (d) | The preemptive right in this Section 4.1 shall not be applicable to (i) Exempted Securities; and (ii) shares of Common Stock issued in the Qualified IPO. |
| (e) | Termination. |
The covenants set forth in Section 4.1 shall terminate and be of no further force or effect (i) immediately before the Regulation A Consummation or consummation of the Qualified IPO or (ii) when the Company first becomes subject to the periodic reporting requirements of the Exchange Act.
| 5. | Transfer to third party |
| 5.1 | Lock-up |
| 5.1.1 | Any sale, assignment, transfer, creation of any Encumbrances with respect to or otherwise disposal of the beneficial ownership of any Shares, or entering into any swap, derivative or other arrangement that passes or transfers to another, in whole or in part, the economic interests of any Shares, or agreement or undertaking to do the same ("Transfer") shall be made in accordance with this Section 5. |
| 5.1.2 | The Investor may at any time Transfer any of the Shares held by it. |
| 5.1.3 | Subject to Section 5.1.4, without the prior consent of the Investor in writing, the Key Holder shall not, directly or indirectly, Transfer any Shares held by him or her prior to the occurrence of a Qualified IPO (the "Lock-up Period"). |
| 22 |
| 5.1.4 | Notwithstanding anything to the contrary in this Section 5, each Key Holder may transfer (i) all or some of his or her Shares, upon a transfer of Transfer Stock by such Key Holder made for bona fide estate planning purposes, either during his or her lifetime or on death by will or intestacy to his or her spouse, child (natural or adopted), or any other direct lineal descendant of such Key Holder (or his or her spouse) (all of the foregoing collectively referred to as "family members"), approved by the unanimous consent of the Board, or any custodian or trustee of any trust, partnership or limited liability company, the ownership interests of which are owned wholly by, such Key Holder or any such family members; or (ii) no more than 10% of its Shares in the aggregate to a third party, at any time, provided that: |
| (a) | the transferor gives a prior written notice to the Company and the Investor outlining the reason for the transfer and, for any transfer permitted under subsection (i) of this Section 5.1.4, such transfer is made pursuant to a transaction in which there is no consideration actually paid for such transfer; |
| (b) | such transferee shall, as a condition to such issuance, deliver a counterpart signature page to this Agreement as confirmation that such transferee shall be bound by all the terms and conditions of this Agreement as the Key Holder (but only with respect to the Shares so transferred to the transferee), including the obligations of the Key Holder with respect to Proposed Key Holder Transfers of such Transfer Stock pursuant to the other provisions of Section 5, as applicable, and for any transfer permitted under subsection (i) of this Section 5.1.4, the Key Holder shall at all times remain subject to the terms and restrictions set forth in this Agreement. |
| (c) | the transferor shall procure the transferee to be bound by any other ancillary agreements to which the transferor is a party; |
| (d) | the transferor and transferee shall provide to the Investor Director any information and evidence reasonably requested in writing by the Investor Director for the purpose of determining whether the transfer to the transferee complies with the terms of this Section 5.1.4; and |
| (e) | for any transfers permitted under subsection (ii) of this Section 5.1.4, such transfer is made in strict accordance with the restrictions, conditions and procedures described in the other provisions of Section 5. |
| 5.2 | Right of First Refusal |
| 5.2.1 | Except where any of subsection (i) of Section 5.1.4, and Section 7 applies, the Key Holder (the "Transferring Party") may transfer all or some of its Shares to another person (the "Proposed Key Holder Transfer") provided that: |
| (a) | each time the Transferring Party receives an offer for any of its Shares, it shall first make an offer to the Investor (the "Purchasing Party") by written notice (the "Transfer Notice") at least forty-five (45) days prior to the envisaged date of transfer (the "Date of Transfer"). The Transfer Notice shall set out the identity of the proposed transferee (the "Prospective Transferee"), the amount of Shares to be transferred (the "Offered Shares") and the principal terms of the transfer including the price being offered in consideration for the transfer; |
| 23 |
| (b) | a Transfer Notice shall constitute an irrevocable offer to the Purchasing Party to purchase all (but not only some) of the Offered Shares from the Transferring Party at the price and on the terms set out in the Transfer Notice; |
| (c) | if the Purchasing Party wishes to accept the offer constituted by the Transfer Notice, it shall give written notice (the "Acceptance Notice") to the Transferring Party not less than twenty-five (25) days prior to the Date of Transfer of its acceptance of the terms of the offer (the "ROFR Period"). The Acceptance Notice shall be irrevocable. If the Purchasing Party fails to issue an Acceptance Notice, the Purchasing Party shall be deemed to have waived its rights to buy the Offered Shares and the Transferring Party shall, subject to Section 5.2.2, be free to transfer all Offered Shares to the Prospective Transferee proposed in the Transfer Notice on terms no more favorable to those set out in the Transfer Notice; and |
| 5.2.2 | if the Purchasing Party gives an Acceptance Notice in accordance with Section 5.2.1, on the Date of Transfer, the Purchasing Party and Transferring Party shall enter into a sale and purchase contract for all of the Offered Shares. |
| 5.3 | Right of Co-Sale. |
| 5.3.1 | Subject to the terms and conditions specified in Section 5, if the Investor fails to exercise its right of first refusal within the ROFR Period pursuant to Section 5.2, the Investor may elect to exercise its right to participate on a pro rata basis in the Proposed Key Holder Transfer as set forth in Section 5.3.3 below (the "Right of Co-Sale") and otherwise on the same terms and conditions specified in the Transfer Notice, by giving the Transferring Party written notice to that effect, within five (5) days following the expiration of the applicable ROFR Period ("Right of Co-Sale Period"), and upon giving such notice the Investor shall be deemed to have effectively exercised the Right of Co-Sale. |
| 5.3.2 | If the Investor timely exercises such Right of Co-Sale by delivering the written notice provided for above in Section 5.3.1, it may include in the Proposed Key Holder Transfer all or any part of its Shares equal to the product obtained by multiplying: (i) the aggregate number of Offered Shares subject to the Proposed Key Holder Transfer (which can include Shares in excess of that owned by the Transferring Party), by (ii) a fraction, the numerator of which is the number of Shares owned by the Investor immediately before consummation of the Proposed Key Holder Transfer and the denominator of which is the number of Shares owned by the Investor plus the number of Shares held by the Transferring Party immediately before consummation of the Proposed Key Holder Transfer. |
| 24 |
| 5.3.3 | The Investor shall effect its participation in the Proposed Key Holder Transfer by delivering to the Transferring Party, no later than five (5) days after the Investor's exercise of the Right of Co-Sale, one or more stock certificates, properly endorsed for transfer to the Prospective Transferee, representing the number of Shares that the Investor elects to include in the Proposed Key Holder Transfer. |
| 5.3.4 | The parties hereby agree that the terms and conditions of any sale pursuant to this Section 5.3 will be memorialized in, and governed by, a written purchase and sale agreement with customary terms and provisions for such a transaction and the parties further covenant and agree to enter into such an agreement as a condition precedent to any sale or other transfer pursuant to this Section 5.3. |
| 5.3.5 | Each stock certificate the Investor delivers to the selling Key Holder pursuant to Section 5.3.3 above will be transferred to the Prospective Transferee against payment therefor in consummation of the sale of the Offered Shares pursuant to the terms and conditions specified in the Proposed Transfer Notice and the purchase and sale agreement, and the Transferring Party shall concurrently therewith remit or direct payment to the Investor the portion of the sale proceeds to which the Investor is entitled by reason of its participation in such sale. If any Prospective Transferee or Transferees refuse(s) to purchase securities subject to the Right of Co-Sale from the Investor exercising its Right of Co-Sale hereunder, no Transferring Party may sell any Offered Shares to such Prospective Transferee or Transferees unless and until, simultaneously with such sale, such Transferring Party purchases all securities subject to the Right of Co-Sale from the Investor on the same terms and conditions (including the proposed purchase price) as set forth in the Transfer Notice. |
| 5.3.6 | If any Proposed Key Holder Transfer is not consummated within ninety (90) days after receipt of the Transfer Notice by the Investor, the Key Holder proposing the Proposed Key Holder Transfer may not sell any Offered Shares unless they first comply in full with each provision of Section 5.2 and Section 5.3. The exercise or election not to exercise any right by the Investor under Section 5.2 shall not adversely affect its right to participate in any other sales of Transfer Stock subject to this Section 5.3. |
| 5.3.7 | If any Key Holder purports to sell any Offered Shares in contravention of the Right of Co-Sale (a "Prohibited Transfer") and if the Investor desires to exercise its Right of Co-Sale under Section 5.2.2, the Investor may, in addition to such remedies as may be available by law, in equity or hereunder, require such Key Holder to purchase from the Investor the type and number of Shares that the Investor would have been entitled to sell to the Prospective Transferee under Section 5.3 had the Prohibited Transfer been effected pursuant to and in compliance with the terms of Section 5.3. The sale will be made on the same terms and subject to the same conditions as would have applied had the Key Holder not made the Prohibited Transfer, except that the sale (including, without limitation, the delivery of the purchase price) must be made within ninety (90) days after the Investor learns of the Prohibited Transfer, as opposed to the timeframe proscribed in Section 5.3. Such Key Holder shall also reimburse the Investor for any and all reasonable and documented out-of-pocket fees and expenses, including reasonable legal fees and expenses, incurred pursuant to the exercise or the attempted exercise of the Key Holder's rights under Section 5.3. |
| 25 |
| 5.4 | Effect of Proposed Key Holder Transfer |
If the Transferring Party transfers the Offered Shares to the Prospective Transferee in accordance with the Section 5.2 and Section 5.3, the Transferring Party shall procure that the Prospective Transferee execute all documents necessary for the Prospective Transferee to:
| 5.4.1 | assume such rights and obligations as were originally assumed by the Transferring Party under this Agreement prior to the proposed transfer; and |
| 5.4.2 | be bound by the terms of this Agreement. |
| 5.5 | Termination of Covenants |
The covenants set forth in Section 5 shall terminate and be of no further force or effect (i) immediately before the Regulation A Consummation or the consummation of the Qualified IPO, or (ii) when the Company first becomes subject to the periodic reporting requirements of the Exchange Act.
| 5.6 | Transfer Void; Equitable Relief |
Any Proposed Key Holder Transfer not made in compliance with the requirements of this Section 5 shall be null and void ab initio, shall not be recorded on the books of the Company or its transfer agent and shall not be recognized by the Company. Each party hereto acknowledges and agrees that any breach of this Agreement would result in substantial harm to the other parties hereto for which monetary damages alone could not adequately compensate. Therefore, the parties hereto unconditionally and irrevocably agree that any non-breaching party hereto shall be entitled to seek protective orders, injunctive relief and other remedies available at law or in equity (including, without limitation, seeking specific performance or the rescission of purchases, sales and other transfers of Shares not made in strict compliance with this Agreement).
| 6. | [Intentionally Omitted]. |
| 7. | Call Option by Investor |
| 7.1. | Subject to the provisions of this Section 7, Mr. Dwight Carlson (the "Optionee") shall grant Investor an option ("Investor Call Option") to purchase certain Shares held by him or any Affiliate of him ("Investor Call Option Shares") for free, in the event that, based on the audited consolidated annual accounts of the Company, the Company does not have any net profit (excluding non-recurring gain/loss) in the financial year ending on December 31, 2017; |
| 7.2. | For the purpose of this Section 7, the number of Investor Call Option Shares shall be 10% of the total Shares owned by the Optionee as of the date of this Agreement, on a fully-diluted basis. |
| 26 |
| 7.3. | Investor Call Option shall be exercisable by the Investor at any time within two (2) months after the relevant audited consolidated annual accounts shall have been issued by giving written notice (the "Investor Call Notice") to the Optionee requiring him to transfer (or procure the transfer of) all Investor Call Option Shares to Investor, free from all Encumbrances and together with all rights attaching to such Investor Call Option Shares. |
| 7.4. | Within ten (10) Business Days after the delivery of the Investor Call Notice, the Optionee and the Investor shall enter into a share transfer agreement for Investor Call Option Shares. The Parties shall take all actions as may be reasonably necessary to consummate the transfer contemplated by this Section 7, including, without limitation, entering into agreements and delivering certificates and instruments and consents as may be deemed necessary or appropriate. |
| 8. | Miscellaneous. |
| 8.1 | Successors and Assigns. |
The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; or (ii) is a Holder's family member or trust for the benefit of an individual Holder or one or more of such Holder's Immediate Family Members; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.
| 8.2 | Governing Law. |
This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of law.
| 8.3 | Counterparts: Facsimile. |
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed and delivered by facsimile signature and in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument.
| 8.4 | Titles and Subtitles. |
The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement.
| 27 |
| 8.5 | Notices. |
All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by facsimile during the recipient's normal business hours, and if not sent during normal business hours, then on the recipient's next business day; (iii) for notices sent within the United States, one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt; and (iv) for notices sent from one country to another, three (3) business days after the business day of deposit with an internationally recognized overnight courier, freight prepaid, specifying expedited delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such facsimile number, or address as subsequently modified by written notice given in accordance with this Section 8.5.
| 8.6 | Amendments and Waivers. |
Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least seventy-five percent (75%) of the Registrable Securities then outstanding; and provided further that any provision hereof may be waived by any waiving party on such party's own behalf, without the consent of any other party. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 8.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.
| 8.7 | Severability. |
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.
| 8.8 | Aggregation of Stock. |
All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.
| 28 |
| 8.9 | Entire Agreement. |
This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.
| 8.10 | Dispute Resolution. |
Any dispute, controversy or claim arising in any way out of or in connection with this Agreement, or the breach, termination or invalidity thereof (whether contractual, pre-contractual or non-contractual) shall be settled by binding arbitration administered by the Hong Kong International Arbitration Centre ("HKIAC") in accordance with the HKIAC Administered Arbitration Rules in force as at the date of this Agreement ("Rules"), which Rules are deemed to be incorporated by reference into this Clause and as may be amended by the rest of this Section. The seat of the arbitration shall be Hong Kong.
The arbitration tribunal shall consist of three arbitrators to be appointed in accordance with the Rules. The third and presiding arbitrator shall not be a citizen or national of the PRC or the US.
The language to be used in the arbitral proceedings shall be English and any arbitral award shall be given in English. Nothing in this Section 9.10 shall be construed as preventing any party from seeking conservatory or interim relief from any court of competent jurisdiction. Any award shall be final and binding upon the parties from the day it is made. The parties undertake to carry out each and every arbitral award without delay.
| 8.11 | Delays or Omissions. |
No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.
[Remainder of Page Intentionally Left Blank]
| 29 |
IN WITNESS WHEREOF, the parties have executed this Investors' Rights Agreement as of the date first written above.
|
COHERIX, INC.
| |
| By: | /s/ Dwight D. Carlson |
|
Name: |
Dwight D. Carlson |
| Title: | President and CEO |
| Address: |
3980 Ranchero Dr. Ann Arbor, MI 48108 Fax: 734-761-9193 |
|
[Xintai US Investment LLC] | |
| By: | /s/ Guiwen Liu |
| Name: | Guiwen Liu |
| Title: | Sole Member |
|
KEY HOLDER
/s/ Dwight D. Carlson
Dwight D. Carlson |
| 30 |
Schedule A
Key Holder
Dwight D. Carlson
| 31 |
Exhibit 6.1
TECHNICAL COLLABORATION AND LICENSE AGREEMENT
This Technical Collaboration and License Agreement ("License Agreement") is made and entered into by and between Coherix, Inc., a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 3980 Ranchero Drive, Ann Arbor, Michigan, 48108 USA ("Licensor"), and Panasonic Factory Solutions Co. Ltd., a corporation organized and exiting under the laws of Japan, having its principal place of business at 2-7 Matsuba-cho, Kadoma, Osaka 571-8502, Japan ("Licensee") ..
Recitals:
WHEREAS, Licensor has been engaged in the manufacture and sale of recognition camera and sensors and owns specialized knowledge, information, experience, patents and patent applications relating to the manufacture and use of such products;
WHEREAS, Licensor and Licensee has entered into the Development Agreement for vision systems and camera Product that conform to Licensee's required specifications for Licensee's products;
WHEREAS, Licensee is desirous of manufacturing, using and selling the Product or Final Product(s) based upon such specifications set forward in the Development Agreement; and,
WHEREAS, Licensor is willing to provide Licensee with the benefit of such knowledge, information, experience, patents and patent applications for the manufacture, sale and use of such Product or Final Product(s).
NOW, THEREFORE, in consideration of the terms and conditions set forth herein, the parties hereby agree as follows:
Article 1. Definitions
In this License Agreement, each of the following terms shall have the following meanings, unless otherwise required by context:
| (1) | "3D Camera" shall mean three dimension camera and hardware and software necessary for such camera |
| (2) | "2D Camera" shall mean two dimension camera and hardware and software necessary for such camera |
| (3) | "Product(s)" shall mean the products, software, components, parts thereof and related products and. software thereto, including, but not limited to, 2D Camera and 3D Camera that have been developed based upon the Phase 2 Development Agreement made and entered into by and between Licensor and Licensee on March 22, 2011, and the derivative products and successor products thereof. |
| (4) | "Final Product(s)" shall mean the resulting Product(s) or Product(s) derivatives as modified and/or manufactured by PFSC as a result of this Phase 3 Development Agreement, and Phase 4 of new development agreements made and entered into by and between Licensor and Licensee. |
| (5) | "Development Agreements" shall mean the aggregate or collective of the Phase 1, 2, 3, and 4 Development Agreements. Phase 4 Development Agreement is included only if the parties enter into such an agreement. |
| (6) | "Panasonic Product(s)" shall mean the printed circuit board assembly equipment, equipment to bond the driver integrated circuits on liquid crystal panels, microelectronics bonding systems and/or similar products thereto. |
| 1 |
| (7) | "Intellectual Property Rights" shall mean inventions and patents, design patents, utility models, copyrights, mask work rights, know-how, trade secrets and other intellectual property rights under the laws of any country throughout the world and any applications for any of the foregoing. |
| (8) | "Technical Information" shall mean any and all information and knowledge which are necessary or effective for manufacturing, selling, or using the Product, whether Licensor owns as of the present moment or will obtain in the future, including, but not limited to, Intellectual Property Rights and Licensed Software. |
| (9) | "Product IP" shall mean any and all Intellectual Property Rights which are necessary or effective for manufacturing, selling, or using the Product(s) or Final Product(s), whether Licensor owns as of the present moment or will obtain in the future. |
| (10) | "Effective Date" shall mean the date on which this License Agreement shall come into effect in accordance with the provisions of Article 20(1) and 20(2). |
| (11) | "Transfer Date" shall mean the date on which Initial Fee in the Article 7 herein was paid from Licensee to Licensor, causing the parties to be bound by this License Agreement. |
| (12) | "Improvements" shall mean any and all improvements, modifications or variations, whether or not patentable, in or to the Products, or methods for manufacturing or using the Products, to the extent the 3D Camera and/or 2D camera is capable of being installed in the Panasonic Products. |
| (13) | "Affiliate" shall mean company or other legal entity which: (a) is controlled by a party to this License Agreement; (b) controls a party to this License Agreement; or (c) is under common control with a party to this License Agreement. For the purpose of this definition, "control" means that more than fifty percent (50%) of the shares or ownership interest representing the voting right for the election of directors or persons performing similar functions for such a corporation, company or entity are owned or controlled, directly or indirectly, by the controlling entity. Such corporation, company or entity shall be deemed to be an Affiliate so long as such ownership or control exists. |
| (14) | "Licensed Object Code" shall mean computer program in the form of object code listed in Schedule I. |
| (15) | "Licensed Source Code" shall mean computer program in the form of source code listed in Schedule I. |
| (16) | "Licensed IP" shall mean any Intellectual Property rights granted by Licensor to Licensee and listed in Schedule I. |
| (17) | "Documentation" shall mean the instruction manual of the Licensed Object Code, Licensed Source Code and any other related material or documentation, in writing or in electronic form. |
| (18) | "Licensed Software" shall mean the Licensed Object Code, Licensed Source Code and the Documentation, including, if any, Updates of any of the foregoing. |
| (19) | "Updates" shall mean all changes to the Licensed Software to correct any Defect therein, but which do not add or alter functionality of the Licensed. Software, including, but not limited to, patches, bug fixes and minor updates of the Licensed Software. |
| (20) | "Deliverable" shall mean individually and collectively, a copy of (i) the Licensed Object Code, and Licensed Source Code, (ii) the Documentation, and (iii) the Licensed IP, to be delivered by Licensor to Licensee. |
| 2 |
| (21) | "Defect" shall mean any mistake, problem, defect, software bug, malfunction or deficiency, which causes incorrect or inadequate functioning or non-functioning of Product(s) and/or causes Product(s) not to meet the specifications for Product(s). |
| (22) | "Business Activity" shall mean to manufacture, sell, use, modify, copy, repair, develop, export, import, distribute, maintain and/or have done all those things. |
| (23) | "Escrow Agent" shall mean Software Information Center in Japan. |
| (24) | "Escrow Agreement" shall mean the escrow agreement originally attached in Appendix 1 of the Phase 2 Development Agreement and entered into among the Licensor, Licensee and the Escrow Agent on the Effective Date. |
| (25) | "Permitted Markets" shall mean the allowable worldwide markets in which the Licensee has permission in which to sell, distribute or otherwise conduct Business Activity of the Product or Final Product(s). Specifically these markets are limited to PCB assembly equipment, equipment to bond the driver ICs on liquid crystal panels, and/or microelectronics bonding systems markets. Other markets shall be defined and permitted by mutual consent of the parties. |
| (26) | Common Definitions are provided in the Phase 2 Development Agreement, the Escrow Agreement in Appendix 1 to the Phase 2 Development Agreement, and this License Agreement as Appendix 2 to the Phase 2 Development Agreement. The Phase 2 Development Agreement shall prevail if any conflicts arise between the definitions and this License Agreement, and these Phase 2 Definitions shall survive any termination of the Phase 2 Development Agreement. |
Article 2. Grant of License
| (1) | Subject to the terms and conditions set forth herein, Licensor hereby grants to Licensee, an exclusive license to conduct Business Activity of the Product or Final Product(s) in Permitted Markets worldwide under the Products IP and Technical Information with right to sublicense to Licensee's Affiliates. |
| (2) | Subject to the terms and conditions of this License Agreement, Licensor hereby grants to Licensee under copyrights owned, controlled or licensable by it, an exclusive and non-transferable, world-wide license, with right to sublicense to Licensee's Affiliates, |
(a) to conduct Business Activity of the Licensed Software within and other licensed Intellectual Property as set forward in the Development Agreements for the purpose of conducting Business Activity of the Product or Final Product(s);
(b) to copy and incorporate the Licensed Software and other licensed Intellectual Property as set forward in the Development Agreements into the Products or Final Product(s) for the purpose of conducting Business Activity of the Product or Final Product(s)
| (3) | While this License Agreement is in effect, Licensor shall not, or cause any third party to, conduct Business Activity of the Product or Final Product(s), directly or indirectly, for the purpose of conducting Business Activity of the products that are competitive with Panasonic Product(s) in the Permitted Markets, nor shall Licensor grant any further licenses to conduct Business Activity of the Product or Final Product to any third party unless otherwise agreed upon in writing between the parties. Licensee shall not unreasonably withhold permission for such further licenses.( |
| (4) | The rights under this License Agreement shall be granted by Licensor to Licensee and shall come into full force and effect on the occurrence of full payment of the Initial Fee specified in Article7(1)(a) in this License Agreement after the completion of Phase 2 Development work as set forth in the Development Agreement. |
| (5) | Notwithstanding the foregoing paragraph, Licensee may conduct Business Activity within the terms of this License Agreement regarding future specification and design development agreements for Phase 3 and Phase 4. |
| 3 |
Article 3. Technical Materials
| (1) | Within thirty (30) days after the Transfer Date, Licensor, at its own cost and expense, shall furnish and make available to Licensee, as part of Technical Information, all technical materials that are necessary or desirable for conducting Business Activity of the Products, including the following: |
(a) Drawings and specifications of the Products;
(b) Bill of Parts and materials;
(c) Production standards;
(d) Drawings for assembly
(e) Deliverables;
A list of said technical materials is attached hereto as Schedule I.
| (2) | Within thirty (30) days after the date of end of Phase 3, Licensor, at its own cost and expense, shall furnish and make available to Licensee, as part of Technical Information, all technical materials that are necessary or desirable for conducting Business Activity of the Products, including the following: |
(a) Drawings and specifications of the Products;
(b) Bill of Parts and materials;
(c) Production standards;
(d) Drawings for assembly;
(e) Deliverables;
| (3) | Within thirty (30) days after the date of end of Phase 4, Licensor, at its own cost and expense, shall furnish and make available to Licensee, as part of Technical Information, all technical materials that are necessary or desirable for conducting Business Activity of the Products, including the following: |
(a) Drawings and specifications of the Products;
(b) Bill of Parts and materials;
(c) Production standards;
(d) Drawings for assembly;
(e) Deliverables;
| (4) | Technical Materials provided by Licensor shall be written in English, and the metric system shall be used for all dimension descriptions. |
| (5) | Notwithstanding the foregoing four paragraphs, Licensor, at its own cost and expense, shall furnish and make available to Licensee, completed versions of the technical materials in the foregoing four paragraphs, whenever Licensee requests Licensor to do so to a reasonable extent. |
Article 4. Technical Guidance
| (1) | Upon request of Licensee, Licensor shall dispatch its qualified technical engineers ("Engineers") to Licensee at Licensee' s facilities in order to render technical assistance to employees of Licensee or its sub-contractors in connection with the design, manufacture, assembly, installation, repair, inspection, maintenance, quality control or sale of the Products. |
| (2) | Daily allowance for Engineers dispatched hereunder shall be determined by mutual consultation using Licensor's current allowance rate in its international business. Traveling, living and other expenses required for such dispatch shall be borne and paid by Licensee pursuant to terms and conditions to be separately agreed upon between the parties. Period, numbers and reasonable details of such dispatch shall be also separately agreed upon between the parties. |
| (3) | Notwithstanding the foregoing paragraph, any and all allowance and expense of first two times dispatch shall be included in the initial royalty specified in the Article 7.(1).(a) to the extent that the period of such dispatch does not exceed totally twenty (20) days. |
| 4 |
Article 5. Technical Training
| (1) | Licensor shall provide, at Licensor's facilities, technical training, free of any additional charge, to representatives of Licensee or its sub-contractors with respect to the design, manufacture, assembly, installation, repair, inspection, maintenance, quality control and sale of the Products. |
| (2) | All expenses of traveling, living and insurance for such representatives shall be borne and paid by Licensee. |
| (3) | Notwithstanding the foregoing paragraph, any and all allowance and expense of first two times trainings shall be included in the initial royalty specified in the Article 7.(1).(a) to the extent that the period of such training does not exceed twenty (20) days. |
Article 6. Other Technical Assistance
Licensor shall provide Licensee with all additional advice and assistance necessary or desirable for conducting Business Activity of the Products, including, without limitation, advice and assistance relating to selection and purchase of machinery, and proper allocation of personnel, by any method considered most effective by Licensor.
Article 7. Royalties and Payment
| (1) | In consideration of the licenses granted to Licensee hereunder. Licensee shall pay to Licensor the following royalties: |
| (a) | Initial manufacturing, license and royalty fee ("Initial Fee") of one million and five hundred thousand US dollars (US$1,500,000-) paid within sixty (60) days (JST) after the Effective Date of this License Agreement, |
| (b) | Running royalty per one unit of 2D version of the Product or Final Product(s) shall be paid in accordance with Schedule III of this License Agreement. The running royalty for 2D version of the Product or Final Product(s) shall cease after the expiration of this License Agreement. |
| (c) | Running royalty per one unit of 3D version of the Product or Final Products shall be paid in accordance with Schedule III of this License Agreement. The running royalty for 2D version of the Product or Final Product(s) shall cease and all grant of license in the Article 2 shall become free of charge after the expiration of this License Agreement. |
| (2) | The running royalty in this Article shall be computed quarterly as of the last day of March, June, September and December of each year during the term of this License Agreement, and Licensee shall pay to Licensor the total amount of the running royalty thus computed within forty-five (45) days after the end of the relevant quarterly period. The details of the payment procedure shall be separately agreed by the parties by a reasonable date before first payment. |
| (3) | Any taxes of whatever nature imposed or levied by the Japanese Government on the royalties to be paid under this Article shall be borne by Licensor. Licensee shall withhold and pay such tax on behalf of Licensor. Upon request of Licensor, Licensee shall provide Licensor with formal certificates showing such tax payment so as to enable Licensor to enjoy the benefit of avoidance of double taxation pursuant to the Tax Treaty between the United States of America and Japan. |
| (4) | All payments by Licensee to Licensor hereunder shall be made in currency of US dollar by telegraphic transfer to Licensor's bank account on email receipt of an invoice in PDF format. |
Article 8. Accounting and Report
| (1) | Within sixty (60) days after the end of March and September of each year during the term of this Agreement, Licensee shall furnish Licensor with a final written statement specifying the number of 2D Camera and 3D Camera versions of the Product or Final Product(s) sold by Licensee during each immediately preceding semi-annual period. |
| (2) | Licensee shall keep true and accurate books and records containing all data reasonably required for computation and verification of the amounts payable hereunder. |
| 5 |
Article 9. Sales Promotion and Option
| (1) | Licensee agrees to use commercially reasonable efforts to promote the sale of Licensee's Product or Final Product(s), where these Product or Final Product(s) are installed, maintain contact with customers, establish contact with potential customers, arrange for advertising, and maintain its employment of technical personnel with appropriate skills. |
| (2) | Notwithstanding the foregoing paragraph, Licensee has any and all option to install the Product or Final Product(s) in its Panasonic Products or not, and any and all option regarding which Panasonic Products the Product or Final Product(s) should be installed in. |
Article 10. Improvements
| (1) | During the term of this License Agreement, Licensor shall develop Improvements in accordance with Licensee's request. In this case, the parties shall enter into separate development agreement and such development fee shall be separately agreed by the parties therein. |
| (2) | Except for the foregoing paragraph, during the term of this License Agreement, Licensor shall inform the Licensee of Improvements created without Licensee's request, and disclose the details thereof at Licensee's request. |
| (3) | Licensee is entitled to conduct Business Activity regarding the Product or Final Product(s) employing Improvements of Licensor, whether or not covered by patent, without additional payment except the event of the foregoing Article 10 (1), as if they were originally covered by the licenses wanted hereunder. |
Article 11. Treatment of Confidential Information
| (1) | Neither party ("Receiving Party") shall disclose to any other person or entity any information disclosed by the other party that is marked "Confidential" (or a comparable notation) at the time of its disclosure for five (5) years after receipt thereof. |
| (2) | Notwithstanding the foregoing paragraph, neither party shall disclose to any other person or entity Technical Information which is not in the public domain for ten (10) years after Effective Date, and in this case, either party shall be deemed to be the Receiving Party in the following two paragraphs in this Article. |
| (3) | Notwithstanding the foregoing two paragraphs in this Article, the Receiving Party may disseminate, in whole or in part, the information mentioned above to a limited number of officers and employees of the Receiving Party or its Affiliates or its sub-contractors or its distributors, on a need-to-know basis. The Receiving Party shall take all reasonable precautions to ensure that such officers, employees, sub-contractors and distributors shall comply with the obligations under this Article. |
| (4) | The obligations under this Article shall not apply if such information is: |
| (a) | Information which was in the possession of the Receiving Party prior to its disclosure; |
| (b) | Information which is or becomes public knowledge without any fault of the Receiving Party; |
| (c) | Information which becomes available to the Receiving Party from a third party without any obligation of secrecy; |
| (d) | Information disclosed to a third party with the prior written consent of the other party. |
| (5) | The parties have set forward substantial Confidentiality language in the Development Agreements, Section 12, and the Development Agreements language shall prevail if any conflicts arise between this License Agreement and the Development Agreements. |
| 6 |
Article 12. Trademarks
During the term of this License Agreement, Licensor hereby grants to Licensee a non-exclusive, non-transferable and royalty-free license to use Licensor's trademarks listed in Schedule II attached hereto ("Trademarks") in connection with the sale and promotion of the Product or Final Product(s).
Article 13. Infringement
| (1) | In the event that Licensee notifies Licensor of any infringement or threatened infringement of any Product Patents or Trademarks, Licensor shall take all necessary steps to prevent such infringement or threatened infringement, as the case may be, including commencement of a legal action or other proceeding against such third party to restrain such infringement or threatened infringement. |
| (2) | In the event that a claim, legal action, or any other proceeding in any forum is brought against Licensee, its Affiliates, its sub-contractors, its distributors, and/or its customers alleging that Business Activity of the Products or use of the Products IP, Trademarks or Technical Information infringes upon any of Intellectual Property Rights of any third party, Licensor shall defend Licensee and take all necessary steps to secure Licensee the right to continue such Business Activity of the Products, or use of the Product Patents, Trademarks and Technical Information. Licensor shall bear and indemnify Licensee, its sub-contractors, its distributors and/or its customers for all costs for such legal action or proceeding, including an attorney's fees, and all damages, expenses, settlement amounts and judgments. If Licensor is not able to secure Licensee said right, Licensor shall at its own costs provide Licensee with alternative designs or technology substantially equivalent to the Product Patents or Technical Information at Licensee's request. |
| (3) | Licensor shall diligently prosecute and timely inform Licensee of the maintenance and prosecution of patents and patent applications. |
Article 14. Non-Assertion
| (1) | Licensor shall not assert any of its Intellectual Property Rights against Licensee, its Affiliates, its customers, its subcontractors, its distributors and/or any other third party using, developing, having developed, manufacturing, or having manufactured, modifying, having modified, selling and/or having sold any Final Products and/or Improvements in compliance with and as long as this License Agreement is in effect. |
| (2) | Licensee warrants it will cease developing, manufacturing, selling, and modifying the Final Product, Improvements or its derivatives if this License Agreement is terminated. Licensee further warrants it will cause its Affiliates, subcontractors, distributors, and any other third party to cease Business Activities in regard to the Final Product, Improvements, or its derivatives as integrated into the Panasonic Product. |
Article 15. Representations and Warranties
| (1) | Licensor hereby represents and warrants that it has full legal authority to grant the licenses set forth herein, and that there are no outstanding agreements, assignments or encumbrances which are inconsistent or in conflict with any provision of this Agreement or the licenses granted hereunder. |
| (2) | Licensor hereby warrants that use of the Technical Information shall not infringe upon any third party's proprietary rights or interests. |
| (3) | Licensor hereby warrants that Technical Information disclosed by Licensor hereunder shall be the latest information developed or used by Licensor to conduct Business Activity of the Products and shall be appropriate to enable Licensee to conduct Business Activity of the Products. |
| (4) | Licensor hereby warrants to Licensee that the components supplied by Licensor and used in the Final Product(s), Improvements and/or Licensed Software unmodified by Licensee shall, after Licensee's acceptance of technical materials specified in the Article 3, be free from Defects, and shall be fit for their intended use, when properly used. In the event that either party finds any Defects in Licensor supplied items used in the Final Products, Improvements and/or unmodified portion by Licensee of Licensed Software for a period of two ( 2 ) years from such acceptance, such party shall immediately notify to the other party of such Defects and Licensor shall correct such Defects at its own expense. In such case after such period, in addition to the notification above, Licensor shall correct such Defects under the terms and conditions separately agreed by both parties. |
| 7 |
Article 16. Products Liability
Language governing Indemnification and Products Liability has been set forward in Section 10 - Indemnification of the Phase 2 Development Agreement dated 22 March, 2011. This common language from the Phase 2 Development Agreement shall apply to this License Agreement and in particular Sections 13, 15, and 17 herein. This common language shall survive any termination of the Phase 2 Development Agreement and shall prevail if any conflicts arise between the Development Agreement Products Liability and this License Agreement. Licensor shall mean Coherix and Licensee shall mean PFSC in the use of this common language.
Article 17. Limitation of Liability
Licensor is responsible for the design of the Product, components of the Product Licensor supplies, and/or unmodified portion by Licensee of the Final Product and/or components of the Final Product. Licensee is responsible for its manufacture and/or modification of the Final Product(s) and/or Final Product components it manufactures or modifies under the terms of this License Agreement.
IN CONSIDERATION OF THE FOREGOING THE AGGREGATE LIABILITY TO LICENSEE IN CONNECTION WITH THIS LICENSE AGREEMENT SHALL IN NO EVENT EXCEED THE AMOUNT OF TOTAL PAYMENT FROM LICENSEE TO LICENSOR WITH REGARD TO THE DEVELOPMENT AGREEMENT AND LICENSE AGREEMENT, INCLUDING, BUT NOT LIMITED TO, RUNNING ROYALTY SPECIFIED IN THE ARTICLE 6(1). EACH PARTY ACKNOWLEDGES AND AGREES THAT THE FOREGOING LIABILITY LIMITATION FOR LICENSEE IS AN ESSENTIAL ELEMENT OF THIS AGREEMENT AND THAT IN THE ABSENCE OF SUCH LIMITATION, THE MATERIAL AND ECONOMIC TERMS OF THIS AGREEMENT WOULD BE SUBSTANTIALLY DIFFERENT.
Article 18. Escrow
| (1) | Within thirty (30) days of execution hereof, the Licensor shall provide the Escrow Agent with the source code of the Licensed Object Code in accordance with the Escrow Agreement. Licensor shall keep the source code in escrow Updated during the term of this Agreement. |
| (2) | Subject to the terms and conditions provided in the Escrow Agreement, Licensee shall be entitled to obtain the source code of the Licensed Object Code from the Escrow Agent upon the occurrence of any of the events provided in Article 5 of the Escrow Agreement. |
Article 19. Assignment, Sublicense and Subcontracting
| (1) | Neither party shall assign, transfer or otherwise dispose of this License Agreement, or of any right or obligations hereunder without the prior written consent of the other party. |
| (2) | Licensee shall not sublicense any right granted by this License Agreement to any third party without the prior written consent of Licensor, which consent shall not be unreasonably withheld; provided, however, that Licensee may manufacture any part of the Products or Final Products through its subcontractors and sublicense the licenses specified in the Article 2 to its Affiliates. |
Article 20. Term and Termination
| (1) | This License Agreement shall come into effect on the date when the parties have signed this License Agreement, provided, however, that in the event there are procedures required under both the laws of Japan and the State of Delaware, this License Agreement shall come into effect on the date when all of such procedures are completed for the lawful execution of this Agreement ("Effective Date"). Each party shall diligently pursue completion of such procedures, and keep the other party informed of its progress. |
| 8 |
| (2) | Notwithstanding the foregoing paragraph, the grant of license in the Article 2 shall commence on the date when Initial Fee in the Article 7(1)(a) is paid from Licensor to Licensee. This is the formal "Transfer Date". |
| (3) | Unless terminated earlier by paragraphs (4) or (5) below, this Agreement shall continue in full force and effect for ten (10) years from the Effective Date. |
| (4) | If either party fails to comply with, or breaches, any of the provisions contained herein and such non-compliance, or breach, is not cured within thirty (30) days after notice thereof, the other party may terminate this Agreement. The parties agree that serving such notice is a last resort action, after exhausting other methods of remedy for such non-compliance or breach in mutual good faith. |
| (5) | Either party may terminate this License Agreement by giving written notice to the other party if one or more of the following events occur to the other party |
| (a) | appointment of a trustee or receiver for all or any substantial part of the assets of the other party; |
| (b) | insolvency or bankruptcy of the other party; |
| (c) | general assignment by the other party for the benefit of creditors; |
| (d) | expropriation of the business or assets of the other party; or |
| (e) | dissolution or liquidation of the other party. |
If either party is involved in Items (a) through (e) above, such party shall notify the other party immediately upon the occurrence of such event.
Article 21. Effect of Termination or Expiration
| (1) | If this License Agreement is terminated, by early termination, Licensee may continue to manufacture and/or sell the Final Product(s) held by Licensee in stock or being manufactured or ordered at the time of such termination and to use the Trademarks in connection with the sale of such Final Product(s), subject to the payment of the amount corresponding to the running royalties. Article 7 shall apply mutatis mutandis to these payments. |
| (2) | Notwithstanding the foregoing paragraph, as long as Licensee's customer owns Licensee's Final Product(s) delivered before such expiration or termination in which the Final Product(s) is or can be installed in, Licensee may continue to conduct Business Activity of the Final Product(s) to the extent of repair, modification and/or spare parts supply for such products. |
| (3) | Termination of this License Agreement, by early termination, shall not, in any way, affect, impair or destroy any right or remedy of the parties that has accrued prior to such termination. |
(4) The provisions of Article 1, 2, 6, 11, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30 and 31 shall survive the expiration or termination of this License Agreement.
Article 22. Force Majeure
Neither party shall be liable to the other party for failure or delay in the performance of any of its obligations under this License Agreement for the period and to the extent such failure or delay is caused by riots, civil commotions, wars, hostilities between nations, governmental laws, orders or regulations, embargoes, actions by the government or any agency thereof, acts of God, storms, fire, accidents, strikes, sabotage, explosions or other similar or different causes beyond the reasonable control of the respective parties.
| 9 |
Article 23. Export Control
| (1) | For the purpose of performing any obligation hereunder, Licensor shall obtain any licenses and/or permits for the Product or portions of the Product it supplies to Licensee from the competent authority of the relevant government, at its own expense, if and to the extent required by any relevant laws and regulations, including, but not limited to, the Export Administration Regulations of the United States of America. |
| (2) | If requested by Licensee, Licensor shall provide to Licensee without delay, any document in relation to the Products or portions of the Product it supplies to Licensee in order to comply with any relevant laws and regulations, including, but not limited to, the Export Administration Regulations of the United States of America. |
Article 24. Notice
| (1) | All notices, demands and other communications to be given in respect of this License Agreement shall be made by registered airmail, postage prepaid, or by facsimile and shall be addressed to the other party at the address first written above unless the recipient changes its address by notice in accordance with this Article. |
| (2) | Notices, demands and communications mentioned above shall be deemed to have been received by the other party and made effective seven (7) days after their mailing when made by registered airmail, and at the time of receipt and confirmation when made by facsimile. |
Article 25. Waiver
Any failure of either party to enforce, at any time or for any period of time, any of the provisions of this License Agreement shall not be construed as a waiver of such provision or of any other provision hereof.
Article 26. Governing Law
This License Agreement shall be governed, in all respects including validity, construction and performance, by and under the laws of New York state.
Article 27. Arbitration
All disputes, controversies or differences which may arise between the parties, out of or in relation to or in connection with this Agreement shall be finally settled by arbitration in Osaka, Japan in accordance with the Commercial Arbitration Rules of the Japan Commercial Arbitration Association. The award rendered by the arbitrator(s) shall be final and binding upon the parties. Additional language and clarification regarding Arbitration is set forward in the Development Agreement, Section 17 — Dispute Resolution, and this additional language shall govern any Arbitration activities.
Article 28. Entire Agreement and Modification
| (1) | This License Agreement constitutes the entire and only agreement between the parties with respect to the subject matter hereof, and supersedes any prior and contemporaneous understandings, agreements or negotiations, express or implied. |
| (2) | No modification, change or amendment of this License Agreement shall be binding upon the parties except by mutual agreement in writing duly signed by an authorized representative of each of the parties, dated subsequent to the date of this License Agreement and expressly referring to this License Agreement. |
| 10 |
Article 29. Headings
The headings of articles used in this License Agreement are inserted for reference only and shall not affect interpretation of the respective articles of this License Agreement.
Article 30. Language
This License Agreement has been executed in duplicate with equal force and effect in the English language. Communication made for performance under this License Agreement shall be made in English.
Article 31. Severability
If any of the provisions of this License Agreement is declared fully or partly invalid or unenforceable, this License Agreement shall be considered divisible as to such provision, and the remainder of this License Agreement shall be deemed valid and binding as if such provision were not included herein unless such invalidity or unenforceability destroys the underlying business purposes of this License Agreement. Both parties shall replace or revise such invalidated or unenforceable provision with a valid and enforceable provision, to the maximum extent permissible under applicable law, that has the closest meaning to what the parties intended or would have intended according to the sense and purposes of this License Agreement had the matter been considered when concluding this License Agreement.
| 11 |
IN WITNESS WHEREOF, the parties have caused this License Agreement to be executed in duplicate by their duly authorized representatives as of the Effective Date herein, each party retaining one copy thereof respectively.
| Date: 3/21/2012 | Date: 3/28/2012 |
| For: Coherix, Inc. | for: Panasonic Factory Solutions Co., Ltd. |
| /s/ Dwight Carlson | /s/ Signature |
| Signature and Title | Signature and Title |
| Chairman/CEO | President |
| 12 |
Exhibit 6.2
LOAN AND SECURITY AGREEMENT
(“Agreement”)
This Agreement dated August 19, 2016, is an agreement between CRESTMARK BANK, a Michigan banking corporation (“Crestmark”), and COHERIX, INC., a Delaware corporation (“Borrower”). In this Agreement, Crestmark and Borrower are collectively the “Parties”. Any person who guarantees the obligations of Borrower (each a “Validity Guarantor” subject to the terms and conditions of the Validity Guaranty) is required to sign this Agreement. The Parties have the addresses shown on the schedule (“Schedule”) which is attached to this Agreement. These are the addresses of the Parties for all purposes and may be changed by one party giving notice to the other party in writing of the new address.
1. PURPOSE. The purpose of this Agreement, including the Schedule, is to set forth the terms and conditions of the loan from Crestmark to Borrower (“Loan”) and the obligations of Borrower. The Schedule is part of this Agreement. The promissory note (“Note”) to be signed by Borrower, any guaranty(s), and any other documents now or hereafter signed by any of the Parties in connection with this Agreement, the Loan or any document issued by Crestmark or the bank holding the lockbox (“Lockbox Bank”), including subordination agreements or intercreditor agreements, are also all part of this Agreement. All of the documents together are referred to collectively as the “Loan Documents”.
2. LOAN; LOAN ADVANCES.
A. Any disbursement of money or advance of credit by Crestmark, including but not limited to amounts advanced for the payment of interest, fees, expenses and amounts necessary to protect, maintain and preserve Crestmark’s Collateral under the Loan Documents (“Protective Disbursements”), is referred to collectively as an “Advance”. Whether Crestmark makes an Advance is in Crestmark’s sole discretion. If an Advance is made, it will be made in accordance with the advance formula set forth in the Schedule (“Advance Formula”); but not at any time to exceed the maximum amount set forth on the Schedule (“Maximum Amount”). Crestmark may choose to make Protective Disbursements in excess of the Maximum Amount or Advance Formula in its sole discretion. Each time Crestmark makes an Advance, including a Protective Disbursement, the Advance will be debited against an account in Borrower’s name on Crestmark’s books (“Loan Account”), and each payment will be credited against the Loan Account in the manner described in this Agreement.
B. The total amount Borrower owes to Crestmark will be the aggregate of the Advances made by Crestmark, the expenses and fees set forth in the Schedule and any and all costs incurred by Crestmark (including reasonable attorney’s fees), and interest at the rate set forth in the Note on all amounts advanced (together with all other obligations of Borrower under the Loan Documents, the “Obligations” and/or “Indebtedness”).
C. Borrower must repay all Advances with respect to the Loan with interest, which is due monthly as specified in the Note, along with all other fees and expenses of Crestmark set forth herein or in the Schedule. Crestmark may in its sole discretion collect any Obligations due Crestmark by (i) directly applying any funds in the Lockbox Account, as defined in paragraph 5 below, to the Obligations (ii) directly applying funds from any reserve to the Obligations, (iii) collecting the Obligations directly from Borrower; or (d) otherwise collecting the Obligations. Borrower understands that all the Obligations are repayable at any time in full or in part upon demand by Crestmark. Crestmark may make demand for partial payments and such demand will not preclude Crestmark from demanding payment in full at any time.
| 1 |
D. Borrower must comply with its representations, promises, covenants and reporting requirements set forth in this Agreement, in the Schedule and in the other Loan Documents. Borrower’s failure to do any of the foregoing and/or Guarantor’s failure to comply with the terms of its Guaranty are both a default under this Agreement (“Default”). The demand nature of the Obligations is not modified by reference to a Default in this Agreement or the other Loan Documents and any reference to a Default is for the purpose of permitting Crestmark to exercise it remedies for Default, including charging interest at the Extra Rate provided in the Note.
E. The aggregate amount of all Advances, plus the expenses and fees set forth in the Schedule, any and all costs incurred by Crestmark (including reasonable attorney’s fees), and interest at the rate set forth in the Note on all amounts advanced (the “Loan Amount”), may not, at any time, exceed the Maximum Amount” or the Advance Formula, and Borrower understands that if at any time it should owe more to Crestmark than the lesser of the Maximum Amount or the Advance Formula it must repay that amount immediately, whether or not demand to repay the whole of the Obligations has been made. Protective Disbursements must be immediately repaid whether or not the lesser of the Maximum Amount or the Advance Formula has been exceeded.
3. RESERVES. If Crestmark believes in its sole discretion that the prospect for repayment of the Obligations is impaired or that its Collateral margin is insufficient, Crestmark may establish cash reserves and credit balances to protect its interests and the repayment of the Obligations. The reserve may be established by reducing the Advance Formula to achieve the target reserve level, withholding monies due Borrower from any payments Crestmark receives, from a cash payment from Borrower or any other method Crestmark chooses. Any money in a reserve account, whether or not it is a cash reserve, will not earn interest for Borrower, and Crestmark may apply the funds in the reserve account to reduce the Obligations at any time Crestmark elects.
4. FEES AND EXPENSES. In connection with the Loan there are several types of fees that may be charged and Borrower may be required to maintain a minimum Loan balance. Such fees and requirements are set forth in the Schedule. In addition, all expenses of every kind incurred by Crestmark in connection with the Loan, any Advance, collection of the Obligations, inspection, and examination are to be paid by Borrower.
5. LOCKBOX. Borrower must immediately notify all persons who are obligated on accounts (“Account Debtors”) to direct all Account Debtors and any other person or party that is liable to Borrower (collectively a “Debtor”) to remit all payments due Borrower to the lock box address or pursuant to the wire transfer or ACH instructions set forth in the Schedule (the “Lockbox Account”). The remit to address on all documents related to the accounts, including invoices, purchase orders, or contracts (“Documents”) must be the Lockbox Account. At Crestmark’s request, all Documents must be marked by Borrower to show assignment to Crestmark, and Borrower must notify each Account Debtor by mail that the Account has been assigned to Crestmark and that all payments on the Account, whether made by mail or electronically or otherwise must be made payable to Borrower or Crestmark, at Crestmark’s sole discretion, to the Lockbox Account or other address provided by Crestmark in writing. The language used in such notices shall be approved by Crestmark in writing. Crestmark may at any time and from time to time, and at its sole discretion, notify any Debtor or third party payee to make payments payable directly to Crestmark or to notify Debtor of the assignment to Crestmark. All expenses for notification of each Account Debtor will be paid by Borrower.
If notwithstanding the notice to Debtors, Borrower receives any funds from a Debtor, including any cash, checks, drafts or wire transfers from the collection, enforcement, sale or other disposition of the Collateral (defined below), whether derived in the ordinary course of business or not, or if Borrower receives any proceeds of insurance, tax refunds or any and all other funds of any kind, Borrower shall hold such funds in trust for Crestmark, shall not mix such funds received with any other funds, and shall immediately deposit such funds in the Lockbox Account in the form received. That means if the funds are received by mail, the Debtor checks will be sent to the Lockbox Account uncashed, and if the funds are received electronically, the funds will be transferred immediately to the Lockbox Account electronically. Crestmark will have sole possession and control over the Lockbox Account. The Lockbox Bank will process all deposits and Borrower has no right to the Lockbox Account, it belongs to Crestmark. Crestmark is the owner of all deposits in the Lockbox Account, and has no duty as to collection or protection of funds as long as it is not grossly negligent or commits actual fraud. All expenses plus any applicable administration and servicing fees of the Lockbox Account will be paid by Borrower.
| 2 |
6. LOAN ACCOUNT. All of the Obligations which are owed by Borrower will be shown in the Loan Account and Borrower will receive a monthly statement either by mail, electronically or via access to the Crestmark online system at Crestmark’s sole discretion. The statement is binding on Borrower unless Borrower provides a written objection to Crestmark that is actually received by Crestmark within fifteen (15) business days of the time the statement is provided or made available to Borrower.
7. PAYMENTS. Should a check or other credit instrument not be collected after Borrower has been given credit for such payment, then the credit will be reversed and a fee charged at Crestmark’s then standard rate. Crestmark, at its sole discretion, may establish reserves as set forth above or not apply a payment that it reasonably believes may be returned unpaid for any reason or disgorged due to a preference claim or garnishment, and in such event the Maintenance Fee (as defined in the Schedule) will still be payable. In the event that any payment received by Crestmark is sought to be recovered by or on behalf of the payer (including a trustee in bankruptcy or assignee for the benefit of creditors), then Borrower agrees to immediately reimburse Crestmark on demand for any amount so recovered and all of Crestmark’s expenses in connection with any such proceeding, including reasonable attorneys fees. This provision shall survive termination of this Agreement. Any payments received by Crestmark shall be applied to the Obligations in whatever order Crestmark determines in its reasonable discretion.
8. SECURITY INTEREST.
A. Borrower grants to Crestmark a security interest in all of its assets, now existing or hereafter arising, wherever located including all Accounts, Goods, Inventory, Equipment, Chattel Paper, Instruments, Investment Property, specifically identified Commercial Tort Claims, Documents, Deposit Accounts, Letter of Credit Rights, General Intangibles, Contract Rights, customer lists, furniture and fixtures, books and records and supporting obligations for any of the foregoing, and all Proceeds of the foregoing (the “Collateral”), to secure repayment of the Obligations (“Security Interest”). The Collateral also includes all monies on deposit with Crestmark, or on deposit in the Lockbox Account. All capitalized terms used in this Section 8A. which are not otherwise defined shall have the meanings assigned to them in the Uniform Commercial Code as adopted in the State of Michigan (the “UCC”). Without limiting the forgoing, “Accounts” will also mean and include any and all other forms of obligations now owed or hereafter arising or acquired by the Borrower evidencing any obligation for payment for goods of any kind, nature, or description sold or leased or services rendered, and all proceeds of any of the forgoing.
B. Borrower gives Crestmark all of the rights of a secured party under the UCC. Borrower grants Crestmark the authority to file all appropriate documentation for Crestmark to perfect its security interest in the Collateral, including a UCC-1 financing statement listing the Collateral as “All assets of the Debtor, now existing and hereafter arising, wherever located,” or similar terms, as well as UCC-3 amendments as may be required from time to time. All expenses of Crestmark relating to searching, filing or protecting the Security Interest are part of the Obligations.
C. The Security Interest gives Crestmark rights with respect to the Collateral and the Security Interest and this Agreement imposes duties upon Borrower which relate to the Collateral. Some of the rights and duties are: (i) the right of Crestmark at any time to notify any persons who may hold any part of the Collateral, such as Account Debtors and other debtors, of Crestmark’s Security Interest. Borrower understands that Crestmark may verify Accounts with the Account Debtors; (ii) Borrower must cooperate with Crestmark in obtaining control of any Collateral in the possession of third persons, particularly Collateral consisting of deposit accounts, investment property, letter of credit rights or other Collateral which is evidenced by electronic entries; (iii) except for the right of Borrower to sell its inventory in the ordinary course of business, Borrower shall not sell or transfer any of the Collateral or grant any other security interest in the Collateral, except as Crestmark may specifically agree to in writing. Borrower remains liable to perform all of its obligations with respect to the Collateral such as the recognition of any warranties in inventory sold and Crestmark is under no responsibility to perform any of the obligations of Borrower; and (iv) Borrower must notify Crestmark immediately if it knows that any Account Debtor disputes an Account whether or not such disputes are deemed valid by Borrower.
| 3 |
9. POWER OF ATTORNEY. Borrower irrevocably appoints Crestmark, or any person(s) designated by Crestmark, as its attorney-in-fact, which appointment is coupled with an interest and shall remain in full force and effect until all Obligations of Borrower to Crestmark have been fully satisfied and discharged, with full power, at Borrower’s sole expense, to exercise at any time in Crestmark’s reasonable discretion all or any of the following powers:
A. Receive, take, endorse, assign, deliver, accept and deposit, in the name of Crestmark or Borrower, any and all cash, checks, commercial paper, drafts, remittances and other instruments and documents relating to the Collateral or the proceeds thereof.
B. Change Borrower’s address on all invoices and statements of Account mailed or to be mailed to Borrower’s customers and to substitute thereon the address designated by Crestmark, to place legends on all invoices and statements of Account mailed or to be mailed to Borrower’s customers, and to receive and open all mail addressed to Borrower, or to Borrower’s trade name at Crestmark’s address, or any other designated address.
C. Upon and after the occurrence of a Default, to change the address for delivery of Borrower’s mail to Crestmark’s or an address designated by Crestmark. Borrower specifically authorizes Crestmark to sign any forms on behalf of Borrower to affect this change with the United States Postal Service or any third party and requests such change to be accepted.
D. Upon and after the occurrence of a Default, to take or bring, in the name of Crestmark or Borrower, all steps, actions, suits or proceedings deemed by Crestmark necessary or desirable to effect collection of or other realization upon any Collateral.
E. Execute on behalf of Borrower any UCC-l and/or UCC-3 Financing Statement(s) and/or any notices or other documents necessary or desirable to carry out the purpose and intent of this Agreement, and to do any and all things reasonably necessary and proper to carry out the purpose and intent of this Agreement.
F. To transfer any lockboxes belonging to Borrower to Crestmark at Crestmark’s sole discretion.
G. To initiate ACH transfers from Borrower’s depository accounts.
H. To endorse and take any action with respect to bills of lading covering any inventory.
I. Upon and after a Default, or at any time in the event that Borrower fails to do so within a reasonable time, execute, file and serve, in its own name or in the name of Borrower, mechanics lien or similar notices, or claims under any payment or performance bond for the benefit of Borrower.
J. Upon and after a Default, or at any time in the event that Borrower fails to do so within a reasonable time, pay any sums necessary to discharge any lien or encumbrance on the Collateral, which sums shall be included as Obligations hereunder, and which sums shall accrue interest at the Extra Rate until paid in full.
10. REPRESENTATIONS. Borrower makes the following representations and warranties to Crestmark and such representations and warranties must be true at all times until the Obligations are paid in full. If Borrower learns that a representation and warranty once made is no longer true, it has the duty to immediately notify Crestmark in writing:
A. Borrower is in good standing under the laws of the state of its organization and is authorized to conduct business in any state that in conducts business. Borrower has the power and authority to enter into this Agreement, and the persons signing this Agreement and all persons who sign any documents with Crestmark have the appropriate authority. Borrower’s organization identification number, state of organization, and addresses where it conducts business is as shown on the Schedule.
| 4 |
B. Borrower’s entry into the Loan Documents do not violate any agreement which Borrower has or which binds Borrower.
C. The Loan Documents are fully enforceable against Borrower and the Collateral.
D. There are no litigation or criminal charges pending or threatened against Borrower or Guarantor and neither Borrower nor Guarantor are in default of any order or judgment of any court or any governmental agency of any kind. There are no unsatisfied liens or judgments pending against Borrower in any jurisdiction except as shown on the Schedule.
E. The financial information furnished by Borrower to Crestmark has been prepared in accordance with generally accepted accounting principles, all financial statements are true and correct, and any projections of the business operations of Borrower that have been given or will be given to Crestmark in the future will be based upon Borrower’s reasonable assumptions and estimates.
F. Borrower is the owner of all of the Collateral and there are no other liens or claims against the Collateral, except the Security Interest of Crestmark or as shown on the Schedule.
G. All of the Collateral is personal property and none of the Collateral will be permanently affixed to real estate.
H. Borrower has filed and will file all federal, state, local and foreign tax returns that it is required to file and has paid and will pay all taxes and all other governmental charges as they become due.
I. Borrower is able to pay its debts as they become due and has sufficient capital to carry on its business. Borrower’s obligations under this Agreement and the Loan Documents, including the obligation to repay the Loan and the grant of the Security Interest, do not render Borrower insolvent.
J. Borrower only uses the fictitious names, d/b/a’s, tradenames and tradestyles set forth on the Schedule (collectively the “Tradenames”), and Borrower certifies that all sales and any and all business done in the name of the Tradenames are the sales and business of Borrower. Any and all checks, remittances or other payments received in the name of any of the Tradenames are Borrower’s sole and exclusive property, and are subject to Crestmark’s security interest hereunder. Any and all authority given to Crestmark by Borrower in this Agreement or elsewhere to endorse Borrower’s name on any checks, negotiable instruments or other remittances extends with equal and full force and effect to any checks, negotiable instruments, and other remittances received in the name of any Tradename.
K. All Accounts assigned to Crestmark by Borrower are and will at all times be bonafide accounts arising from the sale of inventory or providing services, and are not subject to discounts, deductions, allowances, contra items, offset or counterclaim and are free and clear of all encumbrances of any kind whatsoever, except as disclosed to Crestmark in writing and approved by Crestmark in writing.
L. Borrower’s assignment of any Accounts to Crestmark pursuant to this Agreement will not at any time violate any federal, state and/or local law, rule or regulation, court or other governmental order or decree or terms of any contract relating to such Accounts.
M. Borrower possesses all necessary trademarks, trade names, copyrights, patents, patent rights and licenses to conduct its business as now operated, without any known conflict with any trademarks, trade names, copyrights, patents and license rights of any other person or entity.
| 5 |
N. Borrower’s legal name as of the date hereof as it appears in its official filing with its state of organization is as set forth in the opening paragraph of this Agreement. Borrower has not organized another entity or Tradename using Borrower’s name or Tradename as set forth herein in any other jurisdiction.
O. As to all of Borrower’s Inventory and Equipment:
i. The Inventory and Equipment are currently located only at the locations identified on the Schedule, or such other locations as consented to by Crestmark in writing;
ii. All Inventory is now and at all times hereafter shall be of good and merchantable quality, free from defects, except as disclosed to Crestmark in writing;
iii. The Inventory and Equipment are and shall remain free from all liens, claims, encumbrances, and security interests (except as held by Crestmark, and except as identified on the Schedule).
iv. The Inventory is not now stored with a bailee, warehouseman or similar party unless such party has entered into a waiver letter in form satisfactory to Crestmark.
11. BORROWER’S PROMISES. Borrower makes the following promises to Crestmark and these promises are effective until the Obligations are fully paid:
A. To pay all Obligations when due and perform all terms, conditions and obligations of the Loan Documents.
B. To permit Crestmark, or its representatives, access to the Collateral on Borrower’s premises and to Borrower’s computer systems, books of account and financial records. Borrower will pay the cost of Field Examinations as specified in the Schedule.
C. To notify Crestmark promptly of any litigation, administrative or tax proceeding or other action threatened or instituted against Borrower or Guarantor or its property, or of any other material matter which may adversely affect Borrower’s financial condition. The amount of claims as to which Borrower must notify Crestmark is specified in the Schedule as the “Borrower Claims Threshold”.
D. To pay when due all taxes, assessments and governmental charges, provided that Borrower has the right to contest the same as long as it has a cash reserve with Crestmark in an amount as determined by Crestmark in its sole discretion.
E. To comply with the Financial Covenants described in the Schedule (if applicable).
F. To maintain insurance on its business activities in such amount and in such form as Crestmark may from time to time require, and with respect to such insurance if so designated, Crestmark shall be named as “Lender Loss Payee” under the policy and receive evidence of the insurance. All insurance which protects Crestmark shall have at least a 30-day notice to Crestmark prior to any cancellation. With respect to the insurance, Borrower appoints Crestmark as its attorney-in-fact to negotiate any and all claims under all insurance policies and Crestmark also has the power to negotiate any payments on the insurance policies.
G. To comply with all laws, ordinances and regulations or other requirements of any governmental authority or agency applicable to Borrower’s business.
| 6 |
H. To maintain and preserve all Collateral in good repair, working order and condition, and with respect to accounts, pursue collections thereof.
I. To provide Crestmark with evidence of ownership of any Collateral upon the request of Crestmark.
J. To maintain a Loan Amount balance which shall not exceed the sum of Eligible Collateral times the corresponding Advance Rate.
12. NEGATIVE COVENANTS. Borrower agrees until the Obligations are paid in full, it will not:
A. Change its state of organization or its name, or move its executive office or at any time adopt any assumed name without giving Crestmark at least 30 days prior written notice.
B. Declare or pay any dividend or make any other distribution with regard to its equity or purchase or retire any of its equity without Crestmark’s prior written consent, provided if it is taxed as an S Corporation or other “pass through” entity, Borrower may prior to a Default distribute profits to its equity holders in an amount necessary to enable such holders to pay personal, state and federal taxes directly attributable to the profits earned by Borrower for such year.
C. Make any loan or guaranty or assume any obligation or liability, whether as borrower, guarantor, surety, indemnitor or otherwise (a “Borrower Obligation”) (i) that would result in or create a Default, or (ii) that together with all other existing Borrower Obligations would exceed the “Borrower Obligation Threshold” set forth in the Schedule, without Crestmark’s prior written consent.
D. Enter into any transaction with its equity holders or any affiliates of Borrower except on terms at least as favorable as would be usual and customary in similar transactions if the person with whom the transaction is entered into was not related to Borrower.
E. Release, redeem, purchase, or acquire any of its equity interests without the prior written consent of Crestmark.
F. Default in the payment of any debt to any other person.
G. Suffer or permit any judgment, decree or order not fully covered by insurance to be entered against Borrower or a Guarantor in an aggregate amount in excess of the “Claims Threshold”, or permit or suffer any warrant or attachment to be filed against Borrower, any Guarantor, or against any property or asset of Borrower or Guarantor.
H. Transfer the ownership of any interest in Borrower without the prior written consent of Crestmark which shall not be unreasonably withheld.
I. Sell any of the Collateral outside the normal course of its business without the prior written consent of Crestmark.
J. Purchase the stock or assets of any other entity without the prior written consent of Crestmark.
| 7 |
13. FINANCIAL REPORTS. Borrower promises that until the Obligations are fully paid and this Agreement is terminated, it will keep its books and records in a manner satisfactory to Crestmark and Crestmark will have the right at any time to verify any of the Collateral, documentation or books and records of Borrower in whatever manner and as often as Crestmark deems necessary. Borrower will permit Crestmark, or its representatives, access to the Collateral and Borrower’s premises and to Borrower’s computer systems, books of account and financial records. Borrower will furnish to Crestmark the financial reports identified on the Schedule, certified to by the president or chief financial officer of Borrower and Borrower’s certified public accountant, if applicable. All financial reports will be prepared in accordance with generally acceptable accounting principles and will be true and accurate.
14. CRESTMARK’S REMEDIES. Crestmark has all the remedies available at law or in equity (including those under the UCC) in the event of a Default or if Borrower fails to pay the Obligations on demand, including but not limited to the following: to charge the Extra Rate; to notify Account Debtors to make the payments directly to Crestmark; to settle or compromise any disputed Account, sue on any Account and make any agreement to deal with the accounts as if it were the owner; to offset any of Borrower’s or Guarantor’s funds under the control of Crestmark against the Obligations; and to require Borrower to gather up the Collateral and make it available to Crestmark for Crestmark to conduct public or private UCC foreclosure sales. Borrower grants to Crestmark a license or other right to use, without charge, Borrower’s labels, patents, copyrights, trademarks, rights of use of any name, trade secrets, tradenames and advertising materials, or any property of a similar nature, as it pertains to the Collateral, in completing production of, advertising for sale and selling any Collateral, and Borrower’s rights under all licenses and franchise agreements shall inure to Crestmark’s benefit. If Crestmark should proceed against the Collateral and sell any of the Collateral on credit, Borrower will be credited on the Obligations only with the amount actually received by Crestmark and Borrower waives any and all provisions as to notice or a particular method of sale of any of the Collateral. Borrower will pay all expenses in connection with the assembly or sale of the Collateral. Crestmark does not have to incur its own expenses in realizing upon the Collateral, but all the expenses are for the account of Borrower. Borrower recognizes that at no time is Crestmark its agent in dealing with the Collateral, but Crestmark acts only in its own interest.
15. CUMULATIVE RIGHTS. Crestmark’s rights and remedies under this Agreement and all other agreements shall be cumulative. Crestmark shall have all other rights and remedies not inconsistent herewith as provided under the UCC, by law, or in equity. No exercise by Crestmark of one right or remedy shall be deemed an election, and no waiver by Crestmark of any Default on Borrower’s part shall be deemed a continuing waiver. No delay by Crestmark shall constitute a waiver, election or acquiescence by it.
16. LENDER ACTIONS. To the extent applicable law may impose duties on Crestmark to exercise remedies in a commercially reasonable manner, Borrower agrees that it is not commercially unreasonable for Crestmark: to fail to exercise remedies against any Collateral or any particular Account Debtor; to proceed against Account Debtors either directly or through collection agencies; to advertise disposition of Collateral through publications or media of general circulation; to hire professional auctioneers to dispose of Collateral; to dispose of Collateral in wholesale or retail markets; to disclaim warranties with respect to Collateral; or to obtain services of attorneys or other professionals. The foregoing is not an exhaustive list and nothing contained in the foregoing shall be construed to grant any rights to Borrower or to impose any duties on Crestmark that would not have been granted or imposed by this Agreement or by applicable law in the absence of this Section 16. Borrower agrees that under no circumstances is Crestmark the agent or representative of Borrower.
17. APPLICATION OF PROCEEDS. Once collection efforts are commenced by Crestmark, any proceeds of sale or disposition of Collateral may be applied by Crestmark first to expenses authorized by this Agreement, including Crestmark’s reasonable attorneys’ fees, which Borrower must pay, and the balance to payment of the Obligations in such manner as Crestmark may elect. Borrower and Guarantor remain liable for any deficiency.
18. NOTICES. Any notice is effective by either party if sent in writing or facsimile with confirmation of receipt or by certified mail or personal delivery or expedited mail services to the addresses shown on the Schedule.
| 8 |
19. MISCELLANEOUS PROVISIONS.
A. This Agreement is binding upon and is for the benefit of Borrower and Crestmark, and their respective successors and assigns. However, under no circumstances may Borrower assign this Agreement or its rights and duties hereunder. Crestmark may assign this Agreement and its rights under the Loan Documents and Borrower will make payments to any such assignee if so directed.
B. Crestmark has the right at any time to assign, transfer, negotiate or sell participations in this Agreement or the Obligations or the rights of Crestmark hereunder. In connection with any assignment, Borrower consents to disclosure of any and all books, records, files, Loan Documents and all other documents in the possession or under the control of Crestmark.
C. No delay or failure of Crestmark in exercising any right or remedy will affect such right or remedy. No delay or failure of Crestmark to demand strict adherence to the terms of this Agreement will be deemed to waive Crestmark’s rights to demand such adherence at any time in the future.
D. The term “including” means “including, without limitation”, and the term “includes” means “includes, without limitation”. The word “will” shall be construed to have the same meaning and effect as the word “shall.” The definitions of terms in this Agreement shall apply equally to the singular and plural forms of the terms defined.
E. This Agreement and the other Loan Documents will be interpreted and determined under the laws of the State of Michigan without any regard to any conflict of laws provisions.
F. Borrower, at Crestmark’s request, will make, execute and acknowledge any and all further instruments or agreements necessary to carry out the intent of this Agreement and the other Loan Documents.
G. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if all signatures were upon the same instrument. Delivery of an executed counterpart of the signature page to this Agreement by facsimile or electronic mail shall be effective as delivery of a manually executed counterpart of this Agreement, and any party delivering such an executed counterpart of the signature page to this Agreement by facsimile or electronic mail to any other party shall thereafter also promptly deliver a manually executed counterpart of this Agreement to such other party, provided that the failure to deliver such manually executed counterpart shall not affect the validity, enforceability, or binding effect of this Agreement.
H. Neither Crestmark nor its affiliates directors, officers, agents, attorneys or employees are liable to Borrower or Guarantor or affiliates for any action taken or omitted by it or any of them under the Loan Documents except for such liability as may be imposed by law for gross negligence or actual fraud, and no claim shall be made by Borrower or Guarantor or any of Borrower’s affiliates, directors, officers, agents, employees for any special or consequential damages or punitive damages arising out of, or related to the Loan Documents or the transactions between the Parties.
I. This Agreement and the other Loan Documents represent the complete Agreement between the parties with respect to the subject matter of this Agreement, and there are no promises, undertakings, representations or warranties by Crestmark relative to the subject matter of this Agreement not expressly set forth in this Agreement or the other Loan Documents. This Agreement and the other Loan Documents may be amended only in writing.
J. If any provision of this Agreement is in conflict with any law or statute or is otherwise unenforceable, then the provision will be deemed null and void only to the extent of such provision and the provision will be deemed severable and the remainder of this Agreement shall be in full force and effect.
| 9 |
K. Any payment made to Crestmark by either Borrower or Guarantor which is subsequently invalidated, declared fraudulent or preferential or otherwise set aside under any bankruptcy, state, federal or equitable law, then to the extent of such invalidity such payment will be deemed not to have been made and the obligation will continue in full force and effect. This provision shall survive termination of this Agreement.
L. No Lien Termination Without Release. In recognition of among other things, Borrower’s indemnification obligations and Crestmark’s right to have its attorneys’ fees and other expenses incurred in connection with this Agreement secured by the Collateral, notwithstanding payment in full of all Obligations by Borrower, Crestmark shall not be required to record any terminations or satisfactions of any of its liens on the Collateral unless and until Borrower and all guarantors of its Obligations have executed and delivered to Crestmark a general release in a form acceptable to Crestmark in its sole discretion. Borrower understands that this provision constitutes a waiver of its rights Borrower may have under §9-513 of the UCC
M. Small Business Jobs Act Certification – Pursuant to Section 4107(d)(2) (the “Section”) of the Small Business Jobs Act of 2010, certification is required from any business receiving a loan using funds received by the institution under the Small Business Lending Act. As required by the Section, the Borrower hereby certifies to Crestmark that the principals of Borrower and its affiliates have not been convicted of, or pleaded nolo contendere to, a sex offense against a minor (as such terms are defined in section 111 of the Sex Offender Registration and Notification Act (42 U.S.C. 16911)).
The term “principals” is defined as follows: if a sole proprietorship, the proprietor; if a partnership, each managing partner and each partner who is a natural person and holds a 20% or more ownership interest in the partnership; and if a corporation, limited liability company, association or a development company, each director, each of the five most highly compensated executives or officers of the entity, and each natural person who is a direct or indirect holder of 20% or more of the ownership stock or stock equivalent of the entity.
N. USA Patriot Act Notification – The following notification is provided to Borrower pursuant to Section 3265 of the USA Patriot Act of 2001, 31 U.S.C. Section 5318:
IMPORTANT INFORMATION ABOUT PROCEDURES FOR OPENING A NEW ACCOUNT. To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to obtain, verify, and record information that identifies each person or entity that opens an account, including any deposit account, treasury management account, loan or other extension of credit. We may ask for the name, address, date of birth, and other information that will allow us to identify all Borrowers, principals and owners. We may also ask to see your driver’s license or other identifying documents.
20. RIGHT OF FIRST REFUSAL. In consideration of Crestmark entering into this Agreement and making advances to Borrower, Borrower hereby agrees that it will, within five (5) days of receipt, provide a copy of any proposal letter, term sheet, letter of intent or commitment letter from any lender offering to Borrower a refinance of the Obligations. Crestmark shall have the right of first refusal to match the offer(s) of such other lender(s), and if Crestmark advises Borrower that it intends to meet the financial and operational terms set forth in such offers, Borrower will be obligated to enter into an amendment to this Agreement extending the terms of this Agreement for at least the term proposed in such other offer(s), and amending the financial and operational terms as set forth in this Agreement. Notwithstanding the foregoing, Borrower recognizes that this Agreement can only be terminated as provided herein. Failure of Crestmark to meet the terms set forth in such letter of interest or commitment letter does not relieve the Borrower from its obligations hereunder.
21. INDEMNIFICATION. Borrower hereby agrees to indemnify, defend and hold Crestmark and its executive committees, parent affiliates, subsidiaries, agents, directors, officers, participants, employees, agents and their successors and assigns (collectively “Indemnified Parties”) harmless against any and all liabilities of any kind, nature or description and damages whether they are direct, indirect or consequential, including attorney’s fees and other professionals and experts incurred or suffered directly or indirectly by Indemnified Parties or asserted against Indemnified Parties by anyone whosoever, including Borrower or Guarantor, which arise out of the Loan Documents or the relationship and transaction between the Parties. This provision shall survive the termination of this Agreement.
| 10 |
22. JOINT AND SEVERAL OBLIGATIONS. If more than one person or entity is named as Borrower in this Agreement, all Obligations, representations, warranties, covenants and indemnities of Borrower set forth herein and in the other Loan Documents shall be the joint and several obligations of such persons and/or entities.
23. JURISDICTION. BORROWER AND GUARANTOR AGREE THAT ANY ACTION TO ENFORCE BORROWER’S OR GUARANTOR’S OBLIGATIONS TO CRESTMARK SHALL BE PROSECUTED EITHER IN THE CIRCUIT COURT OF OAKLAND COUNTY MICHIGAN OR THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN (UNLESS CRESTMARK, IN ITS SOLE DISCRETION, ELECTS SOME OTHER JURISDICTION), AND BORROWER AND GUARANTOR SUBMIT TO THE JURISDICTION OF ANY SUCH COURT SELECTED BY CRESTMARK. BORROWER AND GUARANTOR WAIVE ANY AND ALL RIGHTS TO CONTEST THE JURISDICTION AND VENUE OF ANY ACTION BROUGHT IN THIS MATTER AND BORROWER AND GUARANTOR MAY BRING ANY ACTION AGAINST CRESTMARK ONLY IN THE CIRCUIT COURT FOR THE COUNTY OF OAKLAND OR THE FEDERAL COURT OR THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF MICHIGAN.
24. WAIVER. ALL PARTIES, INCLUDING BORROWER AND GUARANTOR EACH KNOWINGLY AND VOLUNTARILY WAIVE ANY CONSTITUTIONAL RIGHT TO A TRIAL BY JURY WITH RESPECT TO ANY CLAIM, DISPUTE OR CONFLICT BETWEEN THE PARTIES OR UNDER THE LOAN DOCUMENTS AND AGREE THAT ANY LITIGATION SHALL BE HEARD BY A COURT OF COMPETENT JURISDICTION SITTING WITHOUT A JURY. BORROWER AND GUARANTOR ACKNOWLEDGE THAT THEY HAVE HAD THE OPPORTUNITY TO REVIEW THE EFFECT OF THIS PROVISION WITH COUNSEL OF THEIR CHOICE.
25. RELEASE. BORROWER AND GUARANTOR RELEASE AND FOREVER DISCHARGE CRESTMARK, ITS AFFILIATES, OFFICERS, AGENTS, EMPLOYEES AND DIRECTORS FROM ANY AND ALL CLAIMS OF ANY KIND WHATSOEVER FROM THE BEGINNING OF TIME TO DATE OF THIS AGREEMENT.
The parties have executed this Agreement as of the date and year first written above.
| CRESTMARK: | |
| CRESTMARK BANK, a Michigan banking corporation | |
| By: /s/ Adam Colley | |
| Adam Colley | |
| Its: Vice President | |
| BORROWER: | |
| COHERIX, INC. | |
| A Delaware corporation | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson | |
| Its: Chief Executive Officer | |
| The undersigned Guarantor by signing this Agreement agrees it has been read and understands the Agreement and Guarantor agrees to all of its terms. | |
| VALIDITY GUARANTOR: | |
| /s/ Dwight D. Carlson | |
| Dwight D. Carlson |
| 11 |
SCHEDULE TO LOAN AND SECURITY AGREEMENT
DATED: August 19, 2016
This Schedule is part of the Agreement between:
CRESTMARK BANK (“CRESTMARK”)
5480 CORPORATE DRIVE
SUITE 350
TROY, MICHIGAN 48098
AND
COHERIX, INC. (“BORROWER”)
3980 RANCHERO DRIVE
ANN ARBOR, MI 48108
The following paragraph numbers correspond to paragraph numbers contained in the Agreement.
2. LOAN;LOAN ADVANCES.
Advance Formula: Advances of the Loan may be measured against a percentage of Eligible Accounts and the Borrowing Base.
The Loan Amount may not exceed an amount which is the lesser of:
(a) Two Dollars ($2,000,000.00) (“Maximum Amount”); or
(b) the sum of :
(i) Eighty-five percent (85%) of Eligible Accounts PLUS
(ii) the Borrowing Base, not to exceed One Million Dollars ($1,000,000.00) (subparagraphs (i) – (ii) are collectively the “Advance Formula”).
The Borrowing Base as of the date of closing is One Million Dollars ($1,000,000.00). The Borrowing Base will be reduced by equal monthly payments of $83,333.33 each month commencing on October 1, 2016, and continuing on the first day of each month thereafter for twelve (12) consecutive months while the Borrowing Base is outstanding. In addition, if at any time either the Borrower or Panasonic chooses to terminate the Technical Collaboration and Licensing Agreement between Borrower and Panasonic, then any indebtedness still due and owing under the Borrowing Base shall become immediately due and payable in full.
| 12 |
Crestmark in its sole discretion may raise or lower any percentage advance rate with respect to the Advance Formula.
Eligible Accounts means and includes those Accounts:
| (i) | which have been validly assigned to Crestmark; |
| (ii) | strictly comply with all of Borrower's promises, warranties and representations to Crestmark; |
| (iii) | contain payment terms of not greater than ninety (90) days from the date of invoice; and |
| (iv) | are not past due more than ninety (90) days past the date of invoice; and |
| (v) | are invoiced not later than ten (10) days from the date of service or sale. |
Eligible Accounts shall not include the following:
| (a) | Accounts with respect to which the Account Debtor is an officer, employee or agent of Borrower; |
| (b) | Accounts with respect to which services or goods are placed on consignment, guaranteed sale, or other terms by reason of which the payment by the Account Debtor may be conditional; |
| (c) | Accounts with respect to which the Account Debtor is not a resident of the United States or Canada, with the exception of Panasonic foreign accounts; provided, however, all Accounts originating from the Province of Quebec shall be deemed ineligible; |
| (d) | Accounts with respect to which the Account Debtor is the United States or any department, agency or instrumentality of the United States; provided, however, that Borrower has completed all of the steps necessary, in the sole opinion of Crestmark, to comply with the Federal Assignment of Claims Act of 1940 (31 U.S.C. Section 3727) with respect to such Account; |
| (e) | Accounts with respect to which the Account Debtor is any state of the United States or any city, town, municipality, county or division thereof; |
| (f) | Accounts with respect to which the Account Debtor is a subsidiary of, related to, affiliated with, or has common shareholders, officers or directors with Borrower; |
| (g) | Accounts with respect to which Borrower is or becomes liable to the Account Debtor for goods sold or services rendered by the Account Debtor to Borrower; |
| (h) | those Accounts where Crestmark has notified Borrower that, in Crestmark’s sole discretion, the Account or Account Debtor is not acceptable to Crestmark; |
| (i) | all of the Accounts owed by an Account Debtor who is the subject of a bankruptcy, receivership or similar proceeding; |
| (j) | Accounts for which the services have not yet been rendered to the Account Debtor or the goods sold have not yet been delivered to the Account Debtor (commonly referred to as "pre-billed accounts"); |
| (k) | COD, credit card sales and cash sales; |
| (l) | Accounts are disputed. |
| 13 |
Crestmark will determine in its sole discretion whether any Collateral is eligible for an Advance, but no Collateral will be considered eligible unless the requirements set forth above are met. Regardless of whether any Collateral is eligible, it is still part of the Collateral securing the Obligations.
Prior to any request for an Advance Borrower must furnish to Crestmark invoices, credit memos, purchase orders, evidence of delivery, proof of shipment, timesheets or any other documents Crestmark requests, in its sole discretion, with respect to the Accounts that Borrower is tendering to Crestmark to support the Advance (“Account Documents”). Crestmark will endeavor to provide the requested Advance by the end of the day on the date it receives the request as long as the complete package of information for the request has been received by Crestmark by 10:30 a.m. Eastern Time on the date of the request for the Advance. All requests for funding will be subject to Crestmark’s then standard fees for electronic funds transfer, wire transfers and check services.
Each time an Advance is made, the amount of the Obligations will be increased by the amount of the Advance. Three (3) business days (“Clearance Days”) after checks, ACH or wire transfers or other credit instruments are applied to a specific invoice, Crestmark will credit the Loan Account with the net amount actually received, whereupon interest and Maintenance Fee will no longer be charged. On the date a collection is applied to a specific invoice Borrower will receive immediate credit on such funds in determining availability for Advances.
When Crestmark receives a payment from an Account Debtor, it will attempt to apply it against the appropriate Account Debtor and invoice according to the Account Debtor’s remittance advice. If it is not clear which Account Debtor or invoice the payment is to be applied against, Crestmark may contact Borrower or the payor for assistance. Unless there is clear error, the application of payments by Crestmark is final.
4. FEES AND EXPENSES. The following fees will be paid by Borrower:
Loan Fee: At closing of the Loan and on each one year anniversary of the date of the Agreement, Borrower will pay Crestmark a loan fee in the aggregate amount of one percent (1.00%) of the Maximum Amount, which will be fully earned as of such date and not refundable in any event.
Late Reporting Fee: Borrower will pay Crestmark a Late Reporting Fee in an amount equal to One Hundred Fifty ($150.00) Dollars per document per business day for any day in which any report, financial statement or schedule required by the Agreement is delivered late.
Lockbox Fee: Each month Borrower will pay all costs in connection with the Lockbox and the Lockbox Account, as determined by Crestmark from time to time.
Documentation Fee: In consideration of the extension of the Loan and the execution of this Agreement, Borrower will pay Crestmark a documentation fee of $750.00, which fee is fully earned as of the date hereof and is non-refundable.
Maintenance Fee: Borrower will pay Crestmark a monthly Maintenance Fee of forty-five one hundredths of one percent (0.45%) of the monthly average outstanding principal balance of the Loan for advances made on Accounts Receivable for the preceding month, and with respect to the Borrowing Base, fifty-five one hundredths of one percent (0.55%) of the monthly average outstanding principal balance on the Borrowing Base (“BB Maintenance”), each month until this Agreement is terminated and Crestmark is repaid the Obligations in full, or with respect to the BB Maintenance Fee, the Borrowing Base has been paid in full.
Exit Fee. Borrower may elect to prepay the Obligations but only upon the payment of all Obligations including the following exit fee (“Exit Fee”), as liquidated damages and not as a penalty: (i) prior to the two year anniversary date of the Agreement, the exit fee will be two (2.00%) percent of the Maximum Amount plus Loan Fees and Maintenance Fees due or to become due under the Agreement. No partial prepayment will affect the Borrower's obligation to continue the regular payments due under the Note.
The Exit Fee shall automatically renew on the second anniversary date of the Agreement and on each anniversary date of the Agreement for an additional twelve (12) month period unless (i) Borrower notifies Crestmark in writing within sixty (60) days before such anniversary date of Borrower’s intention to terminate the Agreement and (ii) the Obligations are paid in full by such anniversary date. In the event that a Default has occurred and is continuing at the time Crestmark demands payment of the Obligations, the Exit Fee will be due and payable by Borrower.
| 14 |
Minimum Loan Balance. Borrower shall maintain an average outstanding principal balance of the Loan for each month in the amount of $750,000.00 (“Minimum Loan Balance”). If the actual average outstanding principal balance of the Loan in any month is less than the Minimum Loan Amount, Borrower must pay interest and Maintenance Fees (as defined in the Schedule) for such month calculated on the Minimum Loan Balance.
5. LOCKBOX.
The Lockbox Account means:
Drawer #2158
PO Box 5935
Troy, MI 48007-5935
10. Representations.
(A) Borrower is a Delaware corporation.
(C) List pending and threatened litigation and unsatisfied judgments:
(F) List Security Interests in the Collateral held by creditors other than Crestmark as Permitted Encumbrances:
The following financing statements as reflected in the Delaware Secretary of State, UCC Division, as of July 14, 2016, without increase, amendment, modification, extension or refinancing.
| 1. | Dell Financial Services. UCC # 20111444689 Filed 4/18/11. Specific Computer Equipment. |
| 2. | United Bank & Trust. UCC # 20135183083 Filed 12/31/13. Specific Equipment. |
| 3. | United Bank & Trust. UCC # 20135183091 Filed 12/31/13. Specific Equipment. |
| 4. | United Bank & Trust. UCC # 20135183109 Filed 12/31/13. Specific Equipment. |
| 5. | United Bank & Trust. UCC # 20135183117 Filed 12/31/13. Specific Equipment. |
| 6. | United Bank & Trust. UCC # 20135183125 Filed 12/31/13. Specific Equipment. |
| 7. | United Bank & Trust. UCC # 20135183133 Filed 12/31/13. Specific Equipment. |
| 8. | United Bank & Trust. UCC # 20141176395 Filed 3/26/14. All Assets. |
| 9. | North Coast Capital Corporation. UCC # 20155274955 Filed 11/10/15. Specific Equipment. |
| 10. | North Coast Capital Corporation. UCC # 20155274963 Filed 11/10/15. Specific Equipment. |
| 11. | North Coast Capital Corporation. UCC # 20155274971 Filed 11/10/15. Specific Equipment. |
| 12. | North Coast Capital Corporation. UCC # 20155274997 Filed 11/10/15. Specific Equipment. |
| 13. | North Coast Capital Corporation. UCC # 20155275002 Filed 11/10/15. Specific Equipment. |
| 14. | North Coast Capital Corporation. UCC # 20160570414 Filed 1/29/16. Specific Equipment. |
NOTE: As to the interests listed above, the listing thereof in this Schedule to the Loan and Security Agreement shall not, in any manner whatsoever, be deemed to be an acknowledgement by Crestmark Bank as to the perfection, priority, validity or enforceability thereof. Further, the security interests of United Bank & Trust, now known as Old National Bank, listed above are subject to an Intercreditor Agreement by and between Crestmark and Old National Bank.
(j) List Borrower’s Trade names: None
| 15 |
11. BORROWER’S Promises:
C. BORROWER CLAIMS THRESHOLD: $20,000.00.
E. FINANCIAL COVENANTS: Borrower will maintain the following Financial Covenants, which will be tested on a quarterly basis:
A minimum Tangible Net Worth quarterly of at least negative ($27,337,064). “Tangible Net Worth" means, as of the date of determination, total assets less total liabilities less the sum of (i) the aggregate amount of non-trade Accounts Receivable, including Accounts Receivable from affiliated or related Persons; (ii) prepaid expenses; (iii) deposits; (iv) net leasehold improvements; (v) goodwill; and (vi) any other asset which would be treated as an intangible asset under GAAP, plus Subordinated Debt. “Subordinated Debt” means any and all indebtedness presently or in the future incurred by Borrower to any creditor of Borrower entering into a written subordination agreement with Crestmark.
In addition, at no time shall Borrower make any loans, advances, intercompany transfers or cash flow in excess of $75,000.00 on a monthly basis between Borrower and any subsidiary, related entity or affiliate of Borrower or with any company that has common shareholders, officers or directors with Borrower.
All of the financial covenants in this Agreement shall be determined in accordance with GAAP, unless otherwise provided.
"GAAP" means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board that are applicable to the circumstances as of the date of determination and applied on a consistent basis.
F. REQUIRED INSURANCE. Without limiting Crestmark’s requirement for insurance coverage, which may change from time to time, the following is/are the minimum insurance requirements:
Property Damage: “Crestmark Bank ISAOA” name as Lender Loss Payee
General and Professional Liability: “Crestmark Bank ISAOA” named as Additional Insured for an amount not less than the smallest amount required under any contract with any Account Debtor.
12. C. OBLIGATION THRESHOLD: $50,000.00.
13. FINANCIAL REPORTS.
Management Prepared Financial Statements: Borrower will deliver to Crestmark quarterly management prepared financial statements, balance sheets, and profit and loss statements for the quarter then ended, certified to by the president or chief financial officer of Borrower. Such reports will set forth the financial affairs and true condition of Borrower for such time period and will be delivered to Crestmark no later than thirty (30) days after the end of each quarter.
Projections: Upon the request of Crestmark, Borrower shall deliver to Crestmark, within thirty (30) days prior to each year-end, an annual financial projection including balance sheet, income statements, and statement of cash flows together with assumptions for the following year, broken down monthly.
Guarantors’ Personal Financial Statements. Waived.
| 16 |
Annual Financial Statements: Each year Borrower will deliver to Crestmark annual reviewed financial statements, cash flow statements, balance sheets, and profit and loss statements prepared by a certified public accountant acceptable to Crestmark, all without exceptions. Such reports will set forth in detail Borrower's true condition as of the end of Borrower's fiscal year no later than one hundred twenty (120) days after the end of Borrower's fiscal years.
All financial statements are and will be prepared in accordance with GAAP applied on a consistent basis.
Accounts Receivable, Accounts Payable Aging and Inventory Reports: Upon the request of Crestmark, Borrower will furnish to Crestmark the following certified to by the president or chief financial officer of Borrower within the time periods set forth:
| (a) | Accounts Receivable Reports: Monthly detailed Accounts Receivable Aging Reports no later than fifteen (15) days after the end of each month; |
| (b) | Accounts Payable Reports: Monthly summary Accounts Payable Aging Reports no later than fifteen (15) days after the end of each month. |
Tax Returns: Upon the request of Crestmark, Borrower will provide Crestmark with current annual tax returns prior to April 15 of each year or if an extension is filed, at the earlier of (a) filing, or (b) the extension deadline.
Field Examinations: Upon the request, Borrower will reimburse Crestmark for the costs to perform field examinations of Borrower's books and records, assets and liabilities, to be performed by Crestmark's inspector, whether a Crestmark officer or an independent party with all expenses, (whether for a Crestmark employee or otherwise), including all out of pocket expenses including, but not limited to, transportation, hotel, parking, and meals paid by Borrower. Upon Default, the number of field examinations to be reimbursed by Borrower may be increased in Crestmark's sole discretion. Field examinations are performed for Crestmark’s internal use and Crestmark has no obligation to provide Borrower or Guarantor with the results of the examination or copies of any reports or work papers in whole or in part.
Tax Deposit Evidence: Upon the request of Crestmark, Borrower will submit weekly payroll summaries and evidence of tax payments together with copies of bank statements from which the funds are impounded.
Customer Lists: Upon Crestmark’s request, Borrower will deliver to Crestmark detailed customer lists showing the customer's name, address, phone number and any other information Crestmark reasonably requests.
Other Information: Borrower and Guarantor will also deliver to Crestmark such other financial statements, financial reports, documentation, tax returns and other information as Crestmark requests from time to time.
18. NOTICES. Addresses for Notices are as set forth at the beginning of this Schedule.
| COHERIX, INC. | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson | |
| Its: CEO | |
| CRESTMARK BANK | |
| By: /s/ Adam Colley | |
| Adam Colley | |
| Its: Vice President | |
| 17 |
AMENDMENT NO. 1
TO
SCHEDULE TO LOAN AND SECURITY AGREEMENT
This Amendment No. 1 to Schedule to Loan and Security Agreement is made this 1st day of February, 2017, by and between CRESTMARK BANK, a Michigan banking corporation, whose address is 5480 Corporate Drive, Suite 350, Troy, Michigan 48098 ("Crestmark"), Coherix, Inc., a Michigan corporation, whose chief executive office is located at 3980 Ranchero Drive, Ann Arbor, MI 48108 ("Borrower"), and Dwight D. Carlson (“Validity Guarantor”). This Amendment No. 1 amends that certain Loan and Security Agreement and Schedule executed August 19, 2016 (as amended, collectively referred to herein as the "Agreement").
BACKGROUND:
The parties have executed the Agreement and Loan Documents;
The Borrower and Validity Guarantor are indebted and/or obligated to Crestmark without offset or deduction pursuant to the Agreement and the Loan Documents all of which are in full force and effect; and
Borrower, Crestmark, and Validity Guarantor, desire to modify and amend certain terms, conditions, covenants and obligations contained in the Agreement and the Loan Documents, including, but not limited to, resetting the Borrowing Base.
Accordingly, the parties agree as follows:
1. INCORPORATION BY REFERENCE:
All definitions and terms used in the Agreement, Schedule and the Loan Documents are hereby incorporated in this Amendment No. 1.
2. AMENDMENT AND MODIFICATION TO THE AGREEMENT:
A. Section 2(b)(ii) of the Schedule to the Agreement is hereby deleted in its entirety, and in lieu thereof, the following is inserted:
2(b)(ii) the Borrowing Base, not to exceed One Million ($1,000,000.00) Dollars (subparagraphs (i) – (ii) are collectively the e Formula”).
The Borrowing Base as of the date of the execution of this Amendment No. 1 is One Million Dollars ($1,000,000.00). Beginning March 1, 2017, the Borrowing Base will be reduced by twelve equal consecutive monthly payments of $83,333.33, and continuing on the first day of each month thereafter until the Borrowing Base has been paid in full. If at any time either the Borrower or Panasonic chooses to terminate the Technical Collaboration and Licensing Agreement between Borrower and Panasonic, then any indebtedness still due and owing under the Borrowing Base shall become immediately due and payable in full.
3. REAFFIRMATION OF GUARANTY:
As a specific inducement to Crestmark, and in consideration of Crestmark's reliance hereon, Validity Guarantor has executed the Validity Guaranty dated August 17, 2016 (the "Validity Guaranty"). Validity Guarantor hereby acknowledges and agrees to the amendments and modification set forth above and reaffirms the Validity Guaranty with respect to all liabilities, obligations and the Indebtedness therein guaranteed as herein amended and modified. Validity Guarantor further acknowledges that Validity Guarantor remains liable in accordance with the terms of the Validity Guaranty without offset or counterclaim. Validity Guarantor also acknowledges and agrees that Validity Guarantor’s liability under the Guaranty is limited as set forth in the Validity Guaranty.
| 18 |
4. SMALL BUSINESS JOBS ACT CERTIFICATION – Pursuant to Section 4107(d)(2) (the “Section”) of the Small Business Jobs Act of 2010, certification is required from any business receiving a loan using funds received by the institution under the Small Business Lending Act. As required by the Section, the Borrower hereby certifies to Crestmark that the principals of Borrower and its affiliates have not been convicted of, or pleaded nolo contendere to, a sex offense against a minor (as such terms are defined in section 111 of the Sex Offender Registration and Notification Act (42 U.S.C. 16911)).
A. The term “principals” is defined as follows: if a sole proprietorship, the proprietor; if a partnership, each managing partner and each partner who is a natural person and holds a 20% or more ownership interest in the partnership; and if a corporation, limited liability company, association or a development company, each director, each of the five most highly compensated executives or officers of the entity, and each natural person who is a direct or indirect holder of 20% or more of the ownership stock or stock equivalent of the entity.
5. EXPENSES:
In consideration of the extension of the loan and the execution of this Amendment No. 1, Borrower will pay Crestmark a fee of $1,500.00, which fee is fully earned as of the date hereof, and non-refundable. Borrower will promptly pay all expenses, fees and costs incurred by Crestmark with respect to the preparation, execution, and delivery of this Amendment No. 1, and all other documents contemplated herewith, including reasonable attorneys' fees.
6. NO WAIVER:
Borrower acknowledges that the execution of this Amendment No. 1 does not constitute a waiver or cure of any Default, whether matured or otherwise, if any, that previously existed or now exists under the Agreement or any Loan Document. By execution of this Amendment No. 1, Crestmark will not be deemed to have waived any of its rights or remedies under the Agreement or any Loan Document.
7. SURVIVAL, REAFFIRMATION, AND NO DEFENSES:
Each undersigned Borrower and Validity Guarantor agrees, in all capacities in which the signatory has executed the Agreement or any of the Loan Documents, as follows:
A. That, except as herein expressly modified or amended, all terms, conditions, covenants, representations and warranties contained in the Agreement and the Loan Documents are true and correct, continue to be satisfied in all respects and are legal, valid and binding obligations. The undersigned hereby ratify, agree to and confirm the Agreement and the Loan Documents and consent to and acknowledge the foregoing Amendment No. 1.
B. That payment of the Indebtedness is the valid obligation of Borrower and Validity Guarantor and, as of the date hereof, Borrower and Validity Guarantor have absolutely no defenses, claims, rights of set-off or counterclaims against Crestmark or the payment of the Indebtedness. This Amendment No. 1 shall not impair the rights, remedies and Collateral given in the Agreement and the Loan Documents.
C. That the liability of the undersigned howsoever arising or provided for in the Agreement and the Loan Documents is hereby reaffirmed.
| 19 |
8. RELEASE:
In consideration of Crestmark executing this Amendment No. 1, Borrower and Validity Guarantor do each hereby release and discharge Crestmark of and from any and all claims, harm, causes of action, liabilities, injuries, expenses (including attorneys’ fees) and damages of any and every kind, known or unknown, legal or equitable, which Borrower or Validity Guarantor have against Crestmark from the date of Borrower's and Validity Guarantor's first contact with Crestmark up to the date of this Amendment No. 1. Borrower and Validity Guarantor confirm to Crestmark that they have reviewed the effect of this release with legal counsel of their choice, or have been afforded the opportunity to do so, prior to the execution of this Amendment No. 1 and each acknowledges and agrees that Crestmark is relying upon this release in executing this Amendment No. 1.
9. CONFIRMATION OF LIEN UPON COLLATERAL:
The Borrower acknowledges and agrees that pursuant to the terms of the Agreement, the obligations of the Borrower and the Indebtedness are secured by a first priority lien and security interest in the Collateral (as defined in the Agreement). The Collateral is and shall remain subject to and encumbered by the lien, charge, and encumbrance of the Agreement, and nothing contained herein shall affect or be construed to affect the lien or encumbrance created by the Agreement or the priority thereof.
10. NO ORAL MODIFICATION:
This Amendment No. 1 may only be altered or modified by written instrument duly executed by Borrower and Crestmark.
| 20 |
The parties hereto have executed this Amendment No. 1 the day and year first appearing above.
| "CRESTMARK" | |
| Crestmark Bank | |
| a Michigan banking corporation | |
| By: /s/ Patty Oakes | |
| Patty Oakes | |
| Its:Vice President | |
| "BORROWER" | |
| Coherix, Inc. | |
| a Michigan corporation | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson | |
| Its: CEO | |
| "VALIDITY GUARANTOR" | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson, Individually |
| 21 |
AMENDMENT NO. 2
TO
SCHEDULE TO LOAN AND SECURITY AGREEMENT
This Amendment No. 2 to Schedule to Loan and Security Agreement is made this 26th day of April, 2017, by and between CRESTMARK BANK, a Michigan banking corporation, whose address is 5480 Corporate Drive, Suite 350, Troy, Michigan 48098 ("Crestmark"), Coherix, Inc., a Michigan corporation, whose chief executive office is located at 3980 Ranchero Drive, Ann Arbor, MI 48108 ("Borrower"), and Dwight D. Carlson (“Validity Guarantor”). This Amendment No. 2 amends that certain Loan and Security Agreement and Schedule executed August 19, 2016, as amended by Amendment No. 1 to Schedule to Loan and Security Agreement executed February 1, 2017 (as amended, collectively referred to herein as the "Agreement").
BACKGROUND:
The parties have executed the Agreement and Loan Documents;
The Borrower and Validity Guarantor are indebted and/or obligated to Crestmark without offset or deduction pursuant to the Agreement and the Loan Documents all of which are in full force and effect; and
Borrower, Crestmark, and Validity Guarantor, desire to modify and amend certain terms, conditions, covenants and obligations contained in the Agreement and the Loan Documents, including, but not limited to, revising Eligible Accounts to include foreign accounts receivable.
Accordingly, the parties agree as follows:
1. INCORPORATION BY REFERENCE:
All definitions and terms used in the Agreement, Schedule and the Loan Documents are hereby incorporated in this Amendment No. 2.
2. AMENDMENT AND MODIFICATION TO THE AGREEMENT:
A. Section 2, “Eligible Accounts”, of the Schedule to the Agreement is hereby modified to add sub-section (vi) and the following is inserted:
(vi) foreign accounts receivable, not to exceed Five Hundred Thousand Dollars ($500,000.00), and including but not limited to, FCA Mexico SA, Ford Motor Co. Limited UK, Ford Motor Co. Mexico Sa De Cv, in Crestmark’s sole discretion. The referenced accounts will not be eligible until payment remittances to Crestmark have been confirmed.
B. Section 2, Eligible Accounts not included, sub-section (c), shall be revised to read as follows:
(c) Accounts with respect to which the Account Debtor is not a resident of the United States or Canada, with the exception of Panasonic foreign accounts and those foreign accounts identified in Section 2, Eligible Accounts, sub-section (vi) above in Crestmark’s sole discretion.
C. Sub-Section “Foreign Accounts Receivable Maintenance Fee” is hereby added to Section 4 of the Schedule to the Loan Agreement and shall read as follows:
| 22 |
Foreign Accounts Receivable Maintenance Fee: Borrower will pay Crestmark a monthly Maintenance Fee of fifty-five one hundredths of one percent (0.55%) of the monthly average outstanding principal balance of the Loan for advances made on Foreign Accounts Receivable for the preceding month, each month until this Agreement is terminated and Crestmark is repaid the Obligations in full.
3. REAFFIRMATION OF GUARANTY:
As a specific inducement to Crestmark, and in consideration of Crestmark's reliance hereon, Validity Guarantor has executed the Validity Guaranty dated August 17, 2016 (the "Validity Guaranty"). Validity Guarantor hereby acknowledges and agrees to the amendments and modification set forth above and reaffirms the Validity Guaranty with respect to all liabilities, obligations and the Indebtedness therein guaranteed as herein amended and modified. Validity Guarantor further acknowledges that Validity Guarantor remains liable in accordance with the terms of the Validity Guaranty without offset or counterclaim. Validity Guarantor also acknowledges and agrees that Validity Guarantor’s liability under the Guaranty is limited as set forth in the Validity Guaranty.
4. EXPENSES:
Borrower will promptly pay all expenses, fees and costs incurred by Crestmark with respect to the preparation, execution, and delivery of this Amendment No. 2, and all other documents contemplated herewith, including reasonable attorneys' fees.
5. NO WAIVER:
Borrower acknowledges that the execution of this Amendment No. 2 does not constitute a waiver or cure of any Default, whether matured or otherwise, if any, that previously existed or now exists under the Agreement or any Loan Document. By execution of this Amendment No. 2, Crestmark will not be deemed to have waived any of its rights or remedies under the Agreement or any Loan Document.
6. SURVIVAL, REAFFIRMATION, AND NO DEFENSES:
Each undersigned Borrower and Validity Guarantor agrees, in all capacities in which the signatory has executed the Agreement or any of the Loan Documents, as follows:
A. That, except as herein expressly modified or amended, all terms, conditions, covenants, representations and warranties contained in the Agreement and the Loan Documents are true and correct, continue to be satisfied in all respects and are legal, valid and binding obligations. The undersigned hereby ratify, agree to and confirm the Agreement and the Loan Documents and consent to and acknowledge the foregoing Amendment No. 2.
B. That payment of the Indebtedness is the valid obligation of Borrower and Validity Guarantor and, as of the date hereof, Borrower and Validity Guarantor have absolutely no defenses, claims, rights of set-off or counterclaims against Crestmark or the payment of the Indebtedness. This Amendment No. 2 shall not impair the rights, remedies and Collateral given in the Agreement and the Loan Documents.
C. That the liability of the undersigned howsoever arising or provided for in the Agreement and the Loan Documents is hereby reaffirmed.
| 23 |
7. RELEASE:
In consideration of Crestmark executing this Amendment No. 2, Borrower and Validity Guarantor do each hereby release and discharge Crestmark of and from any and all claims, harm, causes of action, liabilities, injuries, expenses (including attorneys’ fees) and damages of any and every kind, known or unknown, legal or equitable, which Borrower or Validity Guarantor have against Crestmark from the date of Borrower's and Validity Guarantor's first contact with Crestmark up to the date of this Amendment No. 2. Borrower and Validity Guarantor confirm to Crestmark that they have reviewed the effect of this release with legal counsel of their choice, or have been afforded the opportunity to do so, prior to the execution of this Amendment No. 2 and each acknowledges and agrees that Crestmark is relying upon this release in executing this Amendment No. 2.
8. CONFIRMATION OF LIEN UPON COLLATERAL:
The Borrower acknowledges and agrees that pursuant to the terms of the Agreement, the obligations of the Borrower and the Indebtedness are secured by a first priority lien and security interest in the Collateral (as defined in the Agreement). The Collateral is and shall remain subject to and encumbered by the lien, charge, and encumbrance of the Agreement, and nothing contained herein shall affect or be construed to affect the lien or encumbrance created by the Agreement or the priority thereof.
9. NO ORAL MODIFICATION:
This Amendment No. 2 may only be altered or modified by written instrument duly executed by Borrower and Crestmark.
The parties hereto have executed this Amendment No. 2 the day and year first appearing above.
| "CRESTMARK" | |
| Crestmark Bank | |
| a Michigan banking corporation | |
| By: /s/ Patricia Oakes | |
| Patricia Oakes | |
| Its:Vice President | |
| "BORROWER" | |
| Coherix, Inc. | |
| a Michigan corporation | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson | |
| Its: CEO | |
| "VALIDITY GUARANTOR" | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson, Individually |
| 24 |
AMENDMENT NO. 3
TO
SCHEDULE TO LOAN AND SECURITY AGREEMENT
This Amendment No. 3 to Schedule to Loan and Security Agreement is made this 8th day of June, 2017, by and between CRESTMARK BANK, a Michigan banking corporation, whose address is 5480 Corporate Drive, Suite 350, Troy, Michigan 48098 ("Crestmark"), Coherix, Inc., a Michigan corporation, whose chief executive office is located at 3980 Ranchero Drive, Ann Arbor, MI 48108 ("Borrower"), and Dwight D. Carlson (“Validity Guarantor”). This Amendment No. 3 amends that certain Loan and Security Agreement and Schedule executed August 19, 2016, as amended by Amendment No. 1 to Schedule to Loan and Security Agreement dated February 1, 2017, as amended by Amendment No. 2 to Schedule to Loan and Security Agreement dated April 26, 2017 (as amended, collectively referred to herein as the "Agreement").
BACKGROUND:
The parties have executed the Agreement and Loan Documents;
The Borrower and Validity Guarantor are indebted and/or obligated to Crestmark without offset or deduction pursuant to the Agreement and the Loan Documents all of which are in full force and effect; and
Borrower, Crestmark, and Validity Guarantor, desire to modify and amend certain terms, conditions, covenants and obligations contained in the Agreement and the Loan Documents, including, but not limited to, resetting the Borrowing Base.
Accordingly, the parties agree as follows:
1. INCORPORATION BY REFERENCE:
All definitions and terms used in the Agreement, Schedule and the Loan Documents are hereby incorporated in this Amendment No. 3.
2. AMENDMENT AND MODIFICATION TO THE AGREEMENT:
A. Section 2(b)(ii) of the Schedule to the Agreement is hereby deleted in its entirety, and in lieu thereof, the following is inserted:
2(b)(ii) the Borrowing Base, not to exceed One Million ($1,000,000.00) Dollars (subparagraphs (i) – (ii) are collectively the e Formula”).
The Borrowing Base as of the date of the execution of this Amendment No. 3 is One Million Dollars ($1,000,000.00). Beginning July 1, 2017, the Borrowing Base will be reduced by twelve equal consecutive monthly payments of $83,333.33, and continuing on the first day of each month thereafter until the Borrowing Base has been paid in full. If at any time either the Borrower or Panasonic chooses to terminate the Technical Collaboration and Licensing Agreement between Borrower and Panasonic, then any indebtedness still due and owing under the Borrowing Base shall become immediately due and payable in full.
3. REAFFIRMATION OF GUARANTY:
As a specific inducement to Crestmark, and in consideration of Crestmark's reliance hereon, Validity Guarantor has executed the Validity Guaranty dated August 17, 2016 (the "Validity Guaranty"). Validity Guarantor hereby acknowledges and agrees to the amendments and modification set forth above and reaffirms the Validity Guaranty with respect to all liabilities, obligations and the Indebtedness therein guaranteed as herein amended and modified. Validity Guarantor further acknowledges that Validity Guarantor remains liable in accordance with the terms of the Validity Guaranty without offset or counterclaim. Validity Guarantor also acknowledges and agrees that Validity Guarantor’s liability under the Guaranty is limited as set forth in the Validity Guaranty.
| 25 |
4. EXPENSES:
In consideration of the extension of the loan and the execution of this Amendment No. 3, Borrower will pay Crestmark a fee of $3,000.00, which fee is fully earned as of the date hereof, and non-refundable. Borrower will promptly pay all expenses, fees and costs incurred by Crestmark with respect to the preparation, execution, and delivery of this Amendment No. 3, and all other documents contemplated herewith, including reasonable attorneys' fees.
5. NO WAIVER:
Borrower acknowledges that the execution of this Amendment No. 3 does not constitute a waiver or cure of any Default, whether matured or otherwise, if any, that previously existed or now exists under the Agreement or any Loan Document. By execution of this Amendment No. 3, Crestmark will not be deemed to have waived any of its rights or remedies under the Agreement or any Loan Document.
6. SURVIVAL, REAFFIRMATION, AND NO DEFENSES:
Each undersigned Borrower and Validity Guarantor agrees, in all capacities in which the signatory has executed the Agreement or any of the Loan Documents, as follows:
A. That, except as herein expressly modified or amended, all terms, conditions, covenants, representations and warranties contained in the Agreement and the Loan Documents are true and correct, continue to be satisfied in all respects and are legal, valid and binding obligations. The undersigned hereby ratify, agree to and confirm the Agreement and the Loan Documents and consent to and acknowledge the foregoing Amendment No. 3.
B. That payment of the Indebtedness is the valid obligation of Borrower and Validity Guarantor and, as of the date hereof, Borrower and Validity Guarantor have absolutely no defenses, claims, rights of set-off or counterclaims against Crestmark or the payment of the Indebtedness. This Amendment No. 3 shall not impair the rights, remedies and Collateral given in the Agreement and the Loan Documents.
C. That the liability of the undersigned howsoever arising or provided for in the Agreement and the Loan Documents is hereby reaffirmed.
7. RELEASE:
In consideration of Crestmark executing this Amendment No. 3, Borrower and Validity Guarantor do each hereby release and discharge Crestmark of and from any and all claims, harm, causes of action, liabilities, injuries, expenses (including attorneys’ fees) and damages of any and every kind, known or unknown, legal or equitable, which Borrower or Validity Guarantor have against Crestmark from the date of Borrower's and Validity Guarantor's first contact with Crestmark up to the date of this Amendment No. 3. Borrower and Validity Guarantor confirm to Crestmark that they have reviewed the effect of this release with legal counsel of their choice, or have been afforded the opportunity to do so, prior to the execution of this Amendment No. 3 and each acknowledges and agrees that Crestmark is relying upon this release in executing this Amendment No. 3.
8. CONFIRMATION OF LIEN UPON COLLATERAL:
The Borrower acknowledges and agrees that pursuant to the terms of the Agreement, the obligations of the Borrower and the Indebtedness are secured by a first priority lien and security interest in the Collateral (as defined in the Agreement). The Collateral is and shall remain subject to and encumbered by the lien, charge, and encumbrance of the Agreement, and nothing contained herein shall affect or be construed to affect the lien or encumbrance created by the Agreement or the priority thereof.
9. NO ORAL MODIFICATION:
This Amendment No. 3 may only be altered or modified by written instrument duly executed by Borrower and Crestmark.
| 26 |
The parties hereto have executed this Amendment No. 3 the day and year first appearing above.
| "CRESTMARK" | |
| Crestmark Bank | |
| a Michigan banking corporation | |
| By: /s/ Patricia Oakes | |
| Patricia Oakes | |
| Its:Vice President | |
| "BORROWER" | |
| Coherix, Inc. | |
| a Michigan corporation | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson | |
| Its: CEO | |
| "VALIDITY GUARANTOR" | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson, Individually |
| 27 |
AMENDMENT NO. 4
TO
SCHEDULE TO LOAN AND SECURITY AGREEMENT
This Amendment No. 4 to Schedule to Loan and Security Agreement is made this 14th day of September, 2017, by and between CRESTMARK BANK, a Michigan banking corporation, whose address is 5480 Corporate Drive, Suite 350, Troy, Michigan 48098 ("Crestmark"), Coherix, Inc., a Michigan corporation, whose chief executive office is located at 3980 Ranchero Drive, Ann Arbor, MI 48108 ("Borrower"), and Dwight D. Carlson (“Validity Guarantor”). This Amendment No. 4 amends that certain Loan and Security Agreement and Schedule executed August 19, 2016, as amended by Amendment No. 1 to Schedule to Loan and Security Agreement dated February 1, 2017, as amended by Amendment No. 2 to Schedule to Loan and Security Agreement dated April 26, 2017, as amended by Amendment No. 3 to Schedule to Loan and Security Agreement dated June 8, 2017 (as amended, collectively referred to herein as the "Agreement").
BACKGROUND:
The parties have executed the Agreement and Loan Documents;
The Borrower and Validity Guarantor are indebted and/or obligated to Crestmark without offset or deduction pursuant to the Agreement and the Loan Documents all of which are in full force and effect; and
Borrower, Crestmark, and Validity Guarantor, desire to modify and amend certain terms, conditions, covenants and obligations contained in the Agreement and the Loan Documents, including, but not limited to, revising the Maximum Amount and resetting the Borrowing Base.
Accordingly, the parties agree as follows:
1. INCORPORATION BY REFERENCE:
All definitions and terms used in the Agreement, Schedule and the Loan Documents are hereby incorporated in this Amendment No. 4.
2. AMENDMENT AND MODIFICATION TO THE AGREEMENT:
A. Section 2(a) and 2(b)(ii) of the Schedule to the Agreement is hereby deleted in its entirety, and in lieu thereof, the following is inserted:
2(a) Three Million Dollars ($3,000,000.00) (“Maximum Amount”); or
2(b)(ii) the Borrowing Base, not to exceed Two Million ($2,000,000.00) Dollars (subparagraphs (i) – (ii) are collectively the e Formula”).
The Borrowing Base as of the date of the execution of this Amendment No. 4 is Two Million Dollars ($2,000,000.00). Beginning October 15, 2017, the Borrowing Base will be reduced by twelve equal consecutive monthly payments of $166,666.67, and continuing on the fifteenth day of each month thereafter until the Borrowing Base has been paid in full. If at any time either the Borrower or Panasonic chooses to terminate the Technical Collaboration and Licensing Agreement between Borrower and Panasonic, then any indebtedness still due and owing under the Borrowing Base shall become immediately due and payable in full.
| 28 |
B. Section 4, “Maintenance Fee” of the Schedule to the Agreement is hereby deleted in its entirety, and in lieu thereof, the following is inserted:
Maintenance Fee: Borrower will pay Crestmark a monthly Maintenance Fee of forty-five one hundredths of one percent (0.45%) of the monthly average outstanding principal balance of the Loan for advances made on Accounts Receivable for the preceding month, and with respect to the Borrowing Base, sixty-five one hundredths of one percent (0.65%) of the monthly average outstanding principal balance on the Borrowing Base (“BB Maintenance”), each month until this Agreement is terminated and Crestmark is repaid the Obligations in full, or with respect to the BB Maintenance Fee, the Borrowing Base has been paid in full.
3. REAFFIRMATION OF GUARANTY:
As a specific inducement to Crestmark, and in consideration of Crestmark's reliance hereon, Validity Guarantor and Guarantor have executed the Validity Guaranty dated August 17, 2016, and a Limited Personal Guaranty dated of even date herewith (the "Validity Guaranty" and “Limited Personal Guaranty”, respectively). Validity Guarantor and Guarantor hereby acknowledge and agree to the amendments and modification set forth above and reaffirm the Validity Guaranty and Limited Personal Guaranty with respect to all liabilities, obligations and the Indebtedness therein guaranteed as herein amended and modified. Validity Guarantor and Guarantor further acknowledge that Validity Guarantor and Guarantor remain liable in accordance with the terms of the Validity Guaranty and Limited Personal Guaranty without offset or counterclaim. Validity Guarantor and Guarantor also acknowledge and agree that Validity Guarantor’s and Guarantor’s liability under the Guaranty is limited as set forth in the Validity Guaranty and Limited Personal Guaranty.
4. EXPENSES:
In consideration of the extension of the loan and the execution of this Amendment No. 4, Borrower will pay Crestmark a fee of $10,000.00, which fee is fully earned as of the date hereof, and non-refundable. Borrower will promptly pay all expenses, fees and costs incurred by Crestmark with respect to the preparation, execution, and delivery of this Amendment No. 4, and all other documents contemplated herewith, including reasonable attorneys' fees.
5. NO WAIVER:
Borrower acknowledges that the execution of this Amendment No. 4 does not constitute a waiver or cure of any Default, whether matured or otherwise, if any, that previously existed or now exists under the Agreement or any Loan Document. By execution of this Amendment No. 4, Crestmark will not be deemed to have waived any of its rights or remedies under the Agreement or any Loan Document.
6. SURVIVAL, REAFFIRMATION, AND NO DEFENSES:
Each undersigned Borrower and Validity Guarantor agrees, in all capacities in which the signatory has executed the Agreement or any of the Loan Documents, as follows:
A. That, except as herein expressly modified or amended, all terms, conditions, covenants, representations and warranties contained in the Agreement and the Loan Documents are true and correct, continue to be satisfied in all respects and are legal, valid and binding obligations. The undersigned hereby ratify, agree to and confirm the Agreement and the Loan Documents and consent to and acknowledge the foregoing Amendment No. 4.
| 29 |
B. That payment of the Indebtedness is the valid obligation of Borrower and Validity Guarantor and, as of the date hereof, Borrower and Validity Guarantor have absolutely no defenses, claims, rights of set-off or counterclaims against Crestmark or the payment of the Indebtedness. This Amendment No. 4 shall not impair the rights, remedies and Collateral given in the Agreement and the Loan Documents.
C. That the liability of the undersigned howsoever arising or provided for in the Agreement and the Loan Documents is hereby reaffirmed.
7. RELEASE:
In consideration of Crestmark executing this Amendment No. 4, Borrower and Validity Guarantor do each hereby release and discharge Crestmark of and from any and all claims, harm, causes of action, liabilities, injuries, expenses (including attorneys’ fees) and damages of any and every kind, known or unknown, legal or equitable, which Borrower or Validity Guarantor have against Crestmark from the date of Borrower's and Validity Guarantor's first contact with Crestmark up to the date of this Amendment No. 4. Borrower and Validity Guarantor confirm to Crestmark that they have reviewed the effect of this release with legal counsel of their choice, or have been afforded the opportunity to do so, prior to the execution of this Amendment No. 4 and each acknowledges and agrees that Crestmark is relying upon this release in executing this Amendment No. 4.
8. CONFIRMATION OF LIEN UPON COLLATERAL:
The Borrower acknowledges and agrees that pursuant to the terms of the Agreement, the obligations of the Borrower and the Indebtedness are secured by a first priority lien and security interest in the Collateral (as defined in the Agreement). The Collateral is and shall remain subject to and encumbered by the lien, charge, and encumbrance of the Agreement, and nothing contained herein shall affect or be construed to affect the lien or encumbrance created by the Agreement or the priority thereof.
9. NO ORAL MODIFICATION:
This Amendment No. 4 may only be altered or modified by written instrument duly executed by Borrower and Crestmark.
| 30 |
The parties hereto have executed this Amendment No. 4 the day and year first appearing above.
| "CRESTMARK" | |
| Crestmark Bank | |
| a Michigan banking corporation | |
| By: /s/ Patricia Oakes | |
| Patricia Oakes | |
| Its:Vice President | |
| "BORROWER" | |
| Coherix, Inc. | |
| a Michigan corporation | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson | |
| Its: CEO | |
| "VALIDITY GUARANTOR" | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson, Individually |
| 31 |
AMENDMENT NO. 5
TO
SCHEDULE TO LOAN AND SECURITY AGREEMENT
This Amendment No. 5 to Schedule to Loan and Security Agreement is made this 23rd day of March, 2018, by and between CRESTMARK BANK, a Michigan banking corporation, whose address is 5480 Corporate Drive, Suite 350, Troy, Michigan 48098 ("Crestmark"), Coherix, Inc., a Michigan corporation, whose chief executive office is located at 3980 Ranchero Drive, Ann Arbor, MI 48108 ("Borrower"), and Dwight D. Carlson (“Validity Guarantor”). This Amendment No. 5 amends that certain Loan and Security Agreement and Schedule executed August 19, 2016, as amended by Amendment No. 1 to Schedule to Loan and Security Agreement dated February 1, 2017, as amended by Amendment No. 2 to Schedule to Loan and Security Agreement dated April 26, 2017, as amended by Amendment No. 3 to Schedule to Loan and Security Agreement dated June 8, 2017, and as amended by Amendment No. 4 to Schedule to Loan and Security Agreement dated September 14, 2017 (as amended, collectively referred to herein as the "Agreement").
BACKGROUND:
The parties have executed the Agreement and Loan Documents;
The Borrower and Validity Guarantor are indebted and/or obligated to Crestmark without offset or deduction pursuant to the Agreement and the Loan Documents all of which are in full force and effect; and
Borrower, Crestmark, and Validity Guarantor, desire to modify and amend certain terms, conditions, covenants and obligations contained in the Agreement and the Loan Documents, including, but not limited to, resetting the Borrowing Base.
Accordingly, the parties agree as follows:
1. INCORPORATION BY REFERENCE:
All definitions and terms used in the Agreement, Schedule and the Loan Documents are hereby incorporated in this Amendment No. 5.
2. AMENDMENT AND MODIFICATION TO THE AGREEMENT:
A. Section 2(b)(ii) of the Schedule to the Agreement is hereby deleted in its entirety, and in lieu thereof, the following is inserted:
2(b)(ii) the Borrowing Base, not to exceed Two Million ($2,000,000.00) Dollars (subparagraphs (i) – (ii) are collectively the e Formula”).
The Borrowing Base as of the date of the execution of this Amendment No. 5 is Two Million Dollars ($2,000,000.00). Beginning May 15, 2018, the Borrowing Base will be reduced by twelve equal consecutive monthly payments of $166,666.67, and continuing on the fifteenth day of each month thereafter until the Borrowing Base has been paid in full. If at any time either the Borrower or Panasonic chooses to terminate the Technical Collaboration and Licensing Agreement between Borrower and Panasonic, then any indebtedness still due and owing under the Borrowing Base shall become immediately due and payable in full.
3. REAFFIRMATION OF GUARANTY:
As a specific inducement to Crestmark, and in consideration of Crestmark's reliance hereon, Validity Guarantor and Guarantor have executed the Validity Guaranty dated August 17, 2016, and a Limited Personal Guaranty dated of even date herewith (the "Validity Guaranty" and “Limited Personal Guaranty”, respectively). Validity Guarantor and Guarantor hereby acknowledge and agree to the amendments and modification set forth above and reaffirm the Validity Guaranty and Limited Personal Guaranty with respect to all liabilities, obligations and the Indebtedness therein guaranteed as herein amended and modified. Validity Guarantor and Guarantor further acknowledge that Validity Guarantor and Guarantor remain liable in accordance with the terms of the Validity Guaranty and Limited Personal Guaranty without offset or counterclaim. Validity Guarantor and Guarantor also acknowledge and agree that Validity Guarantor’s and Guarantor’s liability under the Guaranty is limited as set forth in the Validity Guaranty and Limited Personal Guaranty.
| 32 |
4. EXPENSES:
In consideration of the extension of the loan and the execution of this Amendment No. 5, Borrower will pay Crestmark a fee of $5,000.00, which fee is fully earned as of the date hereof, and non-refundable. Borrower will promptly pay all expenses, fees and costs incurred by Crestmark with respect to the preparation, execution, and delivery of this Amendment No. 5, and all other documents contemplated herewith, including reasonable attorneys' fees.
5. NO WAIVER:
Borrower acknowledges that the execution of this Amendment No. 5 does not constitute a waiver or cure of any Default, whether matured or otherwise, if any, that previously existed or now exists under the Agreement or any Loan Document. By execution of this Amendment No. 5, Crestmark will not be deemed to have waived any of its rights or remedies under the Agreement or any Loan Document.
6. SURVIVAL, REAFFIRMATION, AND NO DEFENSES:
Each undersigned Borrower and Validity Guarantor agrees, in all capacities in which the signatory has executed the Agreement or any of the Loan Documents, as follows:
A. That, except as herein expressly modified or amended, all terms, conditions, covenants, representations and warranties contained in the Agreement and the Loan Documents are true and correct, continue to be satisfied in all respects and are legal, valid and binding obligations. The undersigned hereby ratify, agree to and confirm the Agreement and the Loan Documents and consent to and acknowledge the foregoing Amendment No. 5.
B. That payment of the Indebtedness is the valid obligation of Borrower and Validity Guarantor and, as of the date hereof, Borrower and Validity Guarantor have absolutely no defenses, claims, rights of set-off or counterclaims against Crestmark or the payment of the Indebtedness. This Amendment No. 5 shall not impair the rights, remedies and Collateral given in the Agreement and the Loan Documents.
C. That the liability of the undersigned howsoever arising or provided for in the Agreement and the Loan Documents is hereby reaffirmed.
7. RELEASE:
In consideration of Crestmark executing this Amendment No. 5, Borrower and Validity Guarantor do each hereby release and discharge Crestmark of and from any and all claims, harm, causes of action, liabilities, injuries, expenses (including attorneys’ fees) and damages of any and every kind, known or unknown, legal or equitable, which Borrower or Validity Guarantor have against Crestmark from the date of Borrower's and Validity Guarantor's first contact with Crestmark up to the date of this Amendment No. 5. Borrower and Validity Guarantor confirm to Crestmark that they have reviewed the effect of this release with legal counsel of their choice, or have been afforded the opportunity to do so, prior to the execution of this Amendment No. 5 and each acknowledges and agrees that Crestmark is relying upon this release in executing this Amendment No. 5.
8. CONFIRMATION OF LIEN UPON COLLATERAL:
The Borrower acknowledges and agrees that pursuant to the terms of the Agreement, the obligations of the Borrower and the Indebtedness are secured by a first priority lien and security interest in the Collateral (as defined in the Agreement). The Collateral is and shall remain subject to and encumbered by the lien, charge, and encumbrance of the Agreement, and nothing contained herein shall affect or be construed to affect the lien or encumbrance created by the Agreement or the priority thereof.
9. NO ORAL MODIFICATION:
This Amendment No. 5 may only be altered or modified by written instrument duly executed by Borrower and Crestmark.
| 33 |
The parties hereto have executed this Amendment No. 5 the day and year first appearing above.
| "CRESTMARK" | |
| Crestmark Bank | |
| a Michigan banking corporation | |
| By: /s/ Jean Hellman | |
| Jean Hellman | |
| Its:Vice President | |
| "BORROWER" | |
| Coherix, Inc. | |
| a Michigan corporation | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson | |
| Its: CEO | |
| "VALIDITY GUARANTOR" | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson, Individually |
| 34 |
AMENDMENT NO. 6
TO
LOAN AND SECURITY AGREEMENT
This Amendment No. 6 to Loan and Security Agreement (“Amendment”) is made this 4th day of October, 2018, by and between CRESTMARK, A DIVISION OF METABANK, a federal savings bank, whose address is 5480 Corporate Drive, Suite 350, Troy, Michigan 48098 ("Crestmark"), as assignee of Crestmark Bank, COHERIX, INC., a Delaware corporation, whose chief executive office is located at 3980 Ranchero Drive, Ann Arbor, MI 48108 ("Borrower"), and DWIGHT D. CARLSON (“Validity Guarantor” and “Guarantor”). This Amendment amends that certain Loan and Security Agreement executed August 19, 2016, as amended by Amendment No. 1 dated February 1, 2017, Amendment No. 2 dated April 26, 2017, Amendment No. 3 dated June 8, 2017, Amendment No. 4 dated September 14, 2017 and Amendment No. 5 dated March 23, 2018 (as so amended, the "Agreement").
BACKGROUND:
The parties have executed the Agreement and Loan Documents;
The Borrower and Guarantor are indebted and/or obligated to Crestmark without offset or deduction pursuant to the Agreement and the Loan Documents all of which are in full force and effect; and
Borrower, Crestmark, and Guarantor, desire to modify and amend certain terms, conditions, covenants and obligations contained in the Agreement and the Loan Documents, including increasing the Maximum Amount and resetting the Borrowing Base.
Accordingly, the parties agree as follows:
1. DEFINED TERMS:
Capitalized terms that are not otherwise defined in this Amendment shall have the meanings ascribed to them in the Agreement.
2. AMENDMENT AND MODIFICATION TO THE AGREEMENT:
A. Section 2(a) of the Schedule to the Agreement is hereby deleted in its entirety, and in lieu thereof, the following is inserted:
“2(a) Four Million Dollars ($4,000,000.00) (“Maximum Amount”); or”
B. Section 2(b)(ii) of the Schedule to the Agreement is hereby deleted in its entirety, and in lieu thereof, the following is inserted:
“2(b)(ii) the Borrowing Base, not to exceed Three Million ($3,000,000.00) Dollars (subparagraphs (i) – (ii) are collectively the Advance Formula”).
The Borrowing Base as of the date of the execution of this Amendment No. 6 is Three Million Dollars ($3,000,000.00). The Borrowing Base will be reduced by $250,000.00 each month, beginning on October 15, 2018 and on the fifteenth day of each month thereafter until the Borrowing Base has been paid in full. If at any time either the Borrower or Account Debtor Panasonic (“Panasonic”) chooses to terminate the Technical Collaboration and Licensing Agreement between Borrower and Panasonic, then any indebtedness still due and owing under the Borrowing Base shall become immediately due and payable in full.”
| 35 |
3. REAFFIRMATION OF GUARANTY:
As a specific inducement to Crestmark to enter into the Agreement, Validity Guarantor and Guarantor have executed a Validity Guaranty dated August 17, 2016 and Limited Personal Guaranty dated September 17, 2017, as amended (the “Validity Guaranty“ and “Personal Guaranty”, respectively). Validity Guarantor and Guarantor hereby acknowledge and agree to the amendments and modifications set forth above and reaffirm the Validity Guaranty and Personal Guaranty with respect to all liabilities, obligations and the Indebtedness therein guaranteed as herein amended and modified. Validity Guarantor and Guarantor further acknowledge that Validity Guarantor and Guarantor remain liable in accordance with the terms of the Validity Guaranty and Personal Guaranty without offset or counterclaim. Validity Guarantor and Guarantor also acknowledge and agree that Validity Guarantor’s and Guarantor’s liability under each Guaranty is limited as set forth in the Validity Guaranty and Personal Guaranty.
4. EXPENSES:
In consideration of the extension of the loan and the execution of this Amendment, Borrower will pay Crestmark a fee of $10,000.00, which fee is fully earned as of the date hereof, and non-refundable. Borrower will promptly pay all expenses, fees and costs incurred by Crestmark with respect to the preparation, execution, and delivery of this Amendment, and all other documents contemplated herewith, including reasonable attorneys' fees.
5. NO WAIVER:
Borrower acknowledges that the execution of this Amendment does not constitute a waiver or cure of any Default, whether matured or otherwise, if any, that previously existed or now exists under the Agreement or any Loan Document. By execution of this Amendment, Crestmark will not be deemed to have waived any of its rights or remedies under the Agreement or any Loan Document.
6. SURVIVAL, REAFFIRMATION, AND NO DEFENSES:
Each undersigned Borrower and Guarantor agrees, in all capacities in which the signatory has executed the Agreement or any of the Loan Documents, as follows:
A. That, except as herein expressly modified or amended, all terms, conditions, covenants, representations and warranties contained in the Agreement and the Loan Documents are true and correct, continue to be satisfied in all respects and are legal, valid and binding obligations. The undersigned hereby ratify, agree to and confirm the Agreement and the Loan Documents and consent to and acknowledge this Amendment.
B. That payment of the Indebtedness is the valid obligation of Borrower and Guarantor and, as of the date hereof, Borrower and Guarantor have absolutely no defenses, claims, rights of set-off or counterclaims against Crestmark or the payment of the Indebtedness. This Amendment shall not impair the rights, remedies and Collateral given in the Agreement and the Loan Documents.
C. That the liability of the undersigned howsoever arising or provided for in the Agreement and the Loan Documents is hereby reaffirmed.
| 36 |
7. RELEASE:
In consideration of Crestmark executing this Amendment, Borrower and Guarantor do each hereby release and discharge Crestmark of and from any and all claims, harm, causes of action, liabilities, injuries, expenses (including attorneys’ fees) and damages of any and every kind, known or unknown, legal or equitable, which Borrower or Guarantor have against Crestmark from the date of Borrower's and Guarantor's first contact with Crestmark up to the date of this Amendment. Borrower and Guarantor confirm to Crestmark that they have reviewed the effect of this release with legal counsel of their choice, or have been afforded the opportunity to do so, prior to the execution of this Amendment and each acknowledges and agrees that Crestmark is relying upon this release in executing this Amendment.
8. CONFIRMATION OF LIEN UPON COLLATERAL:
The Borrower acknowledges and agrees that pursuant to the terms of the Agreement, the obligations of the Borrower and the Indebtedness are secured by a first priority lien and security interest in the Collateral (as defined in the Agreement). The Collateral is and shall remain subject to and encumbered by the lien, charge, and encumbrance of the Agreement, and nothing contained herein shall affect or be construed to affect the lien or encumbrance created by the Agreement or the priority thereof.
9. NO ORAL MODIFICATION:
This Amendment may only be altered or modified by written instrument duly executed by Borrower and Crestmark.
[signatures on next page]
| 37 |
The parties hereto have executed this Amendment the day and year first appearing above.
| "CRESTMARK" | |
| Crestmark, a division of MetaBank | |
| a federal savings bank | |
| By: /s/ Patricia Oakes | |
| Patricia Oakes | |
| Its:Vice President | |
| "BORROWER" | |
| Coherix, Inc. | |
| a Delaware corporation | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson | |
| Its: CEO |
The undersigned Validity Guarantor and Guarantor, by signing this Amendment, agrees he has read and understands this Amendment and agrees to all of its terms.
| "VALIDITY GUARANTOR" | |
| /s/ Dwight D. Carlson | |
| Dwight D. Carlson, Individually | |
| “GUARANTOR” | |
| /s/ Dwight D. Carlson | |
| Dwight D. Carlson, Individually | |
| 38 |
THIRD AMENDED AND RESTATED
PROMISSORY NOTE
| Principal Amount $4,000,000.00 | Troy, Michigan |
Dated: August 19, 2016
Amended and Restated: September 14, 2017
Second Amended and Restated: March 23, 2018
Third Amended and Restated: October 4, 2018
This Promissory Note (“Note”) is made by the Borrower who has signed this Note. The Borrower promises to pay to the order of CRESTMARK, a division of MetaBank, a federal savings bank (“Crestmark"), as assignee of Crestmark Bank, ON DEMAND, at its offices located at 5480 Corporate Drive, Suite 350, Troy, Michigan 48098 or at such other place as Crestmark or the person that then holds this Note designates in writing, the principal amount set forth above or such lesser or greater amount as may then be due under the Agreement (as defined below), plus interest, fees and expenses as hereinafter provided. All payments that are made must be made in lawful money of the United States of America in immediately available funds. Borrower does not have any right to offset, deduction, or counterclaim from the amount due.
This Note is referred to in and was delivered pursuant to the Loan and Security Agreement (“Agreement”) dated August 19, 2016, as amended by Amendment No. 1 dated February 1, 2017, Amendment No. 2 dated April 26, 2017, Amendment No. 3 dated June 8, 2017, Amendment No. 4 dated September 14, 2017, Amendment No. 5 dated March 23, 2018, and Amendment No. 6 to Loan and Security Agreement of even date between Borrower and Crestmark under which Advances, repayment and further Advances may be made from time to time, pursuant to the provisions of the Agreement. Reference is made to the Agreement for additional terms relating to this Note and the security given for this Note. Any capitalized terms used in this Note, if not defined in this Note, will have the meanings assigned to such terms in the Agreement.
The outstanding principal balance of this Note will bear interest based upon a year of 360 days with interest being charged for each day the principal amount is outstanding including the date of actual payment. The interest rate with respect to the Accounts Receivable Line of Credit will be a rate which is equal to two (2.00%) percentage points in excess of that rate shown in the Wall Street Journal as the prime rate (the “Effective Rate”). Interest on this Note will change with each change in the prime rate so published. If at any time Crestmark either abandons the use of the Wall Street Journal prime rate or the Wall Street Journal prime rate is no longer published, then Crestmark will establish a similar replacement rate in its sole discretion. Notwithstanding the foregoing, at no time will the Effective Rate be less than seven (7.00%) percent per annum.
Borrower must pay interest on the principal amount which is outstanding each month in arrears commencing on the first day of the month following the funding of the transaction, and continuing on the first day of each month thereafter until the Obligations are fully paid. If the Agreement so provides, interest will also be payable at the same rate on all other sums constituting Obligations. If any payment is due on a day which Crestmark is not open for business, then payments will be made on the next business day. Payments will be applied in the manner provided in the Agreement. If Borrower at any time pays less than the amount then due, Crestmark may accept such payment, but the failure to pay the entire amount due is a Default. The (i) failure of Borrower to comply with the provisions of the Agreement or (ii) failure to pay the Obligations following demand will permit Crestmark to charge the Extra Rate. The “Extra Rate” shall mean the Effective Rate plus eight (8.00%) percent per annum.
| 39 |
Should Borrower make any payment by mail, the payment must be actually received by Crestmark before the payment is credited but payment is still subject to the Clearance Days as defined in the Schedule to the Agreement. Borrower assumes all risk resulting from non-delivery or delay, in delivery of any payment no matter how the payment is delivered.
If Borrower elects to prepay this Note and/or terminate the Agreement, Borrower may do so, but only upon payment of all the Obligations, including the Exit Fee set forth in the Schedule.
It is the intent of the parties that the rate of interest and other charges to Borrower under this Note shall be lawful; therefore, if for any reason the interest or other charges payable hereunder are found by a court of competent jurisdiction, in a final determination, to exceed the limit Crestmark may lawfully charge Borrower, then the obligation to pay interest or other charges shall automatically be reduced to such limit and, if any amount in excess of such limit shall have been paid, then such amount shall be credited to the outstanding principal balance of this Note, or if no such amount is outstanding, refunded to Borrower.
Borrower waives any obligation of Crestmark to present this Note for payment or to give any notice of nonpayment or notice of protest and any other notices of any kind. The liability of the Borrower is absolute and unconditional, without regard to the liability of any other party.
The Borrower will reimburse Crestmark for all costs and expenses including attorneys’ fees incurred by Crestmark in enforcing its rights under this Note.
This Note amends and restates in its entirety a certain Promissory Note (Line of Credit) dated August 19, 2016, as amended by Amended and Restated Promissory Note (Line of Credit) dated September 14, 2017 and Second Amended and Restated Promissory Note dated March 23, 2018 from Borrower to Crestmark. This Note does not constitute a novation or extinguishment of the existing indebtedness evidenced by said promissory note and said indebtedness is still outstanding.
| COHERIX, INC. | |
| a Delaware corporation | |
| By: /s/ Dwight D. Carlson | |
| Dwight D. Carlson | |
| Its: CEO | |
| 40 |
AMENDED AND RESTATED
LIMITED PERSONAL GUARANTY
This Amended and Restated Limited Personal Guaranty (“Guaranty”) is made on October 4, 2018, by Dwight Carlson (“Guarantor”) in favor of Crestmark, a division of MetaBank (“Crestmark”), as assignee of Crestmark Bank, to induce Crestmark to make a loan and/or extend or continue to extend credit to Coherix, Inc., a Delaware corporation (“Borrower”). This Guaranty amends and restates in its entirety the Limited Personal Guaranty dated September 14, 2017 given by Guarantor in favor of Crestmark Bank. Guarantor has determined that executing and delivering this Guaranty is in Guarantor’s interest and to Guarantor’s benefit.
1. Guaranty. Guarantor hereby absolutely, irrevocably and unconditionally guarantees to Crestmark: (a) the full, prompt and unconditional payment when due of all Indebtedness (as defined in the Loan and Security Agreement between Crestmark and Borrower (as amended, the “Loan Agreement”)), including, but not limited to, principal, interest and fees on that certain $4,000,000.00 Third Amended and Restated Promissory Note (Line of Credit) (the "Note"), as it may be amended or restated and whether on demand, at maturity, pursuant to mandatory or optional prepayments, by acceleration or otherwise; and (b) the punctual and faithful performance and observation by Borrower of all duties, agreements, covenants, representations and obligations of Borrower contained in the Loan Documents (as defined in Section 3), limited to One Million Dollars ($1,000,000.00), plus interest, attorneys' fees and other collection costs incurred in enforcing this Guaranty and any of the Loan Documents. Provided, however, Guarantor's liability is unlimited with respect to the following: (a) fraud or material misrepresentation made in or in connection with the loan or the Loan Documents, including the application and financial statements submitted therewith; (b) the amount of unpaid taxes or unpaid charges for labor, materials or other charges which can create liens on any portion of the Collateral or premises; (c) the misappropriation of proceeds of insurance covering the Collateral or premises, proceeds arising from the sale or condemnation of the Collateral or premises or rentals from the premises; (d) any account receivable of the Borrower, or the documents reflecting such account receivable, against which Crestmark made a Money Advance (i) were not genuine and accurate in all respects, (ii) did not arise out of a completed, bona fide sale and delivery of goods and rendition of services in the ordinary course of business, or (iii) were subject to offset, deduction or counterclaim; (e) any Borrower Certificate delivered to Crestmark is otherwise not true and correct in all respects; (f) any account debtors of Borrower are notified by Borrower or Guarantor to send payments to a party other than Crestmark or other than to the lockbox account; or (g) any inventory report submitted to Crestmark pursuant to the Loan Agreement is not true and correct in all respects. Crestmark may, in its sole discretion, apply any proceeds received from foreclosure or other realization on the Collateral, or any payments received from either Borrower or any other guarantors, to the repayment of any Indebtedness without in any way or to any extent reducing (or without it being applied to) the aforementioned limitation on Guarantor's liability. Only payments made by Guarantor pursuant to this Guaranty, and not by any other guarantor, will be applied against the limit of this Guaranty set forth above.
2. Absolute, Unconditional and Continuing Obligation. This Guaranty is an absolute, continuing, unconditional, irrevocable and limited guaranty. Guarantor will not be relieved from any obligations under this Guaranty until this Guaranty is terminated in accordance with Section 14. The obligations and liabilities of Guarantor will continue notwithstanding any defect in the genuineness, validity or enforceability of the Indebtedness or the Loan Documents, or any other circumstances which might otherwise constitute a legal or equitable discharge or defense of the liabilities of a surety or guarantor or which might otherwise limit recourse against Guarantor. This is a guarantee of payment and not of collection.
| 41 |
3. The Loan Documents. The Loan Agreement, the Note, and all other related documents now existing or hereafter arising and executed in connection with the loan, including all amendments and restatements thereto (collectively, the "Loan Documents"), are incorporated into and made a part of this Guaranty by reference.
4. Continuation of Liability. The liability and obligations of Guarantor will in no way be affected, impaired, diminished or released by any action or inaction whatsoever other than the indefeasible payment in full and in cash of the Indebtedness.
5. Unconditional Waiver of all Defenses. Guarantor unconditionally, absolutely and irrevocably waives each and every defense that under principles of guaranty or suretyship law would otherwise operate to impair or diminish the liability of Guarantor for the Indebtedness.
6. Exercise of Rights by Crestmark against Guarantor. Anything herein to the contrary notwithstanding, it is understood and agreed that the Lender shall not seek to enforce this Limited Guaranty until such time as Lender, in Lender’s sole discretion, has determined that it has completed the liquidation of the collateral securing the Indebtedness. Thereafter, the Lender may enforce this Limited Guaranty against the Guarantor hereunder, limited as set forth in Section 1 above. Without limiting the foregoing sentence, the requirement to undertake reasonable efforts may be satisfied by sending a notification letter to Account Debtors and initiating a foreclosure by advertisement of the Inventory. All rights, powers and remedies of Crestmark hereunder and under the Loan Documents are cumulative and not alternative and shall be in addition to all rights, powers and remedies given to Crestmark by law and by agreement.
7. Subordination/Subrogation. In the event that Guarantor becomes obligated to pay any sums to Borrower, or in the event that Borrower or any subsequent owner of any Collateral is now or hereafter becomes indebted to Guarantor other than for customary salary and bonuses (collectively, "Debt"), the Debt will at all times be subordinate as to lien, payment and all other respects, to the Indebtedness, and Guarantor will not, among other things, accept any payment from Borrower with respect to the Debt without Crestmark's prior written consent. Furthermore, until the Indebtedness is indefeasibly paid in full and in cash, and the Loan Agreement is terminated, Guarantor hereby absolutely, irrevocably and unconditionally waives all rights Guarantor may have, at law or in equity, to seek or claim subrogation. Crestmark has no duty to enforce or protect any rights which the Guarantor may have against Borrower or any other Person, and Guarantor assumes full responsibility for enforcing and protecting such rights.
8. Representations and Warranties. Guarantor represents, warrants and covenants to Crestmark that: (a) Guarantor has completely read and understands the Loan Documents and agrees to all those portions which apply to Guarantor; (b) Guarantor was provided an opportunity to review the Loan Documents with its legal counsel; (c) any financial statements of Guarantor furnished Crestmark are true and correct and include all contingent liabilities of Guarantor; (d) since the date of any financial statements furnished to Crestmark, no material adverse change has occurred in the financial condition of Guarantor; (e) there are no pending or threatened legal proceedings or judgments against Guarantor, and no federal or state tax liens have been filed or threatened against Guarantor; and (f) Guarantor is not in default or claimed default under any agreement for borrowed money. Guarantor agrees to immediately give Crestmark written notice of any material adverse change in its financial condition.
9. Expenses. Guarantor agrees to pay all expenses (including attorneys’ fees) incurred by Crestmark in connection with the enforcement of Crestmark's rights under the Loan Documents, this Guaranty, and the collection of the Indebtedness.
10. Transfer of Assets. Guarantor further agrees that until the Indebtedness is indefeasibly paid in full, and in cash, and the Loan Agreement is terminated, Guarantor will not, without Crestmark’s prior written consent: (a) make any voluntary transfer of any of Guarantor's assets which would have the effect of materially diminishing Guarantor's present net worth; or (b) guaranty the debts or obligations of any other person or entity.
| 42 |
11. Reinstatement. This Guaranty will continue to be effective or will be automatically reinstated, as the case may be, if at any time payment of all or part of the Indebtedness is rescinded or must otherwise be restored or returned by Crestmark, including in connection with Borrower’s bankruptcy or insolvency.
12. Joint and Several Liability. The term "Guarantor" shall mean each person executing this Guaranty, each individually and together collectively, and the obligations of Guarantor and any other guarantor executing a guaranty of all or any portion of the Indebtedness will be joint and several.
13. Assignability/Binding Effect. This Guaranty shall be assignable by Crestmark without notice to Guarantor and shall inure to the benefit of Crestmark and to any subsequent successors and assigns. In the event of the death of Guarantor, this Guaranty shall continue in effect against the estate of Guarantor.
14. Termination. Notwithstanding anything contained herein to the contrary, the liability of Guarantor will be terminated only in the event that: (a) Borrower or Guarantor has indefeasibly paid Crestmark in cash and in full the Indebtedness; and (b) the Loan Agreement is terminated.
15. Severability. If any provision of this Guaranty is in conflict with any statute or rule of law or is otherwise unenforceable for any reason, then that provision will be deemed null and void to the extent of the conflict or unenforceability and will be deemed severable, but it will not invalidate any other provision of this Guaranty.
16. Complete Agreement. This Guaranty is the final, complete and exclusive expression of the agreement between Guarantor and Crestmark with respect to the subject matter of this Guaranty. This Guaranty cannot be modified or amended except in a writing signed by both Guarantor and Crestmark.
The Guarantor executes this Guaranty as of the day and year first above written.
| GUARANTOR: | |
| /s/ Dwight D. Carlson | |
| Dwight D. Carlson | |
| 43 |
Exhibit 11.1
CONSENT OF INDEPENDENT AUDITORS
We agree to the inclusion in this Offering Statement on Form 1-A of our report dated October 2, 2018, relating to the consolidated financial statements of Coherix, Inc. and Subsidiaries as of and for the year ended December 31, 2017. We also agree to the reference to us under the heading “Independent Auditors” in the Offering Statement.
/s/ UHY LLP
Farmington Hills, Michigan
November 2, 2018
Exhibit 11.2
CONSENT OF INDEPENDENT AUDITOR
November 2, 2018
To the Board of Directors
Coherix, Inc.
We agree to the inclusion in the Offering Statement on Form 1-A dated November 2, 2018 of our report dated March 16, 2018 (except for Notes 3 and 13 to the consolidated financial statements, as to which the date is September 19, 2018), on our audit of the consolidated financial statements of Coherix, Inc. and Subsidiaries as of, and for the year ended, December 31, 2016.
/s/ George Johnson & Company
CERTIFIED PUBLIC ACCOUNTANTS
Detroit, Michigan
1(U#%XD^:/AW9'.5KPYK^:U9HIEDD%Y<,NUS&,N?-?"$CCA1:/-X8338=06$+"]P+NZ:2%9F^02;)8AY
_7BKDWA/S4OE^VX^U:G;:A_JON^5Y/R=><^
M3U[;NAQS6E_+_@_Y">W]?UV$N_&MI:W$H&G:C/:17:63WL*1F$3,ZIMY<-PS
M8+;=H((SGBJ_Q \0/X>TRRF_M%K"":YV7$\*QO,D>QCF-'!#?,%S\IPI)XQD
M8.IV6H/J$^B:=]O2WFU>*[-O+I5)H95#QR1L&5U/(((X(J2O.],UC6=>M+.)]?;2Y(]"M]0>>
M."$F>20-N9@ZD!%VC(4#[_4<54N_$GB&]TN^U2'47T_[)X?MM3%M'!&RM,XE
M)5MZD[#L' (/3!'.::UL"5ST^BFHQ:-6/4@&G4B4[JX4444#"BBB@ HHHH *
M*** "JO]F6&8S]BMLQS-.G[I?DE;.7''#'
UW_P<7_M"7;PM/-\/9"
M5B+^'%P?8?-["OC?QE\7K[Q=\5-3\70V^GZ+JUU>-J#V^E6PMK>VD8[CY4>2
M%0G/RCCDCIQ7%_8[Y/#5C"JI]HAD0NNX8P#ZUH-->1:_#-'M\ORMK-D?*.YJU;_\%#_VWO"7C>S\%^']:^(-A''%C3K"RM+&
M]@$"D\K-&CQ[-@SG=Q[U\JW&@^"]&BTW5&FOM1\,WLJ72R6JQM?1X/S0-N(
MDP0 1R,\BO4O 7[0_PUN/B))9S:GXF\.^$)K1HU:XTH37'F;,!=D;D98_Q
M9QSSBN.%-TM8ILWDU/=GJGQ0_P""Q?[65EIT]UX=^,7B.Z32X0FMV,FG66
MSG\T?:O"]XG4(Q.9;63' YX.*T++1X?#_B"R\4:YK%CI.N36[6VNV-AB:UUL
M= S(1\K'J3CVKZ]_X*)?\$#_ (Z_LU>([K4OAC;ZE\6O LI:2(6>!K&GKU\N
M:#/[W Z/%G..57I7PXW[+OQPO=8CL/\ A3OQ.-Y<,$2+_A&[O
224^OX6%]0?6R3A]1)>:SZX%=NC)]W
M^"_>6BS"^K6[]'U&S<7-V;*[)#BX>EZ>VO\ - '!A8VME="!B
M96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ ]UP13H06',]_8 +&L93YAB:?DPZ2,WQ#V3YDDFW7
MO>9B4#.0!YJ'I0>OA[I'Q,?
M/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(BWQP'53QZWB_Y-)OC<0>;-3TS ?Z_C^H^E_;3,&P!D=:/'K<5V+_
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MS7 _ >HC?S(L6HN_=%P>"&O3W2_P PNAK%U09*-Q^0) 2/I]0#Q]??O&7U'2&:SGA;
M2Z'J8/GY$385P_Y+'_%?=O$6G'IOP6].D/DOYF>%I*6LJ5R\#Q4GD+NLR$!(
M7"2,QN0!P3_K>[H=9'7O!;TZXTO\S/#3X]*Z/*Q-"\/F#"06TZ"WY'^!]W8:
M>J^&V,=.NV?YDN%W(DZT>8@>HIK-)$LZLWA9P@F ')5795;^A87X/MEGT]."
MVD() -*=*L_/>(?\IP_U]?\ 0D'\6X(]T\9VC- I*F85
M!_A<_P PM.MU08#BG5;'S0W0^]^S=I]64,[)04E3$,H8Y;1QJ7BJ
Q^@NI=I;2ZYZF[K.-QE+'0IMZKZ_S<.9@T+'(]=D<
MI44:8:L,T\[AFCG+ZPQ$=B3[0-R5MTTYMUYCV]36@+O**_,TA/'HMMMK56T?
M50T&.)^S^'IBS7RNQ>#)_C'2??-)('*LD6P
B\,/F@D\%7*)S3QLK4<,E%3U*0-+,RV>30I^A8 \
MFL;"3X>O:QTR8C+KCUQ^0QDE3#E(*IC8H4#Q-$T4.ET"AXFTN"OX(^GU3
M36_C?%3IY[^5./3I6.F2I9*AZ4U>1KG3[6>2>>!Z*IEE6:2M+K(JO,69B=>J
M_P#M_:JG1=XR>AZLAQ>[:W=/6'6^:]^4E?K*T\SQ/3B<
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MH@,D$+V_5%$P-V!Y#$74\CV^MJH(-.M&[)!!ZC;N^,&Y
$T@(V9F8(X %BB?#2",Q#
MUJ8IM:V<,3Q:]OS[]6F.FC&P)%1T=#XU=